0001213900-15-003597.txt : 20150513 0001213900-15-003597.hdr.sgml : 20150513 20150513170303 ACCESSION NUMBER: 0001213900-15-003597 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150513 DATE AS OF CHANGE: 20150513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DanDrit Biotech USA, Inc. CENTRAL INDEX KEY: 0001527728 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452259340 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54478 FILM NUMBER: 15859166 BUSINESS ADDRESS: STREET 1: DANDRIT BIOTECH A/S STREET 2: FRUEBJERGVEJ 3 BOX 62 CITY: 2100 COPENHAGEN STATE: G7 ZIP: 0 BUSINESS PHONE: 45 39179840 MAIL ADDRESS: STREET 1: DANDRIT BIOTECH A/S STREET 2: FRUEBJERGVEJ 3 BOX 62 CITY: 2100 COPENHAGEN STATE: G7 ZIP: 0 FORMER COMPANY: FORMER CONFORMED NAME: Putnam Hills Corp. DATE OF NAME CHANGE: 20110810 10-Q 1 f10q0315_dandritbio.htm QUARTERLY REPORT

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 000-54478

DanDrit Biotech USA, Inc.

(Exact name of registrant as specified in its charter)

Delaware		45-2559340
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

DanDrit Biotech A/S

Fruebjergvej 3 Box 62

2100 Copenhagen, Denmark

(Address of principal executive offices)

+45 39179840

(Registrant’s telephone number, including area code)

DanDrit Biotech USA, Inc.

c/o Lone Degn

Fruebjergvej 3

2100 Copenhagen, Denmark

+45 30127206

(Name, address, including zip code, and telephone number, including area code, of agent for service)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated file. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING

THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐.

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 9,533,290 shares of common stock, par value $.0001 per share (including 185,053 shares of common stock reserved for issuance to the Non-Consenting Shareholders (as defined below) and deemed issued and outstanding for accounting purposes), outstanding as of May 11, 2015.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

- INDEX -

		Page
PART I – FINANCIAL INFORMATION:

Item 1.	Financial Statements (Unaudited):	1

	Consolidated Balance Sheets as of March 31, 2015 (Unaudited) and December 31, 2014	2

	Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2015 and 2014	3

	Consolidated Statements of Comprehensive Loss (Unaudited) for the Three Months Ended March 31, 2015 and 2014	4

	Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2015 and 2014	5

	Notes to the Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

Item 4.	Controls and Procedures	21

PART II – OTHER INFORMATION:

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22

Item 3.	Defaults Upon Senior Securities	22

Item 4.	Mine Safety Disclosures	22

Item 5.	Other Information	22

Item 6.	Exhibits	23

Signatures		24

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and in accordance with the instructions for Form 10-Q. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, the financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

The results for the period ended March 31, 2015 are not necessarily indicative of the results of operations for the full year. These financial statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Form 10K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission on March 31, 2015.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

CONSOLIDATED BALANCE SHEETS

	(Unaudited)
	March 31,			December 31,
	2015			2014
ASSETS

CURRENT ASSETS:
Cash	$	3,434,935		$	3,008,831
Cash held in escrow		-			2,029,502
Other Receivables		41,120			8,016
Total Current Assets		3,476,055			5,046,349

PROPERTY AND EQUIPMENT, Net accumulated Depreciation		-			-

OTHER ASSETS
Definite Life Intangible Assets		161,062			186,414
Deposits		6,326			7,146
Total Other Assets		167,388			193,560
TOTAL ASSETS	$	3,643,443		$	5,239,909

LIABILITIES AND STOCKHOLDER'S EQUITY

CURRENT LIABILITIES:

Notes Payable - Related Party	$	99,305		$	99,951
Accounts Payable		622,187			711,449
Accounts Payable - Related Party		200,857			212,438
Accrued Expenses		49,619			733,826
Total Current Liabilities		971,968			1,757,664

Total Liabilities		971,968			1,757,664

STOCKHOLDER’S EQUITY:
Preferred stock, $.0001 par value; 10,000,000 shares authorized; none issued and outstanding		-			-
Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at March 31, 2015 and December 31, 2014, respectively		953			953
Additional paid-in capital		25,098,050			25,098,050
Accumulated Deficit		(23,145,352	)		(21,892,007	)
Other Comprehensive Income, net		717,824			275,249
Total Stockholder’s Equity		2,671,475			3,482,245

TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY	$	3,643,443			5,239,909

See accompanying notes to the unaudited financial statements.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

CONSOLIDATED STATEMENT OF OPERATIONS

	(Unaudited) For the Three Months Ended
	March 31,
	2015			2014

Revenues	$	-		$	-

Cost of Goods Sold		44,622			17,739

Gross (Loss)		(44,622	)		(17,739	)

Operating Expenses
General and Administrative Expenses		372,996			326,428
Research and development expenses		151,813			-
Depreciation and Amortization		4,055			6,794
Consulting Expenses		291,998			61,145
Total Operating Expense		820,862			394,367

(LOSS) FROM OPERATIONS		(865,484	)		(412,106	)

Other Income (Expense)
Interest (expense)		(1,540	)		(13,999	)
(Loss) on Currency Transactions		(392,474	)		-
Interest and Other Income		6,153			51
Total Other Income (Expense)		(387,861	)		(13,948	)

(Loss) Before Income Taxes		(1,253,345	)		(426,054	)

Income Tax Expense (Benefit)		-			-

NET (LOSS)	$	(1,253,345	)	$	(426,054	)

BASIC AND DILUTED LOSS PER SHARE	$	(0,13	)	$	(0.06	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		9,553,290			6,880,278

See accompanying notes to the unaudited financial statements.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

STATEMENTS OF OTHER COMPREHENSIVE LOSS

(Unaudited)

	(Unaudited)
	For the Three
	Months Ended March 31,
	2015			2014

Net Loss	$	(1,253,345	)	$	(426,054	)
Currency Translation, Net of Taxes		442,575			(3,354	)

Other Comprehensive Loss	$	(810,770	)	$	(429,408	)

See accompanying notes to the unaudited financial statements.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

CONSOLIDATED STATEMENT OF CASH FLOWS

	(Unaudited) For the Three Months Ended March 31,
	2015			2014

NET (LOSS)	$	(1,253,345	)	$	(426,054	)

ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and Amortization		25,352			6,794
Accrued Interest on Notes Payable - Related Party		1,540			-
CHANGES IN ASSETS AND LIABILITIES:
(Increase) Decrease in Other Receivables		(33,104	)		(44,256	)
(Increase) Decrease in Prepaid Expenses/Deposits		820			8,047
Increase (Decrease) in Accounts Payable		(89,262	)		19,674
Increase (Decrease) in Accounts Payable – Related Party		(11,581	)		-
Increase (Decrease) in Accrued Expenses		(684,207	)		(1,951	)

Total Adjustments		(790,442	)		(11,692	)

NET CASH USED IN OPERATING ACTIVITIES		(2,043,787	)		(437,746	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of Equipment		-			(41,498	)
Net (Increase) Decrease in Cash Held in Escrow		2,029,502			(346,501	)
Purchase of Intangible Assets		-			(7,907	)

NET CASH USED BY INVESTING ACTIVITIES		2,029,502			(395,906	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Notes Payable – Related Party		-			865,976

NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES		-			865,976

Gain (Loss) on Currency Translation		440,389			3,354

NET INCREASE (DECREASE) IN CASH		426,104			35,678

CASH, BEGINNING OF PERIOD		3,008,831			18,794

CASH, END OF PERIOD	$	3,434,935		$	54,472

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the periods for:
Interest	$	-		$	-
Income Taxes	$	-		$	-

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
For the three months ended March 31, 2015:
None
For the three months ended March 31, 2014:
None

See accompanying notes to the financial statements.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and 2014 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2014 audited financial statements. The results of operations for the periods ended March 31, 2015 and 2014 are not necessarily indicative of the operating results for the full year.

Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) (formerly Putnam Hills Corp) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.

DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) a 96,92% owned subsidiary of the Company. The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology.

Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes.

Consolidation — For the three months ended March 31, 2015 and 2014, the consolidated financial statements include the accounts and operations of the DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation.

Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending March 31, 2015 and 2014. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in the United States in excess of federally insured amounts of $3,073,967 at March 31, 2015, and had $2,508,759 held in financial institutions in the United States in excess of federally insured amounts at December 31, 2014.

Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).

Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

Revenue Recognition and Sales — The Company’s sales of its MCV colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.

Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.

Research and Development Cost — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development costs were included in operating expenses for the three month periods ended March 31, 2015 and 2014, totaled $151,813, and $0, respectively. Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.

Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●

Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

●

Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.

Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.

Recent Accounting Pronouncements — In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not anticipate that the adoption of ASU 2015-02 will have any impact on our consolidated financial statements.

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Reclassification — The financial statements for the period ended March 31, 2014 and December 31, 2014 have been reclassified to conform to the headings and classifications used in the March 31, 2015 financial statements.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 — PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at March 31, 2015 and December 31, 2014:

	Useful Life	March 31, 2015			December 31, 2014
Lab equipment and instruments	4-6	$	208,823		$	208,823
Computer equipment	4-6		60,670			60,670
			269,493			269,493
Less Accumulated Depreciation			(269,493	)		(269,493	)
Net Property and Equipment		$	-		$	-

Depreciation expense amounted to $0 and $523 for the three month period ended March 31, 2015 and 2014, respectively.

NOTE 3 — DEFINITE-LIFE INTANGIBLE ASSETS

At March 31, 2015 and December 31, 2014, definite-life intangible assets, net of accumulated amortization, consist of patents on the Company’s products and processes of $161,062 and $186,414, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three months ended March 31, 2015 and 2014 was $4,055 and $6,794. Expected future amortization expense for the years ended are as follows:

Year ending December 31,
2015	$	11,462
2016		15,366
2017		15,324
2018		15,324
2019		15,324
Thereafter		88,262
	$	161,062

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 — NOTES PAYABLE – RELATED PARTY

Notes payable to related parties consists of the following as of March 31, 2015 and December 31, 2014:

	March 31, 2015			Dec. 31, 2014
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.	$	38,235		$	38,235
Note Payable ML Group		16,777			18,963
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC		44,293			42,753
Total Notes Payable – Related Party		99,305			99,951
Less Current Maturities		(99,305	)		(99,951	)
Note Payables – Related Party Long Term	$	-		$	-

The following represents the future maturities of long-term debt as of March 31, 2015:

Year ending December 31,
2015			99,305
2016			-
2017			-
2018			-
2019			-
Thereafter			-
			99,305

On February 15, 2014 and March 18, 2014, DanDrit Denmark received DKK 2,500,000 ($461,084) and DKK 2,300,000 ($424,198) loans (the “2014 Loans”), respectively, from Paseco ApS, an entity owned by a shareholder of the Company (“Paseco”). The 2014 Loans were payable 14 days after the completion of the contemplated public offering in DanDrit USA or February 1, 2015, and accrued interest at 5% per annum. On April 29, 2014, DanDrit Denmark and Paseco entered into an amendment whereby the terms of the 2014 Loans were payable on February 1, 2015 and could be extended at the Company’s option for an additional year with an increase in the interest rate to 7.00%. As of October 17, 2014, the outstanding balance on the 2014 Loans including accrued interest was $836,830 based on the currency exchange rate of October 17, 2014. On October 17, 2014 the Company repaid the loan and interest in its entirety.

DanDrit Denmark has received an unsecured loan facility from Sune Olsen Holding ApS (“Sune Olsen Holding”), a shareholder of the Company, with a goal of ensuring financing until new equity is invested in the Company. Under the loan facility DanDrit Denmark has received the following amounts: on November 11, 2013 DKK 1,500,000 ($276,651), on November 20, 2013 DKK 405,000 ($74,696), and on December 2, 2013 DKK 900,000 ($165,990). The loans were due May 1, 2014 and accrued interest at 5% per year. During March 2014, the Company extended maturity date of the loans with Sune Olsen Holdings from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014, the Company repaid the loan facility and interest thereon.

DanDrit Denmark has received an unsecured loan from Sune Olsen, managing member of Sune Olsen Holding, with a goal of ensuring financing until new equity is invested in the Company. The loan in the amount of DKK 1,000,000 ($184,434) was issued on December 20, 2013. The loan was due May 1, 2014 and accrued interest of 5% per year. During March 2014, the Company extended the maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014 the Company repaid the unsecured loan and interest thereon.

During March 2014, the Company received a 2,000,000 DKK letter of support from Paseco committing to the additional financing to ensure continued operations until February 1, 2015. The letter expired on February 1, 2015.

As of March 31, 2015, the outstanding balance of $38,235 for professional fees paid by a related party and amounts advanced to the Parent are reported as loan payable - related party. The $38,235 loan payable was acquired in the reverse acquisition. The amount is unsecured, non-interest bearing and has no stipulated repayment terms.

A 6% Promissory Note payable (the “Note”) to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired by the Company in the reverse acquisition, payable on February 12, 2014 upon the completion date of the Share Exchange. As of March 31, 2015 and 2014, the outstanding balance on the Note, including accrued interest, was $44,293 and $41,945. During the three months ended March 31, 2015 and 2014 the Company recorded related party interest on the Note of $579, and $579.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 — LEASES

Operating Leases — The Company leases laboratory and production space under operating lease agreements which can be cancelled with 3 month notice. The lease calls for monthly payments of DKK 6,000 (approximately $906 at March 31, 2015).

Lease expense charged to operations was $11,918 and, $7,255 for the three months ended March 31, 2015 and 2014, respectively.

On March 27, 2014, the Company entered into an operating lease agreement for office space from a related party. The Lease calls for monthly payments of DKK 10,000 (approximately $1,579), increasing to DKK 20,000 (approximately $3,393) on July 1, 2014. The lease can be terminated by either the Company or the landlord by giving the other 3 months notice. The Company gave notice terminating the lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.

NOTE 6 — INCOME TAXES

The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined.

As of March 31, 2015, the Company had net operating loss carry-forwards of approximately $2,416,813 for Danish tax purposes which do not expire and net operating loss carry-forwards of approximately $179,661 for U.S. Federal Tax purposes which expire through 2034, a portion of which shall be limited due to the change in control of the Parent.

The Company files U.S. and Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2011 and 2008, respectively.

The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at March 31, 2015 and December 31, 2014:

	March 31, 2015			December 31, 2014
Excess of Tax over book depreciation Fixed assets	$	12,711		$	12,711
Excess of Tax over book depreciation Patents		52,041			52,041
Net Operating Loss Carry forward		2,416,813			2,380,106
Valuation Allowance		(2,481,565	)		(2,444,858	)
Total Deferred Tax Asset (Liabilities)	$	-		$	-

In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meet the more-likely-than-not condition for recognition and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 — INCOME TAXES (Continued)

A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows at March 31, 2015 and 2014:

	March 31, 2015			March 31, 2014
Computed Tax at Expected Statutory Rate	$	(277,657	)	$	(144,858	)
Non-US Income Taxed at Different Rates		97,996			44,858
Non-Deductable expenses		-			-
Valuation allowance		179,661			100,000
Income Tax Expense	$	-		$	-

The components of income tax expense (benefit) from continuing operations for the three months ended March 31, 2015 and 2014 consisted of the following

	2015			2014
Current Tax Expense
Danish Income Tax	$	-		$	-
Total Current Tax Expense		-			-
Deferred Income Tax Expense (Benefit)
Excess of Tax over Book Depreciation Fixed Assets		-			-
Excess of Tax over Book Depreciation Patents		-			-
Net Operating Loss Carry forwards		(179,661	)		(100,000	)
Change in the Valuation allowance		179,661			100,000
Total Deferred Tax Expense	$	-		$	-

Deferred income tax expense / (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

NOTE 7 — LOSS PER SHARE

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of potential dilutive common stock for the three month period ended March 31, 2015, and 2014:

	For the Three Months Ended
	March 31,
	2015			2014
Net (Loss)		(1,253,345	)		(426,054	)
Weighted average number of common shares used in basic earnings per share		9,533,290			6,880,278
Effect of dilutive securities, stock options and warrants		-			-
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share		9,533,290			6,880,278

For the three months ended March 31, 2015 and 2014, the Company had no common stock equivalents.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 — STOCKHOLDERS’ EQUITY

Common Stock — The Company has 100,000,000 authorized shares of Common stock $0.0001. As of March 31, 2015 and December 31, 2014 there were 9,533,290 shares issued and outstanding, respectively.

Common Stock Issuances — On December 31, 2014, the Company received $2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.

During the year ended December 31, 2014, pursuant to the Company’s offering of up to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for gross proceeds of $5,466,450 less offering costs of $156,360.

Share Exchange Agreement/Reverse Acquisition — On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), we completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA’s common stock, par value $.0001 per share (the “Common Stock”) for an aggregate of 6,000,000 shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.

On February 11, 2014 1,400,000 and 40,000 common shares of the Company were issued for consulting and legal services valued at $5 per share or $7,000,000 and $200,000, respectively. These shares were issued by the Company prior to the reverse acquisition of DanDrit Denmark and the $7,200,000 was closed out to additional paid in capital in connection with the recapitalization of DanDrit Denmark.

On February 12, 2014, upon the closing of the Share Exchange, the Company and the its majority shareholder immediately prior to the closing agreed to cancel up to 4,400,000 shares of our common stock. In addition, following the closing of the Share Exchange, DanDrit Biotech USA, Inc., a wholly owned subsidiary of the Company merged with and into the Company, thereby changing the Company’s name to “DanDrit Biotech USA, Inc.”

Voting — Holders of the Company’s common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 — STOCKHOLDERS’ EQUITY (Continued)

Dividends — Holders of the Company’s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.

Liquidation Rights — In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of the Company’s common stock will be entitled to share ratably in the distribution of any of our remaining assets.

NOTE 9 — COMMITMENTS AND CONTINGENCIES

Shares held for non-consenting shareholders – In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements.

Clinical Trial Agreement - On October 1, 2014 the Company’s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.

Patient Name Use Program — On December 16, 2013, DanDrit Denmark entered into an agreement with a Dutch company (the “MCV Partner”) regarding a Patient Name Use Program (PNU) for the Company’s MCV. This program will allow DanDrit Denmark to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner. The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmaco vigilance. The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 days written notice.

Food and Drug Administration (FDA) — The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company’s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended.

Product liability — The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company’s operations.

Employment Agreements — The Company and its Subsidiary have employment agreements with officers of the Company.

Contingencies — The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.

Consulting Agreement — As of December 11, 2014, the Company entered into an agreement with Northern Biotech Fund SARL, an entity controlled by a shareholder of the Company. Northern Biotech Fund SARL provides consulting services to the Company in connection with planning and structuring a fund raising for the Company. In 2014 consultancy expenses were $148,395 and for the three month ended March 31, 2015 the consultancy expenses were $240,000.

DANDRIT BIOTECH USA, INC.

(FORMERLY PUTNAM HILLS CORP.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10 — Related Party Transactions

During the three month ended March 31, 2015 and 2014, the Company entered into various notes payable with shareholders of the Company (See Note 4).

On March 27, 2014 the Company entered into an operating lease agreement for office space from a shareholder of the Company (See Note 5). During the three months ended March 31, 2015 and 2014, the Company paid the related party DKK60,000 and DKK 0 or approximately $3,019 and $0, respectively.

During the three months ended March 31, 2015 and 2014, a law firm partially owned by the Company’s Chairman of the Board of Directors provided legal services of $60,381 and $100,912, respectively, to the Company. At March 31, 2015 and December 31, 2014, the Company had a payable to the firm in the amount of $200,857 and $212,438, respectively.

As of December 11, 2014, the Company entered into an agreement with Northern Biotech Fund SARL, an entity controlled by a shareholder of the Company. Northern Biotech Fund SARL provides consulting services to the Company in connection with planning and structuring a fund raising for the Company. During the three months ended March 31, 2015 and 2014 the Company expensed $240,000 and $0 under the agreement.

NOTE 11 — SUBSEQUENT EVENTS

The Company’s management reviewed material events through May 13, 2015.

On April 28, 2015 Robert Wolfe resigned as Chief Financial Officer of the Company and on May 1st, the Board appointed Lone Degn as the Chief Financial Officer of the Company.

On April 28, 2015 the Company entered into a service agreement with Fondazione Giscad per la Ricerca sui Tumori to support Dandrit in a clinical trial to be conducted in Italy.

On April 1st, 2015 DanDrit entered into a project agreement with IRCCS Azienda Ospedaliera Univeritaria San Martino IST- Istituto Nazionale per la ricerca sul Cancro to perform certain services with respect to a multicenter clinical trial.

On April 23, 2015, the Company entered into a collaboration agreement with Riyadh Pharma in Saudi Arabia to promote cooperation in the manufacturing and marketing of DanDrit's dendritic cell cancer vaccine.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statement Notice

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of DanDrit Biotech USA, Inc. (formerly Putnam Hills Corp.) (“we”, “DanDrit USA”, “us”, “our”, the “Parent” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company's plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

Description of Business

We are a biopharmaceutical company developing and commercializing targeted oncology vaccines that address major medical needs to advance cancer care. We are developing a polytopic (mainly MAGE-A family) dendritic cell vaccine cancer immuno therapy, which address patient populations of cancer survivors to prevent recurrence. Our lead product candidate, MCV, is a dendritic cell vaccine that could strengthen the immune response in colorectal cancer patients. In December 2013, DanDrit Denmark entered into an agreement with a Dutch company that provides access to non-registered medicines for patients with life threatening diseases, regarding a Patient Name Use Program (PNU) for MCV. This program will allow us to sell to the Dutch company MCV for one year of treatment (10 vaccines) to cancer patients.

The Company was originally incorporated in Delaware on January 18, 2011 under the name “Putnam Hills Corp.” as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. We filed a Registration Statement on Form 10 with the U.S. Securities and Exchange Commission (the “SEC”) on August 12, 2011.

On February 12, 2014, pursuant to the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA acquired approximately 100% of the issued and outstanding capital stock of DanDrit BioTech A/S, a Danish corporation (“DanDrit Denmark”) and as a result became the parent of DanDrit Denmark (the “Share Exchange”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of the Parent outstanding. The Parent and a shareholder agreed to cancel 4,400,000 shares of its common stock and issued 1,440,000 shares of common stock for legal and consulting services related to the Share Exchange and a future financing. At the time of the Share Exchange, the outstanding shares of the common stock of DanDrit Denmark were exchanged for 1.498842 shares of Parent’s common stock, for a total of 6,000,000 shares of common stock (including 185,053 shares of common stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the Non-Consenting Shareholders, deemed issued and outstanding for accounting purposes). Following the closing of the Share Exchange, DanDrit Biotech USA, Inc., the wholly owned subsidiary of the Company, merged with and into the Company, thereby changing the Company’s name to “DanDrit Biotech USA, Inc.”

On February 14, 2014, the Company filed a registration statement on Form S-1 (the “Registration Statement”) to register 2,400,000 shares of common stock at a purchase price of $5.00 per share in an initial public offering of up to an aggregate of $12,000,000 in gross proceeds. The Registration Statement was declared effective by the SEC on August 14, 2014 (the “Offering”). As of March 31, 2015, in connection with the Offering, the Company issued and sold an aggregate 1,493,290 shares of common stock for gross proceeds of $5,466,450 and total aggregate gross proceeds of $5,310,089 raised in the Offerings.

On December 31, 2014, the Company received $2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.

On September 24, 2014, DanDrit Denmark signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.

The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of section 404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of Sections 14A(a) and (b) of the Securities Exchange Act of 1934 to hold a nonbinding advisory vote of shareholders on executive compensation and any golden parachute payments not previously approved.

The Company has also elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

We will remain an “emerging growth company” until the earliest of (1) the last day of the fiscal year during which our revenues exceed $1 billion, (2) the date on which we issue more than $1 billion in non-convertible debt in a three year period, (3) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement filed pursuant to the Securities Act of 1933, as amended, or (4) when the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter. To the extent that we continue to qualify as a “smaller reporting company”, as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures; and (3) the requirement to provide only two years of audited financial statements, instead of three years.

Liquidity and Capital Resources

We have historically satisfied our capital and liquidity requirements through funding from our largest shareholders and the issuance of convertible notes, which over time have been converted into shares of our common stock. On December 31, 2014, the Company received $2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share. During the year ended December 31, 2014, pursuant to the Company’s offering up to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for gross proceeds of $5,466,450 less offering costs of $156,360. The Company used part of the proceeds to repay notes payable and related accrued interest totaling $1,432,213.

As of March 31, 2015 the Company had $3,434,935 in cash and working capital of $2,504,087 as compared to December 31, 2014, when the Company had $5,038,333 in cash and cash held in escrow and working capital of $3,288,685. The decrease in cash and working capital is primarily due to the Company’s efforts to secure financings through equity offering and expenses for research and development attributable to the Company engaging an entity to perform Phase IIb/III clinical trial of MelCancerVac™.

The following is a summary of the Company's cash flows provided by (used in) operating, investing, and financing activities:

	Three Months Ended March 31, 2015			Three Months Ended March 31, 2014
Net Cash (Used by) Operating Activities	$	(2,043,787	)	$	(437,746	)
Net Cash (Used by) Investing Activities		2,029,502			(395,906	)
Net Cash Provided by Financing Activities	$	-		$	865,976
(Gain) Loss on Currency Translation		440,389			3,354
Net Increase (Decrease) in Cash and Cash Equivalents	$	426,104		$	35,678

As of March 31, 2015, the Company is dependent upon the receipt of capital investment or other financing from related parties or other sources to fund its ongoing operations.

On December 31, 2014, the Company received $2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.

During the year ended December 31, 2014, pursuant to the Company’s offering up to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for gross proceeds of $5,466,450 less offering costs of $156,360.

During 2014, the Company obtained $814,291 in related party notes payable. The Company repaid these notes plus notes previously obtain totaling $1,432,213 with proceeds from the sale of common shares during 2014.

As a result, we believe that our cash flow, together with the existing lines of credit and other potential sources of funds, such as loans from related parties, will be sufficient to fund our anticipated working capital needs and capital spending requirements for the next 12 months.

We may also need additional funds for possible future strategic acquisitions of businesses, products or technologies complementary to our business. If additional funds are required, we may raise such funds from time to time through public or private sales of equity or debt securities. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact our growth plans and our financial condition and results of operations.

Results of Operations

The Company’s sole source of operations is through its wholly owned Danish subsidiary, DanDrit Biotech A/S (“DanDrit Denmark”). There can be no assurance that DanDrit Denmark will be successful in obtaining US Food and Drug Administration approval of its colorectal vaccine, MCV, nor produce sufficient revenues from MCV to sustain operations. It is management's assertion that these circumstances may hinder the Company's ability to continue as a going concern. The Company’s plan of operation for the next twelve months shall be to continue its efforts to raise capital and revenues associated with its MCV product.

Three months ended March 31, 2015 compared to the three months ended March 31, 2014

The following table sets forth our revenues, expenses and net income for the three months ended March 31, 2015 and 2014. The financial information below is derived from our unaudited condensed consolidated financial statements.

	For the Three Months Ended
	March 31,
	2015			2014			$ Change			% Change
Revenues	$	-		$	-		$	-			-	%

Cost of Goods Sold		44,622			17,739			26,883			152	%

Gross (Loss)		(44,622	)		(17,739	)		(26,883	)		152	%

Operating Expenses
General and Administrative Expenses		372,996			326,428			46,568			14	%
Research and Development Expenses		151,813			-			151,813			-
Depreciation and Amortization		4,055			6,794			(2,739	)		(40	)%
Consulting Expenses		291,998			61,145			230,853			378	%
Total Operating Expense		820,862			394,367			426,495			108	%

(LOSS) FROM OPERATIONS		(865,484	)		(412,106	)		(453,378	)		110	%

Other Income (Expense)
Interest (expense)		(1,540	)		(13,999	)		12,459			(89	)%
Gain (loss) on Currency Transactions		(392,474	)		-			(392,474	)
Interest Income		6,153			51			6,102			11,965	%
Total Other Income (Expense)		(387,861	)		(13,948	)		(373,913	)		2,681	%

(Loss) Before Income Taxes		(1,253,345	)		(426,054	)		(827,291	)		194	%

Income Tax Expense (Benefit)		-			-			-			-

NET (LOSS)	$	(1,253,345	)	$	(426,054	)	$	(827,291	)		194	%

BASIC AND DILUTED LOSS PER SHARE	$	(0.13	)		(0.06	)	$	(0.07	)		136	%

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED		9,533,290			6,880,278

Revenues

Revenues from operations for the three months ended March 31, 2015 and March 31, 2014 were $ 0 and $0, respectively. There were no sales of lysate under a compassionate use program by DanDrit Denmark during the three months ended March 31, 2015 and 2014.

Cost of Goods Sold

Our cost of goods sold was $44,622 and $17,739 during the three months ended March 31, 2015 and 2014, respectively, and was primarily associated with the production of lysate.

Gross Loss

Gross loss for the three months ended March 31, 2015 was $44,622 compared to gross loss of $17,739 for same period in 2014. The increase in the gross loss was due to lower sales and higher cost of goods sold for the three months ended March 31, 2015.

Expenses

Our operating expense for the three months ended March 31, 2015 totaled $820,862 representing an increase of $426,495 or 108% compared to $394,367 for the three months ended March 31, 2014. The largest contributors to the increase in operating expenses were fees associated with raising funds through a private offering in December 2014, audit expenses, salaries and research and development costs of $240.000, $23,225, $40,139 and $151,813 respectively, and a decrease in legal expenses of $59,080.

General and administrative expenses for the three months ended March 31, 2015 and 2014 were $372,996 and $326,428, respectively, representing an increase of $46,568, or 14%. This increase was due primarily to costs associated with the audit and salary expenses due to the resignation of the previous Chief Financial Officer. General and administrative expenses includes office rental, website management, insurance, and salaries.

Amortization expenses for the three months ended March 31, 2015 and 2014 were $4,055 and $6,794, respectively, related to the amortization of patents.

Research and Development for the three months ended March 31, 2015 and 2014 were $151,813 and $0, respectively. The difference in research and development expenses is attributable to the Company engaging an entity to perform Phase IIb/III clinical trial of MelCancerVac™.

Consulting expenses for the three months ended March 31, 2015 and 2014 were $291,998 and $61,145, respectively. The difference in consulting expenses is primarily due to fees associated with raising funds through a private offering in December 2014.

Other income (expense) net for the three months ended March 31, 2015 and March 31, 2014 were $(387,861) and $(13,948), respectively. Other expense is associated with interest on related party loans and losses on currency transactions.

Net Loss

Net loss for the three months ended March 31, 2015 was $(1,253,345) or $(0.13) per share comprised of legal, accounting, audit and other professional service fees incurred in relation to the preparation and filing of the Company’s periodic reports and general and administrative expenses, compared to a net loss of $(426,054) or $(0.06) per share for the three months ended March 31, 2014 comprised of general and administrative expenses and interest expense, representing an increase of $(827,291) or 194%. In 2015, the losses increased is primarily due to the Company’s efforts to secure financings through debt and equity offerings and the Company engaging an entity to perform Phase IIb/III clinical trial of MelCancerVac™.

Cash Flows

Cash used by operating activities for the three months ended March 31, 2015 was $2,043,787, representing an increase of $1,606,041 or approximately 366% compared to cash used by operating activities of $437,746 for the three months ended March 31, 2014. The net cash used by operating activities was primarily due to fund raising efforts of the Company and the operations of DanDrit Denmark.

Assets

Total assets as of March 31, 2015 were $3,643,443 compared to $5,239,909 as of December 31, 2014. Total current liabilities decreased to $971,968 as of March 31, 2015 compared to $1,757,664 as of December 31, 2014. The decreases in total assets and in total current liabilities were mainly due to a decrease in cash held in escrow and a decrease in accrued expenses as of March 31, 2015, respectively.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Emerging Growth Company

As an “emerging growth company” under the JOBS Act, the Company has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

Significant Accounting Policies and Critical Accounting Estimates

The methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. In addition, Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are not choosing to “opt out” of this provision. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. As a result of our election, not to “opt out” of Section 107, DanDrit’s financial statements may not be comparable to companies that comply with public company effective dates.

For a full explanation of our accounting policies, see Note 1 to the financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules, regulations and related forms, and that such information is accumulated and communicated to our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

As of March 31, 2015, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and our principal financial officer of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting during the quarter ended March 31, 2015 that have materially affected or are reasonably likely to materially affect our internal controls.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

There are presently no material pending legal proceedings to which the Company, any of its subsidiaries, any executive officer, any owner of record or beneficially of more than five percent of any class of voting securities is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

Item 1A. Risk Factors.

As a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934, the Company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

(a) Exhibits required by Item 601 of Regulation S-K.

Exhibit No.		Description

2.1		Share Exchange Agreement dated February 12, 2014. (2)

3.1		Certificate of Incorporation, as filed with the Delaware Secretary of State on January 18, 2011.(2)

3.2		By-laws. (3)

3.3		Articles of Association of DanDrit Denmark, as amended, dated February 26, 2004. (2)

3.4		Certificate of Ownership and Merger, dated February 12, 2014. (2)

31.1		Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.*

31.2		Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.*

32.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

32.2		Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101.INS		XBRL Instance Document*

101.SCH		XBRL Taxonomy Extension Schema*

101.CAL		XBRL Taxonomy Extension Calculation Linkbase*

101.DEF		XBRL Taxonomy Extension Definition Linkbase*

101.LAB		XBRL Taxonomy Extension Label Linkbase*

101.PRE		XBRL Taxonomy Extension Presentation Linkbase*

(1)	Filed as an exhibit to the Company’s Form 8-K filed with the SEC on August 12, 2014 and incorporated herein by reference.
(2)	Filed as an exhibit to the Company’s Form S-1 filed with the SEC on February 14, 2014 and incorporated herein by reference.
(3)	Filed as an exhibit to the Company's Registration Statement on Form 10, as filed with the SEC on August 12, 2011, and incorporated herein by this reference.

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	DanDrit Biotech USA, Inc.

Dated: May 13, 2015	By:	/s/ Eric J. Leire
		Eric J. Leire
		Chief Executive Officer (Principal Executive Officer)

Dated: May 13, 2015

By:

/s/ Lone Degn

Lone Degn

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-31.1 2 f10q0315ex31i_dandritbio.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION

I, Eric J. Leire, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended March 31, 2015 of DanDrit Biotech USA, Inc. (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2015

/s/ Eric J. Leire
Eric J. Leire
Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 f10q0315ex31ii_dandritbio.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION

I, Lone Degn, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended March 31, 2015 of DanDrit Biotech USA, Inc. (the “registrant”);

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2015

/s/ Lone Degn
Lone Degn
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 f10q0315ex32i_dandritbio.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DanDrit Biotech USA, Inc. (the “Company”) on Form 10-Q for the three months ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 13, 2015	/s/ Eric J. Leire
	Eric J. Leire
	Chief Executive Officer
	(Principal Executive Officer)

Dated: May 13, 2015	/s/ Lone Degn
	Lone Degn
	Chief Financial Officer (Principal Financial and Accounting Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 pmhs-20150331.xml XBRL INSTANCE FILE 0001527728 2011-01-18 0001527728 2011-12-31 0001527728 2012-12-31 0001527728 us-gaap:CommonStockMember 2012-12-31 0001527728 pmhs:SuneOlsenHoldingApsMember pmhs:LoanOneMember 2013-11-11 0001527728 pmhs:SuneOlsenHoldingApsMember pmhs:LoanOneMember 2013-11-20 0001527728 pmhs:SuneOlsenHoldingApsMember pmhs:LoanOneMember 2013-12-02 0001527728 2013-12-13 2013-12-16 0001527728 pmhs:SuneOlsenHoldingApsMember pmhs:LoanTwoMember 2013-12-20 0001527728 pmhs:SuneOlsenHoldingApsMember pmhs:LoanTwoMember 2013-12-10 2013-12-20 0001527728 2013-12-31 0001527728 us-gaap:CommonStockMember 2013-12-31 0001527728 2014-02-11 0001527728 2014-02-01 2014-02-11 0001527728 us-gaap:ParentCompanyMember 2014-02-01 2014-02-11 0001527728 us-gaap:ParentCompanyMember 2014-02-12 0001527728 us-gaap:CommonStockMember 2014-02-01 2014-02-12 0001527728 us-gaap:ParentCompanyMember 2014-02-01 2014-02-12 0001527728 us-gaap:CommonStockMember us-gaap:ParentCompanyMember 2014-02-01 2014-02-12 0001527728 pmhs:PasecoApsMember us-gaap:UnsecuredDebtMember 2014-02-15 0001527728 pmhs:PasecoApsMember us-gaap:UnsecuredDebtMember 2014-03-18 0001527728 pmhs:LeasedOfficeSpaceMember 2014-03-01 2014-03-27 0001527728 2014-01-01 2014-03-31 0001527728 pmhs:PasecoApsMember pmhs:LoanThreeMember 2014-01-01 2014-03-31 0001527728 pmhs:NlbditTwoZeroOneZeroEnterprisesLlcMember pmhs:LoanTenMember 2014-01-01 2014-03-31 0001527728 2014-03-31 0001527728 pmhs:PasecoApsMember pmhs:LoanThreeMember 2014-03-31 0001527728 pmhs:NlbditTwoZeroOneZeroEnterprisesLlcMember pmhs:LoanTenMember 2014-03-31 0001527728 pmhs:LeasedOfficeSpaceMember us-gaap:SubsequentEventMember 2014-06-01 2014-07-01 0001527728 us-gaap:IPOMember 2014-08-12 0001527728 us-gaap:IPOMember 2014-08-01 2014-08-12 0001527728 us-gaap:CommonStockMember us-gaap:IPOMember 2014-08-01 2014-08-12 0001527728 us-gaap:CommonStockMember 2014-08-01 2014-08-21 0001527728 2014-01-01 2014-12-31 0001527728 2014-12-31 0001527728 us-gaap:CommonStockMember 2014-12-31 0001527728 pmhs:NotePayableMlGroupMember 2014-12-31 0001527728 pmhs:LabEquipmentAndInstrumentsMember 2014-12-31 0001527728 us-gaap:ComputerEquipmentMember 2014-12-31 0001527728 pmhs:NonInterestBearingLoanPayableSunriseFinancialGroupIncMember 2014-12-31 0001527728 pmhs:SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember 2014-12-31 0001527728 2015-01-01 2015-03-31 0001527728 us-gaap:CommonStockMember 2015-01-01 2015-03-31 0001527728 pmhs:NlbditTwoZeroOneZeroEnterprisesLlcMember pmhs:LoanTenMember 2015-01-01 2015-03-31 0001527728 us-gaap:IPOMember 2015-01-01 2015-03-31 0001527728 pmhs:LeasedLaboratorySpaceMember 2015-01-01 2015-03-31 0001527728 pmhs:LabEquipmentAndInstrumentsMember us-gaap:MaximumMember 2015-01-01 2015-03-31 0001527728 pmhs:LabEquipmentAndInstrumentsMember us-gaap:MinimumMember 2015-01-01 2015-03-31 0001527728 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2015-01-01 2015-03-31 0001527728 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2015-01-01 2015-03-31 0001527728 2015-03-31 0001527728 us-gaap:CommonStockMember 2015-03-31 0001527728 us-gaap:CommonStockMember us-gaap:ParentCompanyMember 2015-03-31 0001527728 pmhs:NlbditTwoZeroOneZeroEnterprisesLlcMember pmhs:LoanTenMember 2015-03-31 0001527728 us-gaap:IPOMember 2015-03-31 0001527728 pmhs:NotePayableMlGroupMember 2015-03-31 0001527728 pmhs:LabEquipmentAndInstrumentsMember 2015-03-31 0001527728 us-gaap:ComputerEquipmentMember 2015-03-31 0001527728 pmhs:NonInterestBearingLoanPayableSunriseFinancialGroupIncMember 2015-03-31 0001527728 pmhs:SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember 2015-03-31 0001527728 pmhs:DanishTaxMember 2015-03-31 0001527728 pmhs:U.S.FederalTaxMember 2015-03-31 0001527728 2015-05-11 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure iso4217:DKK DanDrit Biotech USA, Inc. 0001527728 false --12-31 10-Q 2015-03-31 Q1 2015 Smaller Reporting Company 9533290

18794

54472

3008831

3434935

2029502

8016

41120

5046349

3476055

186414

161062

7146

6326

193560

167388

5239909

3643443

99951

18963000

38235

42753

99305

16777

38235

44293

711449

622187

212438

200857

733826

49619

1757664

971968

1757664

971968

953

25098050

-21892007

-23145352

275249

717824

3482245

2671475

5239909

3643443

0.0001

10000000

0.0001

100000000

9533290

17739

44622

-17739

-44622

326428

372996

151813

6794

4055

61145 291998

394367

820862

-412106

-865484

13999

1540

-392474

6153

-13948

-387861

-426054

-1253345

-426054

-1253345

-0.06

-0.13

6880278

9553290

3354

-442575

-429408

-810770

6794

25352

1540

44256

33104

-8047 -820

19674

-89262

-11581

-1951

-684207

-11692

-790442

-437746

-2043787

-346501 2029502

7907

-395906

2029502

865976

156360

865976

3354

440389

35678

426104

<div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and 2014 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2014 audited financial statements. The results of operations for the periods ended March 31, 2015 and 2014 are not necessarily indicative of the operating results for the full year. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) (formerly Putnam Hills Corp) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) a 96,92% owned subsidiary of the Company. The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Consolidation — For the three months ended March 31, 2015 and 2014, the consolidated financial statements include the accounts and operations of the DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending March 31, 2015 and 2014. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in the United States in excess of federally insured amounts of $3,073,967 at March 31, 2015, and had $2,508,759 held in financial institutions in the United States in excess of federally insured amounts at December 31, 2014. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3). <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue Recognition and Sales — The Company’s sales of its MCV colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Research and Development Cost — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development costs were included in operating expenses for the three month periods ended March 31, 2015 and 2014, totaled $151,813, and $0, respectively. Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 48px; text-align: justify; line-height: 15.33px;"> </td> <td style="width: 24px; text-align: justify; line-height: 15.33px;">●</td> <td style="text-align: justify; line-height: 15.33px;">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 48px; text-align: justify; line-height: 15.33px;"> </td> <td style="width: 24px; text-align: justify; line-height: 15.33px;">●</td> <td style="text-align: justify; line-height: 15.33px;">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 48px; text-align: justify; line-height: 15.33px;"> </td> <td style="width: 24px; text-align: justify; line-height: 15.33px;">●</td> <td style="text-align: justify; line-height: 15.33px;">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Recent Accounting Pronouncements — In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not anticipate that the adoption of ASU 2015-02 will have any impact on our consolidated financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Reclassification — The financial statements for the period ended March 31, 2014 and December 31, 2014 have been reclassified to conform to the headings and classifications used in the March 31, 2015 financial statements. </div>

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">NOTE 5 — LEASES <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Operating Leases — The Company leases laboratory and production space under operating lease agreements which can be cancelled with 3 month notice. The lease calls for monthly payments of DKK 6,000 (approximately $906 at March 31, 2015). <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Lease expense charged to operations was $11,918 and, $7,255 for the three months ended March 31, 2015 and 2014, respectively. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On March 27, 2014, the Company entered into an operating lease agreement for office space from a related party. The Lease calls for monthly payments of DKK 10,000 (approximately $1,579), increasing to DKK 20,000 (approximately $3,393) on July 1, 2014. The lease can be terminated by either the Company or the landlord by giving the other 3 months notice. The Company gave notice terminating the lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">NOTE 6 — INCOME TAXES <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of March 31, 2015, the Company had net operating loss carry-forwards of approximately $2,416,813 for Danish tax purposes which do not expire and net operating loss carry-forwards of approximately $179,661 for U.S. Federal Tax purposes which expire through 2034, a portion of which shall be limited due to the change in control of the Parent. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company files U.S. and Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2011 and 2008, respectively. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at March 31, 2015 and December 31, 2014: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March 31, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December 31,  2014</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-stretch: normal;">Excess of Tax over book depreciation Fixed assets</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">12,711</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">12,711</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Excess of Tax over book depreciation Patents</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">52,041</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">52,041</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Net Operating Loss Carry forward</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">2,416,813</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">2,380,106</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Valuation Allowance</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(2,481,565</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(2,444,858</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-stretch: normal;">Total Deferred Tax Asset (Liabilities)</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meet the more-likely-than-not condition for recognition and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">   <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows at March 31, 2015 and 2014: <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March 31, 2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March 31, 2014</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-stretch: normal;">Computed Tax at Expected Statutory Rate</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">(277,657</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(144,858</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Non-US Income Taxed at Different Rates</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">97,996</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">44,858</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Non-Deductable expenses</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Valuation allowance</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">179,661</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">100,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt; font-stretch: normal;">Income Tax Expense</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The components of income tax expense (benefit) from continuing operations for the three months ended March 31, 2015 and 2014 consisted of the following <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="font-size: 10pt;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2015</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Current Tax Expense</td> <td style="font-size: 10pt;"> </td> <td style="text-align: center; font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="text-align: center; font-size: 10pt;" colspan="2"> </td> <td style="font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-stretch: normal;">Danish Income Tax</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Total Current Tax Expense</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Deferred Income Tax Expense (Benefit)</td> <td style="font-size: 10pt;"> </td> <td style="text-align: left; font-size: 10pt;"> </td> <td style="text-align: right; font-size: 10pt;"> </td> <td style="text-align: left; font-size: 10pt;"> </td> <td style="font-size: 10pt;"> </td> <td style="text-align: left; font-size: 10pt;"> </td> <td style="text-align: right; font-size: 10pt;"> </td> <td style="text-align: left; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;">Excess of Tax over Book Depreciation Fixed Assets</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;">Excess of Tax over Book Depreciation Patents</td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; width: 1179px; text-align: left; padding-left: 9pt; font-stretch: normal;">Net Operating Loss Carry forwards</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">(179,661</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">)</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(100,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #cceeff;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-stretch: normal;">Change in the Valuation allowance</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">179,661</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">100,000</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Total Deferred Tax Expense</td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td> <td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Deferred income tax expense / (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

<div> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) (formerly Putnam Hills Corp) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) a 96,92% owned subsidiary of the Company. The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology. </div>

Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, <font style="font: 13.33px/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 48px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; background-color: white; -webkit-text-stroke-width: 0px;">including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”)<font style="font: 13.33px/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 48px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; background-color: white; -webkit-text-stroke-width: 0px;">, and deemed issued and outstanding for accounting purposes.

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending March 31, 2015 and 2014. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.</div>

<div>Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in the United States in excess of federally insured amounts of $3,073,967 at March 31, 2015, and had $2,508,759 held in financial institutions in the United States in excess of federally insured amounts at December 31, 2014.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue Recognition and Sales — The Company’s sales of its MCV colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.</div>

<div>Research and Development Cost — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development costs were included in operating expenses for the three month periods ended March 31, 2015 and 2014, totaled $151,813, and $0, respectively. Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/15.33px 'times new roman', times, serif; width: 48px; text-align: justify; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/15.33px 'times new roman', times, serif; width: 24px; text-align: justify; font-size-adjust: none; font-stretch: normal;">●</td><td style="font: 10pt/15.33px 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/15.33px 'times new roman', times, serif; width: 48px; text-align: justify; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/15.33px 'times new roman', times, serif; width: 24px; text-align: justify; font-size-adjust: none; font-stretch: normal;">●</td><td style="font: 10pt/15.33px 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"><td style="font: 10pt/15.33px 'times new roman', times, serif; width: 48px; text-align: justify; font-size-adjust: none; font-stretch: normal;"> </td><td style="font: 10pt/15.33px 'times new roman', times, serif; width: 24px; text-align: justify; font-size-adjust: none; font-stretch: normal;">●</td><td style="font: 10pt/15.33px 'times new roman', times, serif; text-align: justify; font-size-adjust: none; font-stretch: normal;">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.</div>

<div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.</div>

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">Useful Life</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March 31,  2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December 31,  2014</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; font-stretch: normal;">Lab equipment and instruments</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 173px; text-align: center; font-stretch: normal;">4-6</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">208,823</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">208,823</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Computer equipment</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;">4-6</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">60,670</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">60,670</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="text-align: right; font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">269,493</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">269,493</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt; font-size: 10pt;"> </td><td style="text-align: right; padding-bottom: 1.5pt; font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(269,493</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(269,493</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Net Property and Equipment</td><td style="padding-bottom: 4pt; font-size: 10pt;"> </td><td style="text-align: right; padding-bottom: 4pt; font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr></table>

<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Year ending December 31,</td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;" colspan="2"> </td><td style="font-size: 10pt;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1379px; text-align: left; font-stretch: normal;">2015</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">11,462</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">15,366</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">15,324</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2018</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">15,324</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2019</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">15,324</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Thereafter</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">88,262</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">161,062</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr></table>

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">March 31,  2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Dec. 31,  2014</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-stretch: normal;">Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">38,235</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">38,235</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Note Payable ML Group</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">16,777</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">18,963</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">44,293</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">42,753</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Total Notes Payable – Related Party</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">99,305</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">99,951</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-stretch: normal;">Less Current Maturities</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(99,305</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(99,951</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Note Payables – Related Party Long Term</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr></table>

<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Year ending December 31,</td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;" colspan="2"> </td><td style="font-size: 10pt;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1379px; text-align: left; font-stretch: normal;">2015</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">99,305</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2017</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2018</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">2019</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Thereafter</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">99,305</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr></table>

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2014</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Current Tax Expense</td><td style="font-size: 10pt;"> </td><td style="text-align: center; font-size: 10pt;" colspan="2"> </td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="text-align: center; font-size: 10pt;" colspan="2"> </td><td style="font-size: 10pt;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-stretch: normal;">Danish Income Tax</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Total Current Tax Expense</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Deferred Income Tax Expense (Benefit)</td><td style="font-size: 10pt;"> </td><td style="text-align: left; font-size: 10pt;"> </td><td style="text-align: right; font-size: 10pt;"> </td><td style="text-align: left; font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td style="text-align: left; font-size: 10pt;"> </td><td style="text-align: right; font-size: 10pt;"> </td><td style="text-align: left; font-size: 10pt;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;">Excess of Tax over Book Depreciation Fixed Assets</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;">Excess of Tax over Book Depreciation Patents</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1179px; text-align: left; padding-left: 9pt; font-stretch: normal;">Net Operating Loss Carry forwards</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;">(179,661</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;">)</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;">(100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt; font-stretch: normal;">Change in the Valuation allowance</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">179,661</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"> </td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Total Deferred Tax Expense</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"> </td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"> </td></tr></table>

0.97 1.00 5000000 4400000 1440000 1.498842 6000000

5318151

6000000

8185100

8040000

185053

2508759

3073967

0.25 0.25

P6Y

P4Y

P6Y

P4Y

269493

208823

60670

269493

208823

269493

-269493

523

11462

15366

15324

88262

6794

4055

-99351

-99305

99305

276651

1500000

74696

405000

165990

900000

184434

1000000

2500000

461084

424198

2300000

2000000

41945

38235

44293

0.05 0.05

579

0.07

0.06

2015-02-01

The Company extended maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit Biotech USA, Inc. or February 1, 2015.

38235

1579

10000

7255

3393

20000

11918

906

6000

12711 12711 52041 52041

2380106

2416813

2444858

2481565

-144858 -277657 44858 97996

100000 179661

-100000 -179661 -100000 -179661

2416813

179661

Through 2034

6880278

9533290

6880278

9533290

12000000

2000000

12000000

2400000

400000

2400000

5.00

1400000 40000 7000000 7200000 200000 5 5

1093290

141000

5466450

P20Y P180D

3019

60000

100912

60381

212438

200857

41498

0.9692

EX-101.SCH 6 pmhs-20150331.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statement of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Other Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statement of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Definite Life Intangible Assets link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Notes Payable - Related Party link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Loss Per Share link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stockholder's Equity link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Subsequent Event link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Definite Life Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Notes Payable - Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Loss Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Definite Life Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Definite Life Intangible Assets (Details Textual) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Notes Payable - Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Notes Payable - Related Party (Details 1) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Notes Payable - Related Party (Details Textual) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Income Taxes (Details 1) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Income Taxes (Details 2) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Loss Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Stockholder's Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 pmhs-20150331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pmhs-20150331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pmhs-20150331_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document and Entity Information. Entity Registrant Name Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Type Document Period End Date Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Year Focus Entity Filer Category Entity Filer Category Entity Filer Category Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets [Abstract] ASSETS ASSETS Assets Current [Abstract] CURRENT ASSETS: CURRENT ASSETS: Cash and Cash Equivalents, at Carrying Value Cash CASH, BEGINNING OF PERIOD CASH, END OF PERIOD Escrow Deposit Cash held in escrow Accounts and Other Receivables, Net, Current Other Receivables Assets Current Total Current Assets Total Current Assets Property, Plant and Equipment, Net Net Property and Equipment PROPERTY AND EQUIPMENT, Net accumulated Depreciation Assets, Noncurrent [Abstract] OTHER ASSETS Finite-Lived Intangible Assets, Net Definite Life Intangible Assets Finite-Lived Intangible Assets, Net Deposits Assets, Noncurrent Deposits Assets, Noncurrent Total Other Assets Assets TOTAL ASSETS TOTAL ASSETS Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDER'S EQUITY LIABILITIES AND STOCKHOLDER'S DEFICIENCY Liabilities Current [Abstract] CURRENT LIABILITIES: CURRENT LIABILITIES: Notes Payable -Related Party, Current Portion Notes Payable - Related Party Notes Payable - Related Party, Current Portion Total Notes Payable - Related Party Accounts Payable, Current Accounts Payable Accounts Payable, Related Parties, Current Accounts Payable - Related Party Accrued Liabilities, Current Accrued Expenses Liabilities Current Total Current Liabilities Total Current Liabilities Liabilities Total Liabilities Total Liabilities Stockholders Equity [Abstract] STOCKHOLDER'S EQUITY: STOCKHOLDER'S DEFICIENCY: Preferred Stock Value Preferred stock, $.0001 par value; 10,000,000 shares authorized; none issued and outstanding Common Stock Value Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at March 31, 2015 and December 31, 2014, respectively Additional Paid In Capital Additional paid-in capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated Deficit Accumulated Deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income, net Stockholders' Equity Attributable to Parent Total Stockholder's Deficiency Total Stockholder's Equity Beginning Balance Balance Liabilities and Stockholders Equity TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY Preferred Stock, Par Or Stated Value Per Share Preferred stock, Par value Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, Shares authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, Shares issued Preferred stock, issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred stock, outstanding Common Stock, Par or Stated Value Per Share Common stock, Par value Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common stock, Shares authorized Common Stock, Shares, Issued Common stock, Shares issued Common Stock, Shares, Outstanding Common stock, Shares outstanding Statement of Operations [Abstract] Income Statement [Abstract] Income Statement [Abstract] Revenues REVENUES Revenues Cost of Goods Sold Cost of Goods Sold Gross Profit Gross Income (Loss) Gross (Loss) Operating Expenses [Abstract] Operating Expenses General and Administrative Expense GENERAL AND ADMINISTRATIVE EXPENSES General and Administrative Expenses Research and Development Expense Research and development expense Depreciation, Depletion and Amortization Depreciation and Amortization Consulting Expenses Consulting Expenses Consulting expenses. Operating Expenses Total Operating Expense Total Operating Expense Operating Income (Loss) (LOSS) FROM OPERATIONS (LOSS) FROM OPERATIONS Nonoperating Income (Expense) [Abstract] Other Income (Expense) Interest Expense Interest (expense) Interest (expense) Foreign Currency Transaction Gain (Loss), Realized (Loss) on Currency Transactions Interest Income, Other Interest and Other Income Interest Income Nonoperating Income (Expense) Total Other Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest (LOSS) BEFORE BENEFIT FROM INCOME TAXES (Loss) Before Income Taxes (LOSS) BEFORE BENEFIT FROM INCOME TAXES Income Tax Expense (Benefit) Income Tax Expense (Benefit) Income Tax Expense BENEFIT FROM INCOME TAXES Net Income (Loss) Attributable to Parent Net Loss NET (LOSS) NET (LOSS) NET (LOSS) Net (Loss) Earnings Per Share Basic and Diluted BASIC AND DILUTED LOSS PER SHARE BASIC AND DILUTED LOSS PER SHARE Weighted Average Number Of Shares Outstanding, Basic and Diluted WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED Weighted average number of common shares used in basic earnings per share Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share Weighted average number of common shares used in basic earnings per share STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract] Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Equity Adjustment for Foreign Currency Translation Currency Translation, Net of Taxes Currency Translation, Net of Taxes Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other Comprehensive Loss Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: Depreciation, Depletion and Amortization, Nonproduction Depreciation and Amortization Increase (Decrease) in Interest Payable, Net Accrued Interest on Notes Payable - Related Party Increase (Decrease) in Operating Capital [Abstract] CHANGES IN ASSETS AND LIABILITIES: Increase (Decrease) in Other Receivables (Increase)Decrease in Other Receivables (Increase) Decrease in Other Receivables Increase Decrease In Prepaid Expense And Deposits (Increase)Decrease in Prepaid Expenses/Deposits The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services and deposits that bring economic benefits for future periods. (Increase) Decrease in Prepaid Expenses/Deposits Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Related Parties Increase (Decrease) in Accounts Payable - Related Party Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Expenses Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Total Adjustments Net Cash Provided By Used In Operating Activities NET CASH USED IN OPERATING ACTIVITIES NET CASH USED IN OPERATING ACTIVITIES Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Purchase of Equipment Purchase of Equipment Net Increase Decrease In Cash Held In Escrow Net (Increase) in Cash held in Escrow Net (Increase) Decrease in Cash Held in Escrow Net increase decrease in Cash held in escrow. Payments to Acquire Intangible Assets Purchase of Intangible Assets Purchase of Intangible Assets Net Cash Provided By Used In Investing Activities NET CASH USED BY INVESTING ACTIVITIES NET CASH USED BY INVESTING ACTIVITIES Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds From Notes Payable Proceeds from Notes Payable - Related Party Net Cash Provided By Used In Financing Activities NET CASH PROVIDED BY FINANCING ACTIVITIES NET CASH PROVIDED BY FINANCING ACTIVITIES NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES Effect of Exchange Rate on Cash and Cash Equivalents Gain (Loss) on Currency Translation Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE IN CASH NET INCREASE (DECREASE) IN CASH Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash Paid During Periods For [Abstract] Cash paid during the periods for: Cash paid during periods for. Interest Paid Interest Income Taxes Paid, Net Income Taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES Cash Received From Offering Held In Escrow Cash received from offering held in escrow Cash received from offering held in escrow. Summary of Significant Accounting Policies [Abstract] Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property and Equipment [Abstract] Property and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT Definite Life Intangible Assets [Abstract] Intangible Assets Disclosure [Text Block] DEFINITE-LIFE INTANGIBLE ASSETS Notes Payable - Related Party [Abstract] Notes Payable Disclosure [Text Block] NOTES PAYABLE - RELATED PARTY Notes payable text block. Leases [Abstract] Operating Leases of Lessor Disclosure [Text Block] LEASES Income Taxes [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes INCOME TAXES Loss Per Share [Abstract] Earnings Per Share [Text Block] LOSS PER SHARE Stockholder's Equity [Abstract] Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Commitments and Contingencies [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Subsequent Events [Abstract] Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis of Accounting, Policy [Policy Text Block] Business and Basis of Presentation Reverse Acquisition [Policy Text Block] Reverse Acquisition Disclosure of accounting policy for reverse acquisition. Consolidation, Policy [Policy Text Block] Consolidation Foreign Currency Transactions and Translations Policy [Policy Text Block] Functional Currency / Foreign currency translation Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Intangible Assets, Finite-Lived, Policy [Policy Text Block] Intangible Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Revenue Recognition, Sales of Services [Policy Text Block] Revenue Recognition and Sales Value Added Tax [Policy Text Block] Value Added Tax Disclosure of accounting policy for value added tax. Research and Development Expense, Policy [Policy Text Block] Research and Development Cost Income Tax, Policy [Policy Text Block] Income Taxes Earnings Per Share, Policy [Policy Text Block] Loss Per Share Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial Instruments Use of Estimates, Policy [Policy Text Block] Accounting Estimates New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Reclassification, Policy [Policy Text Block] Reclassification Property, Plant and Equipment [Table Text Block] Summary of property and equipment Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of definite-life intangible assets, future amortization expense Schedule of Related Party Transactions [Table Text Block] Summary of notes payable and related parties Schedule of maturities of long term debt [Table Text Block] Schedule of maturities of long term debt Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of deferred tax asset (liabilities) Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation of income tax expense at the federal statutory rate Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of components of income tax expense (benefit) from continuing operations Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of weighted average number of shares of potential dilutive common stock Statement [Table] Statement [Table] Statement [Table] Statement Equity Components [Axis] Statement, Equity Components [Axis] Statement, Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common stock Common Stock [Member] Legal Entity [Axis] Entity [Domain] Parent Company [Member] Parent Company [Member] Statement [Line Items] Statement [Line Items] Statement [Line Items] Summary Of Significant Accounting Policies Textual [Abstract] Summary of Significant Accounting Policies (Textual) Share Exchange Agreement Acquisition Percentage Share exchange agreement acquisition percentage Share exchange agreement acquisition percentage. Share Exchange Agreement Common Stock Shares Shares prior to share exchange agreement Common stock shares prior to the share exchange agreement. Share Exchange Agreement Number Of Share Cancellation Share exchange agreement number of share cancellation Share exchange agreement number of share cancellation Share exchange agreement number of share cancellation. Share Exchange Agreement Common Share In Connection With Acquisition And Offering Shares To record the issuance of 1,400,000 and 40,000 common shares in connection with the acquisition and offering valued at $5 per share or $7,000,000 nd $200,000, respectfully, Shares Common shares issued for legal and consulting services Share exchange agreement common share in connection with acquisition and offering shares. Share Exchange Agreement Shares Held By Consenting Shareholders Of Company Share exchange agreement shares held by consenting shareholders of company Share Exchange Agreement Shares held by consnting shareholders of comany. Share exchange agreement shares issued to parent company Share exchange agreement shares issued to parent company Share Exchange Agreement Shares Issued To Parent Company. Shares, Outstanding Shares of parent common stock outstanding Beginning Balance (in shares) Beginning Balance, Shares Balance, Shares Common Stock, Capital Shares Reserved for Future Issuance Common Stock reserved for issuance Cash, FDIC Insured Amount Balances held in financial institutions Value Added Tax Percentage Value added tax percentage Value added tax percentage. Value Added Tax Paid To Vendors Value added tax paid to Danish and EU vendors Value added tax paid to vendors. Noncontrolling Interest, Ownership Percentage by Parent Owned subsidiary percentage Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Lab Equipment And Instruments [Member] Lab equipment and instruments [Member] Lab equipment and instruments member. Computer Equipment [Member] Computer equipment [Member] Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Estimated useful life (years) Property, Plant and Equipment, Gross Gross Property and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated Depreciation Property And Equipment Textual [Abstract] Property and Equipment (Textual) Depreciation Depreciation expense Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2015 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2019 Finite-Lived Intangible Assets, Amortization Expense, after Year Five Thereafter Thereafter Definite Life Intangible Assets Textual [Abstract] Definite Life Intangible Assets (Textual) Amortization Amortization expense EX-101.PRE 10 pmhs-20150331_pre.xml XBRL PRESENTATION FILE XML 11 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	0 Months Ended
Commitments and Contingencies (Details)	Dec. 16, 2013	Mar. 31, 2015
Commitments and Contingencies [Abstract]
Payments for royalties period	20 years
Termination of agreement	180 days
Common Stock reserved for issuance		185,053

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!NZ_1[_P$``.<9```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4%NVS`01?<%>@>!V\*B M2:9I6EC.(FV7;8"F!V"EL268(@F22>W;EY(3(PA<&T8,Y&\D2"+G/W'Q%C.S MZW5OB@<*L7.V8J*Q;JG7L72>;/ZR<*'7*3^&)?>Z7NDE<3F=7O+:V40V3=)0 M@\UG7VFA[TTJOJWSZRU)(!-9<;-=.&153'MONEJG3,H?;/,B9?*84.:=XYK8 M=CY^R!B,[TT8OOP_X''?SWPTH6NHN-4A_=!]QN!KP_^ZL/KCW*H\7&0/I5LL MNIH:5]_W^03*Z`/I)K9$J3?E>"][W=DG[@/YX^+(QYLX,\CP?V/A$SDD"(<" MX;@`X?@(PG$)PO$)A.,*A.,S"(>8HH"@&%6@*%6@.%6@2%6@6%6@:%6@>%6@ MB%6@F%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6BF%6AF%6AF%6AF%6A MF%6AF%6AF%6AF%6AF%6AF%6AF/7BK_BXQ#S5.#WPQ1*!A;-)0LR>;CV.:^3\```#__P,` M4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0" M**```@`````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[ M(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7 M:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ M['*ED3!1RF%HT9,9J&74"T\U<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$ M%``&``@````A`'IDP"T8`@``_!@``!H`"`%X;"]?#TSBI.4R#FT!')-TQ^P2&M+1):$=MO&_SZ+6V0' MFA>[/RW?WKKLU^^S$T?5<86BQ-YKNRKYIN6YB?SP^7-R8+ MT765:_O.%V;O@[E?7WRY>_*MB^E'H6Z&D*5=NE"8.L;AJ[6AK/W.A44_^"Y] ML^G'G8OI<=S:P94O;NLM+YJ\*,CQ6)R9[W0SKZ\\W[S:8I M_?>^_+7S7?S/&?9//[Z$VON8-G7CUL?"3$O!'KXA621F8S_`2?70Q;E!.+Q2 MQN$5PI%;91RY13A,RCA,"$=R91S)$4[.<^*$N&^3-TRR^ON,SK^>\_A)Q4>" M:>F?L*\1S*RUF$[^&(81#&FKFJ"J.86"JN?Q$E6'M4V&H+2'3V@MLS*FE@;5@[`QAF@&C[GD#C$^U,$!@*N;;QY=#X MKI1M^`JY,&G3$,1A[6L"PVL":U\3&%X31-N2!7NRMJX(ZHJT!PJ"`X5H)Y;` MQ,IG3:S2M>6WVC7=<<:9EI#=S`IQQH`#4U.[7V"[D'9I"-:&M2<*AA,%:T\4 M#"<*T78^@9IR\F3I>1Y6A'.$YPY=D/3C>D MK7&"&B=MC1/4.&N+BJ&H9%91G1&=`GM'M&4EDZ[LN_\LUF\```#__P,`4$L# M!!0`!@`(````(0"YF)7/KP,``'(,```/````>&PO=V]R:V)O;VLN>&ULE)=1 MVC1@'9:`(2E41M?_M;X3%> M(4*;)UO@_;.[_Y]6^.;3H:Z"GTQI+L4RC-_/PH")7!9<[);A?YN_WGT,`VVH M*&@E!5N&1Z;#3[=__G&SE^KE65LS84XBBE740/JZ MY(T.;V^VO&+?3A4%M&F^TAKR/E1A4%%M[@MN6+$,,UC*/7,NJ+;YTO(*[EZE MLS2,;OLBGU10L"UM*[.!\L[JT*]DGB0+^TO;BF^<[?4ER"Z#PW6%*N#^;S?IK?S.^*\WY(LA'2+_K(#RG^PQ$5]ZY(P2<(O?" M<',D#^+4?2[!0MOU!Z@L#@-US>&+>BABFSA6N8,FRHH7%%I$OM"*BIR1M0W5 M2")!$LD;),@312HI4NEZ_6HB:P/Y6+N)W))_&J:0RARIS(>Y](&ZBS0E4^1. MUH!AR02N"/K>-R4;JCA-Z26MXAW5)JZ',5VF8!CN/U,;^:_=*1EF+O:@&V<6C`1X ML/\99B[VH)MFU\D'@P=C=S#E)NB%I'!=&,AD$LB1:C"7R2^X'`G'>"8^GI/C M!/SHS4F<9GBHOF+.BAG**^Q.XC3#8W5:![L#Y^4%V-/AB0?EM,U.94Z+/'ZG MA8"U2XOP;DX\?J=X6>&1DN#M#(LW<+=BN$4IWM.P>),0;E&&*TL]@D\CF/AF M9[B2U(,7C^*1Z!1O9%@,TA^+)D[Y&-G40W8T'E=MWZWZD0B+WWG^AAU,2^$E ML:(P?,681L,%6IXZ%'Y^190W`]CJ<>G:\?-C8M MI+/`<,X[.*.N:?!*FM,JAW=E^]&];,ZSQ6EN1N>_"[?_`P``__\#`%!+`P04 M``8`"````"$`B#V$=)L$```?$0``&````'AL+W=O2;$25`!1T";]M_O M-=<)V#01O*0-'([/_?`Q-^MO'V5AO+.ZR7FU,-^=^_+XO0 M-)HVK?9IP2NV,3]98W[;_O[;^L+KU^;$6&L`0]5LS%/;GE>6U60G5J;-DI]9 M!7<.O"[3%K[61ZLYURS==P^5A45MV[?*-*],9%C54SCXX9!G[)EG;R6K6B2I M69&VH+\YY>?FRE9F4^C*M'Y].R\R7IZ!8I<7>?O9D9I&F:V^'RM>I[L"XOX@ M;II=N;LO(_HRSVK>\$.[!#H+A8YCCJS(`J;M>I]#!"+M1LT.&_.)K!+JF-9V MW27H9\XNS>!_HSGQRQ]UOO\KKQAD&^HD*K#C_%5`O^_%)7C8&CW]TE7@[]K8 MLT/Z5K3_\,N?+#^>6BBW!Q&)P%;[SV?69)!1H%E23S!EO``!\&F4N6@-R$CZ MT?V]Y/OVM#$=?^D%MD,`;NQ8T[[D@M(TLK>FY>4O!!%)A214DCB@7MZG4TDL M%-3%]YRVZ79=\XL!30-+-N=4M"!9`?$U,)1Q"_5>I!"B('D2+!L3NAV":*`\ M[ULO6%OOD-%,0N(QA*B(Y(H0A0!U-XD0]U#BUSF_*A%@H4340$B+\0)PWZ11 M;=TQP@MO$$4))&BZ$@'>F.Y@82^ZT:(VA&##"+')X(*R,+!,7UB`H<$&"_NV MMC!"H/7ZI#@J)'D(4<0!S71Q`JR)T_H@1DC0M9'K^E2OU_`^"0*GSZHBRY\C M2X`U6=JR,4)0UN(K70K@@;!@CC`!5KO(URH5(V3018,+2D;$:338ZX\WD@!K M&7'5%HD1@AEQ`AI%O@I(%`#U77IG7T5SA`FP)LQ3UXT1@L*(1T*BI2Q!`#32 M5_VOY(S`63$]:1U:$ZGBA,F.SUQ`JU5M#<.CTWZ,006K^X;N;B+0GR)W-#/%=3EV@`)XKZ]*K: M9ADZ&3MZH+5,+#%2FQ-1-QC5#6DF.<4L7R=HTDKN-)>*)0;U^<33[B?ROHC\"P+;L=_0JKI9UD_&WA_T%B0W MX]#\%_!^[3@#FY+R%(Q+?=OK"Z_HH[/LOT.K9A'TVQSU2DF#,6]G)TNDN6 M'G'/:V%D5.Q.3#\N5.;QFU'WE%;EWK.DR*'?1Y[GT$@W/DDC=W<8VG00*M88 MYU&YX"X-I]^\)?HA@,*[82P`?.&^O7\3D M=OMI8_L_````__\#`%!+`P04``8`"````"$`]=DV/^D"``!$"```&0```'AL M+W=OOE0E>>9*"UDG MU'<\2GB=RDS4NX3^_O5P,Z=$&U9GK)0U3^@KU_1V]?G3\B#5DRXX-P0<:IW0 MPIAFX;HZ+7C%M",;7L.=7*J*&;A4.UG)N[TXLZ]$JJ26N7'`SK6@YS'';NR"TVJ9"8@`TTX4SQ-Z MYR\V<^JNEFU^_@A^T+W_1!?R\$6)[)NH.20;RH0%V$KYA-+'#)=@LWNV^Z$M MP`]%,IZS?6E^RL-7+G:%@6K/("",:Y&]WG.=0D+!Q@EFZ)3*$@#@FU0".P,2 MPE[:WX/(3)'02>C,(F_B@YQLN38/`BTI2??:R.JO%?E'*VL2'$TF0'^\'WS4 MQ+5`;7SWS+#54LD#@9Z!1^J&80?Z"S`^!68QNE#?BQ1"1),[=$DH-#L$H:$Z MSZNI%R[=9TAI>M2LSS7^4+$Y*;`2@-P!3+^K\+:35V-9!ZDUO84``-M<3 MX"8@[1$$OCF_=8:MG-?#TMQ8;H6\N2@85CJZA0_&0+O!G MHZQ9CU4 MJ[C:\0TO2TU2N<>)'$"W=*O=87$7X(`8K:_A$&E'KMO=@"'>L!W_SM1.U)J4 M/`=+SXF`6=ECP%X8V;2S="L-C._V;P&G-8=7V7-`G$MI3A&PO=V]R:W-H965T M%?(4G2; M'/_Z>7N18:0-ZTK6R([G^)EK?+G\_&FQD^I!UYP;!`Z=SG%M3#\G1!%-)U3(#0[4ANE>OWBUA8?L6N9>MCV%X5L>[!8BT:8Y\$4H[:8WVTZJ=BZ@;J?:,R* M%^]A<&+?BD))+2L3@!UQH*;Z5!,=*U:G"CH;)02X1CC(ZQ#.]FX"*^!]2#LIQS%&!Y#)Z#\4^)`ICG^_M]T=\L$<.^=[OG!7[7!,O-Z=Q7%%,IQGU%*LCQ20+:3@= M/8[8IN>P6;'/YB]]IW%L%U&.OF[-.PVD M,^Z+R(_N78G+SAVT[@CIV8;?,[41G48-K\`W#%+X`^6.631G8@WS\OB[_`@``__\#`%!+`P04``8`"````"$`0W/Z M$JX#``"G#```&0```'AL+W=O3 MD]QSDYOK\NFM+(Q73%E.JI7I6HYIX"HE65Z=5^:OG_&WN6DPCJH,%:3"*_,= M,_-I_>+P2,\VJRE& M63.H+.R)X\SL$N65*146=(P&.9WR%$*TE:[>1C(EWE*"2,G;H&< M+1\ MPF`VI$DDX$C(BZ`FF8!@L#T8'3<)^)L:&3ZA:\%_D-L!Y^<+AVS[$)"(:Y&] M1YBE8"C(6!-?**6D@`7`IU'F8F>`(>BM^;[E&;^L3,^W)G/?]6?`-XZ8\3@7 MFJ:17ADGY;^2Y=ZUI,KDKN+!\N_O)Y8?.)[[!9'I702F;47"KR]E=E<).I6) M:\U]?SJ;!^,#@M/1V!)^J`26.W5&F&)+AYN$18BC]9*2FP&'`"QD-1)'REV` M;ILI:6N7N]^E#G(F1)Z%RLJ$]4%2&&RWU[47^DO[%?9(>N=LAAQ796Q;AM@0 M0C;2@9T.Q"W0GWBFRNY;3BM[T(&D!]C@2V<.[*"^.8^W;^N!(`L/VFDV$@#M MSI2)NK+MD.'/54HTI&@BN_]EQ$.&%VKS[$=P#D/.U''4]2:?0 M%7"$@1K4;@0G?L0)59W]",YA!"?YG*.8#/5KO,F"K)@L M`5E6Q8G;Q] M@JS8)X&>?3H0ZM# M?[CGA5IDT"**Z.7DT$'WADM'90,H^XD2TS/>XJ)@1DJNHKGS8-$=VO6=S\U& MT/"-NX"['6Y.#8^A3VUPNWL!?6*-SO@O1,]YQ8P"GV`JQQ)M%)6=IGS@I&ZZ MFR/AT"`V/R_PAP!#%7,L()\(X>T#3&QW?S'6_P$``/__`P!02P,$%``&``@` M```A`*I$-7[K!0``-!P``!D```!X;"]W;W)K&UL MG)E;DZ(X%,??MVJ_`\7[R$U%NMK>&D4$%2];>WFF$94:$0OHZ9EOOR?$2W*2 MZ8[;#[;^^.=O575>GH:ZU3%U+3NEY38_[8?ZWW\%7P:Z M5C?):9LJ@?FN;\9!AU>LB*I.Z4 MY^P$5W9E520-?*SV1GVNLF3;-BJ.AFV:?:-(\I-.'9XJ%8]RM\O3S"_3MR([ M-=2DRHY)`_VO#_FYOKH5J8I=D53?WLY?TK(X@\5K?LR;GZVIKA7I4[0_E57R M>H1Q_["Z27KU;C\(]D6>5F5=[IH.V!FTH^*8/<,SP.GE>9O#"$C8M2K;#?6O MUM/&LG7CY;D-T#]Y]EXS[[7Z4+Y/JWR[R$\91!OR1#+P6I;?B#3:$@2-#:%U MT&9@76G;;)>\'9L_R_'!M+=@Q&1@3UM?_I9G4)$P:9C]XA36AZA`_"J M%3DI#8A(\J/]_YYOF\-0=_J=GFLZ%LBUUZQN@IQ8ZEKZ5C=E\2\561>V!U[T+-Z_0>ZXEW'0R+YOP=DW<("0;C8V&;'M4S/ M<=7C8O6OO7%O-NKA-6BJVLS[29.\/%?ENP;3"3I7GQ,R.:TG"YSEN88D$_%7 MHA[J$%5(8PT%^OW%<,187C(HVOH)G(-'W^NP(% MS52F<7F?4$$3R30#WF>FH)E+-`,4Y86")I9I'+X_2P7-2M3TT+#6H@0E=",J M&!,#JO%6DC#SN9(DRY`#4_#CTB2M2&F298G4ZH@"^-I;'3JNQ8]^+-.@"/D* MFHF")E#03!4TH8(F4M#,%#1SB6:`8KA0T,0*FJ6"9J6@6/:Z:@ MF4LT`[26+!0TL8)FJ:!9R30H7VN9!MV(-A]KN)+K/E1R1,V5'`5,R5T!6W)H M%OLR#9HU$YD&^00R#?*9RC3()Y1ID$\DTR"?F4R#?.8R#?)9R#3()Y9ID,]2 MID$^*P7-6J9!W[7Y6,.5'#R'/K#*$?50!_O[K;6/;ILCJJ$_$]J%#P,?@PD& M`093#$(,(@QF&,PQ6&`08[#$8(7!&H,-`[A`PU/\`X$F:GCX80,]0$^F(ZKQ MZ-/XP'90-8W9ZU:_YWGH4=*G`K0L9`-9<0I9/]?\1:7\*+#ZY'G]R??G)]16] M?@_,&H,-`[@DD:TS]9_?1(V3A)ZQ1E1S[\L8`Q^#"08!!E,,0@PB#&88S#%8 M8!!CL,1@A<'Z"LA61,]%L=C\ZBJ7`MCE>2`%1(U2@!?4$=4P*<#`QV""08#! M%(,0@PB#&09S"B[SQ.W0U>?VZDZ^X`?M1QO$CS98/MI@11O<@[OF'&#RH[O3 MAFG`Y=V"+84'$M_*<>;1?6QT$=U[-Q:(+Y")0`*!3`42"B02R$P@';*P**RUM'PC!S,63,<;O1T: M?>VVQSZW"W!FT#P6C9P6M.^ M/<#I7`;;6&8'Q+NR;*X?R+G2[;SOY3\```#__P,`4$L#!!0`!@`(````(0"H MS&PO=V]R:W-H965TF=G=G;IU?+Z1;;HF6LC5%?B)(HQXAU3E>@V)?[U\_[B"B-C:5?15G6\Q*_< MX.O5YT_+G=)/IN'<(F#H3(D;:_L%(88U7%(3J9YW$*F5EM3"46^(Z36GE4^2 M+4GC.">2B@X'AH6>PJ'J6C!^I]A6\LX&$LU;:J%^TXC>O+%)-H5.4OVT[2^8 MDCU0K$4K[*LGQ4BRQ<.F4YJN6_#]DEQ2]L;M#R?T4C"MC*IM!'0D%'KJN2`% M`:;5LA+@P+4=:5Z7^"99W!:8K):^/[\%WYG1=V0:M?NB1?5-=!R:#6-R`U@K M]>2@#Y7["9+)2?:]'\"C1A6OZ;:U/]3N*Q>;QL*T9V#(^5I4KW?<,&@HT$3I MS#$QU4(!\(FD<#<#&D)?_',G*MN4.,NCV3S.$H"C-3?V7CA*C-C66"7_!%"R MIPHDZ9X$GGN2))U*0D)!WM\=M72UU&J'X,Z`I.FINX')`HB=L0S:\V]CX,CE MW+@DGPIH`\-X7F7YU9(\0P?9'G-[BDD'!`'QH0)0/;\"EU3B2XR&"I)\-O#[ M*F\#QH_C0#`[%/S8J@-#2[S)-$Z.-4*X\.&BR.+W^($D%#KV^+&D`X\D\R-; M(0S79K">9@/D0!4PTU4=>*0Z'RA#,T-XBFI^CJH#CU2/+U$(3U&=GZ/JP"/5 MXLAK"$]1=>M]]._Y>*X.[%3?!Y?DET?2`3-%NCA'VH$/I;/\V'7`_/\JA^48 MED=/-_P[U1O1&=3R&FYB',VA:AU68SA8U?LEL5865IK_VL`;C,,&B2,`UTK9 MMX-;OL,[&PO=V]R:W-H965TKS]_6AY9^\`+0H0# M##5?N840S<+S>%J0"O,):T@-3W+65EC`;;OW>-,2G'6;JM(+?#_R*DQK5S$L MVC$<+,]I2FY9>JA(+11)2THL0#\O:,-?V*IT#%V%VX=#.Y( M7:=*%_?[FK5X5T+>3VB*TQ?N[N:$OJ)IRSC+Q03H/"7T-.?$2SQ@6B\S"AE( MVYV6Y"OW!BVV:.IZZV5GT!]*CES[[_""';^T-/M&:P)N0YUD!7:,/4CH?2:7 M8+-WLONNJ\"/ULE(C@^E^,F.7PG=%P+*/8.,9&*+[/F6\!0"; M+O*\.`E>N5/7T<2%`V^7P$9A5+UE1EMMP8@,EHR/+,%@GQ[9#JP@2>=9DH3^ MS!2V-9\G,S0\-V1!=N-E2;`I"\73@5<9HC!QI^OJ+6$VX#UE\%+HRL;UD]QD M*@PC6Z'"P.]0UL`R=WL68O@7_8]*N*T8.TX/J*&=V:P.?K@=30/#MC>HRJ"(KB.#:=V9J` M>1*%ON\/&%.=-7K'O<](C5-#962IV/0@W:/WIC"28W%TSW;HBQ52DU:/KJV8 M'GQHVL)AYJ0W[5>FQZC/P'0:)!9`GH@D20\(XMDK0$E3YQWU)6_PGGS'[9[6 MW"E)#O/1G\0P"UMUVE$W@C7=%WO'!)Q2NK\%G$H)?/S\"8!SQL3+C3Q/#>?< M]3\```#__P,`4$L#!!0`!@`(````(0#O7'`1Q@(```<'```9````>&PO=V]R M:W-H965T[G M8(E)[]T-KNPY(U(H46@7[#P+>AWSVEM[X+3=Y`PB,&EW)"U2=!\D682\[:;+ MST]&3VKTWU&5.'V0+/_,&@K)AC*9`AR$>#323[F9@LW>U>Z'K@!?I9/3`A]K M_4VQ&M_XB`+ESH$H_,&.)'')46O!?5A08J,$D/)LL@/Z\'OZWR?)L`L^+2;B* M@BC^-XIGP^JRE&&-MQLI3@YT'H"K%IL^#A)P[M-C@QD2]K=\08S&Y-ZXI`B. M#*1"08V?MHMHO?&>H##DK-E=:X*I8M\K3.J,;68GNEQZP#M`0S['T'^N9<]F MQ(:M=]W9"?`>8,,9R+4B6DTEV;4DN`0\@86BCV%-AA?0QJ]#FTTI@H(,C(O8 MGR+LK,8VK4G7?CZ1C28F2.`[1GH=Q8@!>8PRS\;.:M9=Y8,X\.-Y1JW@PII- M=JSB9;`' MQ;07CSU2G,J2[FE=*X>(H[E40LC(,#O<=_>A:<;9_"Y(X`#`O#&PO=V]R M:W-H965T&W01/&2&>#7A6CTJUN5GF-7,?6X;ZY2635@L16E,"^M*7&J='&_JZ5B MVQ+R?J83EKYZMP\C^TJD2FJ9&Q?L/`0=YSSWYAXXK9:9@`QLV1W%\X3OBB1?1,UAV+#--D)V$KY:*7WF7T%@[W1Z+MV`KXK M)^,YVY?FASQ\Y6)7&)CM"!*R>2VREUNN4R@HV+A!9)U260(`_#J5L)T!!6'/ M[?4@,E,D)(S=:.J'%.3.EFMS)ZPE<=*]-K+Z@R)ZM$*3X&@"UZ,)#2XV"8\F M<'TS"681C>+_HWB85ENE6V;8:JGDP8'.`W#=,-O'=`'.MCPA%/G?Y8&ZV#$W M=E`[%-0:IO1I%4;3I?<$\Y`>->NQ)N@K-F,%G9\D'O"=(*%NET/:00F9$.<$ M2:,W_S:1-6IPWFUFF\Z+'@&4IDOP<7FL&,K8%B;P:71*"C^*X7D;IG02#^N" M\1:JQP"IG,]@Q1V&>,"`X2DR1&$\B&\P/F:`GC^?P8H[#,,.P?")(9CT&3<8 M'S/$ES!8<8=AUO_&&L/O,V!\S#"]A,&*.PS#)L3P^PP8'S/8$ZJS=#_N22NV M#)W5$`\*OD8-@LQFP:@Q,3X&F5\"8L5]D#`:S@IJCBLDIOZ(I">8Q1/ZE@HN M&3P/<*=KV(X_,+43M79*GL-VX+M3:"Z%IP$^&-FT.]I6&MC%V]L"#FT.FX+O M@CB7TKP^V//F]#=@]1<``/__`P!02P,$%``&``@````A`#^1[Q0<`P```0H` M`!D```!X;"]W;W)K&ULE)9;;YLP%,??)^T[(+\W M7')KHI"J2=6MTBI-TR[/#ABP"AC93M-^^YV#$XJ=CF9Y:(+Y\_?O7.K#ZN:E M*KUG)A47=4S"44`\5BDU\_[Z^NB:;LH'J_/56(PQ?)TV^\9I!MJ!-68"?$$TH? M4ER"A_VSI^_;"GR77LHRNB_U#W'XRGA>:"CW%"+"P);IZQU3"604;$;1%)T2 M40(`_/4JCJT!&:$O[?>!I[J(R7@VFLZ#<0AR;\>4ON=H2;QDK[2H_AA1&U%G M$AU-QD!_O!]=:N(;H#:^.ZKI>B7%P8.F@2U50[$%PR48GP(S&%VH_XH40D23 M6W2)"70[!*&@/,_K2;!8^<^0TN2HV9QK0ENQ/2FP$H#7,4+@?<;WDWY"03&B M8!&0;6,6P+MCBYQ]SQ73ZTYBD4"&+B=!<4PF_8W#-U\#9S2F99!VVUNP=@:; MRW=&,;28M;-;#J.![GM+R[@+NH7;#DHL.K"YG`[%#ET4V%MOC&:0;E!BT.4I)"UR0M@.#[GGGNO+\NK9UFC)ZZ- M4$V&21!AQ!NFP)=":4DM+'49FE9SFG>;9!W&492&DHH&>X:%/H5# M%85@_%:QC>2-]22:U]1"_*82K7EED^P4.DGUXZ:]8$JV0+$6M;`O'2E&DBWN MRT9INJ[!]S-)*'OE[A8C>BF85D85-@"ZT`CW7== M!7YHE/.";FK[4VV_<5%6%LH]!4?.V")_N>6&04:!)HBGCHFI&@*`*Y+"M09D MA#YW]ZW(;97A21I,9]&$`!RMN;%WPE%BQ#;&*OG7@\B.RI/$.Q*X[TC(-$CB MZ>SR!);01]09O*66KI9:;1%T#6B:EKH>)`M@/NX(K#CLM0-G&+H:@C50AJ=5 M0J)E^`2I8SO,C0'A&":*\,:JTY7YC1_8=>C']<@$.NW]C+I-@'LCN#?B!3T&&J7/:$(FQ\T" MZ#"&][4=>*B=]+Q>VV/&9M-SA!SXHZQZS%AH=HZ0`P\=30>./&;6=6^LQ8"$;D&98Z]-#3,)L[D$\GF&ULG%5=;YLP%'V?M/]@^;U\)R112-50=:NT2=.TCV?' M&+`*&-E.T_[[7>.$`6FS:"\)-L?GGGON]65]^U)7Z)E)Q4638-_Q,&(-%1EO MB@3__/%PL\!(:=)DI!(-2_`K4_AV\_'#^B#DDRH9TP@8&I7@4NMVY;J*EJPF MRA$M:^!-+F1--"QEX:I6,I)UA^K*#3QO[M:$-]@RK.0U'"+/.67W@NYKUFA+ M(EE%-.A7)6_5B:VFU]#51#[MVQLJZA8H=KSB^K4CQ:BFJ\>B$9+L*LC[Q8\( M/7%WBS/ZFE,IE,BU`W2N%7J>\])=NL"T66<<,C"V(\GR!-_YJS3&[F;=^?.+ MLX,:/"-5BL,GR;,OO&%@-I3)%&`GQ).!/F9F"PZ[9ZP8)F;Q6V>L]4Q0,!1HGF!DF*BH0`+^HYJ8SP!#RTOT?>*;+!(=S M9Q9[H0]PM&-*/W!#B1'=*RWJWQ;D'ZDL27`D"4']\7UP+8EK!77YW1---FLI M#@AZ!D*JEI@.]%=`?$K,RNA3?2]32-&0W!F6!$.S0Q(*JO.\B?QX[3Z#I?2( MV9YC_#$B/2%,)4!>KQ$2'VI\V_23%`,V4DP1C+:MW0#N7ELPB7N.F"UZR$@) M.'2]$@-.<#0,'$Y";RW&MHQ1FPXV1I&!YOK(!@PM-HH\+8?%++MBW4`;AF$T MZY/NG$M'D"B8>[.H1XS$00\/Q9DF"N&.72Z4.301&7D]OZV=Q<2=R"5(#)83 M1#I$S!<++XC?*=W\?S2:0U.-DZ[=6@SH^-M?X3B-]")DY&1\KG+^3R?-H:G* M::-9S"4GAXBWG;3CT8Z/FLF"I:RJ%*)B;T9?`%7J=_NI?!>8FSC9W\*T[F:; MV[^`:=F2@GTELN"-0A7+@=)S8O!5VGEK%UJTW=#:"0USLGLLX;/(X.YX#H!S M(?1I8>9(_Z'=_`$``/__`P!02P,$%``&``@````A`,8V7X'_!```C1,``!@` M``!X;"]W;W)K.5U]>JY/S MPINV%/7:)0O?=7A=B%U9'];N?_\^W"6NTW9YO>EY;7'D5=XNQ)G7\&0OFBKOX+(Y>.VYX?FN?ZDZ>=3W M(Z_*R]I%AF4SA4/L]V7![T7Q7/&Z0Y*&G_(.]+?'\MR^LU7%%+HJ;YZ>SW>% MJ,Y`\5B>RNZM)W6=JEA^.]2BR1]/T.]7$N3%.W=_,:*ORJ(1K=AW"Z#S4.BX MSZF7>L"T6>U*Z(&TW6GX?NU^)'8P?E#J%'LF/+ MW=L];PMP%&@6-)1,A3B!`/ATJE(.#7`D?^V_+^6N.ZY=%BW"V&<$X,XC;[N' M4E*Z3O'<=J+ZB2"BJ)"$*A+X5B2$SB9AB@2^-0E-0A)&OY;B8;=ZE^[S+M^L M&G%Q8.B!\/:#^%>AQ"[5\V9!DY;V`_86";,<0:B*R M,8*D5X@'LJ[:P*[IVB1X[0:N<]5&_2MM+W^+$*RR[$\VN&$T#$9,;UB"850, M&R96PPA)>\=8P(*4A28B,Q"^GR1,%S4MS3.)AV]*4]&\.1Q3C"P(1JO4XQ9PVFK,(.1/KQC-BXS=GKCF,B&-U;'MV28VFG* M?#ND+$`::G=-:3)EITO#3#:DZ5FDRC;,[8A2DE@1DA"-QPWBGA`9,3PG3.2O>;\

D MT6#CU`,R1:*,8RP9)(FI;5:J$XQHHZJ6+5N%P:;3F*21MD6)0Q9$D#B,HT@/ M#5/=K.@GX^P?E$0Y-\SVC]4-$3?5T5GQWZ/-)9'I"$)U"C-(BN$=PQIJ1;S< M,P0P76X/KOXM<^0'.J:5"(QZX+I&&K52)5,\GV!,H5;<2Z'QKX6.8S_0P:2$ M(B;L-Z1I.-+XV6-3G@SPR;%&)=KRSXY[A<'A34,_3?S0\CB[C3$%SEH2Z'A) ML-?"K<*@P#O*2!"RT.I%9H%(DD((ZKEN2H1RSO!0HBT/]?Q7I44,2HQ)G%`+ MDE@<8A_6QIH+.6AAYMB;-6S*W"J`)'L`V++4AF0%B04!IHB.F=M3A, MV_O#2%1PS@_\>]X&PO=V]R:W-H965T&ULE)9=;YLP%(;O)^T_6+XOYB,D3112%;INE39IFO9Q[8`)5@$C MVVG:?[]CG*8Q65F2"S["ZY?GO#Y@EC?/38V>F%1%/,=#E"7/V9W(MPUKM361K*8: M^%7%._7JUN3GV#54/FZ[JUPT'5BL>!HZL4S M/PI`CM9,Z7MN+#'*MTJ+YH\5!7LK:Q+N36"_-PG"BTVBO0GLWTS"ZSB(I_]' M(;:L/J4[JNEJ*<4.0>L!N.JH:>1@`TEZ*@E=17:J".8'"0&\`R/$=CFC&93@"49OC-<'^[Z,U$KLK)NZ MLJ,_'``(YAA@/!PCAA"/;_Q6E[VQE4#;F^B"3U<3%RQ[_[J#!<6=CV7$+E;L MN[=-K61FJ7S[]?=[#,BGCTIAA_"(QX@#5H\M1* MW&X;=&0VKG'PYI?@&?$`+W:;*;42BS>/HRB<#^'&%`X:1']!=+UZ`#<=P.TU M8W2C$HMG%TV[''1TP[Y1N>&M0C4KX2'SO1DTM+1+ICW1HNM?^VNA8:GK#ROX MM&'P[O0]$)="Z-<3LR@?/I96?P$``/__`P!02P,$%``&``@````A`#$,@FL8 M20``Y^P``!0```!X;"]S:&%R9613=')I;F=S+GAM;-R=ZVX;V;7GOP\P[U`P M'$0&:%MW6^F.#VA=;*5E21'IS@2#^5`B2Q+3%,D42;N53WF#^7`&&!Q@!O`3 MS$/X4?I)YO=?:^^J8K$HJWN2=C#`.6FY6+7WVNM^VWM_^V\_W@Z3#UD^'8Q' MOW^T\6S]49*->N/^8'3]^T?ONT=/7SY*IK-TU$^'XU'V^T=WV?31O[WZS__I MV^ETEO#M:/K[1S>SV>1WSY]/>S?9;3I]-IYD(WZY&N>WZ8Q_YM?/IY,\2_O3 MFRR;W0Z?;ZZO[SZ_30>C1TEO/!_-?O]H[R73S$>#O\ZS?7^RO;/QZ-6WT\&K M;V>O#L:]^6TVFB6`D1R.9H/977(\\O$!^]OGLU??/M>K_OI6\FX\FMU,>;6? M]>N_ODOS9\G61BO97-_8J?_XA9F2_]J^G,[RM#?[;_4O`U@7V?5`;P#L:7J; MU=\Z2$<'^6"6O!Z,9UGO)GG?:;=82N]9_<4PW#ZKSM,AK_2S'Y/OLKOZ>VWP MTC?<'`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`HSODS\3US!1 M,4/R>-WF;#'3/5.UDKW6SM96:W-OO64S%?]<,7V2SA+L"8H\&A3[#)'.;B\1 MI_!TNY6@-R99;S;XD`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`==)YVW[XK#^_I\.C]^\U6OM[R''F\/D]/V[U[Q\=I3LG[U[=W;JGW62L_?= M3A<'[?CT#9[$TC3U<0MIFTI2FLR+A.,A0LVLW4,YA,!PE+B?!VCG%X=O#T\[ MQ]\?^@I7B['<2$U6!W&1*?"T8`IW.H&XD42KEK$TB='P_'' MARV]:K\JGZY>:_O@#^\[76$KZ9XE%X?[9Z?[QR=0%88Q1N"I_MYO=]X21D+W MX],HB1"VO=\]_K[9-\6=-/>PD!+$ZO3G^*O[;]NG;PX[FM#C$N/2BF>PY`*N M(1(D`*;9DP3?R/Y2=.)4N,!;6A%SK/@.2RU'*4K7]/DJ1S].FZS%:9]HWKI# M7:?Z`S_[DA^^>I@'N.?M_E_FTYDT_Q*[/XCL]349GQR=G/VIXTK[^/3[PTY7 M.N`>5CF?8XD@FQA>7J%9HOK(DLH5A#).?QMBT0W*5RZRNBY?JM_HEF/3_7WXYOCT5*A` M(6-9CL\.FE\\))Y?_8I4H0ED?YXKI8([G^!`D!0"?^-\21U$S5.?"X$A3FG6 MV)WY[6V:WXD3.X/KT8#@1TFV(,J:]9S$2Z\ABGWXE_>$$9WW[]ZU+_XL)'2. MWYP>'QWOMY67V=\_>W]J8G1^=G*\3RZ@OJC3L^YALI'\]/?_D?SR0;I@-"5- M8*DJ+98\2(B!IM&T3!-"*9*HP;=^1MAGE!A/\#O1\6#N-AVEUQ9'$=\.\4M+ M)9.L?;P9X'8.1KWAO(_$CX9W1-ZD<(<)N1H2B9JV\L$3PLE>-IV**+-Q,L&# M0UDE5^D@YTNQ0`FCI6',*/,6#JBY$J2)8T0@/ZTG+KHR@]H<59.OW38/%Y9: M8#'F(M.E7&]RD^):7V;\^S;M9\^2_2R?298&9;8X##&>C;!Y29_,Z'`\G0-7 M6"W`!QQ8!JU<1`71+'8"LNT%D27O6Z+OXV"&W^[9'&%K`LYZ@PG)M.3:(P$& MY_=LHO0@8`E+[Y70ZI-A),(UO)#2S6'NREIZ8Q9')H?41YZ,;P0;)JVC29P2+$S*I/_W]/Z8R\XLID"2P984KRL&?)5V^;^:-.K6=T`U9%^__ M*_Y*P>&GO__OEF&!QP7)>,0_/V;V(W_-I_&O\3SG3R)U4`1G`M#Y?#9*;Y.W M@^%P"M'SR9/D8PHJ\L$U6FEH&$7]_8:M(>#DI( M!XVO6A(5P+TF"R>^5CZO0O8X6J`R)*K4CR*N*-)T5:1I/^_P.443PO<;6[!6 M)I6J92,%Y5IYUD;JAXG5ETAR5G%_D(TP83\8-M-D;[>UM_F;9/QQA.Q.YY?3 M07\0#%Q%F%PR`IE04*6E+T\RNB8[?'IEZ'6`$5@68YF3-C MW`FIUMNTE\TM]V9,?3F`-Z_MO4D^[L][J.HH&C=S1N7S+#6W5*3$!/=`L$CC M5A\UU:>^->@EO0Q!FH&^D4:\:Q(G965RM%6[I)P;SU]9UOA/C@:\*+)88!=?:LNQ5UE6.&KYP3=6<]H[Y84_YF5"%P0./)08.BMS$S'4? MYK)'I;(`K^!2M+B,'&L7M"CV8E`2D3S68,_0?@,ILT;L@!+$_*/^9Z>>X`_K M8^A*ZI+YI-T0^%@C@+NFJ@@4@6A@+X,^N9HCQWC4\TL<7(A--86E/$O:9NZ3 MV0#J!70NDCO)4M17)5T;<,G+5;PW\8\T6Q:XO&\J8./9-E7Z[;HWX5@X)>4A4VPHX[6Y655,&73P!Y((K()U*;
@=5>OHXH.*O_% M>L1_82,D,,0BZ+:9<8S6TR8OBUDSW4O9<1P*H$WH#_(454:4Z@KW3I./-V/W M$>7OB+>0R8*3/G]:7'\A/Z?CT=-]?UFHL+=<'F3Q45/BN;Z4&OYA8\W-J5OQ M8>LJ,#;8413Y[I=F\)@ZNOI)S)`5_)#T%&7`:LBQ!H-4B`(V^C!_79!G%0V/0HS`G$6R];DPFA&+)XH.:1H* M$%3S$U_%DG=!YU4)<`$=)*B@4L&3$/_^6>=9^^\Y-HP9#L8@V%A,1-(:>DP*D91A,N@07GH?$*F@6_FABO07WT":Y M#$TGUFM5X2H,B/&'FQL89^PK[]O*858I8%.H_D1OO_*R<0>ZU-&.P M4*_AQP<.3WB>X\'6QYXP:$H3`@JI(84$,/IE1<@'"L3WK$NJ^)IHWV$EJD.!DSTWX$.R<4&,^]F(@+\0V+24-8>4P3T6 M:&)X427HIB+=4`3=MMI*"L8B&0ER?Y42L&RN4&A_*!^,KP;>0H+ZJ\EZD#&S M@0-:&"`Z?'HSN+[!*1C24TBIH)]=DBX947Z=6TY=XM53:KOO:8]42I5HBXG00*G11-6*;@"8#`CWL*DB)\D MYXOY'Q["'\HQ`,95QFI"0#W%!<25O55WI/WX>*NU_F*KM;?[8KD+Q>YK")X%B?5B@I?A846`!)EO=XNX3%A`>OR MKZ:S9UYPHG,!6GA3S,2 M3/#D!_<"B;%+7"Q.'3J`U`'52N8H*`:6%IP,B=A-FD,,T0B5'`,EB/$KF-K* M91(+E@33DQ2QJ"=H;P6#:`D7?>B(,HZ>*>9)VG$NOU+.<,G)I1H)=@J>Q$$& M8WF*X,V>HLS)Q'J.#*5ORR=/.9#OTE]"A)"36DLA;JW2T*ATS(3IRRLR4!*^ MZ>!'R\Q1<.W@P)TJ?;OU9!6;'=>;`[^BYUFT+0[5M@AM8MMB6'+T'R?@!K99 M5"F%$R<"8,F\`7+E2$M!RA'6P[NEVJ7/W@&$?IKWI\GK,?]IF>-RU.Z\MI"Z M\<5]>L)5=)'R\O?;G7U[O4N%H9=L[=`T1\9!O30?20T:YWF%=XD6?&8_H\[4 MJR)VA`'"\A<9"6%Y$".!6"GNCR#PSMF$[#]"6_*V%*Z%V_(3X">?+DDG$\+J M8(!-0KSWSL"2V-<@'=_#S0&(8BTDZ95!D*O9)]N38\EMK2B4-,YON%((AW'Q M@,O#CI@9R.FIA^82?6./*L"FEE;)]4K)P",=F((2QD[&H^NG)RBD_D(3[5?1 MQ`:+E",JUY1!B\0HR@`%%34E&3F:JF=NX"H:$RT7V4X-FN1ZX8_6(7& M4[SF8?WOT(!EX;,?^B@,<$F/4LM4XLD^H_4E"E&E?K/P7=H'-%S1RK+U9DR( M)STFA,^$&<]<*8T\SJ??!,^3&8@]:?8Z!Y(1X%MQC7*@@B[^OJIBC;]+(,B:\[LR@PT6 M[2IK$+S9JXO(%.JU-BZ>7'%?ET[T3K5]"!+?+-D1(S/?5OUR*5L!3`&V.M`#2$Y6E0VHY(-#03S[% MO0Y??97\'TU(4BEJ1#<97WQ@;8;!*\+Y136)OTE M?>**4+!)9%S*[+O][UD[%5@IBJ&G_L4:O9X*']3[9&3;I0. MGS*5U-AO%^?265 M\=?;K_5MR"[+SZ1S<#_97=^!=Y9X:&&Y<5U_`^BX5%GQ!.MY@Z1H(2C&'T1> MU5+SZ1)`+/@D_FQ"DTCN`TD&]Q\RG# MGEL4HE`.M\/+H8P\10`90/-,&!X[UB>KBE5MFDLSNTD6H'(!W5U3)#7TX$X_ MP)!#^!$*&)\B@J$\`I>&YDA7BBDF`,<"FT!N7KD:"G"A3BL)9RK\`'4-1/". MSE[[WR+F9$SP(F=*JX:+)D)_O=6HVOW^RQ9;'HP^C.4F!3\.+@@$8#WP M<="`\>U"?5S;-@&DY#*[28?P&UX6JP\;1"17SKI,6AW093\R;S`%(6GU#?/1 MO9,2@@GQ)4"R?[GP:SG*8=BDA8+PK-&BX9GC.0W=5];`#%Y#/RD0\G=#*MM4PWN:,$9]_#Y-&-!E!@+5YT`Z'[.W:TXD*;-CP;KF MJQB0:SG"(TD0JC;BR5,_U06ZUBMYO7!JI<4L@2[NEIE%8=>8*B+ MUH@#=$S<1J&8\"OQJHI07?`32&^NE_;G"6$EL-4]'^X,Q.2,6!.'V391@H^6 M[#GFQ/XD&ZE=IT*3Z1-U:=@_AN@<=CQ"#PAOY^GD[AD*_=[%6#=` MB'1,V,K0(>2CRHZ32J6NZ"=E;H!=40M`B%1SYH7'&SL;K9<;6^Y!/28U47+E M$"C/6-%*M!>`**B+"7H<09ITB`UG6'44K+'[7VD7D=%'TN*?>&+`*`0&426B M\LZ;Z8Q=3\'V"KDDP^PU0HU4[2!JYIO@21CA]$+]RU7,?KS4-_NKZ^$Z;R^X M*)!;!11T)6N$B>N^2>$0>";IQ?9ZU0-1"%]=H70LJJO0`="1I"W$A/-E%@F" MQF\8E`-!OFL2\<[<0[/ MV?DE;P,?&%$+;/Z14O"-%$FL\8WFM@<68U/]'(-2;M^-U3[K4V$B\@K48@=# M2SBOAF!A[JF`6AQUC0D]:8WQQ#RQ`KGKO<0AASDF)(^C(/A$DF<=/N._3_GJ*?C,\-+L7('QQ#T_RUB4 M$<@U[J<0JG20/?5D!;YG]F.6]R@HKBS5'2FJ='\(_)=^^7%9`?L7,8(+BJ(2 M#(?\A]=1)*FE]0]AK82\?!C%70KVRRKFY:8GJRMX>N<)%YL0E]$]N>BRN`&] MII*HW*!""(H4V!:HB)Z'GBIP2`9;6$>``HAR+2UE8W"1Z!.0DH*=V):-TXO=QG/]@RLC7;*JIS`J41IDD%S*/L[$2& M5;D\]R&"3VO,[:F,,.NE!:V$-_!X2'B4*APP^#VZIE83OS)((Z'5IJ_7Y27; MC@-U`80:/#6XC[X)P'.B&&FVADP0)SSTMNRLJ%=!A5SAD$%]ZEJMPG^0%L1- M;V)"J)+*+S2@PK';JAC'=&QEZL17+Y\*T!45"D6%T6+%Q=H,2IJ>T5KN#AG/ ML%!]$7+BQ80>.D3FK#&;^5!/\?T74DTW_%ON\5U@94%#_[9J,>;E`R`*%.5I MV4AV4YAP:/(*TE"NWG(W#3M\\#HJ;=0__<__[CHFYHQFKT[DB"<;N%^7JEY: MV!!FBHG^O\Y1N_)/K3W2)-F4L^/3D:$H'8(JI/`,5P5UR/\WS=-N:D>,5D5O M>)!8<"_V_<*C/\06!0Q<#_]0UD7=I+[JO?>D;)OS). M6#\K+=*:F%;(3IY8D3GCDOH+[(2+GT:2!;?'5E"V%@DSY)>1IQ!(6#Z6S(AP M%5DT>#HE8=Z/+/EH>/FH3I6@:51\%H8J5%^,7RV_5FKA:H>%&SSQC-+-*$M/ M*EEJ-^0TE%;QK9S1Y2:H&5$<]XV/E6\F?I2*/;'=D^4'H5).N<)V*J)GKU'7 MRJ1(=6(S8>GPN2?@?K0*1YGN#(&V*3=4&QK.`V=,*$*?SY[BX=]"`>L/49"_ MR%^6$6F7&;/#4.7^VAE00VW8J`#12B(5GK-92C0+YI4B$WEU[5]JV*E4\9F1 MR[BEJ7"[RUUE0MQM^@,&(>+`:%#AO"!*]##3&"O.*O/E96M+D&J1+VI$T.Z< M6)I`RY0!O0R-;&GS5S$/C^04A:-&5&BV!H"4+`FI&V>HR'C1=RV_$:M')Y:^ MWSGZ"4MHV]V\XD#]Q$BA=+*^>KJ^F:RU.^_C/YXDC_:1W:)A M.%GSH/#EQOJ3WR7%<6=%JG+QY399U3MLYK-'))B+,8MBIVC%%DA[)7!B8$#1 M+JC.VSGU2.@HJ7`]*OE7<8#$,2.@YPMO`/8+H"H;XGL-9YR?9KSI]5,;55HC M;-C+C/<5;\BK34=L@!*?3$+<[PP$LXL?R=9B\F^+Y(<$%$/!T4CPCG:I\=XE M)\Z-K#_`ZP]%(Y8H(@S3()3*04K['F=8>E`KTC9"Z5N%,UI_^8(Y5HN3/TO^ MA%48>QE#UA=W"HDRRVAHC:,C+U746]G5HA>5-U2!0O#Q/)52JF"OZLJ7^JDA M(I^].C,:8&;U$N3S4"VARBMHJOF*Z;1N[+Q#>E5 MXU&MU]FRJ5U^VSBUX+IXY%6ED@:IPCK=T8?L4;8T]`W9;]C/M6M\,S;D1`=4 M+]:2?DWP-C(,&A/PL6\2JOFM^Z9TMX\V%W]6%/M?U[4Z1-'O;! M`AQEAXMD14$C^1;O[2AWN^";UE"CA2Y19&D;_GOO1M19>G6HB_%BMJMT%:OC M+O]ZDEY:=VSHH30=5C3=UF=Y7'\@J2+W0WO.*BJ=J$:.7:D<@X8`KCA*<&US M=Z^UO;=5GV;IK!T=8;&`]Y5<\K0^UD*_9/`-0H7$N?WQNO'=XYW-K4*:EA/; M39*U8Q]J6W,M>[T,`[*P^EC$>WCXX)#C*(Z[AT]/CH\..2N"'+\^.42% MZ\#)^D3&S%O&S#_SR_;#>#2D3U@+#:17BI/Q&_R(1W?O[!`[B0"*O^`!,@QJ M(S2OOQ73*WI))LK:O#S."TK;8I9)43:%1_E'J(;PT>.-W8W6^NZFDVWCY6YK M>XD"5L>)H\N6P(.A7#<#`!P(B6"`2S)+&6RA.3$Z@=C4X)A6^A")_BLKBG6B M)NXA^7M?/<0V*#_>9K.;\]+CW=:+O6WO&+:FGV"QJ@AZ MP0Z8#=6/JIZH\Q'FA@*5VB7JOYQ:N+;BX,Q[&%F%8[3^WQ;TB2:*=V*4Y49X'MR^H:?/_9+,J6MJ>%8K5 M7#/CDBJB]'1[25'SAAT1NZQNM9OO6$XB@43R&H=0?MS)F+Q&1&%G/J(](JOD M@#G2;CY11:7FD\Q>"?G%A^].$GNSCKS=WTA5JE]$_7SV28RNPN#XZZ6 M07%!@!$P4F5L)2K@\H6!;4A`F'BYRQ1+]SRJ15O#JW>OR[\+A"5B)@]HN<+22IU0KVXU;YX^9V:V/OY1-@):5:[!P5:QIOA8VB++4X MTI1DJK8VG9.!Z8TY`J&C^`6=8;DH/^(`1YSM`2K6A.W7K%L2$I2R=:#[]VK8 M\/1[.:7O(H^,!B#]]`Z/T3JN-$H/ST%]2HHL?%PDD1X!NH4MG;BX=QJ[4N#J M/=OQ\=W+O?\>-7D`AI6Q;)/%0I(Q?"W:2'`G61\%+C*9(Y:K$Q\V]^*9`74J M",UI`'5&.E'WHV;62%6H:Y6$QIUECUS1JAU1H_()3 M=7]CN6J`/:-/6(?>;KR(B-"LU6I?;%H!=/U465DE"*UC7#O1'[_) M!IQYCQR1'586+TVNQY`37'!PT-S,0HB7&'_.0H8KY@^3^W]3G'_*:Z0U84W[(B4C2U3/QL5W;3Y M8K>UNZ-FP>KK*MC!,/[Z]KJ=)Y&L/7ZQW=K=VQ5.$#+>+XRIG^#AK^\5JFUC M=Z>UM[<>U(OK-^M(4=;W'=T>#I1KUWN$7V)"I=H1ZUI8W.PIL*C1"@$,%N"N M\/4B-MG$+V(MTYDZA_1I%2+$[6>KO5!>#B=&B!LBU59H/1.4@D2;NU5)CLNJ MBTK!$2)!(3,L,<^*#>6EBQ@!>*BL"`TE?NQDFY2$US4EJ=A>4/X<)>@?+@3= MR/Y!.G"8$2)#*,836UIRV$M.$=G"LDIOA1S4`E\&/G8#9_I`;SZ(_Z!?,#X_ MC__$;HT\*,M?`A_$H<:1_TJ,N$IEUQ3LPQCQ?N$M5%F*XQ3)*WSA96"?1?K0 MK;7@^N"'*+$J!D5@A?B*<2TU,+^97I;C@C*F?QOMA5<1"E>NH.OF/;",ST^J M`6-D.F_IO;J7VFYP,EU5-5IG0N"MEZW-K1V+.(F-KTBZN'MPE5DQC3RJN7/5 MZ,?3:RX8>&;]#^J4L,*^L'".WZ=TK87*RG7S$VQO_!^]NJ<+T11->I*Z",K" MFY(8.S1)&`@BJ2*--C95#E/R$8*L8N,*-B&+0.!4Z*K+$#B);V3&J+=2OYI8 M>Y7OGKU3L<7;MY>BIG9R3T@4SV%2A&&-R%#^OABIZC>+-7(UA@=LKW:>T7=5 MC`0W,BKLU0BB_AKB+E14R4;A]"O?=BSJP=71NX[I"CWN6#]8W$80_<#%8,8, MYGV'+AGV\O=':VZ;`$0RQ8*JDUKZ4'-'K M$4>(N^=O%EFZ8!'PH]<%HT3_\:/G]Z3Q+C1(>W M-B?==BQ;T?2"E9_/7'>@=:I3?_4N4"O)(^7II4[,4[Y`*`NI-\5JTPF[V4.+ M7MD(;)_Y\5Q6Y`R=$70:JR?(&HY-*LQYVO*C?%3-H64DZDA%+32(L"=?,8X= M]D,)#&[W`>4)H\J9EKDXZ:-YFIHT40Q[=M#'L+> M^HHREV@^QMO=VWBIY7/_R8O6)@DY`?;S./8+:>"S48!Y._$?XHT M@]FTA$1(5=1HL]7:VMMZ(D__#W-H%=SU1:H;ERB&IJ`E.X,Z#,TZ58D/V&"#08"@>X=0X"W;P%$P5\3G-8VNGS\YVYEIT'3Q^QH+"^!"OP;R M[(CZ%O.#U[CXBDHRI`MB'XL1%`[$BV:6=`X)O>+PY'MT#&=$G[T[3+KM_[)" MT^R:IKGOM6X%2&(D/Y%$W`P5?V:?=ZO:V:`AJJOX)LA]T6A2)1]V%#VB#5O$ MNEQLHY;$3*?7^)8<:P-GO-@_`@O0H#^,3IDDMIH`US:>2[:&^SBT4TQ[P;S5\'(\_L&TF^T(*KN!I/!4^4X_<,"1-;Q5Y$Z- MY4RG3^!_DC#H++:82P`Y(;4_77!@`$:#:6,8SKQ*#MI!9AZC3)*0$Y80HD<] M6<:*:\225/&@*44KO#Y1SD@;WO`:E-0.AX]H+(')T:W6->1=#`OQKK>"^5F% M.%36DA[B+NYOD6R@3,D5/A",[`4APP?D3TYX"]N M7RW;V4(7C`@;/,O(-NZ<+^&Y6Y'S*V[5F_J)86+"@)H*%Y$8F^>OG93WV2W5^8])[**:J_NB M)\2-X>BY8,MDPF,S]8*"DX(,MLCB6L4,=D2!T3MVS/(/.T$^6$*T@,`@]8L$(X_B&=OZ16] M%'H-U+6'UW'I-R;:$2(Z<\3/O=A1*:1;CBCSPL3_O]MK,]8TM@[8C@:AJC35 M\A6TV5T28+?L=L65C3=1%$]5-"7LP@F"-QH/:BF:#:.=+\Y.BL>6D'>2GX=W M)(.LU)4*-P"E31HO.&=+*NZP5UO85!=;UF211QB^[)E MJF1K&T9;'T?*-9E:N'X3VW297Q"W:+`P6M61IZ))ID*9FBKPXRG5!O3G5`X=)KI?DI MR%B'JYS8S_>;+JU(0MT#&79*J!G>!D*L!67YQ//!I#1HJFMQPK3KKZMKL&Q^.UXJ:% M)CKW7,R:+Y'S00/\0L]E:;*UX*#7<;06+I&M/]_W.P%"NO4!G-?@Q*RB6\1V M`^,]3TK6HR?#]AO@/=_Z.2!%%L'SXUX3+GWDL`>]XBJCSSVBE2V79@Q5"[XL M&K-#I+^DYQ9W2M?QL_CK/3F*^R\Z/%7WU@O/A]Y[(Z+$MN+&LW5*^WF(7R6! ML5`1&XPEWVP#Q@W2'FKK\""6(H01"O2!:U4E<@(-X@_W;'RV$4QA3$@>&OOK`A[YW".^JP*1U M5]BY1AP8N+"C6E@BDZ*-U$OB_6`(-<@]]!.70./*KO:XI`+`F`XIV:J^JDBU MAQN&Q=#$,AY<9!$VZAL2<&>*4XKK\W7TAC=B_7;5C<]-[]PCM96KH#N_#9>! MUZE\0.K;>"&D+_G9"H@]O&^>EU#1<+J3>+E%='>F6,B'^!V MA@P7D-]3(XM!?\SP;DL?H'^L/:6\B#RHE-!9(-:L<%YC>@1L%;MREQ":'+-- M1D&YVAZ_UM559UP+L;1\$A]2B&!QHH@:O]M:&3]_XDCK6(_W5!;WT)E3'1J? ML'T?%`'$BU*4*%F^UV5!4G`W%:;$/AE&H/3!9X]W:'`KA3;8NRI":?[R/@+! M:LUSWG.WO!SE$(5JQ4@+2_.&O#@WL]*=2\3R>*-/V_%K[Y0#6S-&B5F)O M7%\-)GM;U&S7*[*Q@'W9OFN[9YN`S6-IPWUK>Y?>^YUU"B"6[B*_+_OLAR+I MC8V=W=;6[GK-#3$>[RR4ILM[FIY?A#:!?^5+IT2C6IK*?`-K"Y7(%UD/4S1I MK1!?KM9[=^^]E>JCAS;_L,NH/G_Z_&E\I?^M=WK%5HA%TEA3A-:$2A7'R7_% M!?U_N9+JV!+<"UI!Z%N?5=Q.-('W[3E>0$V4VO MN;>*+>ZFH9:O5L([#?LY?\DU1U;WJ3-?)RC8?_@]1V@+S[9'9,6N0--RX:(- M4H,DE<+6347#R@F$[Q9I"G9^Z=U%I!^*3BW#`1-]@8.2M8TGYK.CY4@S2N&$ MSG;LAYQP7UH=Q(=<.E8QZ3*`A?L3;@NDH$V63(M=VW00+G6*NVR"'T"A<_OT M,^<$]?QLH\K>5MZJH]NZAR9V.J0*J#I\E@NP))(2'#LB7H,?V.D6#QU<+::E MJ;`K##0:(LXQUD4:3(\,@=YP(`Z'AF$BF[1R;=X"8G5OJ^P!@"V+=Z.I/JL4 MX4/[\3;F*9I6S1PN(HO"&GQ[GP%*3.2*^!%VOKU8,BF>5)8WI-!]V[*=T)53VI0\D.C*:^C$%+GL@%!4[*RRE3/+2^(M^8;F$P?F##;3P M"-8"36&6E*"@R%>$&J5_)Z;H%4Z&*U)'O,4S]S0GPV"@K,6 M#]$O"%WCN9K19EMWE3B%-U&PS;W47O0ZXJ*4^K73D72V154^JY?&+6`M3K)T M,Z"[9$WW`_H^=C\>38Z8#IFI:)(R_R`TQ_$;6;;])D2 MTFA!'3OXA?M"*>!8"Y+[PE"7#C;70X%-#%76==)3NDI,6V$BLU1<[DJ&/LFS.0;&+WYG#M3RK+^2/^',+>L!II+MIR@(6Y0,0G.@17S!>%EK4[#' MPC.=/AZL,&C46M6?178M* M-=BU;V!XO5E7*+UJ5LIJ=I=(0D7\7-@B@3$J&@'@.4&=PP]#@XM6%\`H[T3Q M!H<&:NG>2;7B>[^G3,*^562H%/;HVEA47E]X^9ZD%\UT[XZ[[PY/NYVD?7J0 M[)^==H]/WQR>[A^OZ*_;L^S7S_BNC&?#E6+24>I?E]\A+*)Q*];-]J_&O"_? MZO]^K3O(8<@F=Z"S&(R;=;6&^GADS@+XT!A?H<]I=-2%[&AOFO+]X!8[>-U/ M?[L:R$&!(YL#`XKR7HUA-!M]ZH:Y%E;_,R,;6%A%2M@N4LGP$.7$BMD1^@)< M,7[-4RHVZ5G_KFZ'*#;4FBJ\;Q*QBB^_)I?:(>6-8E4YC*K6W9WE^'%!D!<% M'9$E!>6F4PIZ-53A&$2S84JA)D&E7P_'O?;>C#M MZ1M_0#O=.-?#YR;XLU?AT))?61E\_H1+7VRZ]?2@H1;%K#C*O++RXOME][?] MO&.7\(A,-UG2G[4=@&8 M>&V(D-(@=SOOAX;]1=QY1[]UR*3).64-W5QR3/SRESG[M]2JQ8<:/.@DH]D' M9$/'H2$I$Y#'%&$?*SV>?H4&W=B<^J#1=`?#Z>&!9?G((%\S?M/U*WIM_\*N MDW,1)BRC@'U7[&(63AP8;QRC:4_].=[40Y8!3'+_<`W0=]G0R?A]VOO\?PP6 M;G\Q6("]`(>)RX7DRM^KC3RNX`KY77G0`&/8L7;<]9*EP==@Z'H"31>YD&P7 M_RHGT."NF)&G<4'8A"41Y?=@[SP?4=HVM6T2%9.S]]3W^/J^B8>#&98#@QK@FHT&I`(U> MT/U.B:#0<*G7CB3%D9%(+ZZCSTW4:#)6'.@JJ9"YV`PNV:@LQP6H\@"QH'2B M]#HG30^YG+%/]#.R>Q5U/`;S<\*@[:6PY?>LNYCYY&-Z"<@$@AOA=6(Q*2U! M7$!AZM<.:U+M&I&TLPB#].!U=1>ADPZCVY5>\1]T_GF,3N2@1X\$`<*:D\:0 M/`.`]F&R=TS%34[C<)>^19N&BE.#WM2CYPE?W*8PKRY'KK3>55C3.UB*19!FV=Q M3$+AWG+.$GNI4;\D^QE>P6>Q*\G`*-YT5MUXN>['FGS$]P6/<4M;4?1>+.,> M<1N-94L/\CEG1O0Q^V6U;NWHH/U$D4:#V_%K:`Y1'1#PV=B%J8-([(*EDIB5 MRV"\@7TP#A3,"/A<6X9[C=;ZK,^#SLN!+.7"SVP>([<]OT*U>B$63B8/-PZW M\?(O=B'/R:@:JB0JO*KC-W1:$YQ6'+JLXV_=(R['T_U*;<).'97!W)(2=1Q* MU\A,T!N%)-#MH8%NYGPGKQ+'M=C@0`YGS(X-#*QZ7U$NH7_XFP05__202=]>DG1F-ARITP4$GA"3(: M'>"X9@%5/"R]%MOP@5LGC(+*@`3N7^1(52OTUA@B:O`B8ROILQ6'Y8BX`5^0 M+08C!(ZR^J,!+41CR:;80:-!`CB](2L((:;_##XKURY0K!2ITBBF#P M`F&1BB+2P;K!DY?$V\E1H!B!%L55W2E.?34!BI?38W%I+=+3F,=68_F!<_OIREQV-+CRNVV!4SWM M?H>1P(TFU$92%JYLAJM@!F1)6NPE"]V%/;/!<"JNBW0)`8*I$Z&KE="+*4TB M60FXBC-%3LU5U*[R(FF\+B(@K^1OJ[@$1/6)M]7:P MO#F.F:GR_\O>N>W&<1QA^%7F0@9H@)9)292E(!#`DPP%E,AP*0>(D8L5E[(6 MH;@"J;4B(V^1%\[W5W7W]/1,SZYED\Y%KD1H9WJZJ[NJJ_XZ^6B<$5]:OL5^ M^,K2Q]VC)STI>\?4WS;$O6;;'#*/A9?1V&T/YQ^KH*1-YLB+G!-8>3Z;R^XT M$JA\7)ASY]A0LBEXJTOTO+;Z_1Q['E#)[LJ@^]^@-SI2WS>#8K"X5"5NF!G- M`FU)F>^X9>QRFF;JK2=A*5`,_G.]+O`'JLC/A+V;PJ4J[!0M?T?B*B,8=Z=7 MQ!CB*).+X@*)?5QS!DHS2$I;DY:%-H`*83_-%DCY*]+.8%M)"O6,0:47K[7E MP>4G07A;'#YCM:PA?FR#Z6.:W,B1B5$%B6&2)1!!_;LZ-P-']BZL"#NNN\9D M+180:CYT5"QYD\Q(K:``K\B3YE*_:O:":_TYZE`SV3T]DO7HOBBDK##&M0KN MW`??KHTHJ2QOJQ>##8$A\2:(*D`4/1QVOMJ)-,(F#_7\F:)J9T?+AG;IFO7U M--RT=L^EZ]G\&\H(T(`Z.5RR5#WP/*`0.')O^]$3"FCL&$L%E0A9+H3+2J1` M"%DU*3%9H,N."?N1,1]XS,S`.5:':&QW1A32\KDY:ULT]1QP]2='O&^OE`JR MO15@JOH0SC=M$G,6L[MR]5*-1=:1\Q9E#I*!78\EE;6]M/[<#VNGBNMZTK MISI550LDLV`PUYS0EI*/+:.,J3K[[_":*B#&^@)=FLME2GV(4-XK M&!ZVQJ`LA[QGS4FA7T]VOG,B/V!"CZC_UIE48.[V>/Y?*`>X:950_B+VZ;!C M$.$*$`S1B=I^V@IP&0#1Z'PF[;2W3U)I/:VY.5282,DRY>\W(])V\GIOM96E\E:E9!"_.+SXA)Y)VA9TH+U-$O%4( M2;U]=3WUEHSD#!69.<1V@9VJ+O''YF^+R[7WZ8.7M\<\MJ)7R9L6 M+VG1&Z/'OGH#-B*2.]LCJ]12G=&.%$)V)^NSTF#7,Z;LR4Y]G,W7UD% M],''9U$7"`AP\(3BF7J+`,%:10L(:!W/O,"_VJ^%G*B_+4H9^1GW0-$21 MDE8')AU>G[Q[;'=_P1,VFS;'8"4S_-Z`8L&_BUN7&36Y!Q97+OY<`%9EI>,] MT]*%#895*YO'5WU)K1(JC2%?059#AR=^,\@D2>D2@D7)SURI7;J,;%\XGEVI M7)"@ZXPM"'$Z_SR=O9-7ENM&5M%DNIS-F]UKJD_@03%L^+VTA_-%LC'TF,X+ MS)1!XCJ_>%/_";J'AH#$#SM"YM\,*K,WH'YY,^_@=NJM;K)\;UY9AI@0Q&T8 M%CC9+L#GT@.13FCC2M/>MPR7@GPKOH]B&0II0K MU9R=>!^9][3Z5.8X34:+Q59`?M>A?]=H"]-&51<^%7QKDZ.R'##;ITDW,BH9 M>FLD[D2N4IA]1'G`D=C\K`*J-ALMXZNHK%1B7F(XM^8!6'>6NW." M]5Y+G6!MUR$?TLI_*UB^B&Z"$$J6L'5\69*-CB+8.J\#6OV0N=9Z?(M M)!),,IM&3#:("C;202>A.%XV^XB2%JE_IF;J'0N4A0H#[]]RQI33V)7LC$3T MEI!5@,130`\SZ^<\.=PB2B#_GFQN];DQ6+(!NZ'Z7E*DJ MUY!LN<5(KM^6W"7JE*$IMQ8!J1M*9(]R*HJ2C&5`)4CM,JCURFLYZ0I`F?)7 MQT"G6Y3?W9U.`2/U@$;KA^)WUAT?!X%7\M:`3B8IHO_)1) M(FF#0@&54BB#0J]C#\V!JQ^<[EPJ`9SO16G`M+YMGN,=0_\@,R)T`"$T\.H& MJ&E@A/WI#>TP((K]<=C61.AJ&&JVIUSNP9 MW4TH=<4JHF\JUF5ACO>`?KY[N/GT,)?X\:*$HO<.'.ZWQ[XHG1A;BLW# M!.]Z,G69+&68ZX;&:;QBI-[E\SRU',U,",Y):!5L-O:FQ6T^WYWL69S>X(/[ M"PH8!0^O/[\[L6#2QIL'/]RAZP8AIM\3\>!>7^2!]Y'M[05?,7'!0<2+JDA: MW6)A^1XCIIH(ROV!]3"Q/3S,._SQ9"IR)U>M/-=&6+'<)PCXV0/([BO:`KI! M78DP=WH)*X=OQ(;^.4&AF%/VO[`\RF]*J^25:IO!T4FDM>`O>!N*[:4JC%HK M)UVXH78;P8&8T=6,6'`EU3C]"=O\PJS1DD-=]`!F#;,.0@YH51^& M7``J/WUS!"0Z\\J>`QX#0*'E17/J93B-=)+S$P7E=87[QV<_$"Y\09#H M>P;A8\`.#MS53T2;OS<@6W\2/#:?V7\;A52LW>P?XB;QJO$W/EE$P'OC0TC, MBQ+QB/MX5#C4VAPFQ3_2U,55<(BV6A[3E[O?'\*B_]F-D`2'71&R9DO%V!UB MV#N4[R_&\Z-=9AE7M9Z11`\)*WT]=_V`!LT7LY6N`K-!6!^E1[95)]JOH9YC MHCEV'_`PV=-$%`CR]E+^/=@-4,X"B12Y(>M#83N4LJ13BMG#\4^OT"T"2E*P MB@1(*3Q>R(O(;,N;$Q%J<,_-5$$@"DPTH"]2OWQS@"GML'?KMCDW#)WN6[^K MSEANU$,($3W726594-F*C3??;JAVV]=9EOV`P:.;I.%Z:!X\ID5E?/4$*IOB M?]\@J?-V4(&(YP%6,+1FX_!D\K5)8R0_9R'LPT@9N/QUM*VL4MC,8U;-L/8C MB,-M3L8FXZ9E]6:@FR!]V^RI[J@;?-`K=X)%NY=`E]1YXS/G?*18(TY:JE+6 MF2:0!]@BH!Z:=^>'J!$8=^F>_$-"(CBOZUV MD795G&(`BN_0^\*X9[1U90]>G*==YPOQ^3Y3GOW\G?>9F=#T*[L M$K]Q-LY4T/2F!YMFV"O2M7U3FKJ]68Z?-+LC=5+NZ3E-]4.DDLV6P.<0+^IT MU6[,(PV$R_F\,N_X2?!(TJ*W$QM0G4T+.5_9`-&E*3$7+Y1$OO?AMA8''1I<@ M@-&DHK-J6#!6)0]W4%8ZU"XQ_4"911?T0X1OE% MM^XD<'HB26*BG$;&$"N=$0<7^'@NN1HV7D\.FGL]YMIJ7K+R6EU,@/S[J<)9 M.0W,0FO.+%_7P[$?'XS]V&M)_)?I%=]T#V;OQU^S]#."\^E\TENRW79V+.`> M";8HY5TDMY=4.>W]#)M5D(!*!7DTNTP$A?:6;^Q-+2%G%5Y0ON8BG.HS#*]B MM!Q(26""\58^.24K'(T3[%$=/"0J#E\WF`LSBA>5+Q]_NN(#TKY"[&?].R=. M*2B`%ONY^?&E16#\HQS12"N4PU/06[]>[IFI?Z5#X-%O6#JHM%EBD$TWZ7]S M[;G1S5C=>Q$3/I0[,=PD+0<),[0',2#:4DBCWHERE$EERM&G\^Z"O"I"GH5Z ML>\22O;%F$'/5,]])\J1!RG8_#MZ_DT;$='"^^WWVQG-T1!MJ?I,XLS>2#!_(R MW+VGIV\,%'0E13/*L<;:*3U:ZRUVYN64_FO+]U66BEH9B789JK)AO6)ZHNVQ M@RQ?M@1-!AQK;#*/AL?7L4)SIX!0NU<5"3'RZ!K$6/'VBMD/GXYF(YS*)EX8 MM;NR]GY\KR1[?JID_P_6I8_884U77<4R:/F`S`$OZNFZFPVEK?OS"GCEBF^N M),AJ1;MR!>\ZQ&A:5HTRK\:UYE5TZ2K960#NJ!C11Q&6G\T2H59"=Q0A]JM$]I':J4>MGU;-I`61&IJ`7R06U4;0N*NL MGT^F>7G4^!LUB?/X*XF_]]Q):C=I[T:+`7D]UGIU=`((U9KA$OF&:I`5[?+, M/-?C-L=Z^YS.XI^+EE%2:S?Z>JTIIUM>3:^GG/;[9A,X1P!@16;91AYS]=0> M((*WG!:MQ.^C&'OV_N"/L0U\^:/-O/:F3>7LTZ(Z%>)ED_;<*TU_`FQ#HOC* MM=;6Z>8`-?C1^'N#^]0LI+[V_JO+-_0L:C3_OU,9A%"A"__C4+Q#>BNXZ69S M=%EG"?\(0$CM$Z_1F/`L<*=?PGXE;;GSK]5Q>AYY%9BLKHXFC@ZR>[.A],KU M@F)BZI6`W[4<'F8&'Q8TECY0'_V`BF*P?W1;;J()*+(66.1@VN\M`> M4+MB!#JYWF^V0EI/.4(9H%P]\L><,7=*V(JCUVCTGCN5.4EAEM@66)Z!8IRA MT]WV64U4K8G^S%+WQ%UY2C(>[M#KATZ,H7 M5[-U.BT_I`B7`VNI9$4%`KNO1X"&0L25VZ^=3W8,TT6VWELUW5(=2X2%^L8+ M_0=SIH,J&VD-5*55S1W&DH3#Q5,N^BSKJ%G^%N`#]5.JG?[:!.01MQF48_8: M?=9&+E&VR+\U@DV$V[AI3%ROS$5D:#R?*\F]_6!4#/B55V%16@#4X3'[\4'E MS7T!Y!*_-OE15L7FR2([@R'>]MTHR8S@8;NYH1PDR%[%E;GL`4CUQ_U+ZPZ/ MXY-@\]8!5;XWJ4$>Z*9"@BGBW>(PL+W-6^]8W`S,W,D4S."D3?=>]9CU]_W@ M(E#U;K[669Z!@;=+SG9U=_"QSN).HO?QKA98_2"VD[*D0X*VLV5DCG)R+RI- M1&H238$9AB\:PMPYW>70@=N#6`@&"X56FY'\:OHAB;:ER$!G:H3^RB)?`Y/*Y6#VJ_/^N M[9XA`",ZX=@[M:LXOB-?'(6NLE3?T&NMG-B1)4<&+:/\,5K;)A?EYO>DT0$G M7\^Y0,9T'K/S[^_QX^:[ES`POGC)RH^CD=FY;)N&%\WBN1\]CLR_/#@7`]-8I6XT=X,X\D;F MJ[Z*XNXZ47X9M%G(1N MBH_)8VNU3#QWOJ)!8="RVNVK5NCZD9E)N`YG*D)"-WE>+R]F<;AT4W_J!W[Z M*F291CB[_O`8Q8D[#0#UI6.[LT*V^+`A/O1G2;R*%^DEQ+7BQ<*?>9LHAZUA M"Y)N;Z)UZ(3IRIC%ZR@=F59YR,B^^3`?F5>FD9D\B><`\9M_K>/TVU]E?][] M[MV[]C^_^?;O?_;F__CAMYO?_?"-V2K4,)GPP6Z9E^V=8O%U)KF56W![LX@C M9D@'-!%;U\]1_%/DT'<(!IA'/[N]6?UL?'$#'.D0O%DDX MJ"&==IMHY0X[D;+AI`U]9U-VU3N;95VGZ_0;M4R*Q4V_D<*NTR25>Q0Z[_MW M9Z.S>65UUN5E^%P90`G7+(L^4G='?O<=>ITC3LX\H9W&8T*J5/1%ZC55&Z4H M/(,N*3A.ID^L05:8W?T@*!=WW1XM?W#D]@;KS-1+(@-$++GR*6]R=>],[H5>ADP518U0QYGT M3R#T?CR<-(]T,APV+=1R\&I8Z/L>O1H6ZN"_26.@1-<]HS=7N5(=#D589`DU?%*KW50.7/,P4-"\VY MRA!H\BI#H,FK_88K<%^[5QD"35YE"#1Y5?26&LQ5-`(UYRI#H,FK#($FKS:V M^,PK\%"[5QD"35YE",[MU6);-;F_=T2G87-EUMCZ.-=%B_C#=8E=(_:ITSB9 MXXQ-<1JBT\8>,3MV>Q-XBQ0[TL1_?**_:;S$O],X37%^X_9F[KN/<>0&>-LJ M1A1_=XS$&2"<[!F9Z9,_>X8RJ<&0<9.I.)6&LNK9M)NP^W:[;_>LJVS#UI#J MT)O[ZW#3NE+WUK@$C<3M?L,9AU&I)`^'JLG5(B_D[E,<(5PM/*TX`#%1A(3B MB"9LK!J^JC:R$6HVL@&*-K(1JC8B=;8E5\'D/%[CY.-;!SO.H-T6N[Z#XV6[ M0`9\2\3L';/)Y]XA6QC=.T:5TX(\U)>-W!A;]!*KXRV6[AFQ:>>>`5NLW#-" MU48Y;K9:7+8NJ#QO0?*&;^GGNV#DI1XSQ\P+@L]4R_^V**HNV9O\VFBNP#,-8-LFH'&>YR&;Q^6H=3+W'$A0%"A3A*[=7J MTUC,<=7G]X'_&(6>Z"F9F9CODSCU9JFX<$'TANOP=&OPX*RW,IYC]-LU^L'3 M6?2C9['5B>!%JWX$E[+^)N.!+M'(@QHNX$&]"T^3"+`S+1#`"3H0T"4E.0<( M3QT(L.(O$"!`*P2`LR,JCLE#+)1+E8B!2B7TGTHE:DQAI:3RA%;6E5_HWV&E M(Y7?HVAF]1:!7M&,#SL`'*6RKL3J*C',[GFK]2?\2,_)>[RP7O!5C0[ M9?&R>-/K%;O+O$.LCE%N^Q98SXL-X90AT%!R4\W1 M31.F=^T8N*LPU:NEB&*V[DT8KIS(4,K/$RA73M;:M.11^>-ZE?J+5S[G'%XY MFZ:C:8#'4W9(=!RO[8B9H_-_FQ?4HRF2$@O`7;.FG)6.:&@7BY_:K-D;`F(! M42S!U,%LG\].`Y'-MP?0=4Z$-56V^[;7("^#3L-6K4-W@SDG774._=]!6.?0 M$V0HGS;$948';@!XSNXF\*OBK4EX)V:/+NM2((_O(=0G'I7\^/HJS..-S85: M9@2.A047#N_8TLFQ54L$CZ:B;[!WBF*`J)=?3)>-`-JK7%SKH6$;(WI%Z`ZQ M:^WD*^W*7I)!-V7C(3+M7QL7QOL9T8IE03;54'Q/UWZ`FSVH241]OAG6SG$X MS@[FG9E=LM`3RV19E+Y,%HK-H;(@(9=%O5\F"W%VJ"RHSV1U82V3A]A#<6%(+DOFOJ?(O;W-C^(<5H6+3%;!Q655?J19@LF"R8?* MJOP(QW%9,/E0694?@9#)LJ'D4%F5'^$%+@OA=JBLTH\V%9J*KYXB]U=;_2C' M*C6<57!Q694?Y5CM*L8JEU7Y48Y5,OE07)4?(97Q9>.+0V55?I3KA*U8)[B- ME1]E[GN*W+^MJ'+$6XH1GTFI?(=WC".:YU4XRJ147I.CO*L8Y9F4RE]R?-N* M\9U)J3P%>(3I^KY\F;/Q@37QY>"Y'R@:51%T/W+,G`C-XV35X-.HI3B9*?W M%,7]/HY+CF0)%CZJ`/H#'KF'I_D9X"5C2(YAVG<>(J;,!9D>NJ+J$#$8G:&1 MXX\:!8>(P>A,C%Q4:?VD(N9#M%R7'I)K*4W=*B(^^M&S-Y?!3W#=5)+&,`[!4<#S$.+%9BGA3411E_-5-(LH6*77? MQ&B-1=5I8JS^YR_5'3:"]Y0>2BGNO2GW`Z!W[BW<=9`^E%^.S.K]'\4=B0BF M_%??^U_B5(@8F=7[CW2K)[(8-^2@W'Q M#R[LKM>[&/;&=Q<]>S*^NW.&;:L]^0\HHR=X7N,1D$<\(5,\R1,GBCOV]2K` M&UL[%E/ M;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z M89UC1"SF67"72( M6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3! M*&=:Z]=;5W9R^@;`U#*NU^MU>[66\/7.=K?;=/`& M9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L) MC]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z M%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ M@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509* MNE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y" MOZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=! MO-29#`P<7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B& M2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1! MM]=A5M-"G9E;S8AFBJ+#+5=9F]B(K5"MQ:FNP; M<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;' M*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T- M,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4M MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U- M9O]2!=( M.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNU ML&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]V9U:!2&DJAA6[ MA8.F*8EQ2.-3@4NA2!C.D8#X>48JWK`5\2UT!6(OI^HAID4%%`>2$_%>DYI& M$:^>CR5EZ)"#[C=GBN*&NWX8T1)>6*80 M_L7O3ORY[=U#`MO5H?W1'*[,("OQW+C:%8*CEUKD,DT&;-Z-F` M_@7UO$+R-#@K(&Z2K#+2IOU_68=T2Y(GR1*8`VC M-<+^&D;;*[J&Z7@&PN%DWEYJ"0Y,^&XK.YW.ACG?*HRZ4F37[71#J!OVNB'J M&0;!P@UP>[`2#+?6(-BY%JS"+.LSY]EZ_^SZ;GNX-%2^>;UT9L-GZ-\K?Y>' MJ#'(\]V!!_K@"KE=GP3K^K13M%68)DAOH37*KN]W;'OI:(^> M__A"E&!-C-\5O+Z;MPJC&D_S[3[PAO<\V^=5;PD@&[U3I@8JC0$7]'[$A*;N0X!4I[ M,H=>9VKF4`^"5O7+\D`%C`KUWPQ&0PSW@ST!<$JI:![D!NVPN?D'``#__P,` M4$L#!!0`!@`(````(0"R_6[KN0(``/\&```9````>&PO=V]R:W-H965TD+8'/N\;GG7BZ;FV?1H">F-)=MAD,OP(BU5!:\K3+\Z^?# MU0HC;4A;D$:V+,,O3..;[<]K6C-!M"<[UL*; M4BI!#"Q5Y>M.,5+T0:+QHR!8^(+P%CN&M;J$0Y8EI^Q>TKU@K7$DBC7$@'Y= M\TX/;()>0B>(>MQW5U2*#BAVO.'FI2?%2-#UEZJ5BNP:R/LY3`@=N/O%&;W@ M5$DM2^,!G>^$GN=\[5_[P+3=%!PRL+8CQEEHG*!@3`%0EN.P,,(<_]_<`+4VPQ(?6>`^L$272O%=6KU+ M]\20[4;)`X+.`^&Z([:/PS40#_:X9$;#_N<7&&5);BU+AN&3`2LTU/AIF\37 M&_\)"D./F#N'@>N(B<,33#Y@;$5!X*@2C)NJ_'?Q!C$6;,788EIU=VYC>G*2 M!'-U^3DF&A$S*6#25(HU+(:N?%N2#Q\LC%3`#13 M!6^?;,&@<')RDH0G)SL,M/-8F21YS;Y7EP^8T\I`U.5B+/A43'PBQF'F8I(Y M)A\PIV(6[Q%CP7,Q<;2<'W3G,).:N(UEW^+A*@W25_FN1FX0N4],,%6QG#6- M1E3N[9`)(7#<'>??;=2/L/$%S)^.5.P;415O-6I8":&!MX2TE9M@;F%DUW_` M.VE@\O2/-?QH/X`&XE-(,"VO5^.O:_@4``/__`P!02P,$%``&``@````A M`&Q<&,:\"```P"P``!D```!X;"]W;W)K&ULG)I; M;^)*%H7?1YK_@'AOP!=(B)(<-;@N1YJ11J-S9IX)<1+4@"-,=[K__51Y%WC7 M7C[!3#\TR9>U-UY5Y?(R^/ZWG[OMX$=YJ#?5_F&8C";#0;E?5\^;_>O#\,\_ M])?;X:`^KO;/JVVU+Q^&O\IZ^-OCW_]V_U$=OM5O97D[MU?7JK#;G5TOQY>Q_7[H5P]-T6[[3B=3&;CW6JS'U*'NT.? M'M7+RV9=%M7Z^Z[<'ZG)H=RNCN[XZ[?->WWJMEOW:;=;';Y]?_^RKG;OKL73 M9KLY_FJ:#@>[]=WOK_OJL'K:.M\_DWRU/O5N?H'VN\WZ4-75RW'DVHWI0-'S M?#P?NTZ/]\\;Y\`/^^!0OCP,OR9W-L^&X\?[9H#^LRD_:O;SH'ZK/LQA\_R/ MS;YTH^WFR<_`4U5]\]+?GSURQ6.HULT,_.LP>"Y?5M^WQW]7'[;BKLTHG?I.ZVKK#L#]/]AM_-)P([+ZV;Q^;)Z/;P_#;#:: MWDRRQ,D'3V5]U!O?Z_)$I"*VJ2AB;N-31)IJ,\G=[<7M,E"UWR MMDMZ]:&X@V[\N-?3H3UW2Z[OV2WDZ3Z>R*P75G:N/( MO9ZZ]!_<,4UWLWJ*U7'U>'^H/@;NE'036K^O_`F>W+G.IV5#DWQ>2'^UCMP" M\DV^^BX/0U?OEDCM%O^/QSRYO1__<`MV'30+TKC_SYHLF<>:)?9)8D5Q4O@5 M[-]:8=MVIPTI\86&V?SV?EHQF[\SH/HUCL?Q.YS[C167NS'ZO1& M"P+N[3\QLU+I>H26-%@8JIF`&%$A@IE.2IF`*#FDP>KT5-GK9''`V> M.]W[#YX7/PS=SL#&*HM'8D$:VN3\$EE*4$B@)-`2&`DL`Y$==VS][7BQVVDC M.[FP0QIFA\!-I1I&61D<`R$)EVNVQ_TUX M+!W+)4T:YI@`37&:=QF6)8J7=%5H66$DL`Q$?MTV$DVQ#SV98Y]?MYLJZ?PF MGK=%$#'K@=!LBZ51@%Q])M<@-T`L)[%K'VA8U+O@EN(/OS1E*;@E$7=+)%R< M;J<3N;47B:Q10#00`\1R$OOTV8/Y]+.;N\W\@E]*+-QOGHH`M4A(%-QUK1ZP[Y*+F>1QQ<)B[\L@X':II"4*-!J( M`6(YB>WZ$'*]78HN[N#:Y)B)77>1D(CLWC3;E)`L@Z2U5P!10#00`\1R$AOV M2>1ZPY1?8L,BRB_\)P1N$9!ANJS("28%]RN)"EU:C09B@%A.8K\^B5SOE_)+ M[+>]Y:"LE9"HAC^V-@H@"H@&8H!83F*K/H1<;Y6B2VQ51NB$1']AE86? M9F2*(&_-*R`:B`%B.8FM^O3!K%[8CBFKQ!9%Z%\D+-#0;3*0XDS:\SX50Z7. MFM,MN09B@%A.8J<^=_1W2BDE=BIRPB)A428XE:0`C0*B@1@@EI/(5RIBT^"+Z!* M`=&!A`C2V<=`E>4D]B["TH4Y[0I),ORG).+>>6SJCO]0I(#H0,+%JBM]&2BR MG,3.W0SR6>]W$Y#Z*IF:9"P.(CX"5-:Y&1<@5T!T()T-#,@M)[%K$9XNS#>& M)O=Q1)P0%BF)N%M)"M`H(!J(`6(YB7WY4-+_'*8(XPZS#8/RJK#P'\V[J>:^ M)"E`HX!H(`:(Y23V);+0A?G"#"3OOQ8I:;@M20K0*"`:B`G$W8#Z+P`2^)#. M\I+894<,NGQ#GF(,RC)Q;5\$$;<+V0\IK8IPA"_>[$TZY`)&[#%D%$1W73 M>><2).V0%$`4$`W$`+&<1(;]FNV_"S7J^%J293+C!E'K8@FD`**`:"`&B.4D M]G550LHHZGR^NP81]T5E+2E`HX!H(`:(Y23V=57Z<6`0=2:69Y)<]D;Y?/;VUR$I.*L.=UB M*B`:B`%B.8D=BP#4+\YFE&BXXSP3U[%%$'''$(1`HX!H(`:(Y23V=U40RBC2 M7-B"9.Y9AK+6:0%$`=%`#!#+2>Q+1)_/`UZ&D2?'4U(&G&4HX[ZD1H%&!Q*V ME\D%7HR##TYGHHRXBQ#&3B[,:%?:@1!`HM;6,I.D`**`Z$#H+M(]?93-P*?L:WF7R&IDJ%'?NT01,POD`*(`J*!&""6D]C?5:$G[Q-Z@HC[@M`#&@5$`S%`+">Q M+Q%Z>LX;AA^\VK1O M5QY>RV6YW=:#=?7=/_29N6$[T_,#J5]3_Q":X,ODKFB>ZA1<)W?N&3FG'Y__ MX)X??5^]EO]<'5XW^WJP+5_<6TU&-RX='.@)5/KE6+TW#QH^54?WY&CSXYM[ M4KATSV9-1D[\4E7'TR_^#<[/'C_^#P``__\#`%!+`P04``8`"````"$`>%2G M]8<#``#L"@``&````'AL+W=OSXYG M=XVW[U[*PGEF4G%1[5PR]UV'5:G(>'7_V M;]]L+T(^J1-CV@&&2NWF(E57-1LPIF('O+[V2\LHU#!LYA4/D.4_9@TC/):NT(9&LH!KTJQ.O5<=6IE/H2BJ?SO4L M%64-%`=>KWG MM;?V@&F_S3CL`&UW),MW[CW9)"1TO?VV,>@G9Q';425S>2YY]XA4#MR%/ MFAZ^L8*EFF60.=?!C!R$>,*E'V'(AR"J`6`0];L+K?R0`-PY,*4?.5*Z3GI66I2_#(BT5(8D:$G@_V+F@^6<+/SE M#1QARP'_+0&97C6$/5-/]5HJ+`^4*NE5-L?C)!IC_[0K8@=A[ M!.]<:"?8L(+4/._]K?<,YJ"UE:0@PB M:NPG4;!:!7=C1-(A;"'+6X0@>"QD-0X3&P0$`T<._ZKAI$/80E:W"$'P6(BU MW]@@T)%\/YN18!9"J^385#.R'HM..JPM";]LD[L7P6-)5IC8((PWIK^)U>!) M![&5K&]1@N"Q$F(=$[&!+-MV]==682=FOFFH4?\0:-;IEC1H2XEU<,0M9N2* MU=Y)C[%M(7C<3+'2IN,2-G MK+Y/>LR5'#P!!\Y,.VGA>G%5.G:'MYC!8=N.K)IJ6D=A&*S_UK4I'W.7,)_& MDLDC2UA1*"<59[P;$%C9C_:7G?86TD_`M:&F1_:9RB.OE%.P');Z\Q48),W% MP[QH4354-V8*S4;4Z3**8$6J$+V58Y_?5S=?=(B76\ M+7BC6\CI!UCZ-/_\:;;79F-K`$>0T-J-&_I!J6QO$]4URV-!"FYA:&+DLIX$6+K8+6!8B!ACOT;VO9V2--B5MP MBIO-MKL36G6(6,M&NH\>2HD2T]>JU8:O&XS[/1ES<63WBRN\DL)HJTL7(8X% MH]WOR3&RM]U^,++[)%C#9 M6"9?@+76&R]]+?P6OLRNWE[U!?AN2`$EWS;NA]Y_!5G5#JN=84`^KFGQ\0)6 M8$(1$Z69)PG=H`'\)4KZSL"$\/?^?R\+5^=T=!]E#_$H03E9@W4KZ9&4B*UU M6OT)HN2`"I#T`!FA^\-Y>BN$!4-]?"_<\?G,Z#W!GL$K;<=]!R93!!\#"S:& M4/\7*8;H(0M/R2DV.P9AL3J[^2@;S]@.4RH.FN=K37*N6!X5OA)H;_"(@9]Z M_'?2CU:\V%OQ1?#>GL,&L@=OZ<6]UXKL<9"<.<$,W>[$BW,Z/KEXE&4#-Y@+ MFM`RWNWR9./L9L3=G.$G^_7"6I:/A-#@*4Q*Z M2(&I8`E-8XG06S\!*1*'W6$X%ZDOR,7^,PYMW^)L.,"AZ7@%;]Q4LK6D@1*1 M&PO=V]R:W-H965T7WJ<_R1-[B/GW\<#Z/O>547Y6GMN..I,\I/ MFW);G%[6SC]_LT\+9U0WV6F;'GWWQ[?RNI;O<_S9@013O7: MV3?->369U)M]?LSJ<7G.3W!E5U;'K(&/U'ML"_5OD;[7Q^ZC>EV]I56R_%J<< MJ@WC)$?@N2R_2:G82@2-)Z0U:T?@SVJTS7?9ZZ'YJWSC>?&R;V"X`\A()K;: M_HSS>@,5A3!C+Y"1-N4!.@"OHV,AIP94)/O1OK\5VV:_=OSY.'B8^B[(1\]Y MW;!"AG1&F]>Z*8__*9&K0ZD@G@[B0^_U=>_#068Z"+QW08+QS`L>%A_I"G2Z MS0?F=Q?%&WN+P`WF'TAHJ:/`>Q?%'2^"8#9?/-PMRT25N!VQ.&NRI\>J?!O! M,H`BUN=,+BIW!9&[H5*%[0?OO; -!OL@H:P?R@V&I8<)]?_+=Q>/D.TR2 MC=:$5./:BJA3R!DAP\8*P*L1=FDW2CI-UXAAD&+`,1`&F$!=^N+`'#*+DV#>LRO M:7R[.^*:9M9KK`+#XC0++&>?#]O-[4++1FL'EF1?5]\+^OCMS`F51FTNT%DSS]OY23'4P<@O0"4.E<2=MDO-33Y=RMNF'ZGK ME_1C#)([$1AND&+`,1`&L)*'S"UGP@>*E342;I% M&6.0=.#](.R^)+TOX?)2C"N`^A9JC=>60#HQ>T9$ZKJ1/P8) M!@R#%`..@3"`E2YX$3/=89N&;(32]M'-,M2:=]-6UXVT,4@P8!BD&'`,A`&L MM&%+M_*^/W4?C7M-MI`DAC)"4$$Z( M,(E="NG*!L]X5WDX\Z[I^\CAA)VH&_SE?.DNC1]4NTCKCE>V MNN<'MR\I=$9GK>R16;>OH?&*G0-[Z0'')-8:]ZW>0F) MP@A)">&$")/8F4N#,SQS98>LS'WTM!.ZAF?2F6,2$TU""",D)803(DQB9RJ] MC9'IP.U,.2)8O?W=F#[>NH9MTAEC$A--0@@C)"6$$R),8FMO*-G*^CQ]W MM>B27T1(K(DJTVQVI4P):<0(20GAA`B3V"5`QFU@":X9.+S'>4JD]R^5'YH% M6G*I4DQ(0@@C)"6$$R),8I<`>399@AG;7]A1V7Y):D@"^]X:'+'M.R,D?D;F/$5$^ACU^]ARQ<1$FNB73^:JPG1,T)20C@APB1V]L@`#LS^BA&< MH44?>MCV183$FJB]X^JB3T@C1DA*""=$F,0NP2\Y0SBR';`U*I'>&J>M`[!W MHTC'N>P#,2$)(8R0E!!.B#QF[E>@*H$Z-59GD,>\>LFC_'"H1YOR59X(RR?1 MGO:GU5\\>:J&>.BNX,00^*2_`(?(Y^PE_R.K7HI3/3KD.P@Y'$I_\!``#__P,`4$L# M!!0`!@`(````(0#75#4EB@X``.12```9````>&PO=V]R:W-H965TWTY^W6UW:TW;W?GS<7D M_&SU]K!Y7+]]O3O_US_U3]?G9[O]\NUQ^;)Y6]V=_[[:G?_E\Y__].G[9OO+ M[GFUVI^1A[?=W?GS?O]^>WFY>WA>O2YW%YOWU1N5/&VVK\L]_;G]>KE[WZZ6 MCT.EUY?+=C)97+XNUV_G!P^WVX_XV#P]K1]6:O/P[77UMC\XV:Y>EGLZ_MWS M^GW'WEX?/N+N=;G]Y=O[3P^;UW=R\?/Z9;W_?7!Z?O;Z<.N^OFVVRY]?*.[? MFMGR@7T/?X#[U_7#=K/;/.TOR-WEX4`QYIO+FTOR]/G3XYHB"&D_VZZ>[LZ_ M-+=^<7U^^?G3D*!_KU??=]F_SW;/F^]FNW[\Z_IM1=FF?@H]\/-F\TLP=8\! M4>5+J*V''OC[]NQQ];3\]K+_Q^:[7:V_/N^IN^<440CL]O%WM=H]4$;)S44[ M#YX>-B]T`/3_L]=U&!J4D>5OP^_W]>/^^>Z\;2_F5Y-I0^9G/Z]V>[T.+L_/ M'K[M]IO7_QR,FNCJX*2-3N@W.IDN1CN91B?TRT="@_1$J[-8@7YCA<5)>XIG M")5^CPU<7,_GL\7U%;$3+9'?H2;]QIJSBZMF;(@"'AJB MWP^%=!/MZ??8P,=":FBD'3H^#+E#IYX,ZO(P<(9QJ);[Y>=/V\WW,YK<-#1V M[\NP5#2WP2N/P$,^CV/RCX8DC<7@Y4MPXK-M*B8XLPT(-;58*^!+H$I@2V!*X$/@.7E)9C;FA"_#]R$]R$W'!4]PQ2 MLMHB$6S!550)^A+H$I@2V!*X$O@,B$30I!:)J"]//!:"]=TYS>LT%FZ*`.\/ M-K34<80=$`6D!Z*!&"`6B`/BQ^-:%G)C&;2 MJ#L:<8(4D!Z(!F*`6"`.B,^)2`>MM"/2$:R'='`0]Y%D_0Y$`>F!:"`&B`7B M@/B9!(B$>>_FWDQI8]& M/!L4D!Z(!F*`6"`.B,^)R`NI#Y&7TXM[L):Q1Y(-`"`*2`]$`S%`+!`'Q.=$ M!!KDS8A(!W,9*J-L5B-2B'I$&I%!9!$Y1%X@&7/0-KF^.]V[S4$*T0F,Q^@] MHZQ_$2E$/2*-R""RB!PB+Y",.4Q M1Y3/?D`J;%F$LT*RZA%I1`:11>00>8%DS$'IC(@Y"J,\YJ-6RJ?X53G%CU:\ M5*J@^T,:T@#I$6E$!I%%Y!!Y@60:@@X:D88HF_(TY$HJ3G%`J@'4(]*(#"*+ MR"'R`LF8@\89$7.41'G,N4J*,0-2U,'0SX`T6AE$%I%#Y`62,0>Y,R+FJ([R MF'/!%&,&I!I`/2*-R""RB!PB+Y"(N1TGY`9S*>084:]E9_'K8HHGJ^,41]0C MTH@,(HO((?("R32,TW8M:CM&:=WN$"E$/2*-R""RB!PB+Y",N=1VIY5+BP*. M45JD.T0*48]((S*(+"*'R`LD8QZGUEI4:XSR?D:UAE8](HW((+*('"(OD(QY MG%IK4:TQROL9U1I;T5DL6PANY$+0)RM>"#2CY-X@LHQR]W2+3;IWR8K=>T:# M>YF9H+4^ON"'[8WB@IU1.O0.D6)T->SFMY.FV,[HDP$?M6:4/!M$EM'1<['W MZ9(!>_:,*OD(HBO/QW"UMQCV=7ZP.$2YEIT+VXCH9'<<#A2Z[*\N6?'QJ812 MQ69>5.RC%2UOPQV2]JJ\1Z*3'W9M$-F$3K3F?MB:3WZH-3G*@JS[W[(:!6&> MU0,**UR6U>*60-<>K3ATA:AG-!M2.&\GLR+)FBW:XQZ&0601.49_Z-JSQ>!: MYBOHOSQ?/QAZ42[F28I(#KWBWD'7'JU2D@#UT2J.LW;6+*Z;PI-&3P:11>0* MY]/K23,I]C^\J"83%73DB$1%V9DGZH"*T52L(5U[M$J)`M0GJWQD%BN=KEDU M\\+*)"MNT2)R">4M0OZ.AYJL\A9%2J?CY/!@+N4P(VHUFZ#E%6^RX@!50JDB M+GMUJ\*]3E;LWB"R"9UHT=6MBA9]LJ(694K'2>LI2FM&F>1"I!#UB#0B@\@B M/*[)IE)N9(F,D>GY27$1WR2IU??25=ST@C14-(HO((?(" MR30$R34B#0>%1AOP',W]-**\ZP$IM.H1:40&D47D$'F!1,RS<(!GS.&DW M0VG'*%U4=XA41'3U%_8W9NWDIK@LZY,%3QN-?@PBFRH.KINKMEA?7+)@UU[X MD1D9)_QF*/P8T0Q/2J4'(1-?JL_39]@92LR(Y/5_N;W1)2N.62'J&1VV?&ZN M;FZ**W'-%FG@&T06D6-T<#V;7<\+%>S9`G>39N,$Z&!>K,M1; M'$]B"E&?4#Y6BHMIG:PXX0:11>02.N'>)RMR+T?4..4Z0^4:43&BBOV=+EEQ M@`I1S^C0[5AJQ)%;E%F]")%EW=JFC1)RMR+T=> MT*H?EXRS*&TSR<@HEQ+1*B&%5CTBC<@@LH@<(B^0C#DHVA$Q!_-B:8HHEXR` MU`Q0CT@C,H@L(H?("R1BGH^3R8.YC)E1ZM0.D4+4(]*(#"*+R"'R`LF8Q\GD M.,X%4S*XN6?'D58AZ1!J10601.41>()F&<HS9FE$UQ1`I1CT@C,H@L(H?("R1C'B=+YRA+&:5. M[1`I1#TBC<@@LH@<(B^0C'F"X'KD@%[]HQ0(L.&:%J$\HC[F(1BHO2,J1EZINY)52M/!EZB(@B-5 M3$.CLN(=?;%[DRHRL@GEOHISDZM;%?WNDQ6YERD=)^T7*.T9I7-5AT@AZA%I M1`:11>00>8%DS./D^R)J]4PW,,HN6Q$I1#TBC<@@LH@<(B^0C'F<5E^@5F>4 M]W.T2DBA58]((S*(+"*'R`LD8QXGINGS3>4.)",JR?1A>7V2K'CR*D0](HW( M(+*('*+P\:GTJMDA#8>/21T^XO.ZVGY==:N7E]W9P^9;^%`4G:`^?SKBPU>L M[N?3V[#W07%`R8Q*9K62Q9P^?34,@;+.8D$EP[2!DBLJ&:0LE%SSA[3*DAE] M8HON7%>.;49U:".Z5G)#)8-N+[W-)Q3/6`SO^U$LH!G05K)31VZ#V=2LF4O-'CI)62ANK0F]BU$AIO]+YR MK81R36_UUDHHUX?G;,K^:2C7]#IHK0[EFEZ:K)10E6H-JE"UIS17L]Q0ENF[ M"Y46&LH+?9V@5D)9IK?RL80V@&[#C@^6T';.;=B_P1+Z-MV7FJ_[T'S%_CYT M<8U39]7ZZLOL]@LM/]CP/?5AM0NI!ZL=&-:+BA]Z.^HVO/N$+=`K0E12\T4O M1E$4M1)Z^.0V/%Y2\48EX>D0+*&M24I[S1MM+5+::R7W4\HC/5&,WNZG(9.U M5-Y/Z:CI>=-*'8KGOAI/1R7AO2RLHZ@DO))6*Z%XJG7H?;7;\'H6UJ'7UF[# M6UI4Z.J8O M#6[V]'7!X9_/]#7)%7V[;1(>*'[:;/;\1VC@^'W*S_\%``#__P,`4$L#!!0` M!@`(````(0#'J:76$P,``,T)```9````>&PO=V]R:W-H965TGE>PP*K`(MVUW'R]YW9 MQ82+&]LO-@QGS\R9"\/Z]K7(G16E:QE6\A(.D20\8OLU)9$LIQJB%]EO%)' MMB*ZA*Z@\GE?W42BJ(!BQW.NWPRIZQ31ZC$MA:2[''2_D@F-CMSF9D!?\$@* M)1+M`9UO`QUJ7OI+'Y@VZYB#`DR[(UD2NENRNB,SU]^L38+^<'90K6M'9>+P M5?+X.R\99!OJA!78"?&,T,<837#8'YQ^,!7X(9V8)72?ZY_B\(WQ---0[BDH M0F&K^.V>J0@R"C3>:(I,D<@A`/AU"HZM`1FAK^;_P&.=P=7,(Y-@!FAGQY1^ MX,CH.M%>:5'\K3$UD^48U1SP7W.,9]YT'HS)>1+?QF/DW5---VLI#@[T#+A4 M%<4.)"L@/JT'A"!VB^#0A9Z&6!44X65#%M.U_P*)BVK,G<7`[SNF0?C@M/$, MWB[WC&#TC)G%4.ZLH>UF=-K-^!HW"`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`EL^_JR;PYHR2FZNBJGSM-Z]T@G0OX/MQI4&963UXVY8T($WC\>7NV$Y MNYK.K\LQF0\^-X>CW#B7P\'ZZ^&XV_[W9#3VKDY.2N^$/H.3<71RH>/$=Z1/ MWS$Y^(5^=&KM6=.G[U>0BPL=9KX#??H.TZOB9CJ>SER8%SK.?4?Z[!<:3;#V M%.FS5V@+WX\^/Q;:F&JF/9+[SX>"&YUJH"VI>G5CKY1%:^]R0.:C+E% M%2QZ&-$?/)3&>37F@#R<; M6KQ"I!60&H@`(H$H(!J(`6)3PE)`8;`47`[=6=.$HI4GB7V6Q>Z-:)5)C.;< MJ#H;A0350`00"40!T4`,$)L2E@Y:0'NDPUFWZ0A!/'B2C#N0&H@`(H$H(!J( M`6)3P@*E(>P1J+/F@7H29W\%I`8B@$@@"H@&8H#8E+!`J0Q[!.JL>:">)",* MI`8B@$@@"H@&8H#8E+!`G0I.+WB79[*SYH%ZDE[JQK.;;-J>C4+%UT`$$`E$ M`=%`#!";$A8["8P>L3MK'KLGR2`#J8$((!*(`J*!&"`V)2Q0IV1Z1-J:\U`# M2F8NHAJ10"01*40:D4%D&>(Q.QWS\GV0/7:1"C3X$E(POHAJ10"01*40: MD4%D&>(Q.\G2(^:3PF$Q>Y2.,Z!Z[!&M*O%B/(=(!,?>S M!5]43+0*[FU`K7N>&2=E>F3&*Y^T&CR*IUZ-`=4!S5O17UR/,XDGHD$X:QE0 M]*P0Z8#.GB=Y/OS9S,\5;$.?CGPX+9/FP]WH%#-WA_P+'3OV*BA-C4>T_L1R MF%_S\ZM"Q\7Y_.J(DH[3[#Y(>*MB?+J1NBG*+*DR^@E)58AT1!>.9GYY-!O] MT-%XE3GAE&;U\M74/:7(+BD>%33!DE1F&:FB58BW1B0"FK1Y&\_F\TQ.RV!1 MG(=$(=*(3$#>]VF#1NN9):F7)NF$LJ+* MSJ`:GZUB40$2P>HT\HM%>0V3$3JIT"G6F49D`@JN%_E*8(-%1U$YD=W6/;3JOD MB+SNG)SLD5)GGHG&$\KJ+EN$*IJ5KB-9A0#KB))H\FH0W5:9>QFM@GN%2$=T MX8BFVRH[HHU6=$26TJ*?#F_->4H#2C0IHAJ10"01*40:D4%D&>(Q]]/AM/KF M9110U$<5HAJ10"01*40:D4%D&>(Q.WW\\:GC)D@V=0)*Q]E;152CE4`D$2E$ M&I%!9!GB,3OYV2-FKU:3%;@XR^ED#LZSNXHJ6H7Y7",2B"0BA4@C,H@L0SP- MN;"^?+5V+VWRH?ON,?*8/4JG.*`Z M=(Q6`I%$I!!I1`:198C'[/1CCW+W(Q M.V77(^:3$"1E&V;J0^$1+?+Q]B:_=ZB"5:((`DJ'WON*2`8KU(>%TUH]3MU+ ML_34SVK-O<[#._NJ/02_R4`D/*)KAW/3I9]9)Y[_?HJL0$7F$:WB/HA,(5;1 M((Q9C4A$E`SC---!,EKE.LB]+>LQ&JTYUT$!+4(@V<&K:'`.!)&(Z%(@T0H" MZ2=N2A0W'L41R:]WT2`&IB(&E'5EIE/\72FF42RYW55 MZ)/*14SK)&I7?"$:K,`8U(A%1X@LF2K2":/JI MB1+5A$>T,H;SK()5.A"^8T0B=/SCA8KYX=743Q"4*`@"2BZ.B&I$`I%$I!!I M1`:198C'W$\0E"@(`HH7M`I1C4@@DH@4(HW((+(,\9C["8(2!4%`Z3A[JXAJ MM!*()"*%2",RB"Q#/.9<2;C'E[/R:DY%W/-;0B6JC("H)2X^(IZJ=32M0I`<4:J!#5B`0BB4@ATH@,(LL0BWG23]*T MYOP"&E`^MXJH1BN!2")2 MB#0B@\@RQ&/N)_$F*/$"BH-:(:H1"402D4*D$1E$EB$>O?J-5G/[GC@$)M)*(%"*-R""R#/$4]5.$$U2$`:5E@8H0K00B MB4@ATH@,(LL0C]FIL8\_6YIX\9:N_![%N5X%JXAJ1`*11*00:40&D66(Q]Q/ MXDU0X@64CK.WBJA&*X%((E*(-"*#R#+$8I[F$J_]XL+TJK_P;SUQ]1<0G_WY M%QFB59CJ-2*!2")2B#0B@\@RQ#/43Q`ZV92]"`@HED"%J$8D$$E$"I%&9!!9 MAGC,N2"\_,)GBKHOH#C5*T0U(H%((E*(-"*#R#+$8^XG\J8H\@)*QQE%'EH) M1!*10J01&426(1YS+O+^_.Q'_3<]B[WDMO\F_X9.M(JS_]PQ((%6$I%"I!$9 M1)8AGJ%^DG"*DC"@M"J\540U6@E$$I%"I!$91)8A'G,N"7\Q^U'V34&]58AJ M1`*11*00:40&D66(Q]Q/XTU1XP44![5"5",2B"0BA4@C,H@L0SSF7./]>>E/ M>V'AJG?6?^GTSU\YA([Q.E$C$H@D(H5((S*(W$[>]NS;DSBEZ+0S][2-7T]#-:[KV[7+:T7][=G?-H2_#"=TY[@]I4$M-R$W<+0XO81M[MNH:6@ MEO9E&+24U%*Z5Q_0,J&626?+E%K:RH0^,VII97O>,J$^=-_8<9P)]:';I:X6 MR@'=5'2U4`Y(>G>U+*BE?4F3G\'TFLZMW2B=MY34AYY;=GFC/O1TKZN%KA7)-STBZ6BC7]"2AHZ6@O-%W++I:*&_T382.EI+ZT&N8KA;J M0R\KNEHHU_1(OZN%[7>U4-Y.+VSS M\2DH;_1]HJX^E#?ZUDU'BRO1+DX)Z(R?PN^,GH+OC)U*IK-BQA0Y;;G!,Z(] M&TNW(Z.KI:26KOAHNP9YZVJIB_E2G%Y99MFB'Q/XU'64!S=8'4=_<&GOXI3T MKB-_FBP_T1*'83RX&N[B%,1#9Q`5M;@M(NB+]L\LW>Z8KI:26KKZT-:9I=LI M@GUH!\W2;1BAEM$Y6_0#!^^KY^;OJ_WSYNTP>&V>:"F^;E]2[4\_D7#ZX[A[ MI_M0^IF#W9%^VJ#][PO]E$5#V\VOW8WMTVYW#'^X`YQ_'./^?P```/__`P!0 M2P,$%``&``@````A`/W$'W83!0``91,``!@```!X;"]W;W)K`( MV,WNM^\87^)+FE*I+X>3W\X,\_?8'NS-UX^F=MYQUU>DW;IHYKL.;DMRK-KS MUOWC]_S+RG7ZH6B/14U:O'4_<>]^W?WXP^9&NM?^@O'@0(2VW[J78;C&GM>7 M%]P4_8Q<<0M_.9&N*0;XV9V]_MKAXC@Z-;47^'[D-475NBQ"W$V)04ZGJL0I M*=\:W`XL2(?K8H#\^TMU[46TIIP2KBFZU[?KEY(T5PCQ4M75\#D&=9VFC+^= M6](5+S7H_D"+HA2QQQ]6^*8J.]*3TS"#1-IMCA4HH,/N=/BT M=?:6FWXX4@;-G M>>=C!7[MG",^%6_U\!NY_8RK\V6`@B`J+CY\I[DL840@S"T(:J20U)`#_ M.DU%IP:,2/$Q/F_5<;ALW7DT"Y?^'(&Y\X+[(:]H2-.,ZY(SRY8["8!:L0A1%]_1//!?>$)_<,ISE"V%$P/+DC6L^6R%_/ ME\_?&'%'>$[+U6-#/58N+89BM^G(S8'E`(/97PNZN%`,T43)F%I9Q'^J(12/ M!MG3*%L7UC&4IX>)][X+5AOO'>9*R4T2VP3I%@=A02<&C9J:(#-!K@`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`R(I,6=+@+LM"&>)HP32$\\B(DPN+!Z6AC6:Z!MZ6 M5`T!-J/I&GCK4C4P=*^# M\15[H-\I-#MU35@H$U:R#K8&U4G70!O6=`V\O:D:.))U,+[_#D@:W.M@H8Q; M/:N#ZJ1KH(UJN@;>UE0-#,$P*TLV,B;"`4FKNQ`+9<**%6.U"NR%K3KI0FA' MFRZ$]S]5"$/!4NZA!YBW8_\=#^+\H".1(M?>H7@LOD-%R+>5R$`P(DP).ZVS M,U^#NS,^X+KNG9*\T9,X[`>[C<3LFB!9Q?"E`0%,OHZAPS_@R(=[A?%JP/1` M],9A/)\;?X%.$M/684>#2XK](Y[04`_LDR"&(Y0=)YG'<$*Q^7X1[]G68:24 M+&(X#-@.21C#1_@#'L7P\?N`+V/XZ`3NR1?`)<>U..-?BNYYJ6[[\;=OI^/H:U[517E>CZW);#S* MS[MR7YQ?UN.___(_/8Q'=9.=]]FQ/.?K\?>\'O_V].LOC^]E]:5^S?-F1!'. M]7K\VC079SJM=Z_Y*:LGY24_4\NAK$Y90U^KEVE]J?)LWSJ=CE-[-KN?GK+B M/.XB.-5'8I2'0['+W7+W=LK/31>DRH]90]=?OQ:76D0[[3X2[I157]XNGW;E MZ4(AGHMCT7QO@XY'IYT3O9S+*GL^TKB_68ML)V*W7R#\J=A595T>F@F%FW87 MBF->35=3BO3TN"]H!$SV494?UN//EI/:\_'TZ;$5Z)\B?Z^5_T?U:_D>5,4^ M+]8I%UYI`N@OZ-3P5*#%,F^M9_OQ;YY78_G]F1AWRT? M++(?/>=UXQZN;\O1O9V7Q6%T4FT>A3Q%E-K$6LWL6XX;?G/N1%?>S M9DKO-SSON2=]F3.ZX^XTLG2FJWFR]LC M7'$_^A1^'QRA1;G030U+BDYU=6INB&-=9Y7^N8[R(Y=KB9ED_X@+OC70:9=/ M;7JZ69,]/5;E^XCN>>JYOF1L!;$<%DPD9G?9UU3]4:92BK(HGUF8]9A4IQRL MZ?;Z^F0M[,?I5[HE=MQFTV.C6VR%!"_1_JL3!,/3'NC0!23D/,K;`0+JX)/!/X)@A,$)H@,D%L@L0$J0(T MJ6@-T:3J7_E$/C'K]7BAY=-$!](`"0$$@&)@21`4I5H8E#*#Q"#6>MB<*)D!A`7B`?$ M!Q(`"8%$0&(@"9!4)9H8;`NA_L+?7GB9M2X&)_IO^[VQC%R-Q-WE`O&`^$`" M("&0"$@,)`&2JD33ATJ^`?HP:UT?3I1D`>("\8#X0`(@(9`(2`PD`9*J1!.# M5;,#U&C-=3D$4E821"XB#Y&/*$`4(HH0Q8@21*F&=&58#?CQ^XC5]D:B"*1D M"B(7D8?(1Q0@"A%%B&)$":)40[HRK.0;H$Q7(5+Q(M:*#=MX,+'4G`'D"BM: MZ92"9JFO1)ZPDK%\@73'!]TQD%;BND*!9*P(42R0'GZEAT^DE0B?"M2&UR5E M=>(`27E9J4K*D;STK07(%6AYG0M/(.GH"[1L-W;VS#**R$`:B+&%`LDP$:)8 MH&MDHX9-I(&(G`K4HQHK%0>HQBM+536.:'V4*78WTZ=R:UVMQ$6Y'-FS5J*% M;_[.B,%@RR$@-V!9K_>`;`R1=.,DX@T**-.5<8#E&/F1DG3(2,G MC=%MK:N5S$F.Y"QX:.4C"B12[P)C<0S[K8S%.9)6XKIB1(E$-WI,^ZUDC[KP MK.0>(#ROT*58&RH(>'ZJ%V7N/:25&*#+D9;%UUC"RI>.:GA8?Z^.JI51=H0R ME@@?(8HE4F,9/2;]5D:/J;2B'G7A67D_0'B^&U"%5S<([5'LEA:)=BYD]>HB M\A#YB`)$(:((48PH091J2%.&?I^'*-.:ZVN!0+*NV2)R$7F(?$0!HA!1A"A& ME"!*-:0K,VQ[8^/V1B"9(%M$+B(/D8\H0!0BBA#%B!)$J89T9=A.Y.-W$_N5 M,'X_!**%1*EIC/W'5EJ)%<1%Y"'R$06(0D01HAA1@BC5D"[6L(T+/7(%L3A2 MTPB0*QREE8?(1Q0@"A%%B&)$"2+V#%FNDITRW3/A[J';*:]>\FU^/-:C7?G& MGO?:*ZHSK[A[&+VQY^)IM-EBS1QV1D$9`BWT!)OVZ'TM*VII2SS3QZ9HM"3T M^-CL>7AO--NFEK8^-:,M'#JK[XEUY]"Q=0^_=^@$MXM`FWF&[46RAO;S#=NI]+7-JZ?.A;3SIV]="+Q5\[HNU85/5 MT\>&2=O'*1UZXR\H?E\#':@XF]Y+VE(+.PC``=+QBL/.`["%CE0<=BR`+72R MXK!SD[Z6.;6T/M-KGM`+#9?L)?\]JUZ*Z`683]FB^ZEZ)Z+XTY85^ M=.FMAK*A-QG:?U_IU96<-B.S"1D?RK(17ZCKZ?5EF*?_````__\#`%!+`P04 M``8`"````"$`QZ70J#`-``!#2```&````'AL+W=O![?G8 M?W]%FA2[V'VV9=S+9J>Z296*K9)$D;[[]>?FK?.]WNW7V_?[;G73[W;J]]7V M:?W^?M;K,\X)^[E][^8UIOE^KU[[.%V=TD?V^?G]:IVV]6W3?U^.':RJ]^6!_#?OZX_]JFWS>J2[C;+ MW==O'[^LMIL/=/%E_;8^_!$Z[78VJ]O?7MZWN^67-YSWSVJT7*6^PS]4]YOU M:K?=;Y\/-^BN=R2JSWG>F_?0T\/=TQIGX&7O[.KG^^ZGZM95_7&W]W`7%/KW MNOZQ%__?V;]N?_QEMW[ZV_J]AMP8*#\$7[;;KS[UMR#0&.U?0,!_+>S6?O: M@"3+G^'OC_73X?6^.YSE.-^A-_S!/-1K$9_J9F%Y/M'4\\Z.B6A^7#W6[[ MHX/JQ*GM/Y:^UJM;=)P$/-)H)/U?BD(%W\DGW\M]%Y<5Q-JC#KX_5-7@KO<= M0[>*.8]&#F-+I<(\)R&=1G,,B9:0F3@#$ M$$-;,ARBNNVZ3"KZ1O==C()0<<@:/1YS4&")PD(A3B+$"EU+5J?9^&14Q83H MC`HZ,6E*26-.6C1)B;.3"#'$%7`Y0Y\<&*9^'R,BU%&(DP@=&V=Z^;%],A\[ M(M,\,@IQ$J%C0\#+C^V3^=@1$>>M$"<1.K:_&Y86,)W=0*>6+N`[8EX186.8 M%.71)*5A=!(AJG.F>KJ`?3+3B8B022%.(G3L"M>OU.GTP4,V'SU!V7$6&L+] M\D@[9#$!;X=BH,X0.)HGKM\DZV,5(7'^&G($,0'O=H*`OUE,AC?3]I52'7V3 MR$4(92KL;UK42FJ8KS)'$//U1BCXGA$LVJ843#IIN"4M*@4Y@IB`][G+"417 ME`0B)$M&0:Z2$!/P9GAXFI.$+O+K*R8V#!+Z')#7!I,UYNDH'NF8J*E2KVDR\:*49"K),0$O/5= M3B`:I20@O3,24)"K),0$O/]=3B"ZI20@#3024)"K)$0$!H7-^HH93*;7N$SH MBCTX01@`X3+SHF9R5O).1Q`3;F7+`VW+"1+7F(8<04R@L.7313O0UIN@?(DL M-.0(8@*M?':@?39!4@'MLY3%!+P!BJ*]_L8TB%8J"CI!5#*#?EDRL:&X,>6& MI5G*3A'B^RT&?RX``Y@EBPPI;/$-#>.U"NNM"0(X@)>`<4 M(W:&0/1+J4"$9,DHR`TDQ`2\`PH"OF2JJYYZ!]%+);D(X>C9909563)-5G89 M"3%?;YB"[QG!HKU*3M)Q8\DHR`TD1`3\Z^OE!$(V6V^"A,MHR!'$!%KY[%#[ M;()$R6C($<0$"I_U)3.;^XFEMB]*0^W!">*2*>#R_0Q M^BW?K(?:@1/$!5-,%RUR5BZ8V%>X4S%;[Y87>\S09Q>7>(2D7`IRJ6'(8@+> M_BXG$,U2F-PP0KDZ%AIR!#$!;W^7$XAF*0E(_SRZ[%!!CB`B,"I<-A3,8'K% M"U/HB8VRE,4$"I<-)3-&#RT]9J3]-T%<,&IZ-S84C[ZY M(6J(V;:RY)&VY`1)N;0E4Q83*"SY3,%HXQU%2!:,@AQE,0'OB!=[S"CZI_"8 M!$D%8E:&'&4Q@<)E0\&,PA>RUC6C+7C46+`TF7+.-V=EDVD:JIIIYA(4<0$9@4+AL*YJIGW]`3#T^"N&3*B=^AN6L;\[*]1+[TA8S:>7((;NH866_BY25!70$L5J%(Y^I%^V[DPC)>E&0 MHRPFT,ID)]%1Q:-O@O+I+C3D"&("AGVI<3)"6+61ERE,4$"E\^ MHY.VWFF$9-$HR%$6$VCELU/MLPG*I[O0D".(",P*G[VX:$)#MMP$B:))T.FB ML;/R?!\S;F7,,VW,"1*2:<@1Q`0*8SY=-#-MOPD21:,A1Q`3:.6U,^VU"9(* M:*^E+";@?5&\M/JB\8^_9Y2(;BJ>JV81DA43(?PY83.I(6?EV3ZFV\J99]J9 M$R3UTLY,64R@<.8S.FD[GD5(5HR"'&4Q@59&.]-&FR"I@#9:RF("A='ZBKEN M">=,FW""$!$E4\[CY:SF<88@YMO*EV?:EQ,D!8M9&7*4103FA2^?+IF0S6:< M(%$R&G($,8%6-CO7-IN@?+H+#3F"F$!AL[YDJBOF\>;:@!.$"A8%4\[CY:RF M8`ABMJT\>:X].4%2+NW)E,4$O&\*3SY3,-%EA1?/(R0+1D&.LIA`*Y>=:Y=- MD%1`NRQE,8'"94/!7#6/-]<.G"`NF7(>+V?EDHE]Z7?LN3?0RTIK;VXP(9R!85-(;*N+ M)UCQY>5[3"_EB=8LZJ?)RQA8R+Q"BU:^6_6U\388::&ME_,*%H7Y^C*Z8CZX M\M,[Q:Q`@^'*%C54SNZ)-%%#L3OM/7YW;`OS.::7HZ?,&?N*%!8VXH:3$C5T MW%A[W!"ZJ7]MW5MMO?M.L/Y>'NP8_[NE]1!7X7;T#/R.A8T,?"Z\1 M.C;RL9'=;MSL%"[;S2>W#GYN'&T^121HJMK,$`F5JR)S1.96;[C2/8>PX;AL MA>O/Q\*^WS(V1S,\OEG\T`C/558$$N(9QHI`0#Q<6!'(A[N^%8%XN!T;D1EZ MP^NC%4$;O"A9$>B--Q@K`KWQ:F%%H#<>XJT(],;3M1&9@@$FT:P(CH.Y(BN" MXV`2QXK@.)A=,2(SC`(F$:P(1@%O]T9D@MXP)VY$IAAM3%9;$1P'L\A6!,?! MC*T5P?A@*M6*8+0QQVE$)FB#+V)6!&WP1U%8'2V+ML M1:`T-A5;$2B-W;XZ@E]:^63WA09&_J,?9@OW%Y2!?QK=?HJ_Y%)J[R].H\4C MAM$<>0RB.>X80G,$,8!A_'K-@?$++A_+E_KWY>YE_;[OO-7/>%CMAX_XN^-O MP!S_<=A^X"$6O^.R/>"W6\+_ON+'>FK\M$C?KZA_WFX/Z1^0M-?\_,_#?P$` M`/__`P!02P,$%``&``@````A`']SH6-V_WW'&)+9SH:$O+3C'Q\=GQC/$RV_OY<%ZXW535,>53>?$MO@Q MKS;%<;>R__G[:1;95M-FQTUVJ(Y\97_PQOZV_O67Y;FJ7YH]YZT%#,=F9>_; M]K1PG";?\S)KYM6)'^')MJK+K(6O]@I' MM=T6.7^L\M>2'ULDJ?DA:T%_LR].S86MS*?0E5G]\GJ:Y55Y`HKGXE"T'QVI M;97YXOON6-79\P'V_4Z]++]P=U]&]&61UU53;=LYT#DH=+SGV(D=8%HO-P7L M0-ANU7R[LA_H(G6)[:R7G4'_%OS<*)^M9E^=?ZN+S1_%D8/;$"<1@>>J>A'0 M[QLQ!).=T>RG+@)_UM:&;[/70_M7=?Z=%[M]"^'V84=B8XO-QR-OFK*">OF<325Q4%"WO\>LS=;+NCI;D#2P9'/*1`K2!1!?-H8R^JU> MVREL49`\"):5#=D.FV@@/&_KR%\Z;^!H+B')&$)U1'I!B$"`NEXB[%N5^'// M+TH$6"@1,1#2$AP`[EX:,]8=(_RHAVA*P*#I2@1X97O*PE'0TZ(VA&#""+&I M,J`M#"S3%Q9@2#!EX3`T%D9(W$5J!CGHNIX1KU2#>"P@OM>3:-H@@55M(H.\ MJT?C$B8QR3#'U(@0Q1QE0!,0Z`)NYX<`Z^8$9E00$G;F@#6^F2_J\R",K]@2 MZJJ$+5"AKE2,BRUBDJXN&E(1.4IZ*: MWF^65+44'D,3($#[-/A]#8'V3KSMU5VNFXML=&X4XD1HH+ M8P*YKYN:ZA!*`R4U='6BYMYO(59J+:[#X9,6(D:J9,1SPVCDH88!1.@--+I. MHP=,S#^LY.!I_]L@-C0D%#%*H5-'=!%&R;]=8^FXUL=FK9<8L*$7R(P#DDJ, M--*CGL*BRS-:P$2/L*YKL31[`44,2F"$Q3X999P*F;E>X)-K!\)H&)^X..X4 ME!B%-J$(NFVCUB[@U`R)H+G(OM0MNEEZ4:&*`7@D).B6C1IDYL9^3*Z<"/:E MKM'-TCL_-6.92)!R)-01W:TO]04V[@N4&'F?2-#-H$H,.AH%?AQ><^M+K8*- M6\7H9T@B0;=U(M$$G7=U"S;N%I28[4*"<&W/(VYD'.]40[CNM?<`\2:K]HK; M![=#FR=BB(X\$8+RTF?A'63D;BII4+WK!^%00O5$-!K$)^*PZ*M%CRH%08I# MD%R:D"ARAY+605*F0FAT]5V!W=4Y.K1IW;!OJ0[;BU3GN5[L&I%/)0]"?,\+ MAZ*M>V!;H"3S$$37>$.&7]KJU%TS M/5CZ_\!``#__P,`4$L#!!0`!@`( M````(0"L([E>P`(``/<&```8````>&PO=V]R:W-H965T&UL ME)5;;YLP&(;O)^T_6+X/9W)22)6DZE9IDZ9IAVO'&+"*,;*=IOWW^XP31LA: M93<)-J]?GN_`Q^KN1=3HF2G-99/AT`LP8@V5.6_*#/_\\3"98Z0-:7)2RX9E M^)5I?+?^^&%UE.I)5XP9!`Z-SG!E3+OT?4TK)HCV9,L:N%-()8B!I2I]W2I& M\NZ0J/TH"*:^(+S!SF&I;O&01<$INY?T(%ACG(EB-3'`KRO>ZK.;H+?8":*> M#NV$2M&"Q9[7W+QVIA@)NGPL&ZG(OH:X7\*$T+-WM[BR%YPJJ65A/+#S'>AU MS`M_X8/3>I5SB,"F'2E69'@3+G=3[*]777Y^<7;4@VND*WG\I'C^A3<,D@UE ML@782_EDI8^YW8+#_M7IAZX`WQ3*64$.M?DNCY\9+RL#U4XA(!O7,G^]9YI" M0L'&BU+K1&4-`/"+!+>=`0DA+]W_D>>FRG`\]=)9$(<@1WNFS0.WEAC1@S92 M_':B\&3E3**320STI_O1K2:^`^KBNR>&K%=*'A'T##Q2M\1V8+@$XW-@#J,/ M]:U((41KLK$N&89FAR`T5.=Y/0]6_C-DE)XDVVM)>*G8G16V$$#7(T+<0\1_ MY_Q,8L66Q-;`HFW=!GCW:-'HN=>*=-Y++D@@04,2FZP8>NE](GLHP\D`8#Z* M?.LDKG$L]&ZP<0$`+D.`]Q]LQ0`X?/`H]*V3++J*3:`7XSA)^]"[_.TN)$DT M#=*D5URP02/?SF;%([:XMW6%N_EP8F M3G=9P0>&0?\%'H@+*&ULG%A;C[,V M$'VOU/^`>%_`7')3DD^;K+;]I%:JJEZ>"3@)6L`(.YO=?]^Q!UC;I+E\+[DX M9X;C.3,'G.6WCZITWFG+"U:O7.(%KD/KC.5%?5BY?__U^C1S'2[2.D]+5M.5 M^TFY^VW]\T_+,VO?^)%2X4"&FJ_*U@*3M+1,!?#GQZ+A?;8J MNR==E;9OI^8I8U4#*79%68A/E=1UJFSQ_5"S-MV5L.\/$J=9GUM]&:6OBJQE MG.V%!^E\)#K>\]R?^Y!IOJD*]$]!SUS[[/`C M.__2%OEO14VAVJ"35&#'V)N$?L_E$@3[H^A7I<`?K9/3?7HJQ9_L_"LM#DP([FQ1?[Y0GD&%84T7IC(3!DK@0"\.E4A6P,JDGZH]W.1B^/*C29>,@TB M`G!G1[EX+61*U\E.7+#J7P21+A4F";LD\-XE(8D7A\ET]DB6J,L"[WV6T`MG M"4DFM[GXN"]5II=4I.MER\X.]!XPYTTJ.YDL('-?']S-4+'_*QA42B9YEEE6 M+@P-U(*#RN_K*"9+_QV4R3K,!C'P.F`LQ+9'2$&!WL`1ZJ9SO*Q=3T6")16I MI>2VP07]NJ');#M&D/D`,9A`A70FLEH1].1U1C)HY<;:QJ/8HK!!#':@9+W5 M%@P&D$9G6X`M`N:7``8SF(?[F4FPS2RV MF"$&F3U=I*8C+(!!;?((-0DVJ<&$6=00`YCFTRW858K";FNSN:RH99+*, MXL1BB1BMJ;0%@X&\VUDF<+NM9="MMD:,QD!;,!C,30;7VUJ"[;U;Y=\@IFOK M8#8;Z7,%8#`C,-^/%T=%V1SM+NI`6GGT%9.%],:')2+HJ##!0Y^.K:<#Z2PP M3*V8+!YR8H*^:MK/U.K1#J2/4A3/3-!V`-EW!B)M\O&RH+F:Q+X<'WU1I5ZY M>EDP[$)9I$4^S@*-]88X"-)9:"NF.-(--1;79T@^!(V&:"0.@@QQDL`6IP>- MQ'G(=LG8=Z/$>D+8=""]'+W/CJ[^0[9*T")OB*+YJ&J6;1=VH34L:[TA"MJC MV9BVLY'>0[^&>F1N'09OVI-@,OT2S>P9RW?ON_>0"P:N;MMYS8B>T_PW96>],TG\N%ZW?9*2W=&-\3TOC\_;G MG];O>?&E/*=I-2(/MW)CG*OJ[IAF>3BGUZ0YTO9CV9+(PKTEV,QH/3O$1'_GIE!U2-S^\7=-;U3@ITDM2T?C+W^Z9!?[^3B);MDU??:J3&Z'ISH]987RMNMC1A$PV4=%>MH8SY83VU/#W*YK@?[*TO=2 M^G]4GO/WH,B.OV2WE-2F>6(S\)+G7YAI=&2(.IO0VZ]GX+=B=$Q/R=NE^CU_ M#]/L]5S1=,\I(A:8<_SNIN6!%"4W8WO./!WR"PV`_HZN&4L-4B3Y5G^^9\?J MO#'LZ=B:319D/7I)R\K/F$=C='@KJ_SZ=V-C<4^-#YO[H$_N8[H8SY>3J37` MR90[F;5.K*?.R8-?IW'6$=`G_W5KU4;PH-^"]Z-/,>J/=%OR;K2`Q,]];)PK MWI$^VXX/9;4H&9JY85G1"-_-#49F-E-;9XJ;5,EV7>3O(UI^-'OE/6&+V7*8 M4Y$CC8LV:WZ4-)0MS,LS<[,Q*&Y*B)(R_>O6GD[6YE?*S@.WV:&-I5KLA05+ M1>;6U8&G`U\'@0Y"'40ZB"5@DBRM-I2S_X(!\8$$0$(@$9!8)DJ@-(4# M`F76:J"<=*M^#\0%X@'Q@01`0B`1D%@F2J"4A@,"9=9JH)Q(,PK$!>(!\8$$ M0$(@$9!8)DJ@K*K5GW3V?$P9,/!9QQRI&G"B/OYFVHINC<1B<(%X0'P@`9`0 M2`0DEHDB"Y47R)'=P))\XO(1>0A M\A$%B$)$$:)806K,K(H9$'-3]"@Q=+6(6((D2Q M0#TRL%)F@`R\\I%EX,AN%\7>`N0*),M@K5:Z#+SCLO7E=QU%S`&B$%&$*!:H M'JJ:#:S0&2`#KXMD&3B290#DLM<+[`&Q;,Z`$PO60VL@PO5%G\YS@"@4J/6L M/5^CSD!XC@7JT8/50P/TX.63K`=']+R1EO]2G?`].PHP/5;MA+N(O`[)OIY4 M7WZ?E377!`XZ*R%#B"CJD/R+6KK&?5;R+ZHIQBHO65+V*L%>L%=+/WCC)`Z, ME"UZ5<&137MLI^Y,>Z.P[ZQ$K"XB3Z!9G9.K^71JKS1/OK"1<[`9%0U!.`_1 M*A*H<;YX>IK82VWB8F'3DX:L+/MOFO&"3LY(CI2,G&DG[[W56HFP7$1>ASK] MK;F6W7YG)7P%B$)$48<>N(\[*W*OYAJK\G3=YM9X^>^YQNM#6;<&:;FFG=KW MM(19DDKIX"+R!'J8:^`I$-WD7`.K2%@]S#6YFZ*9/:S^K0A\A$%B$)$$:)806K,K"Z5U\;C MFI^EO7:D$TB>9V[5(1>M/$0^H@!1B"A"%"M(C9G5D@-BYJ6GM`G0/4PM`^V. MT@-'?RO768D-ST7D(?(1!8A"1!$B=F7$A]INB\T54/-B_YH6K^D^O5S*T2%_ M8]<[]`3>KEOO%"P]'YDT-O'GKX MRJ&#>@^W)@X[SO:UT'CIT-?38E,?V@*PA:I1QZ,:$%NHFG18P8@M="?WW!L[ M^_D>^QT3JX^35/75GJ;(\XS\]S7L9@Z]=L4![>8.O:7LX0N'7NKU<,MV=G0> MPI8]M>Q[6^@L2W+TA4''.VKI\T9'3U*DKX7.0M2GCL5LHZ=[Q7ORFOZ:%*_9 MK1Q=TA,EYJ1^8!?-S63SI_J3GE>B2\4 MHMG>26__`0``__\#`%!+`P04``8`"````"$`3/?(@"P$``!`$0``&0```'AL M+W=OU+1,J.Y*%GBOS/I?]O^\65S$O6+/#"F M/$`H9>(?E*K602#3`RNHG(F*E?#+3M0%5?!8[P-9U8QF>E&1!V0^7P8%Y:5O M$-;U-1ABM^,I>Q#IL6"E,B`URZF"_.6!5_(#K4BO@2MH_7*L;E)15`#QS'.N MWC6H[Q7I^FE?BIH^YU#W6[B@Z0>V?G#@"Y[60HJ=F@%<8!)U:UX%JP"0MIN, M0P78=J]FN\2_"]?WT=(/MAO=H-^`)&7@6X@5= MGS(TP>+`6?VH&?A9>QG;T6.N_A&GOQG?'Q30'4-%6-@Z>W]@,H6.`LR,Q(B4 MBAP2@$^OX+@UH"/T+?$)!.:9.B1^M)S%M_,H!'?OF4GUR!'2]]*C5*+XSSB% M.BF#I5-[H(IN-[4X><`W>,N*XNX)UP`\G`LD@;YWZ)SXL!\AC(0&OFY)?+L) M7J'HM/&Y-S[PV?J$K4<`0=O($.WZR.B,D;$KF,J],73#D.$P43\,-CT"ZBX7 MBHL2?]$I@L1?6WR3@?'11/7J@E7=NC`@62*C(S%Q';"P[`5=64$;IU[=RWGK MU$L$(G83N5PQ.NOH;8>-Q:T/$KP>%IW[L(V%Z%W9W0^W4W#1N8]K+&ZZ>'IV M-KBF(XYGMZ-\X,)^"&.)^LT_L[M7_;"7FX_._5#&XE83PM;MEG,95WOW@1L3 M%(%'5;?_(=0U`1J]+6AC&DC:DOKU'(2-S/6I;&37F"P6SH@_M-0_TBXC:9!@ M*P(-D/@#-5DR'T%NQ?V)W)A<(>`[80(1KG(UPEG8U$0NH>B1[5\5X3`'] M%@O1\$$43I*V]K9VUCEQAY:Z1^IP):T!(-@`"Y,4'+H2;DSNUB&6AI&%*%S- M1D\DO;#?F<9D\;`8YH%,4KCVMJ*=4SBQ%'Z9!^UM(3="=WD@DR2LO2UHH^H! M'BP):S6LP#B2O:ME8DP6"_$9%B;)&^\-UCG;F`8*LN0]4H>K:M*8!EB8)&%B M]-H]2!O30-*6A+4:0$TCR;M2)L9DD;`\0\(D=1-7W8W)K0?WMJ[OU\_ M3"X)6-H$:"/6+@D:8.C%$%GZ11+".;GBEJ176@48+5M$?,X)O5M'-$G>VMN* M=D[>D27ORQM*>UO(C=`'B)@DX$E_SC&& M"#.OFJ&P8/6>_V+;%^L[,S\'[2\POU9TSW[0 M>L]+Z>5L!YAS74YM)F#SH$0%S8$^GC`BVO[ MW\?V?P```/__`P!02P,$%``&``@````A`/$[BQ:S!```71$``!D```!X;"]W M;W)K&ULK)A9CZI(%,??)YGO0'B_(IL+46]49,M, M,IG,\DQCJ:2!,H"]?/M["BB@ZGA-.YF75GZ>^E/G7Z>V7GW_R#/EC9152HNU MJD^FJD**A![3XKQ6__[+^[90E:J.BV.J?E:W4AI%9` MH:C6ZJ6NKXZF5OM^NWA.97D'A) ML[3^;$15)4^<\%S0,G[)(.\/W8H3KMT\(/D\34I:T5,]`3FM[2C.>:DM-5#: MK(XI9,!L5TIR6JM;W8ET7=4VJ\:@?U+R7HV^*]6%OOME>OPM+0BX#>/$1N"% MTE<6&AX9@L8::NTU(_!'J1S)*;YE]9_T/2#I^5+#<-N0$4O,.7ZZI$K`49"9 MΤF@&'8"_2IZRT@!'XH^U:L"+TV-]6:OF;&+/IZ8.X68<\7SXC,.A'X[$3TISNR[#3@L]-83!:V;MXLRKINP)S`!RLKC&;4;K#A/E`M;;V0_>S MD8,A8RI;)K-68?;"H%10;F\;4Y^MM#$878S8\PA6#TS6E<%!!IX, M?!D$,@AE$(V`!K;TWD#Q_1_>,!GF#<]JQ\%@EB$9P2-X$U<&!QEX,O!E$,@@ ME$$T`H(1IF3$_5G,:X%%KU5K5`N&*8WTKHV!%8%GN$?$1>2`B(>(CTB`2(A( M-"9"ZI"&4`./4V?1,)-@K1C-@[DXN+LN:"B(/2)N1^8C(<.T1:%#'\1-]!#Q M$0D0"1&).M)T4;`#EJLG[C1V\@[N.C')'Q.V(F+NTF!SZ("[M(>(C$B`2 M(A)U!.<.H_I$[BQ:S+TCQE#SB+@=&>>N+Y?2N/=!?>Z(^(@$B(2(1!UINBB, M.W3HB=Q9M)A[1T:Y(^)V9-YL'\94E\N]_[U/&VGXB`1]*[8I@:HEFAGVOW/5 M:*PAF,`.I^.]\O%:P*)%$SH"IX!^=3!,:778]T&\/RXBAYZ,A19B8MZ=(-V6 M//7[(/ZV`)&P)^.W2349W0D:OTWP$0P0?&1G#F/&#H(_.1_RG84U%"UMB0$; MUV"I-16=V/=!/$D7D4-'K*;XEK9I&DM)QD.-?$0"1$)!>+983(VY-%+1N)%@ M%#N0_3>GFI:B51S!VT9>21OS?HCJS<+H,*!!2[>E4O:&**[E8Q1@%`[H@7PT M1(&\Z!L[T8UG*JLP6Y^PT_;C20MW(KG$.B35F'QB&Z)XKBY&!XX>E1F/&=9* M'Z,`HY"C5OQ^J?&8T0K?WN':2T%.RC/9DRRKE(3>V/U,-V%&]+B]/+ISYS!G MNYC$@[D#RRGF<-G<-B^4XG?L$GHG?F=Y<") M`_.]Y>SO<==RX#"$XUW;@8,"YI'EP'$!**WY`WM!_X^1 MS0\```#__P,`4$L#!!0`!@`(````(0#0;+(=O0@``'\G```9````>&PO=V]R M:W-H965TGOGW6TY2+KLJPW:N[CP,S-F-G,AN/BLN^/!POKYOQO_\5__8P'E7U[G+8GX\E+>SKL:OMY>I]7U5NP. M3=#Y-'5GL^7TO#M>QJV"?_N,1OGR7NA6Y%:==#?VOWH[7"M7. M^\_(G7>WK^_7W_;E^0H27XZG8_VC$1V/SGL_>[V4M]V7$XS[N^/M]JC=?!'R MY^/^5E;E2ST!N6G;43GF]70]!:6GQ\,11J!L']V*E\WXV?%S]V$\?7IL#/K/ ML?BHC+]'U5OYD=R.AS^.EP+!`P(YJ.P"<.8N)XLZ7RX<[8 MUUT8?&+3`&5=>=FK". MKX0Q#]J.Z,SX66)`1BB59R6S&8,%<,\KR.9O3Y`(C]-OD('[CK.5',=F!,A0 MZ:9D0PY$'(@YD'`@Y4#&@=P`IF"+]@:2\?_AC9)1WN"HM@B06=PW$9(()!5(]G>RN1EBF:3*<'/;OK\L*;;M3(?82<86JD"3M#,"B5JD MRRC7JKO'T_@6LO=(OO4'ZD0)]E9@X9A#"44(M>75>K5>LTTK1@;I M)!)*)90AU$I[WL/BP=Y[EQ4!2"B54$;0'?F<6"!OFZ5*U0%FM94MZ&$_MXXN=JD' M+G_2"XB%@:&$(H3:V^ZLULLEK]B18J:4[@%JIY*5(=1IS]0_GE.FD&V3JED' MV-25N*9-NNHU;6(3)G`T"X<2$D2!8K&)^EDBS81\0H'88DK0G1:S?A9K,2<6 MR-N6JHIV@*5M`:PRV=AIV6*]A_1C2'NI&$8AF8 M2"B5@9F$6MG6\74BX;$4-ND#XP#&'$HH(,L?, M1A,3"[42":42R@BZ(Y\32Y@U[)G`U<\$V,]M![E6_KEL:PLPT,R_5LM=:?\B MU*+GR!@A8B52*Y6L#"'2RA%JM.QIJ(IJ<\'^]&&IVY7CQG;80JM]&95(*)50QK3[JGTK MRK9)EA. MBUD_B[6HWGRA%EM+VS=9VG<7SL7MM0B*TZD:[Z?$<\^'7STE M#J>,OCI'E%?@D-!7QX#R"CPO04Q3E3"SX'D'8OJN;#U_V]=^X/E!'QYZ/OPN MWM/VPH=?B24>>S[\5BSQQ//A%V/`I[JK\/K3=?=:_+F[O1XOU>A4O$#BS28K MV-=N[0M4[9>ZO$*)"R\RE36\^-3\^08ONA7P0LML`N27LJSQBVI`OSKW]!<` M``#__P,`4$L#!!0`!@`(````(0`+0;6M>P0``*H3```9````>&PO=V]R:W-H M965TL'KK1\', M]VB=L;RH#UO_G[]?OCWX'F_3.D]+5M.M_TFY_WWW\T^;"VO>^)'2U@.%FF_] M8]N>UF'(LR.M4AZP$ZWA/WO65&D+'YM#R$\-37-Q456&9#9;A%5:U+Y46#=C M--A^7V3TF67GBM:M%&EHF;;0/S\6)WY5J[(Q0_=;_S%:/R7$#W<;L4#_%O3">W][_,@NOS9%_GM14UAM\`D=>&7L#5-_ MY!B"BT/KZA?AP)^-E]-]>B[;O]CE-UH)<+!U_OE,>08K"C(!F:-2 MQDIH`'YZ58%;`U8D_1"_+T7>'K<^>0B6T6P5+T'EE?+VI4!)W\O.O&75?S(I M4E)2A"@1^*U$XD4P7\[B"&H.B(2R(3'?<]JFNTW#+AYL&BC)3RENP6@-PNZ! M8!+,?<3DK0^;&GKEX,+[CB3))GR'E+] MMK>;$=/E$I$X]7)'3TWB*2Y_[>4B''2`;B`W/88!,5LGT@DR@6V<82 MW:.8&!2/!T)<:53IB.X#<><+""(WP0@;]"[+XMD4F$BVS#\WN/Z=@@_.LY1+:N?`W9 M+L23&!;9AK3$VG8A-AA&%U8PR$#S-LM":.MC;9!0+P7SVTN!]JTOGH2WR#;F MN8=W;.`],(?BM_%'$T[ M^!WS!2^V`58A8^__*:\BV`>]KX^_](MN0 MO@#32R+,6^:%E)^@= MCCI8"V&ULK%?;CJ,X$'U?:?\!\3[<(0E*,DJXS(PT(XU6>WFFP4E0`T;8Z73__98Q M=L">;:6E?0GA4'4XI\IV*MO/KVUCO*"!U+C;F:[EF`;J2ES5W7EG_O5G_FEM M&H06754TN$,[\PT1\_/^]]^V-SP\DPM"U`"&CNS,"Z5];-NDO*"V(!;N40=/ M3GAH"PJWP]DF_8"*:DQJ&]MSG,ANB[HS.4,\/,*!3Z>Z1"DNKRWJ*"<94%-0 MT$\N=4\$6UL^0M<6P_.U_U3BM@>*I[JIZ=M(:AIM&7\[=W@HGAKP_>H&12FX MQQN-OJW+`1-\HA;0V5RH[GEC;VQ@VF^K&ARPLAL#.NW,@QOGKFO:^^U8H+]K M=".S[P:YX-N7H:Z^UQV":D.?6`>>,'YFH=\J!D&RK67G8P=^#D:%3L6UH7_@ MVU=4GR\4VAV"(V8LKMY21$JH*-!87LB82MR``/@TVIHM#:A(\3I>;W5%+SO3 MCZQPY?@NA!M/B-"\9I2F45X)Q>T_/&AT)$F\B02N$XGG66[@1!_@""8.N`J. MA]\/2D<3<)UR5U;@A:OU`R9L7I"QOFE!B_UVP#<#%BU8)GW!MH`;1Z8A"LO+ M($O]7Y6&$C.2`V/9F;#;H(@$EL?+WG=66_L%6EI.,4<]QEU&)"*"]8_1IBJ0 MJ4`^`VQP)&U!C_X'6XR%V1*"C@*X^_04#R)"I*0JD*E`/@,6'GS=@P\[Y]=K M7G2")>U,6%ZR$VZX66H\\AC8/T)DHB&IAF0:DL^1A7)X_;SZ[RMFP;#Z8/%) MR;ZS5B1/0=!N&>1&_C(HF8(\Z2N=D'L',PW)YUD+%[#/'G?!@D<7HJ;'"=F, MV\%SW%!1*Y^+C%0B,Y.ALDDR'N2Y(ZWK!I&R`G/)`KP+/U#AQ_VPX*4?CGB> M\!,I?N1SZ4=#L@D)N/C0CQ22?)ZR$+_ZB'@6O!0_(;(9RN&4R.=2O(9D'!&5 M#WTO6%8@GZZ$3W=\^FC1<$8):AIBE/C*)K<(S@2)\JDR#6(X MKR%?P6':/(P54O`CFT)_$7_T8OB1U7F.?@R_83I^".(#Z&?"Y1M@FNR+,_I1 M#.>Z(T:#3J#9L59PV@Y\'N4W%/>P@&"FPQ3FR/'K!?XW(!AG'`N"3QA3<<-> M(/^)[/\%``#__P,`4$L#!!0`!@`(````(0#ZIKPU$08``-@8```9````>&PO M=V]R:W-H965TJDY6YV MD\UF+\\THI(6,4!?YM_O*>I"51W'UF1?QO;S.U_5N=3A4+/\_EF=C/>B:[\KS867^_5?T[VF*;-<;52?+&8]G M5I659Y,J>,T]&O5^7^9%4.=O57'NJ$A3G+(.]M\>RTO+U:K\'KDJ:U[?+M_R MNKJ`Q$MY*KL?O:AI5+F7'LYUD[VV%:ZV4?H'_*XJ.5_C;:8_T1-^7NM_)< M0+0A3R0#+W7]2JCICD!@;"'KJ,_`'XVQ*_;9VZG[L_Y(BO)P["#=4_"(..;M M?@1%FT-$06;D3(E27I]@`_"O496D-"`BV>?*=&#A^X+9PN?#>[C)>+*UW*,2<<3:88ZL, MGS-(U1'90`="'8AT(-:!1`=2'=A*@`5A$;&!FOP_8D-D2&RX5QL.#,%RM$!P M!C<)="#4@4@'8AU(="#5@:T$*(&87`G$!(KE>L_@-4&L5B8<<5$3]FRJ.KJA M'.@_W%,?(0%"0H1$"(D1DB`D1$C)&`(=#@A9+M/JE`H2#R($1**$9((*TEZIIW95)"X]%864B($_?B!"!%V M'R$NO&&(%`Z$!`R9]QW&&=M:.87B=ZX:(8T8(8FP(GT+5%TUOJGXG:MN90TE M")!Q)0BDG3HS\B3]XK`00S4>#(%'Q9#ZN59#OB#QK04"DEJ;#@$2TAG2VN;_L`2T<%0.$"REAZCJZRIQHH'%E\QP5`Z0/**,^WT M765)*ZHA)2.D?"1O5YM-)TZ8#_@^-PS2ZDWK-/[`XH;!`$G>Z,407F=I\M'` MXO(QAI(!NK%B>IVEK;@=6+"B&E(RC#X04CJ[:B.7UNXW-F-!_(?"U1NOSUF. M2$_`H6$Z"3$4<:@W5+TA@^4#WK`Y5"X0!BU^,OOXMB#PY`48"AG$&O6U=J08 MJ4Z0V>\!)]BH*#M!(:AR-FIII\ZW!6%P`D'AP)+2.-5J*QI8J+;(_/:`(VS< MDQUAD,B&MKA/KE3($Z6_R6$OLP@*!]9-1V1#-2-D>GK`$39LR8ZP`4UD1'NY M\,F)`D<@94-&$!0.K)N.R(:J(V38X8X`ZXO^24Y/Q;4$8_$!0 M.+!N^B$;JGZ0>>1^/]CT(N>#33S*V#I#CU;!&IQ!4&@+Z*8S@H6."1DA[G>& M#AQ*4M@,,A>UX\.!0.<"02%CW>I2LA%-`;WRI+=;5=$<"K\XG5HCK]_(=2;L M:[T4,+UK35P/WG#!;1V?>O#2A_&MZ\&K'\;A\>"1YP'^!6YSGZ_A&W++>X6_ M<3RXA<$ZFXD'=Q,8?W:]9WB&7OD!MO1,NX_FW,;UX%T;6_BNYU_#`]>#&P;, M#Z8>O&]C/'(]>.O&>.QZ\.X-N"4V!/?*E^Q0_)XUA_+<&J=B#XD:C^;0[QIZ M,TV_=/4%$@BWO'4'-\K]GT?X'X0"K@C'(R#OZ[KC7\@"XO\DUO\!``#__P,` M4$L#!!0`!@`(````(0!31LZ6(`L``$TV```9````>&PO=V]R:W-H965TTFN;05]F8P/+Z\.#R^/))J^__7'?C?Z7A]/V^;P,%9W MT_&H/FR:I^WAY6'\^W^^_+(8CT[G]>%IO6L.]AB_GL]OJ\GDM'FM]^O37?-6']#RW!SWZS,^'E\FI[=CO7YJ.^UW MDV0ZS2?[]?8P[C*LCK?D:)Z?MYM:-YOW?7TX=TF.]6Y]!O_3Z_;M9+/M-[>D MVZ^/W][??MDT^S>D^+K=;<\_VZ3CT7ZS^NWET!S77W<8]P^5K33QOA7HCVW] M<6+_'YU>FX^_';=/_]@>:JB->:(9^-HTWRCTMR>"T'D2]/[2SL"_CJ.G^GG] MOCO_N_GX>[U]>3UCNF<8$0UL]?13UZ<-%$6:NV1&F3;-#@3P[VB_I=*`(NL? M[=^/[=/Y]6&S^315"!]]K4_G+UM*.1YMWD_G9O_?+DB95%V2Q"3!7Y.$ M*%SHD)H.^&NO>J>R:4[7O-`M,]WPUW:[F>RD&WBKHUZ?UX_WQ^9CA.+$T$YO M:RIUM4)B*V!'HY?TSQ2%E)2DH"P/8ZPJB'5"&7Q_3!:S^\EW3-W&Q)1AC)(1 ME8V@>:*TF@$3\.U)0^G_`VG*0J3MY4H+L%%X#&V$[:(9(!AB:GV&*:H[7I=6 M1>KT,,8L]"HJE4H&91>#`K,4J@#1'!&LD-IGE:=W\[[L;IYO2H2*R1G59)%[ M5$W0G`4I-9=!51]DQZ,Y(MB#)F=_64L*;AG:O*5!F'(!HCDBKHV1WGYM"I;7 M-HBKM2I`-$?$M2'@[=>F8'EM@[!Q!XCFB+@VW2@]>YC#=*Q/W5PPE$?2,@CW M#*467G7T0786-4<$TZ5D>KDZ*%C2,0A3*4`T1\2U%9:V+U,Z2^F>8PS]9J': M5+@-L463++Q%4YH@A6GKK2)9^.*YJ%X]`L8:$CNRX9P14/CU5Q# M;M]&PP#2BD-20[)@1J#5,,'Z&OI$0GF\=;3TI"GI.8U\@`N8+!._"/LH)R"' M)'^R<8__`OF'TC=W`UX`*O.8E;3&?/XJ\1X9*A?E^/<=@P(`5\[_2@%0M#12 M$K/C9*]6A9`6D!20'-X34*GD,XO(W"NXALG24Z=4)@JTV5++_!KHH^RHM.L8 M:$@W"C:$*QJ:VPI?1`;B1A1`6G%(:$CKY78";70[B5P!__'=1K%GF!#2`I*< MO!O,95&2_B9B]2XMQ&[1(:0%)`EXMX?N50?F.'!I)N&-PT*\AO`&Z=60B[)C MT@*2;,FU;ZZAQ'@\JR$+<;E,E(.TB)($R*)O)V`,G1,P$"^8`-()AR0!\MC; M"1A'Y@0,Y(9;T0,9F9.#M(`D`3))1J`MF*S=21A<,\9O.3L#P5AZWU&)]PY5 M)7V4JQD.2<)DO8SPE25FC)IS,I"3ITH"2`M($B"7O)V`\52,IU<@67H*E(F) MXF440%I$24[DDK=S,I[*13$0%R6`=,(A08#>^SF!MHSFBT_%RD7U520@R7>04:>A45N("19"6D"2@&?4E\LX[>W8*9`L/05*&\6J M*(2T@"2G07:/=*C=^R`K>0K"'_;=)% MN1HRN<)7L720=[?17ET'1EW9**>@%I"4BTS2ERM'TJ%R=6:+F>J75[+TI"E3 MX\A)K(("TB)*#50AI`4D"Y+%,%%H#,_C/T#DU5LV7@($@1S_/*O7>MZNTC[)# MT@(29#//]B_/8!LMEX"%F%HAI`4D"7@^3FHMEY_9T"K+\3V-2EA=B+5`AI`4D"@VP_ZVW?Z91._65HH]@R#"$M M(,G)NQ-<*:S0[S,#\<(*("VB)`'/W*FPDBDR#%R'F?%XM@XMQ&M(I=ZV1^6B M[$1K`4FVWIW@BES&D3DG`W&Y`DAG')($R&.9:UTA0-&>$1B(%TP`Z8Q#DL`@ MW\Y"W[805\!$.4B+*$D@XMMDG%>4,&[+I\)`2;]G6V4]Y-:<2KU-'AV/L7,>O^UOE!:B%6,@RY53#S*;>E(NF2?-R_QF3%;5M@6 M-#UTL6BB46Y'0S(>9,NST)8MQ(LFM&41)0F0 M=3+)KN@4VO',0+QH`DB+*$$@'V2T;;0T6@LQ!4)("T@2$R6BN9S!R+RT(0M MA"E!VNY4C$J]C8G*15G/T@*2?`?Y`K MK(:\_8?*1;D:,KG"K9E\D%.WT=ZB"VRYLE%<+AXEY2*39+;3RI7,/[$?FAN[ MQ:5Z==*I]^Q7VBBIH;\[XZ*M9-54\[@@/?F>>]I_.2=R\R[9-3::-$R6?>1D3EHAQ_DSXL>9SB%:OV MLO.WT=Z$FYL!VXJQ40ZBP\*M!S("W>'?[M#JOCZ^U%6]VYU&F^:=#O;.ESAN MVL/FU/$\617(A&%Y+5#&'DCV6HI\CC[MP5ZO!0:RTK"'2+9\@99V"05]EFA9 MQOK,IV#0GFKV^\SIL'2<`5KP5!!C@/'@=AVV%'FZ*N#+80MNN.@352?/T))% M^\S0TJY5GW6>HR5ZG1FRX94EPF"&;'B7B+4@&Q[R8RW0&L^RL19HC8?,2$L. MK?'T%[84&:D3TZU$"VV^A7W*#./!KEBL!>/!#E2L!>/!UE"L!56%/9M8"T:* MS91(RPSCP;9!K`45@O?Y6`LJ!"_:84N1HN*Q?1RVE&BA[P%B+>"&#?I8"V8! MK^B1E@RLH]Y_(==!"W^#%6C"G^&HMUH(YQ3=; ML1;,Z9]@3:RF2Z:J(JE.BAW@E$RD M!8+&F)4*U\=!V[!'H5#O.#X:MN`X+/K$6@H%I$QR5@?,(NVX%) M9:+!QW!:-A&\R%9%=.1DD)'X$L42K7T41+3R4?BQ.BE1#&UM3_JBPX]YWM8O M]3_7QY?MX33:U<]X)IBVVS['[N=`W8=S\X;'$?RDISGC9SSM?U_QLZT:OS*9 MTIO'<].<[0=(/>E_"/;X/P```/__`P!02P,$%``&``@````A`)JEO3)4`P`` MKPL``!D```!X;"]W;W)K&ULE%;9CILP%'VOU']` MO`]@LDVBD%&FHVDKM5)5=7EVP`1K`"/;F^U$\J2C9Z\,JFX*".7>('KL#(6"2^WD?O[U_/=O>LH3>E:AH6\A4.D*8_9DXAW!2NU)9$LIQKB5QFOU)&MB&^A*ZA\V55WL2@JH-CP MG.MW0^HZ1;SXNBV%I)L<\GXC8QH?N,F@VM`G[,!&B!>$ M?DW0!(?]WNEGTX$?TDE82G>Y_BGV7QC?9AK:/8&,,+%%\O[$5`P5!1HOG"!3 M+'((`#Z=@N-H0$7HF_G>\T1GD3L:>^']A$RF@'S^;,AO`AN\UI+/UR\;#S7]G"PP)C5+K(^\K4]D5-:E7CV[YY'Y%!&C;H3HG.J3CLJ-CT80SR MN1R].=9V<32UU3`YW85PD,(-NN.MIW"['MGMH6!RRSZQ/%=.+':X^H2P#]36 M>BU;FY'OVL>+-7C$'M3_P+I4T2W[3N66E\K)60J<@;DVI%VX[(,6%<0).Y/0 ML">9GQDLQ@QV@@!G.Q5"'Q_00;UJK_X!``#__P,`4$L#!!0`!@`(````(0`! MJN%_A`,``-P,```9````>&PO=V]R:W-H965TNGSFL[U_SS'EA4G%1A"Z93%V'%9&(>;$/W=^_GF[N7$=I6L0T$P4+W3>F MW/O-QP_KHY#/*F5,.\!0J-!-M2Y7GJ>BE.54343)"O@F$3*G&A[EWE.E9#0V MA_+,\Z?3A9=37KB6826'<(@DX1%[%-$A9X6V)))E5$/\*N6E.K'ET1"ZG,KG M0WD3B;P$BAW/N'XSI*Z31ZNO^T)(NLL@[U2:%$HB=`Y]E` M^SDOO:4'3)MUS"$#++LC61*Z6[)Z\.>NMUF;`OWA[*@:GQV5BN-GR>-OO&!0 M;>@3=F`GQ#-"O\9H@L->[_23Z<`/Z<0LH8=,_Q3'+XSO4PWMOH6,,+%5_/;( M5`05!9J)?XM,D<@@`'AUK*'IQC_O9C;)#=]X(W@^"FM=ZMAC3Y58^<&IX/@B&DB]:GNXZGBI0 M*\E@68-:WF&,AGM'L/%>E]-:^DE!@,-I$=RFK2R^$5>S^<$87@2W>:VE'R[> MMXUI1IGZ"Y3DE<'&8*QV?:0/*;G@;K$CATJAEB[]!T)DS;>@(%]MP2R;! M]3[T18RW%+:_W8<+URT9I6R#[E3KDK9)1]Q79K8O:4-@\H#ZM2Y/,DK!!MT) M^I*&_8Z&L0]!,.!&,@?;3DZF=A]FY^\D?Y3"#;KC[9+"?53JX*$UZ`XS$H"I MKP=_E(@-ND-]2<2P'+:"'MZ'2KP-T1DN$W_SMV'>Z8/=)>VNE3.Y9Y]8EBDG M$@?<$WW8GFIKO<-N34FZ]OEJ:W=;K_X&=LN2[MEW*O>\4$[&$N"<&GE+NYW: M!RU*"!0V3*%AJS0?4_@7P6"#FN*=G`BA3P\HBOI_R>8?````__\#`%!+`P04 M``8`"````"$`@CB_.`<%```C$P``&0```'AL+W=O4(/:7Z:Z__\ M'7R;Z%I9Q?DAOM"893)F61Q M.:!7DL,_1UID<04_BY-17@L2'^JD[&+8ICDRLCC-]4;!*[ZB08_'-"$^35XS MDE>-2$$N<07]+\_IM11J6?(5N2PN7EZOWQ*:74'B.;VDU40XUY\L M+[),W5C,:H/^36(S\$SI"PL-#PQ!LH&R@WH& M_BRT`SG&KY?J+_J^)>GI7,%TNS`B-C#O\.&3,@%'069@NTPIH1?H`'QJ6?ZT!FX8W-H0;CV3,HJ2)FDKB6O946S_YH@BTLU(C87@2L7 ML4<#>^):[N@!E1%7@:M0^7(/QCP7KCP7"OR+O8?(V@*X\ESK80=@BKF/;`8; MC^R!8[OC26WD'?,L.07PA:=.!V/+G`[',`7W,H7OULWX+W?=:`JAKBL_KN+% MK*#O&BQ6Z$5YC=G2MSPF+"JJZ8BLL5^5&-064WEB,G,=/(7J*6%=O"V&ICLS MWJ"6$QZSQ#%6-V(E(ECA,EE?!6L5!"K8J&"K@E`%.Q7L51"U@`'&2??`L/_# M/2;#W!/C7@IPL]-6K!(1(L57P5H%@0HV*MBJ(%3!3@5[%40MT+%JJ%C5OV6) M>F+1<]UIU9/E#+L6+)L8V/Z$!RM$?$36B`2(;!#9(A(BLD-DCTC4)AU[8*B= M2KIO#XN&%0M[9VN]C11_>-"MK%:(^)S`1BJ%+&?<%5JCM*`W;=)-V\@@,3]; M)!0BLI-9[1Y-N])[&22DH[90QUC85!\PED77Q@KA)2(J]Y(-U[5J7=N<3&QE_]A*&=&7 M$)&=)'>:VG_:5"1EH*F.Z;#P'C"=17=-;X@-F^YM_;KJO4(&B8'ZG`Q_:3I* M"1#9<.+4(B-S-%9F;HM20D1VB.P_DXW:*1TSX?CQ@)DLNFLF)U.YC%>(^`WA MAVMV1EFCF`"1#<_BQ3B:.E.U&%%.B,@.D?VGNE$[IV,6K-,'S&+17;,:HE2> M,JJ5#)*5Q\E(>KQ&,0$B&TG:9:[L==O>(&6;#660Z-$.D;TD=UJ+>H-NK76\ M9L\+#YA=AW?=%@A:;2UTY8Z_ND6)T?D]?5]\Y'AP[\7Q\,K@R>[A2_8JH8_; M'IRQL#PPWF*\=;]7'?\>"@@^/7C@?''DT_"*XAJ?R!]Q<4KS4KN0(TR2.6`/Q$7SDJ/Y4=$K3!X\ZM,* M7D[47\_P,HK`-FP.(/A(:25^L`;DZZW%3P```/__`P!02P,$%``&``@````A M`/_&G-$R`0``0`(``!$`"`%D;V-07B^CVJ^TVWR" M"ENC)@1+,?:B`*=;P$7>7Z--00N>>#X`$SM1$0C M4HH):3]<.P"DP-""!A,\)AG!W]T`3OL_+PS)65.KL+=QIE'WG"W%,9S:.Z^F M8M_W65\.&M&?X/7RX6D8-57FL"L!B!WVTW(?EG&5&P7R=L]V;ZY-O&\J_#NK MI!CLJ'#``\@DOD>/=J?DI;R[7RT0*W(R2_-92LI506@^HU?E:X5/K?$^FX!Z M%/@W\01@@_?//V=?````__\#`%!+`P04``8`"````"$``7FO_Y4```"I```` M$````'AL+V-A;&-#:&%I;BYX;6P\CD$*`C$0!.^"?QCF[F;UH"))%A1\@3X@ M9$<32"9+)HC^WGCQTE`T5+>>WCG!BZK$P@:WPXA`[,L<^6GP?KMNC@C2',\N M%2:#'Q*<['JEO4O^$EQDZ`86@Z&UY:24^$#9R5`6XMX\2LVN=:Q/)4LE-TL@ M:CFIW3CN5>X"M-I#-7@^(,3^`2']4EFM_B/V"P``__\#`%!+`P04``8`"``` M`"$`\*T,+@8#```V"@``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0`` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````"<5EU/VS`4?9^T_U#E'5*@ MFB:4!K&V$TC=J);`'BWCW#06B1ULIZ+[];MN:)O";?;QEMCG7I][[H<=7;U4 MY6`%QDJMQL'9Z3`8@!(ZDVHY#N[3KR>?@X%U7&6\U`K&P1IL%<_5E&%I10,7M*6XKW,FUJ;C#7[,,=9Y+`5,MF@J4"\^'PT\A MO#A0&60G]Q% M0!F%WB+;@T-HY6[G(% MPFDSL/(7RG8>#!ZY!4]G'*RXD5PYI.5A[<_FNZRM,_%/;9YL`>!L%"*@7=Q\ M=K'=;SF*1\@5P?AUB/2++1/<..282E>"O1?IW^#9@O_YB,3A2;[2 MF,[9'58K:;)#V0W,%6#81%>U@0+400IH8CM[;S[AMJ!/::J*F[7')'*I)#8" ME@"[%D(WRI$FKQVV;A5^;F3M8R&A4\BED@[87.:`:<"&7J8WDEO-L]('G0Z4374GZ;2GU7ZE)ZTXE$DL6[Z^N@<9K$/ MV2_/.F=^8PDM#Q MH>,/ZYH<7-!OKN2Y5$_VOD[U%(?S]LUQN!AM1FJ&M_%V?[\0W>!SPY3>R:3` M&P&R+>;]AG\A/;3/P/AL=#J\&.*#HK,6A:_=AF,V_@T``/__`P!02P$"+0`4 M``8`"````"$`;NOT>_\!``#G&0``$P``````````````````````6T-O;G1E M;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+```` M`````````````#@$``!?&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/79-C_I`@``1`@``!D````````````````` M8Q,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`*I$-7[K!0``-!P``!D`````````````````41T``'AL+W=O&PO=V]R:W-H965T\4'`,```$*```9`````````````````+&UL4$L!`BT`%``&``@````A`-4%\9F[`@``S`<``!D````` M````````````"C,``'AL+W=O&PO=V]R M:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#$,@FL8 M20``Y^P``!0`````````````````44$``'AL+W-H87)E9%-T&UL M4$L!`BT`%``&``@````A`)H3#(]#"@``IU0```T`````````````````FXH` M`'AL+W-T>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`( M````(0#C*)KH:@,``+$*```9`````````````````,Z;``!X;"]W;W)K&UL4$L!`BT`%``&``@````A`++];NNY`@``_P8``!D` M````````````````;Y\``'AL+W=O&PO M=V]R:W-H965T&PO=V]R:W-H M965TO_`L``&%#```9 M`````````````````/3*``!X;"]W;W)K&UL4$L! M`BT`%``&``@````A`/W$'W83!0``91,``!@`````````````````)]<``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`']S MH6-P`(``/<&```8```````````` M`````!WW``!X;"]W;W)K&PO=V]R:W-H965T M```9```` M`````````````)C^``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`$SWR(`L!```0!$``!D`````````````````G04!`'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``M! MM:U[!```JA,``!D`````````````````WA<#``#.#```&0`````````` M``````"0'`$`>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%-&SI8@"P``338``!D` M````````````````]B8!`'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`((XOS@'!0``(Q,``!D````````````````` MDSD!`'AL+W=O&PO8V%L8T-H86EN+GAM;%!+`0(M`!0`!@`(````(0#PK0PN!@,``#8* M```0`````````````````/U!`0!D;V-0&UL4$L%!@`````R -`#(`APT``#E&`0`````` ` end XML 13 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes (Details) (USD $)

Mar. 31, 2015

Dec. 31, 2014

Summary of effective income tax rate reconciliation

Excess of Tax over book depreciation Fixed assets $ 12,711 $ 12,711

Excess of Tax over book depreciation Patents 52,041 52,041

Net Operating Loss Carry forward 2,416,813 2,380,106

Valuation Allowance (2,481,565) (2,444,858)

Total Deferred Tax Asset (Liabilities)

X

- Definition

Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets

+ References

No definition available.

+ Details

Name: pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Deferred Tax Asset Excess Tax Over Depreciation Patents.

+ References

No definition available.

+ Details

Name: pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, netted by jurisdiction and classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51675352&loc=d3e28680-109314

+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9

Property and Equipment (Details) (USD $)
3 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Property, Plant and Equipment [Line Items]

Gross Property and Equipment 269,493us-gaap_PropertyPlantAndEquipmentGross $ 269,493us-gaap_PropertyPlantAndEquipmentGross

Less: Accumulated Depreciation (269,493) 269,493

Net Property and Equipment

Lab equipment and instruments [Member]

Property, Plant and Equipment [Line Items]

Gross Property and Equipment 208,823 208,823

Lab equipment and instruments [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life (years) 6 years

Lab equipment and instruments [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life (years) 4 years

Computer equipment [Member]

Property, Plant and Equipment [Line Items]

Gross Property and Equipment $ 60,670

Computer equipment [Member] | Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life (years) 6 years

Computer equipment [Member] | Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful life (years) 4 years

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 16 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9

Loss Per Share (Details) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

LOSS PER SHARE

Net (Loss) $ (1,253,345)us-gaap_NetIncomeLoss $ (426,054)us-gaap_NetIncomeLoss

Weighted average number of common shares used in basic earnings per share 9,533,290 6,880,278

Effect of dilutive securities, stock options and warrants

Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share 9,533,290 6,880,278

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 28A

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1500-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

ZIP 17 0001213900-15-003597-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-15-003597-xbrl.zip M4$L#!!0````(`&:(K4;!44 M-@$LBYB$.H[;U\4`\$@X0L73;H%;_X\'GIZM:Z^`? MI]_]Y<-?:S7TB5C$P2XQD,<@'UW^6?OM[.%Z4ATUC^0CX4A%_RTTZJ)2EP2Q M@43I6%2.90&U;_X7U6J3ILXP@V:@CM^`="3.\OR4"UOWAL1RT0U`Z5$H^TK= M`>_QTJ"N[:!?PSY%OT^)-_4T\!QFX/$ANL%C)"J':(J@<2RT`$'8R5O7,>DQ M_R\"ZBUV/!H.V,>#@>N.CNOUU]?7(T&`FE*S*;6.='OH4R+(LG@0EC>I]256 MGK=U9#M]*"G(=9[=!0(GQ7FN0:<5HH75>I`Y+;K0]*OLEQ4U3:O[N=.BC"85 MA$;%^F\WUX_Z@`QQC5K,Q98>PT*78)\O3YFM2&)S68V@Q*2"95N6-TPN;[A. MW1V/2!T*U:`4<:@^K;>Z4KR"SS@WD:N-@*ONI*AN>Y;KC.-E&=&/^O9+/48E7-`A-K@,9"<7)FSY(+L]S?.F+5Z#6"V%N MWZ\BD\EPGM:A6A]P#KD#X-#QF_@1[(#WD M3\MC[.B.;9+ED[<^3-18]$=[D^C*DX/#L.!SFSW?]9[%UO//V'KF0_(D M",_!_Y_N$M,/9@V"1J;N>/:;&CP%]+.#?';$J9^,_GGGEX/3F4K]4)^OS!NL M)_<`S**V$>G1UT\N)$S$26S-:L]R)RFS^O483]9ADBP^7Q!]D4E)Z;O,)%&" MN5`\DZ04)DE[P"1I=YCT_.B"C\6=G\L_/*#@W!Z.;`M^LO8;9<_P2L[!Z:38`ET? MZHE=1`8@@F8'QUP4GV_M%SZV/0LM=$D\3/L-\;5PB55KG$M7IBD2D*RI":F5Y):2>H*296$HB15 MD";V,BZIB>F5I%:2NE12I9H@Y2^IYQYS[>&S*">+JJ@NIN^47PQ<<-P+$(P( MGT0YPO=(_A2T,5]!C78XR$-';4OBVJ@#+B/JN95,5]RE3[A<9] MKDB7CZTR'_=92-_=B:&`;UQ(R"&TC<*^@K'/ MUZ2/S4N?8E_)@'$%^OE4Q=9XM]6,0>CQ'/R94DF@HP03O3NR$&HB*444DM(K M4PQR9:^(G'VVH)#G$(.G[H<8;QP_FV-$<5&S26X"4TMRR!J% M+?E;SS?821#2I/1*2"LA31-2N9#3C#,/(%%*I69"^GUP3G5\;P*"MF5PJSCB MU)V-9QL+A)_BO^OUJ$X>1UC?DPWQ-4B;Q/B3"2S'#,N;FF&Y)C7S-\/RS267 MG/!4L#(?QEZ0G!T/UHF;H^O=K_11S[SB+\'U@K$6?D4$;8M:FOE'%BO5,)7YA^^!K,ZDR==^ZJ7L/DEE9KLIRE2/'L]7]SUZ""^:G MF_FM[I\?O2XC?W@\4OX"_YF6GTO?#]DM,A:P-H@4CLZB48FL+#/7/V^-&@:7@[8T:!JQ1"ORG!6"MVA+O39"C2`;2._YXCVP_) MV"`LM(+22C3F1(-K6\\ESC3O'4E$Q'(DT?A-R<)&]L/J\/`_8>X9P0ZU^CPT M'RK:1\_BNP)7U,*63G&@=CN6OA]BLX6)V9H7E7BE/)=`W^Z)HP.I,(F'E#'; M&4*.=,V&JN5BO, MTF)@>RPDU?&+ZOC%-RGX[V&W:K=VC/98&-8_NW.-N[:#77#JWO'MG$0B*PG* M+$$KXEK/#]CJ!T5O\!L=>L-W)U[;1_;6M]T3)LZT8(R;E1R7*/MP>J6`]TEPWYW>_4J"^\UJW/FK/'L6QHU%NA>85-1] MIRHJNS/G?O9XS*NGO_;WZ:^=E<$JT%\%^M^#'%=Q^_<[MM7YV!TZ'[M+@E&= MC]VI\['[)AK5^=AO0Q:J\['O[GSLGHI7=3YV_\_'[I+HP82SA^0)O[4]=V`[ MD\#0!;8H&T#R?@A+,A6A8,S14@TO>_Y\]'AT10SB8/-]C'$20?L^T"(?T/'B M0">E[_0622/#M\G^6JNASQ9UT2/Q]3]"M=HD_;N_=/Y/_)^K7^]_(F_DHJ$V M6[\_D#_H:6?PA;QG'[2&>ORS\DEL:LJQV.IH M#?'RX[$F_GRLJ5=J\^KC94<-.PB0>+QK/C1L@,&-.3@-TX<$,\\AIZ$<^9D3 M]).\R6_>1D*+GQ\O%IJCS%8DL7D,>9NW]CSB;Z5P*--V#?H"(W@:*7P+ZSG_ M!-Z672_4YXD7Q`*+:R4UNRZ#8DW4X^B74S[R(@3'N^59&_+QXI=?4D<%\E:U MQL7RTO3W)V(2^X%O(02[!P^D3V%=#5/@%@\)"F7]@?2RW',!&WN M3-S/"4`/FXP$?<>:G_1Y[CE\]^:*,AV;O\,:Y3+8Y^_LV7\IEYC/2,":H,@5I+&
-"Y MO3HXU1JR+&E"3*4LP<4IF`:S,!NT+8/_P^-9+]CTMX[=<^PX8RC[*S:]Y"FP MQ8>49X1P6Q^A@L_,%K@@'^H;X9YYEW+D#XCP0G0!#NR9AM\0-;7P9'&L)HCIC MUUJPB3T'Z`DX6QYTY[T!5Q(A[L!Q17MCS MD4%1%055V@9[J--9F&E;>GF3NBDJ$6V:AB0[VGQXK,K2AFB_!D]%\$%485X9 MY8$O+TEMRJW6)OA*,2^2K&G"@GG9%$Q.!D4%5U*1EX'A>VPLW&2+;,U1PLY- MS!@/'ALE6F=-TQH1)WX#=%^7J%S.J*4RIB9SHZ*IL,@1WCUSMC^`L70JM*3H MDNI=\BZ_TP5+/7ZIV9!WAY/Y:$I-DX4=$H]RS\:NL++-YKMGS#>AS<$4420-[)C7-H6HQ9=]LP#V!Y<3A*T+KBV`>X8.'/8O,?4Z%CG>$1= M;)9BGQN"UA(:T9AB,IC,>'.RP]O@?2`NIA8Q+K%CP4J"@3GQAIYOL2](CQ]D M+8/5-?#A-/`C(E[$:F!YDI'/"-0D650:_D.!, M\K7-^%;&7>\)OY4R"YH-:6XML`G$PJC+9\2:8K,E*;E0Y^NO@6T:Q&'!X<_RD4P[?/]\3QS[T5,@Z1@^41@I2#4^&('_"=T;,>QKRIVG)P2J,J M.)`8WEKYDQCYCU'*.4E1"/Z71LH\L+Q(V&9`2B*APYA7Y`BLO>I9'TX6;FX( M9[W#O.6R:&U,!?$ILA+:0CV)TO,5Z2[R*C%]G=>YME-A:Q"1'\TE&)JRZ2G: MQ&Q/SU@?R`OQ/)2`M?Q2T>;WQY98FLWZ#?G6#!S[WJ?;-M@C[#^*H3LN4V$ MIJQ%QR76?S9H6?>R%%62UH+VR;$9NW?L7DHD+U>.U>98%NE\>TQ98XMSO$K# M1"S^+@&L\-O&D%K^%5R7OI#+MQ&QV#H7+C/R3I9418KL#:T`E"_VK#&3IJ1I MZE;8'P@CV-'YQ:<+4"RF[=\H*)+K2U5;-C!9CSHWQ)8H1V/@2^#,G7)WH"', M]RS@;Y/P/SCWA_S^Z)]^>O$2K,8N2ZZ#J0`:LBK6V,6<=6GP7S_GK(=OMM%2@JU71$D4U`2(,Q39068U_BVUH;24M4%.SH>69O5% M6=,B#M-<_]F@9;9&BK`6LBO;(;1O!:=^].A)TD^86IS%#P2;J9&#`NUYKLBR MBJ*L24HS>EUP;7!)8A#(K[_76KR41N_J)`#(CB_K658Q>BQF!<);V[+C6J"T MV5Z#Z:Y$?/Q4*'GAS2RSK69+%3<$/%.M5XX]Y,"HY4&%4/?R`^:D!\(_?2N. ML,LW6"'8CD$M[(P[+AGZ%_R@IF.;IM]7,*1EF#5)%1I*5)H*HV9WF)953D2I M(;I(`M7`4=:=7(,N7B'SVS`(BHA&,#8CX3W"& M!I#6?@$-T2>W'M])O>OYU2(1\(('*"5(K[9:@M2,6.[MT)9";SZ;$HWXID1V M>I<="TQRA4W?3+2-?WG,]=_$2SG8F&]80([JLQP@E\^![.%RJ1$]'GA6D==1L(\I-P)R+H% M)HN"LBD!?FQ\L>B]0T:8&N%BPM_]"=X.*D%#M@2E&0;M-P!6$#&9-2=_LVX; M6M*'<>Z2;@D18DUM+A6L.41YP\\\!IH4W2RXA(:HU5],R!*H"(K*.BMA0I>@=N4S)FWBI[LD%'VY9.?3,Y+?R! MTYT1!45N-J-O(JX/KC"2,M\%%8"HZ,LDF]$4?-/,'^4Y'<`;^8F84#5XG;B$ MX9$5M<&/D*\/*G<2,C]2$C[YO!D)T\LB>!S.P+;^AT=YP#_^NFCQ@P!Z(2), M*P'EC3[O"'_25.A8+["Z*UOWR%I#$U;KG@1PA9&4E[!G(PF*ZX08_M97]`VK MXL>DI3:T9F1(TI#DA#97V8[BX#<-L*7#?`/F8O/>ZYI4O^OUB)-V-+_`W;UL MP,[!";&''%O;ZR]B$Z6$=/]FD7_6T[]AS`-^MN5_#"#\GNWD@D!PWVRMKZ(O MCQ^ILBHDB\U2BM>8R.&+>N7JIOEYL#ZVPBC*=:Y<`O]U]ZYW^:8/P""1!Y"7 M.ROY`Q)E[YIL@JU`FC+?L!#DEI:=JN02P5>-YEVI$D:*?W]OU1='DL$52%36 MH9+46.QU6ZIF47):^DG%#?O.59E$SN#P[M?;L2CF_,PF"'+EP2/M6[1'=?YE MBR""!_K]WN9?)"7L"3H_,\&DYH/J]'O3/3'HR_=]]^2[O_`?(\3_:"]\0F`-FWG&/TMN$L;%N)?&&0]Z.,86>!;A*G4XI\2#1LS MB0M"66,CS(T=+\<1G:!7VS%FJ7[1UP%UB9]&(N6H8;\R(.<$<;IJS'6(JP]F M!6JOI/N%`A;>->3:7T@-*KF#H-4#SB#.GB[_X_;NZ1*)Z'L\')W\K26)T@EZ M_'QSTW[X'=U=H>\??N$VN?G=Y]OGSJWG]#]W77GO'/YR%NI=R?M MU4>[S/JC!K5VC?D!UT55.-DC3LKJR-T11CX-",*@5_Q'(OA*H3=Y9QJ8%OKZ M#/$7#CP+>P;`,(Y0QT(NU+-'U.([X'8/V&3AOE_X$&'31'@6XD0_`'I]@*BE MFYX!M2QS'$)$#N'?RN#=1BK\",.A$\9@T8!<&XW`^O"70WN8.E"3=SS#Z&^, M`89#:(K?XV$W].4(`/BV/P%0X,M3OP?P?J'XI!2W3$]X_[ MP8U&:!SRR<@-ZG(J/EM\M)"_9//YTAX"73J.T`)6P^";C`8"RNTA=8/A=1%E MB'G]/MA]R','P#=H,7"9P@J)\+L$Q@'["*#DOSPK^(2M#S\^<%'A`K9QEOG\ M!A&V8VSBU<(W3*8:MGG"$/A)P;>^PZ&$$0S$,[&3(\0%/5E&YD<]&/!4.8&I M`&BG,DK]836`K_P>*6\ZF!IA"'C:YZ27G@?38TRP M>8Q:(*Z^&/.CD/X'/J"'RDV M-Y_](I'L5Y*6X[&T'-MS(ED_HA_X^!!N,.X]U\)#]!,U30::Q!G]B%XQT.]0 M&/N)5H9DV\$1Y>FK#LZD"V+B5S[I@4?@27O<*HDM7RN("-K!Z(6`?3.);ZL\ MAWE@4%%WPG"PK%W^77+.8G?@V%X_T(28A^T#VP6]''+]"W#[H,^XL@0C:D5T MR*2U2F54*J,$E;'3O-JE54A$*3YQI=BN/\+,19!,P>4\#Y6*[P&!IHBI&4AK M@Q=G(M_!$,1$-7I!+.#AEYABPTA3#S7I/Y#]:D$[;!I@G[@>H7(-/)[P!_@T M??#/V42[.>'[#;X],&8O.!QR1][K8=WU`J^/DZC+?K@$_E&X[1``.3 M=.*Y?@8OU:4PE'W_Y\BQ#4^/N#P##UJ%Z@3[#CYO0>=NK8.X7NO[96!P#2"9 MZD@GX"!Q&V/Q%L>5SJMT7EEN$G]`RH%53GMFG"-1A1EO(Y&>.^O_VWO7YL21 M9&'X>T?T?ZAWGM[8[@C9#1@PS)RS$;0ONS[CMGW:[MEGGR\3`A5&.T)B=;&; M^?5O9E:55`)QLP46=D7L]AC0)2LK*^\7=L[[H5`+&L(2L80>8`.I@TZ`U"UZ M!"H//>O=AYSL$O81?_UIT<\_?;*8IE*A,H&M/L@DFU4A8$MK?U$\P!4-VO!@ M!GKG,-FZ/L(H'"DW>48CP-$841ZP/!^"9Y/Z(PP<,/T&]IC//C%GLDUL.0)$ M\*39EXE^E?I+#D%%=9&)%&*1K$7VB/^T+"`[_#\394,*#P,*2(KU6OA^]D#S M$#Y0`T6T^,0-<["(2":C<&5NV:@VBV5HB#U4WQ%2?,9_N!2$%P\7/9F9C;OJ MX%J(^7FL:37G@,;L8_W=]$2YFW6KV9R]/G?H@BM*7;]%]-JP-21RN;\\0A?(1(60@!SM6 M;0Z=N*@5K\DMT!V/.0C?F(,5,0P\+WA4\BR/&BO/F)%5*7[A'BZU5ZG']R-T&Y)O0B8L+.(EQ*Q:1ZY!%2[B$DN>`8"SW7H?!9&132MY5QJYO$(9!(#-A*/5O@]+2E/U4L6>8"5 MES^6<85$>7@UAVO&>'1.8:5,9\E]FC8$$@D,A3&\&>T2>#%NAM(M8FUH)#[F M_;OLJ9G[FWON&)TSF=MGH&/1'%]S?'=U?,]EK`20HHJ6V6TA.P45Q@X/U[E5B7=YNU0B?@T!VV'>E_'K MKWF57G-+Y)2LD$^PDA7-%/6^>=BR8(V0MY*71,6AI<4OZ]L>Z431B/-88SB@ M:2@4$U,`S83>[M#;*8"8A8H.@&.F:BL+*8(_\Q,V`J_6L"_`149Z;![VY7!42^(%&2.G)X@UI"-31)F MWD"E>E+T3';/TLJ]R;TU)ITSTB;1:%AGG')&)22".<]#0L%&&T?SLB'PA#P. MV-!+!G&B`G?X>X[3P_D.-(YN:Z1+$,/#?1F%FZ=NQ,%LY#&EI=FX,DDZO-,Q M4L)(B9TI>9C*@(>%_M!R"-<1!LH7C#J.2^88,JJ1>S\"Z]5SX6%H\_1CH&R` M(Y$)"0FP$QL#_B('`14NX#VQ=#=KZB,Y'Z((C;D^%TD7/`,P[XX>V8YBP:"/ M<6\F(0(!<.-$'+7";`87G2P8@$M[C;!L>/YM`7#/@S[V!7[N`E1A,'91;)'[D%!GU6\ M(W<75W>1N"3QZ"!=#X(H/F34L\!Q8\IZ0E5M;/\;_@7YRA\Q=D21(D*)X"XD M[`%R+BV_).+#Q`-F]"!<3I/%KY:^;.Q":K$$5!-X,#EB/$`@'6#I]2R$"JU% MGS1`?#(U7`B%%@3<+KP7/BFIM^6$/=/;KZ""BDH0];_"!Q`ML&2NFV-$GPU\,?]D5?\F*4)FH0EWEA\*!N2A(@="'J'RGMTM:5]ZD M"1R*.24BM=KPY#DKGS3G"C]/#VN66(\"W7?L$.RI+P'\Q\K9LN>]VR^Y:%#A MC2>!0PG[(B]5O[]W>Y*[_2Z8N`-VU*KE4IEP6LJCZXDHCNA3O`"Q]!AAKHDN M4#(R*-&5YSAL38XS%$;U(SQA*OC)(<,Q+AD31&12)(F2F@+Y.F9/)IY<=C3+ MHDD^S$"Z!A#I6@[9!0;'D.$Z',4'3F"6MJ)Z/^$,`PM]%0"U9+*#,&-#CGR? M9,0C&SRZ03`^P&"" M>3Y1JDM9J")1GGY>IX)/BF_@,0CY@\L?540Q@^IQ!,H5%\S2#'%A"&%*9@3")<(VV+T"%/9ZJXPL:%G('+/8&YI-[ MIE!_@.V"E1:'[CVF3-H26B4O+-9/XC13&YW\(LKX,^A(:345ENI1I5UJTZ%# M$^"8A*`UYI2N7W+WV8[($M&6C5=F*9\><3.61N,QGRH(HU^DJRF6+KNL,(&R M[]-L3^D($YFCF>$]+H2!V(U1W'7R%AC6X MND]]M07']QV5[5#(_`W'-1QWRUC[IE@,=MVB4R4U1>&_(B\0GHLDHAP`-@96 M0Q-`BOX1B6E.DV6I&2.(%"`P%(1(%/+-Z< M'D92B%:]%WU2'#32F7.F`3#_>DH]U_B]4(<0`\B4X3S_J4$B7@F?!%=>`$_& M011`Y(*'-\AT+/V:0RGIY.IU=O)(3!]Y#19)B:P;61V6>>QG(CO"N@>54[@I M\`I8)Y&V1>HM/=5 MR86B,1'DX!+1,N8BV3?%4)!)B_"7B_Z3"$D"HRP9<*8:P##)G6;&(F5^$SP@ M+7?$KBZ;!!]R0=C(]K*LQZ\GOPEDH?;AJ03Q!S#:T6S-7E MJ_`A:4Z@U07":,RY(_X:Y1T2*@`<:A@K<$)0KB!6P8IN+>2851%/S/!S:77H M71@.=7?#E\3#H7\^NPH.@6;K.0]"T6[!I9G#(VWCDW,D?+SM?<%G?1),#KT= MK'=[PMJU%BMX9-X;DTJ'*%TZF@HL1-^#6!C(2\K^Q,J%,!JY$[&MN(-93NJ` MNA+QT!*WBR1?V"=0CZ/$ID@SQZ8WOM#14=:%Y`P5]0NR^`">'`EZP?=,1(&K MP]$R"HO>19X&TOLI"8F'8V$%H4-7^I@%AP:L#])LI"R?-$S;)PM):8-F`)^F MR/`3\AO?J*H(?"R\:BQ*1Q5XY]=?Q-_DGPAJKM&?^O=S>;9-UI9/8/_$-#A M%$H:A5WH)"IG).E'ZNI4KMSCW&E&H:&1[0WI=WBOG<2C0#!U.:=6J'+4YU13.V"1C M)DW@6U0W*6U$/4""F,+\.5BQA68>MNK#/\%VH_1B55V)59'TP0/,^;*)1,C& M%$2"1TVPXV$4Y8MW9%:A+$70G'H8"O[:^_M9QI;KO_14<247M952M<8C;$^F MA^S;\D51@96>%Y=Y*E.\#.?SR==KIV&)UC=T@LT$%^]Y_$#M$<`"2J/\%0E[F3DE>G%:]1 MG#A**Y>U3W39$$3,F+JO1,E$9:T6W6FXG>%VNPN^4_XM]:K;A+GEK%:9Q!OC M0PICYLHF%*'KXV9--TKQ"3H8J%UA)Z$T%R;DU*PZRER4E/F;*DMDB&,5X4QU MU2QHYER9<[6KT-*(4>A*`<-\D^?\3(W">M]'C9 M*6NT:TQ-JLQ@.*06/H/LH1.1C$\EMJ*<^>SF]A/I^WW*W96"[5'.2DP+#'R: MEJA7Z,KR4JW0498:4'&OD.F'3,U\7`Q![MT%3_V8YLV!.0$6"3K1:5$"<@Q& M!QB,%J+;P?>A9I0#\Y#=J&MFX)]-XW>*X!6`JDT2/C*1;N3Z!W#7`3R03U71 M\D1X?DGF2(R2RS2&L!2=<3!Q4)T46Z#R;*W&."1QII MMN-(?A^P\NX]2YH:426*+R"O_XQ+! ME>JO')Y6880\2/+!V.*>/D]LQY&?->R$"C6@:U*?,$48<3#Y1;_0F<%AL[.0 ME#"%^6!$6BSB^O#H:,$VQ8G M2Q93*?@OT1G'ZH?LNH]E-R(0*IB2RC_]3Q+$Y,]T!TH)(#$M6*]T/^#1$#WE MA!:A<5E0'5;@YG,=*=-LB.E!L45BB8+92\1"F-*\AFX.%IV9L_Y%5M\O><+.>9YO& M=VJR,]^^2(NF:(X02T8ULQ%3:?7G/17S%MZE"J`<.=HD7C:1J0`@D?).6;%1 MOK&=UHXN4P!4L+B'V5A>.@A)E.XZ+C:65CFHV,DO+5`S#,4PE-VEB`[PO&A\ MY28,?/A[P->*EEYH[?]%1[&8XJ<4T)2=HPN;A'R?T"G$ZAV\[Z#68!][M]_5 MAT_LIUQ#7_911D;KM4\_XR`WWY$=E`*IA^@7]WS;FV(<\">F/3,M6*<9I0B;Z;$#F0;U*'$8GT.!$O-/42Y M5]IG#?<$$7"(B33(R1V1RB%KBL3,.TM3S[(+*&"9?_DA^R?PST!4C?DB5JCW M-TAOQG[I&NJI=)X21#"JCE6?6*[@4[[NRJ;*VV.(^SV`U;"^)V#M.BW=\..\ M-J/S/<6[9*$WL3/')?N!VDZ$*M/)<_F#N"ZO^@A:U]ISIR2OF4U_C=+IGIA" M(DK13=6(.1*%M5!-&5ERNPDTRR_,$R!D:-C MA(6BQ/Z(VP[E,XI!73K8638(7CA3?K'6&?LL)X%G\^O7FT6N3R]7O2-OL.50 MSW?2II.GJ>V2WE?^#/-*TGR%!*BG3S!OY":8WWR[OCG[=OSXI96X"J%G07=9E77II(Z*=+Q2\1#O.2[ZLT'W M!M18G?#HBT9#E\="^T$6;AO=F8[N(HY_Q]&Q*CA/A```,W'[:0NE9% M*\L&0^?4:$OP,-TG`9F:J]7W[,$?L[\I"A.PYW\CF'YF9!,O7=?B&.FZBUC^ MD7T'4TFQN&9N+QQO.J?_?/S5VN-&I3"DL\9K=\'[(/N\. M-I1R;X?Z*@+&6SP$NA95S7/0W*MS(!-8UE(KV/Q,RO\S&'`^'"[2.#9FI*PDU"L8VPCAKD^\>OGQ''[4^5\,4?.@_>KP MT-Z43#YL`XIF8Q8,ZBFW#(Y&K6-U&D?;@*:U*4ZVNT6MEZ2/C7&Q'?JHOT[Z M>*;LT.89EZH*B?5L+")/1+U_F(F1:DKLTE7&C4$K69)4$#6"A';L+=CZJB37 MV>VRVC6K?5S;[D95A((J`H8A9$/(6[;KGNI)?LI]"_6FG3BS7_[P/@F"]^_* M/6I+--5VUVIV2]547]YXV=-=?^M[OH\&B?H:+U+UEDO<7%C^T]-&G^O3/A?N MQU*Q4@I'+OD-1ODRRE=N61]WPG(VIJ%/AH(-!;\J"JY4/&CU^IK+5W?%8[9D MIO@ZLK*Y94GYK.>7P&568+"R/*:Y\"@Z0=+W^,Z\_&5PENY2IG3L_.+ MJXN[LX/+B_,S=G%UU[OZ^\67RS/6N[T]N[LEBC`E,X;O;1EGO?6J8F3';MD,;)IB`4X%%.D-3YV`5[R'9F@4=>PVY\`4.+U0@=,V8T[>+M+'_P4'C,E9;[E, M][R,7BNEO)08_5R2?]EQ_DKY&]6I.SKN;IHDF1;`F/3J"J3/UNM6L]W8!C!O M)'MV*:&7FOWY\EZ\"H2BEE!RRSIJEXKP*A#OML-$2\GWV)#O3LFWT:P<`O:7 M]W8,\1KBW5_>VS7D:\BWPKQWX_R9.YQ!0!T]32J8205;;UF=CM4HUSK=STJ2 MC>+V)CG*Y)FLM9CW[_)24(1P]CC?)`O3KQ%NQ^C\9#R*?K["01HW8HZ&"DO\+YO9Y>]N[-3^.W;W;],>-Z$YW>!LZOZ'"1.;/IBE:RMOI4N<:958%>JK"!AO M\1"`]#VL[ADP;1*?G8M0[\YE1JSRREX%_L$%DC^/8O:%VS05[3*P?29-17:; M^"%.ECQ/)S#\'98R81?^X'!K.29O/,%E\_Z!1QVK<;2]A*.7CW28]H'/R7_: M'GF\^?PGM)-39OGU4G!'$]7<752S;1T?EYK"\_((,%N^?,L[5K?]ZKH-[;I5 MPDKEM_T7[)4P=J,H"*>,^)SF#KRZ_')Z<8=>O!H[0PUR@FHB`'!Y>5)-G?VE M@W`F]%W0.K9I-2K7`^7->#X,(9='R`WKN+4WA%Q-7?O]NY7"]RZ(X:$B-J64 M[ERH5`:I;NPPGAJ5;&;=5KQP"]E,+SW?][*[1 M]/,D"4,<;?/5CI.0)M4;9<4H*^LMZ^,NV+5IGFD(>)L$O'7A\]*],W=;V;"J MCPOSQ$U&^+-IUF2$ M/SLC?)N.*\\T#GOB,_;'[V<:AU4ZB?`)&73E>\Q,!IWI(/82<9LMFS$[I]OW M[TS[,$.[^TF[IG.8H=N]I%O3-,Q0[GY2KND7ME?1!Q/]?O%`1!6K9$VKL"J& M^ZI[WIZSJI=(EJIN\.]UQDQ,G&DQSJY]=L[[86*'4U9OB<9-U,Y)1.[J'36H MZ=3V3T,W9J?S!UVE^$DVAZ,>C M[,=&TZIW.Y^8%P""V$>,)JI\HT:-6D50AX(H_;+^RZ?\$"9+S%"ZL2,^"%AO M<`75Q4H.A&(?M5>*Y^BO$U.>,E#8 M(VAQ:74X`?AIR:L#@^BDN MO]_V6!!J&R#"I):8(C48A`G<[ZH.#G;,6G_!@8#PLY^,#QGL76\2NAYK=!?M M$CY(8HH:H8CG!8@Q>\Q]!\?^`77!#X`S&C+%PW':]6L1#@)_#F9ZTR!(/,`^ M9T!P`N.,1?N_Z`U"A(QP-1D]*L1'B M_"Q8R?%AK?:70]8CH*\'<8#!L/JQ0@C>$R1Q%-LB7M:W/=L?<#4B3%LAO,E+ MZ)HYS-,XK`)$4[V$OAK_!T$$93$&#Y;AP1F<,IGQWR:#B@;V`6I8;10F?X7.2+VK/Q"O7XF?PNB?Q M,_RRD*?E@2_F<%5B;(OXV@S9&,9F&-NN&=ORHYCQ.%!TU'G#TR>`QP,1)9-) M$,8Y=P"#+#,F-E<2`8G#ATKD\\!]@$34*.)*>;/V'$@,3[ M^8^)&PI.-7>=(0)S<+8X6KT@L7Z)GV/(/H@&@>1IF83!D$>1/`^+`>AX!O&<1D*4*!_10?YYXO`H4')7HC2W M!Z!2A)D>$?(''D9I&GRYQ55;9DCYKL\YO_%%W@ZQJQ*;[O5&,A8'GK79^6_GS M)MV^2NPN/GY6L?>W(?7,9*(\HIE>JRO.MP@0.Y->4N6O+1@CL9;;%E%E+?'8 MBD5^$`W(Z+$?FG6KVVRE)@#YND MW<$\NQ_`,U`\(9,"#=%)!L2_"7+0LTB(I"^BVYA]#[QS3!6AL$S@F0,01GV. M_\%R/>"*Y!8Y$NP5%A>[`ZXL*'S`P/:\B'12NL*;,JF81ZI_/ M2R628N@;<'T"%PPD[J)+/(<.>9[!*'%@T^FJ>_=!&18!77^D#KHN_-0#[NT' MGA&JN")]K7K.+&IURTMN4TNXZ_MHEG@*"=I["/G9LP*?(A-'\Z[*;/#H^E:& M;IM<^&#Y\3O[QYY8(V4=X:J:*.V#VS<;HR,G3/ MM?LBSP,>`ILGG=VH\0U0$LBN-WA/G_M\Z-)=2B%$/Q433@2'`IBDNI5Y`?%BSWZDK>6`@4&<4R=RB:`2K]P.?4P,DIE.)$+53P^H M#8@GB*>1:I`:GB`^46H[7`A0[AA]V7"V%PO#*;8SLAWB-C.'F([M@3JV=%3S M6FK#:M;;5J=^1*?OU/;=:)0_?8+PG0`U2QF)ID/SE+?5C[M6NUVG=WT_O#T$ M#=.!)WC(5V??*%\%5FR0W&/4_JB)N9K$ZP1G$==%(U#I\41Z[MA%UHG).I*= MRC1IX`LR9J$8D@@JFI-K3NX.=9*ABQUOB>ZI7$4<-DWBP?.3T)=""Q"><$;@_/@!-;X#614E_7^#9"(ZAQOY#UO8GMJ'>/M,6=@YV<@4UI8%7Z!6?U1*MW'HM!9VY)#YV>QD&?1O6D7^I"%CK6:1\MHG="DLNO-%^CJ4`(A^2M[* M_/24+\UXQ_#6],)=CTUO+0'F%=)=90!YBP=`2>$,IW@8\@BNR+%H[MVQD)T; MUA1%J[JEE+`X1:/U[ERWU%6]F\Y^#'!$%5CMZ"$(8`W"H>E@C_"!*YR,Y^X/ MR@E&)V*YV_*KPA:MKU/K9,RTG&6,4)WH_D5#Z#LF]#38^/KP8'9_C=T_ MZM2L>JU=23Q47J_;V$7PF^TE0J?K8=`$TYVJZ[1XZ6:EY7<'WL[QVO%T7.#8 MG;K5:K>VO6'/&I%K:-G0\EJTW&Q:G59G#VAY#_3NPD;#ZDN\Y&?67=&Q/HCA MU:NQBDO:YIN17 MQ)N32EE7>),W9?(&MX&UB_E*G4G(L5Y%MF%1M2SWB4O7Y%/BW4A5Z%#E-'92 MN??=/T7VNB,*!SD3C6C2%-P$'A/&MNNC[B'*7-3355U/Q&P6/P8`-9^(!'=[ M,-KM&U0!SYC;LG.F5B@D,BFU7$CLN>X7E>50GG\@6NZ(+E<2-`'6T`TC3+`` M(.!'>'U:\X)/3,M4"+!GF4I"Q7 M0Y]EQC/#QGJ^4_Q2K;4G?-_G&<*=V4;I8^S`Y3X01ONJT@K`P`H&4(R=B+6P MD?O;K6*B$B87*Z=AQ7DTBSQ<6+7O3:F_?B10XARRK]C@590'JV\C@5:7VJ3A MIC.QZ?BU3S4C]+NVDO?OX"Q['OTF9,E7QVO\%M)$LZSHKU+PWT=@+QYPC/YWZ6E83XA_QM5F"26P0%0 M3\Y4?XS;5`_Z!GK,=M)&3=;W4[.^/S:.CZUVZ[@BB"DYAF32O9^0[IVGC_HV M(K%/1LP6XJ\OE^5]%?@'WV_UAD4T&?%4EEW'Q#!-?O>NL]^ZQU:W6\W4-[/U MV]WZW62=O`Y=<3E?.^78+IJ<*-+791C9KJEYZ_%JP\/,KIND[2Q\55U/PTMG M$9E$U\*2:]%DKW)9KCORE;Y_9VCZ]=&T&,JX3S1=.=5Z&RG!7+.@D)N, M5Y/Q^GHR7@WQ&N+=6^(UZ=HF77O';5YQ("<`*SA[X^>78W\O;) MB269TZ^Z[.6E/2;/\G97T&7RK/7LW&=B]"!#PF^8A/Q)T,%>\_%>^!6?32#H&T^]U\)@7[^$7&2E[* M1:"CZ+G/RF68OC1@U8"B8NC9&ZUQ+5]%P;"++SCLXG1^4IW02V49E4)4ZB>Q':L#)R/;O.?:NQ>1; M4\5J*OZ>6_'WMJM8#46_/HK>^QK6]^]>VCXH*94@-W/(%*Z:VK]7%WHUQ&N( M=V^)UQ2NFL+5'6(MU08*ZE4_:Q6K(8\2+X[8)'0!):XWS0;!A!PTH@B0B=6G M?#P)0CN<(AK1\>C(UIL#P'*?QX^<^V+HB.^PH>N#=>S"G3C908Q6$6!HPTC^ MZW,2'=S;]N1GD24"6LNIF"Z4A/P.5O;%"P9__.W]N_]2UYW)R3`W/+P=V=I% M5'$+'[[QX7__="+^_OWHZ]GOM?KO_V/[OV/IVEVM]KOXW]WU[T?UW[_:8?[[ MG_Y629):6F2ZVW.HTGNNKN_.V#%+1W`T?F&7U[>W[.;L&[O]1^_;V4QJST3] M53GD5NB\%G$Y@[/5Q?EI23QS[-AFT0AGOF1#M2(!@SF?`0 M+@8NDD[I$E-D<-R69)GJAT>.F@UV'`9^:-]SYB?C/MP.;)&>0"'I28!Q9^1Y MCNLE-(P&'C*&IT4QLJB"\G^$P0VK_[T MJ3F$NXZNEZK;YPLK%Q<\MW>8-'LN&<0=,H@9%!2GR?9#]GEW\'T-J&/)&3*K M)4"]('E("VL/:+\<=^96CL1+]!78Y3%+Q>P.:+B\;3:DO:>D7;T.+:]EARL" MQALEM#5ZLU1HAS=AGZNR54K+PZEW%DP.RUDD!\=%B2O'JU"!68(?,3GP4YD[ M\IQDP')?_NP,K_+RNYZ2"&@U6D?64;-5"?QLA42>D@98[LLK1")/2`%L-MI6 MK=6L!'9F">29[%3+GBA'_#Z35_YSL7]/N?"$FT^Y$OMVY`[20?69*_&UN$=> MYK1L=#ZZ5NOHR&IT:Z\+!V;7EX+0MCJ=FM4X[E0.!Y72,#=4*9>F2*_DGF\?[?C1--*I/F4 MUJEJ!UD^QJ6QFHH-#;]6&JZ:>K]$DI$W>SU!)BXMP0I`&;8DVB\S`I(XBN%* MS#=09D-ZZ78M!\-%7C,7V9'A4Q$BJ@@8AI:WLJP=F7-;D8Q9!C=^,EEZ)K.Q M3)R=;SPLR*+K3X+QQ/:G;&0[\+Y\!B+_3^(^V!YVQRE,PUZ87JWG8-_BHT:! M!Z<].H,'QM,K4(4*$K=-3O;N<[([N9SLV[OKDU__<7UY>O;M-OW^^!=V]K_? M+^[^-1._-545IA9E^U1Z(O@1,1&-`#.D:N1[EV-G$9.5QOA_9B?Q*`C=/X$= M9AG8)SJS^U`[A`OKAZQ'OQ4PS5,^X&3@R6^;R$!#S/:&?U(M6SW?C:($;4.X M43/M+"R?F?`!6G7>]-#0A#E)VS])>G[/2N_+W+%C%T#)-I5M::=M9;[QM9^_ M9&T@YHZ9E<\72I^JJR\AW`1'RGGB.S\T4DY!A1^^CT<4,/#HQB-F8ZW;@QUS M8`Q#(!L.39(0CW[,XN")!TL[HYI&&>4.4C*!Y[,/ M]>P,?FQ8^=/UZ:G'"X^SC?59+OE>)TG?SWGW( MZ81\_D9UW_#-``S\R,7SLTI9O_;9.>^'"1:(9X<)3^M@`(M#?4,(7W)J\'`L MPB@@FAU79`;`B;#9(I#81[SOIT4___3)`K6=*CP!Q5Q4;=H9]/AP,!_^HL8H M%ROS;&!/W)B*UM$\F5DG_A4,B[X]M?W3T(V!X_I`.W\(6!5R&K49/*<_U'_Y M1!"`:6/+*GS6YP-[S-G,$W.L=F+3O*"!Y%&S+[NAG_67'+*+>1T([\K#93%N M@XFDXT.PW%E^!Y]G5_P(:^#R.0XQQ/IAL]OI-!L:TU0W?;_MY1:D/]S"Y;$' MVTLX^T`&G,;[9Y>:,R9UK"(`("7L>Z"/>Z'GL78JC01$2)P#+Z%UUCLMJ]8Z MFC&"0J*X\/#>($[KBGL84?7$&WM1 M%*@6UO,8ME"BR>?E,$\@2W<<\(R`.2XZ_F(:'"/`T2P MQYK6O(JN0YS;L^#1AYO[4^8*=']L"!#Z@1TZ(E<);(PX"`4?XC_X0(1F02+8 M]X+G+"!T>S()7#\6L!%EX!'&AW]1#S_=Z.%P(#2E))D$ONR^$8'822DB12!H M$J`Y%7(GY'`@,Y&R\1$>L'J/SJ.+O@V2(0[:%1]:F@R!^SX<9VY$N.]# M0_H5\ZX\=#]&7(&BOQN8B@Y6[JB%4G.:T3UFV8@2``"*?#MQ%CRHG-@P&3"2 MRZ*=8[NBA8544!:P7>`%X@+WST6"Q!QW<]QW>=Q34R`5:TNE4=[^5L?$!8-Y M;/\[`#J>YO0'=PP:#"A-<&"+1=Z<$B&<$\6J1)A316Q5L1?X9'ZT*N%O3GA?"J*G2ANP-L]B1,P+_X(Q`'K8`QP!TBG(!!::PHA[I,N#4`U0J_?% MCV,;L8:G=NS&T@BPQ0.P'926':%;F-1>RI/R6K<^1)LG)R";;62C+8'A#TS& M(JZ5C!,/+5A\0:0:T1<^R4CVZAY6U1?@*:DFARW7?YM8>RVT-L?B3MT'%\!T MED5@2^9R,J#*0AO3%D&+2H"7.2D<=D3Z3X$#0S0#=87Z0/\=VU/F\(%'YE1" MGHQA@@\A"PR>;3_8KH?)D88EF<.U\\-UZ8+I[0C[]QO*T0U.V864KP_20X>R MV,N>9\&)B:(`BSA0^(:P!'(]'H!5@5.0?77AL/W_LA2JC#KU4'QR,BKK]1*D0N$H)3LC' MMNN3Y43C8POS1-=.`=7S1M$[Z\:(@:CG.Y@/"F_A_@"6:Y)'7_KP4/)H-Y<\ M>G+]]>O%W=>SJ[M;UKLZA<]7=Q=7?S^[.KDXNS6YHX;#OQR'OQ4^&S+0T&@# M^`]DN"N-6BKFF9)T?37K7R.29:]!'>V,!!@%4HZI>`*!]]\1'0;P[$TA'Z+5SRE?8$',5LIWI!1: M&,5QYUOQ&U?!\_C/P0`0_YW[@7W(3L-#UO,`+\!];H-^R,-`13K7`Y8I+*E-T'V+;?[,'DLJ/F[_D@/AZ\EL.=M?/P`<`,T2$F!F,(V$4!H987"C,4XIJ MB?PYJ1:06$%_$)QL6UAN13E/8*YAA!K/!P;>C6PQ%L'.I<:-H'#@FV-@Q4#8 M-V%P']IC33X79:T6%;V`_$@SY^MMDB!'J7C8K/HF2Q#5TSC3UZF,;V*'7(9W M*6U1V1BR6N4T`10M3/B$T\]N@"O[/,QQ`4Q]#$DM!"ZZ`#_LX\W5]T_I:)(B M(0F/1ZY&7%[<0]HW34#.,ZPG5`8M0PLEU\&;<'V4C"B*&Y"?*G[$/M9KBN-' MG](H?YAQO'@$+[\7(EI#E.#3VA"IP_2!` M"*&#`:;TQP&9GJ+,@+80LQ$(&((X+X`\=RC*N8'SDX=-,N%H'A@7`8F3T/^# M4Q&"\-11ZS1I^6`"$%@(PD@$`#!(&*`>`Z(J3(2?S0+6C)"Y`QEEG,`=8WL0 ML`?WWO404X>Y(DMZ^,2>SF(+TY.#J>V!;H-@,$H*Q4%@0?HG-L04BV[4:)\B MO!2?$=EH=%(E18+21U@HBL0/V9F+20R8]@N/Q]`")H>#S2+%X\QAJ'=JS+&G M@-(0HZ\^6J`@=8S0,4)GYT+G/`B$"7X:)O>LYP#59N5&'\]/>Y_6#SS@,80[ MJ,X9@.!^1,&Z]&"K@F<\@F!GL+X;R-/,$^K*A=S)20;`;#XZ`(X(*L`BL8'(2U>4*3R!<*L,2R'4`P0-BI].4%V7/ MXPZ8&,!(D$K@W>JEY/ZAFC1D$$E$[&N4P'WHR4`S[-_80!)=*.Y]``P;6"M: M$0!=B`ZDD$OEJ-J5:-JXCL(8^!-\+=D8O3H>+@ M![#I6/Z*O%ZD7P,KQH?:$V3U@#0E%Q%DX+,SRP)4"VR`T('?:%LP%1P#&$@[$*%AHC=8[O./.)%:HO@T7,$1=(1 MP/#(Z$NWA<^\D@P)N,6;6@O5#QQMQ:(IR->Q;+^L-D4^)\N.#^T)K1U=J[A- M^E?IEJ''32,X-/%=)!40,/*TX0.UA69"ZYP[M(]X[BUQZ!&;)T$TYOB.W@!$ M+M8'C(G8C4PR,FGWAI#D?RJ8/'W_;C,AE+JZM..5YM3+HS=_JDA[YECI0D5" MHD07G+'61!(AOS13FYLO.DQV0V?&$Q_80++=(XTXP, MV;T,.0-B#T2N4B\[YQM)$;V``X_8;5;C0,>"9Z_(L1)0YF5UXVS0UYP$'0T^5'B;!\5`A&M"[-P5+VH2=&*\-%5 M$**AY:>9#><)$[;WK=+BQ@`)C!-A=X=>)YP\MBYW*490;SDB3)$PB.]-CNU M'O/%BT4US!//]GUE/@&B$N53LJG"@(6V-(_R\2I*CZ-,#_E:X#938E=^I&JW M/]2;'>NH*SH_JONUYKK%O75%4'SA,QNB;+TP27JS?&<]4_H;Y3\X&'R9WN%Q MLPE%6TZ3=MP'=5I*8RNO*#FZ7EL109:[1C&S*=/WK2@US'!OTS)\BVT`5S*V MXJ;A.5&BE$J?*D\G]A0KN@2?GLUYUI_Q\99C\G#,6?/3H=D\0_!;;30AR+IQ M/)_I.:<729L$3HA'N6^9GC2D7$5T.S`"4_IHERA!&I6W/AVRXI.W4;]^ZO`B M/-U"CHB$B--??VUGK6K@$ZNA146AN1_N6+A2D?26M5Y1EC3)HBF+#Y4Z=U M+/M0`4#-HXXYP.8`[PQGQL.PIH?A29PNCT7A.W!2MX$4V(5ID7D*_BR-\\R[ ML(&/(#>$^E'&$GWXS,L<8],O?5+NA3J^6D]W[_<(>!'BJ-,'!$.T3 M[?_>)'0]UNA(P?L-ZSYC]L_`&ZK^R:)@^F3D\B$[3P.1U[*'\HQ93P75OJ#D M*+8T,R-K^GR)#>-.^7U:=[G>L[=W(O9;)!K*+X7R%^OK2CV>5=O/`]^Q_W21 MFO\.6B-8K=@EV;/9-Z3>`=R7N.PN&0>A*]+SX`3`V5+]+5RJ!$ISUTD@Q)2- ME^6HPS47L;W-N6B&]M^@M$RIGW@TD;\JWY\A?;`6*=-_AO1%87[O3Q>L-YM= M1Q/N`(YX:,LR?C>V@9YS]>X7MW<'[$(4XP?LB@X.UE/(,Q.F9\:C*OTPH&14 M'E+E8-HK1AFJLV4K=JXR/G^JJJ]*F1/U6J2)U-Z7N7]FFC7,G*QO[M1V1MBU M`5Z/_/_63AR7]4*[#P=*5`*-,6PR"-(<,>47S9<1H2J&U<&<7#Q9.?,$:UNMA+QUZ?BQ(*85*9D+NY[G.FH4C"IJU'\1QR(_@$BWF.D2 M[>='ONB7)%KT2Y#DJ_@_XO[PT)NRFR3V[3'[A^MY8,\$X>03S8P`]0SVGB(H MKC^`K_%D"MU+]!V1\X].N6<_4LM6GP&=BN[\0GNLBQ%4#WR$'<+HE.( MZ"N$#X)QWY7#:/2B^OR@"PN#D]2V/B1^8.4#K^IIU1=I52)^(].>R#(JC:LJ M]?76F.*=;'Z%0=JTGZ!@*A1$P>9S.IL)4ET<64FM7LA&9\;8B#0C&Z",L:G3EIS/&\^J+.>`H(JRV0\BGZ64QJU(8W;4U72 M4!12D'^O/HF,:/=/.%<-HJ1%DR-STTVU9VPP2U*?[5K0F7.349'ZI+129T86 MS7JJW#3(FR5#]V(J-*7LYM;,P$2%A_+'-:(*)Y:A(?90?4=(\1G_X4:S[5W7 MFQ&(!6BYV8!4E29VLVXUF[/7YZ[%LY]5Y!0%G57"UN)!B[:JJ9T95TP))A11 MQEJ@PE%"VY[)F:./J"YC;3%?EF1O=DKVARQJHK66;'_>E-.=#CE=>\8I MU9!JG9/3T[>@CF9V'.D,8UK2A5CG4X;*%E.9]?2)LKF=RGEOUM-R\D,&_`A^ M%=,:MNZX,7;%&D;8@J*Y=7&TI&9..85RF[ZBC(^=SY=^K96G/4A?@ARRH*=V MKB.2)'/AI]*+88=%#,Y*>>62^S2=%?OX>EH5+OIG#Y0&&&O98$+[4,_4NI9[ MKFBQE[J)!CH.#^=5]B6I:,O.G'XV`?, M"8DIN0BV;R[J[;_P97V;>GZ".L5YK+$:4(T4BE64A][NT-LCU8()N)$;.`>< M!II+32JD1MW$98`CX?!C/^%RYKFLE%WW\38VR;OGL\^>P$-MUZ-^J5D*KH"% M&#=^M8!S'S*-J[![V?/`85X0*-G>:I&W$@!5<^9*`<7)H0$JX_O-/93$(\F?/G5#L[ M&F$A-?P'9TX]V!Y2^TY$Q0J?%X(D.@'B'QIPFWN^=%UNQ ME$5R#3EN!T@D8SJN'$Y`U"&)!^<%`!2WL2WGE0(MX^MP2*#HGTB!*M%"2U3" MB/*<(ZMV?&1UV\?($/('6NA'",R'AM6J=:SC5G>;X-CQ?(W/X0+E9QVJU,GX M)L03%4]O`*LQW(EWD[^*L4F=Q=7=XENIK$06.@-B;"A M-DI>QXVIB2^J#C0Y'6<_\$=;MOGM$[[',GT;AQ]A1UI'-;O%]G<>R#<1)%G\ M:NG[QBZOE)$DO758%2E/H:1/]R[*B$@R$/J+^[:%U.795Q^=AM=TP8 MG44$:2DT%5%V00Y)1I-$'F(#).HG^T.V/\\JA(\^;28NUV41.ENY\&.<`-_W M>(\@/'>1\5T"Z(ZXR_"35\I/LIUG8NM7L9)3/B3B$`,)W.QV2=O*CS'!.06S M&D%J->!)L=K()C(7QFB[_2DCAQ)= M>0[#UN0P0V'4/<(3IH)_'&)?Z3AC>M0ACDM3!C-TZ'58EN"E+7!G6#+)@QE( MUP`B78`)OD4,?S.6 MN9+]Y7CE&"4-,M3K\-2-0##8WO7P$A1SND$\8;_4L"@KBA6+ZT` M_UP3J&6=V"I>4;XML;?_VYF*R?30(Y/#PWY`IWU-H4DW>'2#$&Z6;)\=I?JQ M1<7EL36K)^-4#2D;:!:W*J.D,&L&U>.(BQD2LJH2VW62$XCDZ,`-!\E8M4C' MJ>,#,2%'>L\&=AB*QN-ISDEM'D)!H6'(DFYSB9+\,:7-WG"*N0ZKZC M,EX*!?PRJ6J8VMXP-2.C7M-V?E-,64PI0-8M["?AHB5'IQS;@[D5;`S,E?R5 MU$>%XKZA&Z5C<);*`E2P,\8`8B0B8PK%D4A12WEG)#F6T,H!CGN03R+G5_9H MHB>2D;#JK>ATY6"ES?"EI:^GT@%-/LIQ=VY$0@SXWY\:).*5\"D=3U4$3\9Q M%4`4%H$WR!1&_9I#J1G(U>OL5PP!1][,`?5J[`67F4A*;.6C;<+#!6:8<-7A M%;#*K$I\#MQ0!\P3)1B1``?'(@HU0T#B!_`L_U[,GW*4;PP=97>C[`LT9/NJ M9$91F`@\<8EH&0>3XH[B6C2MBQ#EAEIC*@VX:$-3[0G65[X[+@49OPDB0'%Z MBQ,&KX>W*B&SVJ9:U=EI)3U=&77M2X^O-[4]?97ZCTQ#.YG$3>AXKI.X43BB MW?:R)&X<)SH_CEM-_,[2FS+#1,G'*,*X=RQT=,$$L385D&]/4'<6([#ET.R+ MGBH1$8GBI(F+87C2;%,Z/4W4H[1&7T7;R0@(:2@VI5+I*_MKE/>?JGR)4,-8 M@<^44I_Y`,.YKLRV2%-9JK%J8\C MF?.FAH5A45`8C=R)V%;L'W3+BPLC@:^6'1N\@Q2B8L9>OQ<"P,>HPWR1"8$)Z`]4&: MMI>EQ\/JN?M`8IB4&!M4-II,)B=&8F&&-J10#)%WX7<%WOGU%_$WN5.Q&PUJ M$E+CH:DB;NQ)7$6S\&\FI%<*V;0(Z3=4`7J.PYT[^\=^.4T-JS>2^+5M#XE8 M.I.,#B6#4YDKB2^0PQ=^EH@\>ZL>2?NM=S=;MM5H9>5Q_D-`S%'8+Q25)TZH M8E>BV8F\.I7K]P'F\5'FP,CVAO0[O%>-.W;5V#]XN?Y`(925%,E7C/Y"F4#< MEJ&H#""4/Z&CDONRN8!!D<6&0M033EY\-XH7:M$MV&H./OQ=(@,GM^-00G6M MS!$EF?V=`;1.($:C2W1%,I,S33TB#S&V(B5!(;+]1*&KLKSNT5G@HRC#HK1T M++2P,+,%"G4D$SJI/Q75"\(3U60499"N)2I6H`7>5@B)F)::))CKUO\$^QLRJ]7 ME;U+"S*P'!$[Z=9;=:N# M/2<+>]^S:S&5K!C2%!",CZ@<6ZXFTIZ;*V4S:PB6RL-(Y4)S6U"[-W+L@T7.,(Y1.",#/9Z&2O7NB;6$"E MMR=+TZ)*`3B0&SE#\@X#66X0XT,*LZN4.2Z2G(Z;-=T?@$_0P4#%"O25+$L2 MAVR[H1C?+?SD5*.03:=&'PC6H\]4-CGCQB]_Z2UJ%AVAAKM&E-TE\%P M2&W'!ME#)Z(HB%HQB+879S>WGTB1[U-!AE00'CEZN5`WEX5.?D(%!EHG!UF7 MKY5,RY(G:@(A=*-#=NIZE.N\&(+^C'-EP8[04P?Z-.B!.28L**FJ(,* MY.#[4,/,@7G(;K)A[CGX9\N)G")X!:!JDX3S4:2=NOX!W'4`#^13U=QB(MQI M%*W*W+SW<%@H')G$64<`4=_Z@X<#-]JT3FD%E\D5L]IN2,;/5Q&,S=*S]XLU MF<3!,C/-C'/L56VG*%+&0/=O*CT@BX]<9-5W3];GM`C_..,CT4P9BXS5T^#: M]$NEE;EK:8*=1C[=75N4QL#T2(_PNBGWDG`QW"\SL2Q-F0'SHV1X@*%R"'?,75!T)ST.A1@!Z-5-:+5@R0:AD8PQKK8KK@U7+UE%'B$[J$0RM;<;HV M@M*6D5J*N,IB6.J`)1)OTQ<*-Z\BSAEB(^_2`1R3W&D;8;/O<#":2E)&:,B= M^Z?PR`*`H"!%,N7*7T"9D>Q/%?UL;._7P/+7<:7$Y)=_.EARI?56^SC=U'+U MK3YQA`-JTSV)8,?47UO<,W(22S#^^Z>:^#RQ'4=^3K$7/@-U8#=1GTYU".)@ M\E3)'CL%<-1;U,EK[3T4';@*C^73H*H4Q<=.J*>K(*O-=N[+=G[WJ::;-/9';/PK8YNJ@=9\57I1 M>62^^:EJ!IN-_,!R>BN+.6?5`%@%QRFZJ-*@+2Q)X!%-MHJT>R;V5-P`WX0X MUB&[08T^\K#;"]@00"ZJ$YF/5>G4OUG<+G('?U#E?U9-+JL51!DY`@4;5RM;=-+%P[1P=/;'G>\2OAV>R1X&I)7]MB86&B59Z>U32C9:U MG)[%=;)LB*F%Z7RA!7,Z\%0CLE&IHFP9T=H$DQV!R?$)949J@VI"8*@NE6ZD M&=*P+OM>9D>@)O='UE%1]L.?38BPAT,:]IUJ=OG^UUJ2CQ;LL&0&I4I[B;)N M5/?47*SP+M5@Q)&C7TF>%*%"U:C,`"3JEJFT+LHW\]=:\&?JJ4I,[6$%C2,>LL^XH_:B,3P\"'/P=BA=M.R:P&?<;#@YLIC#N95X5M#<@)ZZ9I5]KX(3;@86QC,M$4^[@@BX!#3Y9&'.B)A6[9D`#8;HU:;::79!93!EG_Y(?LG<*Z` MDKFQ#`^3Q_1.A^G-.$Y.0STUT:,T<$RSQ'Y&6&WL4W7CRN%-AUO2`"J37EW6 MX&G#]);C[#JMNO;CO`ZAV#4)W(CM!&S/K->KQL[N_JA7%W2)--1V!)3J\%M2'-V4-_\S<%JU>*$R! MD2.#A16@!/R(VP[5)XEAX3K862(P7CA3EO[T%@I//2YKS9.IM+J[WTQ^27RT MY&`GP3BTQZXW_7F-P--30Z/E!SMG(Y?]((Z#\:)P)+E.!3T5JAXK8DWKDJ"$ M^$```SSO45Q$PWN(AT#7/:IZ#YEZ=`RUE8:5:43"[_O\,!IP/ARL2H#;- M8:O5CF8-0H\/ER[PTN[/3`-Q9RJ'2T*]@K&-$.[ZQ*N7'\_A1YW_Q1`U#]JO M#@_M3;7L[&(/!'=>L),C%138I>N,FX,6LF2I(*H$22T8V_!UEWCVG8WJB(45!$P#"$;0MZR7?=43_)3[ENH-^W$F?WRA[<"!VV) MGMKN6LUNJ7KJRV/`[/E>[OD^FB/J:[Q(,K.E95!1A%EX";6OYQB'EU/HW,!? MN!]+A=,)V-:>B3H6!#P:^*@BL5#UJ]ON;R MU5WQF*G4+3$=:*5O;\D;2K%=2GU^"5QF!08KRV.:"X^B$R1];VE5:*E>_C(X MRW,6<[!;CO(B]%()(`S1OCFB+6SHH&<4K\H*UG.(;P#X;GK@^V)@WB MOO!CV[]WX=%B)/MY3*LO,U3F4KQ#<\EEY7M7ZZ4GJM.W=%Q=]/@?)IX:=)Z*I"V4:]; MS7;#9&UL@1$"H9>:=?#RVF,%7"!+*+EE';5+17@5B'?;[HFEY'MLR'>GY-MH M5@X!^\M[.X9X#?'N+^_M&O(UY%MAWKMQW.8.>YU2AQ@3@C0AR/66U>E8C7*M MT_W,8-S(7VR"A:9MBNO-SKT=A,@WTI3`M.9HRK45Q$PWN(A..6#P^J>`=.5X]DA MR'IW+B"ZRAES%?@'%TC^/(K9%VY36^O+P/;9C1Q8<)OX(0]U;7O`ARS>$4#%97*G4Y2J/_"9)B*49S**&0[4\BZ M7>NH5JIY^?((,%N^:LN[K7KE$%"^#O[^W>[;S'37Z#)SDH0A=E+^FDZ%-E6[7L-J%Y5:,6S9A-]F4%#O`;Z"YAB-80[=X1[9K)PNLF]18G!&=6Q_4063YR_%/>CTT3E.JF MN6[3'O=,$Y0G/F-_0HJF"4JE,Z.>D!94OAO`I`69;B@OX8[>LFY6"4^T:81B M*'3*(YGG/(A#T/NW-D_1+N4GN]B!IL^)B)28/B?[ M'``R?4Y>>XN'K,_)XI"8Z6YB2/\5DKX*"&<8-:U.*F[Q/".^^(16)V<_!I@W M'PP9*'DL@!4`U,$?S-%&M+)S]P=WF$TJH`E85Z6[2;UA'==+S?:M:`S?=#=Y MTE"7K9''FT]C6(MIWM@Q*!FE\LN7]S)5P"6T&(16PZHUJU=]9[;\S6UYI;3# MC?HV\9A=3W@(+(Q:WF%)I1V&4[@E?+1#QY#VSDB[837K;:M3KUY+'[/KV]SU MHT[-JM=>W0RSBH7C?[.]1.AI/<\+'FU_P*OI:'CI,*&)RQ<4V@)O[M2M5ML4 MBQL:WF,:;C:M3JO4]-#JU8L_49=^_^YY(?V-6I>(#DXJVDY.!8JWLX]:M'VK M9_LM)K&8,EQ3.VZ(UA#MTW*M\)/)4UJ2IY3')F4L%>6G;91C5IRF=C8<\D'L M/O`+?Q",.3SIFQWS;WP0^`-X#)EY)E?-Y*J97+7]M?S>2L).FJO&3(Z8(;G= MDYS)PGJ)+*R38#Q)8FGZVS'#(:0#_'P;VW$2XZ0!5&FVENMCU6+T!MMGQ[6[Z+2-&^ZW_+.=@I=Y*!<(%P M,6+>L*RWW-W"[/9;VNU*JU[/2)ZR3?*423S9;%GUXZ[5;E=M2L&;\6H:2BZ/ MDFLUJU:K[0LE5TI9WD8:5>8A(`T2VAF@-T2Y) MFBI*`-H\>ZRSKVS/WRE!'< MI[;O1B,M4Z.:3.2E3=EG.1TK9\N^C0[GAG0-Z>XIZ>Y5['F%NTE42B_2B8S+ MM#0O8W5#=F_`=VJHUU#O_E)OQ0V=ES;HTS8?\^%J]E$&*CZ]A(FOH^=Y3\HE MZ+TD4"\/0870LA=ZX%I^AH+^NU^P_^[I?-/R7NE-RU]>E%9`[KV8D-KUVM_< M;K]_M^_[77']HWQ.9SJ-&R9G=OLM[7:%5+FTZ\%QM[@^>2-^MZK_N!D_LV5P MGM(+80L5':87PA:FK;Q<4X3R"R6JTA1A'\+R)R/;O^?,]5D\XLP4[YF2)U.\ M9RCYK5/RFRK>JV`0/]?NW$3Q3>'3*PE_&J(U1+MW1+MVM=[&57;%Q7K_Y+@7 MW.F!"+/O^56"0ZJOA[**AC`&4;G3%TWB M04F)!U:C=60=-4L=PVM2#UY3ZD&ST;9JK68EL%/U>0S/Y)7*I\=LX=1C/GGU M,'EU$(S'@<\B;;9`FAGEFD_$H^IE^//LQ MH**7WGW(^1AD3&_PG\2-7#2?;GB($2:4346I92<)V%ICS"X[YWW,(FOFLLOJ MC8+O+_F][9V!)(NGO1]N]/N-C?W),%?.]J=?.4+]$TM\5[QIDH3\)^;P@0NH MBC#F]+?:8??XOSYO"O^+KAE'4]-KSN`M\31+#"0,G)`8OT6K5:S_^3BJ']9J MI>-(@U-052GIAILB1UNX4'STI5]BD=5H:#97HV'ALM8C!?SMPH=5^SB6(O#_Z<8CC;)ZOG.-@X>!$U::8.H" M5>L0S*8K7H%'<=$_N.=\@77X$6KX\M91X(%\BT0:,1S[JN+NL-GM=)J-IPBBA+NW`4YOK@GW'H!'MMK,*TEB\^ECM-EUYHY6(297O3[]?#W>D<1 M3SV/F(+O"Q;Q(W)_]EWOOW^*PX3_]/FI4`"IGO+!/!1%W^\"BL8"*!H5@Z+4 MXUP#R7E4[]1;=4V]G`7\^:LZ6K"JHYWB=C44Y;/*](AO$;O-!>MJ[A2[JZ'8 M,^S."])%Q3/;Q.[:4)2/W4Z]TZJ_.'9?1C1W:LT-*$L#XL2>N+'MB4X:MS+I'.1>E*.8;U(G>NT:JVC;*D;KV9;J'CF(C\].+DPL_@BN?SH![5 MCH^Z[>,U0"7M%]NN\)[C@)9K_UCACMFXNG&%;ZG1DBKX`B`6`&F[H)'_QGTG M",NQ<$&>GWB`\3[](=EH/>WQ>^Z,OT M;CKAQ)DN[7[Z-5P"1`"B$3]$DFU_([,'+_UJ_W#'R5BRK[_=M/^5$=$::WH5 M*'#]'`J:KP0%*)F2F(?I;V]F\]=8^0[V_.\AM@S(V`!S2Y==[O6/J[M>MGE:"PO0[/K&T*OE&;+1<":-+O$0.\- M!LDX\<#H=/0VTO"WQZ6_'W37,';_I.\7`O42;+8LV'>/CW*.\,$N$))K+KY: M@9C;8KFD-;>XI9](_=7/`.F96*ZM!N@7?NWV/BV$3.KYE M9YPK`/'ND7L/7+9_V`&IU.O-=B-;R/,`?OK2_\7M\.XQV,F*6T?M]E-7+.%\ MYD*QZ).%>K!4!?>9216;J'BP5KGWZ4GM#4"QVN5Y0 MQY[.HW+0Y@2Z@SVY4*J=!Z%^X_:%6?NXJ^W?0D#*@O:9Z&_66JT-H;T,_/L[ M'HY/>3]68SAWH`<>=+M'>@RW`(QG05F2=@90UEH;0WD5Q#RZL:?4%]\L*W MJTR5M3W;UH3*A'.+2DRI8&Y/()<#YBY4AS4A?6%NH(/UW:<:7K3-E\)5K_]^ M%3S,Y_`4?O^-D[E_8X,=?X=M.&W*VHR^3/5?R%ETF_C\VHNX_X_`PYA^;Z)" M,0AQ+"'.G&N![5_[?!U/VG&[K#@'D:`/VY7!*H-8IS^0J_KP()U-NM;O<-86">!KI;8`.%&"C\ M?KL8`%5S'1KH-)M'S;>#@0)9,)NF^7QQV%J0)%?T_08HN+'A_<&*A>>`7&/Y MC=)%88677^!%:==KG3+IO]Z9]SK)^H7Y[U]\]8UFO=MY&ZLO(/VCLDF_R.6X MR!59^O*)Y:'EOL[22V=ZVUKZE==WW!A8^?_C80!2'?]S!B\.)Z$;\>C2&ZS$ M"??7.0KU;K.U%7P\-U6UTSAZ*<`JN5'-AAY#G\,'Y:#V!H,PH4`$#WD47ZRJ MH:Z\Y"I,N:VIE-LERWTN2JK+T)^%$D4^ZG<9EKJ.1SR\'05AC!ZA+T$8!H_4 MI::,X%,53U/K6,O77Q,9V\'??G*CY^(/7YOEP:D'?(/%B)Z"[@-_G:SK6$_3 MV0`'6T'>OC&Y*B%OO_2)8GRV2\>GC+A,3^'&G0N/)YD+?\.=.J@U#FKU1=C0 M%[7>TD]Y-`C=R:J^)/4J.HW^=C?B3+5R`&`Y3GUB8[DZYN#.!D.:5P4&%JOC M1%K\/_/@,1%[=.,10P`80<"&83!F7^TI7,AP9UD<,/C7L:<1LS$`1T\:P/M$ M\J=Z-J$-OL25J4ZRLJ,'7G)J^Z<`#_OB!C$?C-CWVY[%+OS!(0M"!JP_3.Q0 MO;-UN,[.:GN6C]+!JK:;8K#,[M%?KX-U/>&AC^5MU?`)?L1_T^"@#W`/^GU,]^O0IY$VYM1*+E;U$#X._L'Y?R> M_1CP*()/UP\\U.LPSMT?W!%IP;O(/:TWCNMUZ1)Z"HQ;7&!)6><[7^"-C7V? M=[)[K4:MN?'B)'Q;6E@YN_;*#NM012=V&$X'0;AHQTZNRFL/NK4 MZGEK>FWXMK*LDFIOF_5VIWY4_K*P509M;<_S@L?5#6=*VJ5FL]EI=98L9QZN M4I=1UJYTZJUVJ[QE7+IVW_4H319$VW8+)):DPY8!5YEINJ+_8VS'"2H1%_X@ M&'.`[1L'"`8`%V&8'&1"+?C"?3YT=V"0'=0E'3\1PNTN[MG%PL?'[=;Q\Q=' M48@*[9J^9YO!MKTE/3>A_+B+N;1/7%(6/2J\Z2I`OV,RB+&>3MZ]E5U:PI+* M!:T\KK0`KC7E4:ED7=>[Y:X-UU96\ER+XKC;;M>?LA)%+E)$46]$L$TO@X'M MP2-VP&F6T'!90)5:^B*!2K%<"10]'9KR3G9J!,F7;VIE;P%+6X!K=_A:9MN^ M%*[6AVD+$B-/VQO:ER6KL86B8UT`M[JTYRJQQ;)DXZ7-BYL%SSJA_O07_I). MHEO"N8-EEKJ/SUCFK(U;$<'W?'!*U0JV[NWZ/5UH+XE'0:@Z-)_:OAN- MX.MUJDAGG6+K^;&W?#V\/S[D#;_?66Z"B^?76)XR_19<`/;FA:.ZU7D+0 M&O3TM[M1&"3W(]:H8077)@#H&[)T3)?64OP+#7PO^6`6=L-N=SJUQK'FG]P( MQ&VN[?F=OKNMHZ.&7G3YY+4!F8?4>=[VM%%`42^.0[>?T&2VNX"^^X)AP!M1 M]M_#N=/W=%_IJLT:\P5V`G390Q$6;-$ICC+ESGJC!5[JC"P"L7U:284)4)S2ESYR M"P:--)KKK7IF$24M^QD';]&TQ9=<3JGBH`+;L^5#N,4U:Q/Z;D)W@,4+]-WR M(3];%'>_3S"?$D&8J<-H'WK4O@*0/S&NOT^0OPQ%+1ER>1=@ M["MTE,JI&RY+)J^ND&[%U7H%WZ\Q(JNI.R%+742)J%%C:'>'EV:I6%'P;X=: M2)?:`FH*RAC6F.OZG$7L`7XVG$Q75`JR-SA49+L[`BL9-[D%;(>XE"!8C*.T MS^$3450LHC`1>!LTE%O/%FCI5>"K<#$Y12?3/O)>6:%"7/A:\6EYINR&\T1+ ML3/JM6[>V;;)TG>)LD;1]^5/D&_6\U;7\[$!ZX-MXB("`S3*L4W^]1Y24$$I M0[/=;K:*T;5ZV2EWDJ[^Z#P(OP53V\-L9V'=+BTHKP`'\Y7`''%(FB/9\YRKP![N;(-*H-YI'>L'2>J"5OIJ2 M"I=JM4[K^%FK$1FF_^`>:1\@?7;,\N?>_WS@RAO[MA0X)?CO`C*80K[92,!R M2V'J3;W[ZOJ@;6U!I::Q?75]2K]2392N'WT>1B-WDC50^C(5KI?R*62VT5,3 M&SUUVUV-"6\`'RP+%O;_'1RP\R"(_2#F[%:8DNS@`-?LN?X?/P_E;Y?P@?V@ MK^+IA/_W3UQV#_I)?AL&'GP[BN/)SY\_/SX^'O[HA]YA$-Y_!MYP]!E__HP7 M_H2/_CSW;/H6;W%_QG_AX_\/4$L#!!0````(`&:(K4;&4Q7X'PP``">M```5 M`!P`<&UH&UL550)``,0O%-5$+Q3575X"P`!!"4. M```$.0$``.U=;7/;-A+^WIG^!YW[M;(LN[DDGB8=Q2^I9_RB49Q>[U,&)E<6 MKA2@`J`EY=-3'Y/G=T>?'Z_:;H]_>__C#K_]JM__\,+AM75(O'`,1K3O99HC! M;TVQ&+6NOK:O?"PH:_T1TVIUC\^.3XY/6_+'QU'(N(_F/[?NT+S5_>7GUNE) M]U6K>WK>?75^\J;5NVNUVVJ0`)._GA"'EF2*\'='(R$FYYW.=#H]GCVQX)BR MY\[IRMUZ*3%:_[MNW M;SO1O\JF')_SJ/\M]9"(U%3(5RNWA?I;>]&LK7[5[IZVS[K',^X?*1TP&L`` MAJUH^',QG\"[(X['DT"Q'?UNQ&#X[F@R'O&VTN/)6=S[IPM*.`VPCP3X3RA0 MDO(1@.!'+47T\^!FC?,3J9Q7IZ]?G[XY]NBXHYIT\DET%&\>"KPPB)1P*SE9 MXQ%F`H@/_H)+16^+\2)SH-[:$($"@+)U/20C1%H>(OX4J3KD[6>$)AVEGPX$ M@B]^$VFL?=)--/Y3\NLO/<[EJ!TZ%7-Y@?BH1WSU MQ]7?(7Y!@>2"]\0%8FPN9^P?*`A!P[U9_TVH>VQ=0,2\Q1CRQQ3.Z_:>M.CP M<#R.J+6Q@/&B_Y#1L4[!BW%I&3E:E/G`I%.3/BWDDDDZ40R@X*@U!?P\$O*? M*H?PBDM]3"]A0CG6&=IZ._1X-E9T0_T&,@`W``VD[3P'P M>Q`&<]^HO_M0&>HA@?#,*0@C^>XI\0P]]4K3SOLJ.;W&1$)UBU_`OR$RZGC& M4K\)3Z#CNZ"CE*)>XTHK?].^BD0W<\M5@I6X+6YA7KE=&@!0OKAF;KOZ&5\X MS^M7>ZZW77?)[AE_G]$),#'OR_!;R#5!1503M<73^REM-V?1T`MK:/YNBI8[ MFPM6\"IM[1:C)QQ@@<%@KY71N%IN[ZD`WD=S%1H-(%";U#YB$3\!XCQ*?Q2+ M84.E1N/*AV;3T*S4XIZ_6X2_B03FL@PO].J<;AF4+4G;W)D*6 MHPCW?+ODFX7@6[GX_#Y-@2I/Y`2?7]S!9X5+LT77$0SRE*_1ND.KS2=!O;]& M-)!\<15LBKE&^1F-J]X+P!"D+OV(DZ)T\:VBH,*N;L2E6K$TP:IQ MI-$T&;-:&J[GG8W*DO<__K#ZWXZ*8CX)^7^5['T8/DR`1:/QSP2%72*#]2ZO-/TBMH=R_K+5W7>TJR8C?7KE[_B3L@SU>SB0P=M":? M;EMMN/`1B&0@D.M-SQ]C@KE0[+Q`PH[.EQ3TK'$AS05@TYX*I7Q.`,]/#+O,:+"M_"H,`SY[5T6=.YTKF7@5C*\FT[;;(\KK1V M`8@T\ZFE936:<7SC:2%6ABD:QF#5%I`0NBY3\0*9WZ=:WF^(``;<8$G?;%FC M!14J?-..4E(63Y'*K>B:,CDTB0\YO?DC0X0C3['U$6&B9LD`4("_@FZ+94&D M2?C9Z,:]R&QA?;&H4:K78)ZMMFX25IG2NG>L]&WQN98RRVA&"AA*&;]EUS[` M4)I=W.X1S8!?S>2&34J""6+S&ZFUJ`Q3]I0*#2+UQ))KP=W?J#4:207*S`T- M5J,(QR.?&M2DF;[N.0\T3B`-9_Q M2!6;?49?L!3[P_PS5]>?EYN1GB?P2U'Q_4Z'J=H]K1ZOE#M=2A\JU?F4PAX@ MUYU(Y1U$.;4$2=D9(`Z7$/]Y0Q8;CN2VDO[.L%'W@T?=3(DNOJ"2YGSS`1$K M\%.=OT/HTPHLSHA:U1+EG$&G.>DSF"#L)UO6J+HA?B8B[W#:AL3!(FNOS.*S M\!IJQ=(2;%Q#M9K8FWT/%GT+]9F5Z#N&^OKEXVUL8(/2/Q:QJ=K$/O[MO'UL MW'BV-8K-[M^G):24F,#_VB7XU6MP6^]I+8C\4$S2)2\6,$:)Y`U_/^#C&#W,>[--)9$''/U#5`IIXTL%#6 M3FO<<&I`RGKW, M481[94+9C[OW@6'J;WI-70F%#9D:P2TC;D9<;QO%NAKT[U$=F<[<\2=?]ZB. M3/?A7CGVU7`(GG@87LV\D5Q/88`$/)!LO6C<@169A@-NIS+#NWF:DL0MBEC4 M&T7JM?@`#P$O`R84!4R^>MHHL/AZC0FQ_12NF(Q<XH$2.=1]B2<*UY:S-P+3[,8*1*%RM2[&3Z+R#V.*4[LXH%O8,W MAJ7B7"Q+*2&*'%ZW>2A+\?NP@UAY+GX?R%Z8:QKJ[ER6)/A=V$&L.K/PT7DS MD&UW:P:*X/=A!I'J7"QOL9.E-Q3`=FX+ZU0/WB`VE&A4183VLYLL&K7B:71+R?,C,-,,>F;SRDM7:OAT3XU36P=1!9_O MJ<<>+^')X*N=6:T;@U6FJ,9;L$J=:G=G7K5;CUOMUN57%;B&!ESK7+M#(F31 M.<$`)LEI]\.PSS#Q\`0%-\0B^;8=72?F[RILNGE;0FVN>]U"D8KS;*7('1;N M3N?4["4I2*F5)'B`D+N;/K.6I2![5H[>X4'N;J;,7A1]TCD5/55H[.P6.Y5)B+.ZJ4`I;EN>H>V@5B;#ZD;(J8KTN8"=/>BZY9JJ7HL+9>/Y-B])/#_CU5CB_TA*HJ,?G4B#F5)L!;2CN[#7?RWP?+XL@H MBK$DT`2@;'5BG.O==_KG=)O\SVEE":#3RM_ECB-4^Q"FH&/E'UF-V8E>R^T1 M_U:.%)00IZ!_O0\[&T&5^D:KF6)BP3+PF]$DE(&Q(U M7L,TA&!M>;#2SB[OW9=$JR"]:-K]P%"RS"'N)LA:Y]LJ,5B24,-0*Z&I"C[D MFH[\6#T!F8=B67(-P[*TU@PS@ME7U;>(JI5Q]8%]&B$&UJ>J M69WW$U5GC51QY/*?"`>YRDFGBI[A/AP_`7L87N(@5)]T4)SQAU!P@8@O9ZTF MDK&E5'6,EL-?BK$/B&//7LX<.K7&X27!W0S,+37G8H`>/<2A"D!0<$''8TIB MYGM",/P4"E5@_DBCWTDAU/6*J%JDQYCR9^."ETIV0/P0S&07.M[JID1'L?4D M:H?GQQU8.@BSP]G7XZ^ M/EYU/Q[]^I]__N.7?W6[?YS=7WY]F/YYW+O[J7GA^C MJ/-MW5>G?WQZ?'(\Z)"/C_,DPAY8_;MS`U:=_KM_=P8G_?>=_N!S__WGDX^= MX4VGVZ6#!'[X?0(P[!"F0OSE:!['R\^]WO/S\_'+)`J.433K#4Y.3GL9X=&: M\O,+]DO4SZ<9;;_WQ\WU@SN'"]#U0QR#T'UM1;OAM>M_^O2IQWXEI-C_C%G[ M:^2"F*E)RE='2$'_ZV9D7?I5MS_HGO:/7["7\T5HO#@?IMC!^][ZQR.J+A"Y M$0K@/9QVTH]?[T?;S?PP[GG^HI?2]$`0D)$H#Y_CU1)^.<+^8AG`[+MY!*=" M$;/Q*>?O*<\_T=YZ-;@AGV%(9TS7@U.0!'&#O&WWW1"G:`'\L!U&UUW7XI-U MT5W`Q01&33)9ZK<.AW/"3.0F$]C-!6^03U[O=;@-43QL=,FD'3*>,H9DG2\7 M<]REV^;)Z7JS^.DA62Q`M$+3!W\6DJW8!6$\=%V4A#'9O.]0X+L^Q!(0O<0(" M37;E_=7D^AJ29Z#^#"TWJ\G#B!@["]+5"\0I%K&NLL1=U%WA,7*_SU'@$9,* MDIF=3Q=M%J4],4[)0](/?6KB7!.V2@P3,AAZT,M8IKTVO)4P`Q"YI6$#:G*A MB+O/LCUV"O"$;;0)[LX`6/:H`GLPB''V#5-I]Z2?VE@_I5\[#S&9U72K(++" M$?F(LU$",($!&]L1$SLG:YV9X/B1+DL5;AFAT]]$=QB5>28/NJRW])FG941. M([104% M]"D`[^@'JO=W!;V3KYQK.`/!)3&DXI7@R<*A!P*E;6MV@UE#[\@SC7P#9CQ/6[<+YY,!F.JI MG@>CEL`M+CLN'P7CC!'P;"*=YD[_Y,<%C2MMTU96(QX%V=/'$=MIO&\@2""9 M8XQC-1]#U-KIMQ(5VR.XFL)FV`[VM1QO$ZH#(B7]]9P>NPO`TGJ:6N=[$T.C8Z9L( M)NUI,FCJ(9L`[_<[`488)]![1"57;!?`N1TY_58B6#8!+)0[`_1GX];9FM%Q M$M-T.IHI6'6NM4GK]-L)DNW?\N**EJ'TP3A*!'YU,3H?A9CPZ`T7 M5`]52//HG;Z),%,K:(K$RQ#[U/SCDOEB0\\CNSIXD8>5!.1._X>((55(]QI^ M:!L#X),'[#<8>B@2>BGB%L[@AP@,50N8@V$^&$1W6J*D.?%S+N`3#!#+\+Q\ M6<(05SVT*MLY@Q\E`"05,X>R3NRG&2AO_!!%?KP:A3$DS]!X_!P2OV7N+U]W M@K/5VO*M`%:C%V=PZ%&B'87.01=$B7KE9,\VTC^K\K+W??"9LG(74!`*_%PK M)'_*&YM(!G7GT$L".)X*V9.FB2IV82"!5$GE(K=,7:S#3C45BG>V>B1C2Q). M%5K;D':J`:8@)T!)3GM2-(1BDI&E>9`*K4VGK"KBH0EF2;Z_$YB6I+BVCVJ3 MV50")_$:3/*A"1NCD-AD[&5G+,R54FIG-,55<QST[\*@V3'*:=K)I]VQ^%*6Q#`?I$BE0M93XJ6PU ME-18H>DFDSZ-J=J29[JNSNW+=[X!+_XB64BU7Z(SFE*[,8D%H:`-=NW1-U&8 MDKZ+=$9R8_7TO<&N/?NX\*GT%<-I$ES[TZH`D$)K,TFP382!%(4[`"S_&R&\ M4R2'-323Z=HJ@KE<322U-@/>T'631<(*95S`901=GZ5KDL\!3'/TA@L4Q?Y? M['NA:!4P-S6$F<39)B9$DQIH(HFVY75_"ZNF0U4S,TFQK:[Y5"I)6NL>3K5D ME7SV?CC^6IWG,0(A!FXJJ_1<2];4Z*F6@#E\MBK]HGS$I=&?@?,N!2BDIUUZ M$A[VT9>:K+)`DW(G5AV$:>(L<-QU9+?&ORR5(I,=GVP3FS[ZTE.Z'#C[#KQJ M`V1+Z*LEI/9PB'6+PBQ%Z`P"^E+0-0)A6LOO(0DC'\,K/P0AL9X#XDDERU'H M5I]OU>C2Z-$7?ZUP3KKJ"=@FEC%,N;A9CRL#BD]O]%!+`P4A]VT6`O"S-&3B M>RQ\C%&T*G#RB&Z#B>?'C\_H?S!"XQ#2/Y=TMBSIM,#7@63U-#9`2]5E&D:Q M27'MB>$"J+Z$)\'`&-6"?T\B22)JQJ]&*FT4M\=T9/0GN#K-0IGCS!:7,!) M+,>10VWVU&AGO/B2V+/N,OZ*\TH!F"*YV?.EVLALB"*)6^XK`":O#6U'1.`M M#O86!WN+@[W%P=[B8&]QL$,"Z"T.5K\V8PC'`8;A;RB@Q1F&2TD6M[#!8<2P MJMAO3\MW`$,7276[0788\:AMIEL,0UU\C_VA1(M%FL,(!FUPW&(1NKI1.N6H ME"UQF>I0JKHT]B3"4(\W3F,1"B\P\LC;B<*8-%`%4MH5.2LR*#5W^`U:BM(H MVZ0B/:NADLM@C07:&"R66*+-X&/?*PI?0V)DT%)$E%5IXCR'VFR&MG@A\($1 M"-#B.YT(A.0!*'F!LTAD-F%:5:%\OELT4.E8Q*"0*S(G,IMHK*W($M\M6JIL M+$*A,"<+9&93>O656>:\Q9+%=+0KE$1R;;Y2F:D3N[,RRXRW6-F7#>8_015E MOI*9*.]N"_R)69$YDICKJS*DM\-U&?MDJ1\`F&"JI$3-3 M@W1W998Y;Z*0;(4Z+_W97&QO\LC,%`'=69T;G#=1D;5"G;>^BHWY2F6FFN?. MRBPSWF*M5&8[J*SSG,A,-<[=#:,BWXU4/&W!#U7U0,T4T:R?++`E1(M^T]!U MHP1Z67[Q2.%BJ8HF9NI9[JYQ%7ELRC8C,J6I32I9@%O4SL"DEU8GV8PKBCUG M`^-X3B\S0E%,<^+.4!2A9S^<59T/B)HX`UO.<_4PJI*G"9^P&:"R19[6']X! M-\4>G($MA\AZ,&J(UX1KVM@[ZBZ$'KXBBLCN.1A/)::"N)$SL.7T6@^[:HGL MN:"%%:#`T4+G!++W8:T=<**4/CJ>2=!KT.G,%AO>:@+UV+ M48=T4K`[OJ^@^.;"33KGU&3LH9XW5A*BS:M7V"'EZR599"%2!\.[@Z3W6'@U M7'4KY_2P`@^*(EETZ4IY][P!<4(OG[@@4A9/=FF(H%J48A').#S.RL2E#CH*Y*E_7U%;$AFZK M&2]A!.@E08P+;X@QC/&UPIN,U0V-OL?(94W]M45Q;N1YD<%TY*$\1_C1AJVJUR#"8IHF]7#$KBR/!-QDT.] MAZ92HK:5/YY.?1\B>-[F-_(75W5O[*=T4IFNP8]9!))'E![B/6-0O(1QN`% MXK2(?VRFAMFKJA#&YR"*5E,4/8/(TPS^"5L;B`"*N9(%_R0MC<;]JC0L7018_@99C$P(+JG@!0?8J%$UCR6MCF4VG>B)J:C=F)E MJX)C7W2N47@LL;Z;PVD/\;8+$/IX3@:7%&(JDQF-JU7-:TY<9YOU]K3Y]?CA M^`J2SD$@52F/UFCH3%.O`OY;?+$H9S"MN#N#L9OD:*CTFUK6OO-A/Q$JP*X;#$Z?2C]7V!_"0VG>9&XB6:0&C*8]X/ M?XB1^WV.`L(&#>[X^9UZAMQQ=F/!>,K84G'`N?1&DVX8*VK]74'OY"N'O1UT&<;B,"Z'JAU_O;V'"E^$ MIKU'596OF1#N19LD+;GMTF>#0&G;FMU@UM!$UM:JX4U]1_7:MVO?`5I%A.Y] M(%Q)]VT.M9%@!V_B\C=K/L?6J)]F2/B>#Z+5`\BW0X7L.&X;J\JJZW@+%0+9 M4W6HP-LM6)"/A;>GY.E7TL:F*ZM7@B#`344H>Y9:V_C9XF>T`Z1]CZ[1W5CZ MP,IIS-9?5ULI?'!*(EBC_((3M"X,D9Z__?4:3:[V^S9;F:WGKAG(E,AAS\E6 M@5%B"8TC%H3POH$@H=5R&.]J<(E:FZT>OSML5?+88W-LS;-"80J=959H9K9" M?=UUMB&(/94/MSA=%\K1`6G=PFS1^[KXO,I@3ZU#QMZ:L8LD(C.'K'4?K9?] M+7QFOU2?T"BT-UM=7_<<3E4B>TH;"EA>S[H:*&YT8+:R?S,P*CLS>;U`?+8EH3=0B;-P\/`=+/P;! MFO5[B&'T!+TK%%TE<1+!K%ZMFN&HUI?9NQ=V-RG5I;/HAH:S!!,A,2YL).OS MY:R6:3I=QQ$38!+`VX0JD&A(S6]H9@"S=T)HSHGF1&ZD=*.H/.F,;$LS$,/A M`B6T-.J6=R3:M^4MS5XHH;-1J\G22$E&KLN]CL%BC++ MBDA:LQ&PX,A>=@,VDME[,XQM";GL^;QHX<+'YF9PRY.B-(S9VSC,[!"YX/ET M:.':RD8GQK:-+1WD\V5O`;5=IO>>)@MW.+/WA9C93K84 MD$^3.E&]YM.3.,[K*"RDC"@F*LFZ,7L9B6[X7%.P'-H6+B+AS\@26^C]FK4G9? MBVJ2Y>B:SXCB70XWH@H'P5TR"7RWPN?7[L/L?2J:J&I)E2.ZMP#>>K?_#0;> MV8K..O(5X85]F[Z-SHR`7<_'E#HV>[-*4^=ERJ+F(`N"`L``00E#@``!#D!``#E?6USX[BUYO>M MVO^`G9NM=%?)W>[I>4G/O9#:U-46+D,T;BE1(RFWGUR\` MDA(I@B``OISCN1^2]MC`(1[@O.'@X.`__L_3UB>/-(J],/CC-^_>G']#:+`. M72^X_^,W7U;79W_XYO_\Z7_^C__X7V=G?[NXG9&K<+W?TB`AGUF;C4==\M5+ M'LCD7V<3UTO"B/RO_N> MO/OVIW??_W3^!S+^3,[.^$=\+_C'G1-3P@85Q'_\YB%)=C^]??OUZ]1 M_R:,[M]^>W[^_FW>\)NTY4]/L5=J_?5]WO;=V[]]GBW7#W3KG'E!G#C!^MB+ MDY'U>_?APX>WXJ^L:>S]%(O^LW#M)&*:&L=%:EOP_SK+FYWQ7YV]^_;L_;LW M3['[#9^#*/3I+=T0\?F?DN<=_>,WL;?=^7S8XG_VU`[YV$ MNIS^!T[_W0^<_K]EOYXY=]3_AO"67VZGM7`^E&BEG=[^B0PQPAL:>:$[">R& M>M)[T#$O$R=*6HRZT'^@<:_"Q/&M1ESH.=!8Y]1N;@_]AII3I@2IW9P>>W8X MUJ0Z3N.)/,X@U]3\YQG[?FED]"FA@4O=?&R\IT);"L)"RPKE'ZY+Q'RN;L.H MC'.W?8C/N/4X?Y_JS'_CO_DUMTKC@(E]XB7/TV`31ENAKL=W<1(YZR0G)(8N MR/_ZEW?G/W[\\0\?O[O^\X^_ZA-Z^Z=\!DH#CF@<[J,U-4*?+D)Y9,[=KY_? M?_MA^N%\^L.GV0>#D7'#QLAPVTV#LR_+;_YTL-=.X)*T(RGT)'_/^_Z__T@' MTQVVI"`$`P`\(X!8F0=U%_ZW0>MFGQ8?`N3>-Z?(QE%9ASC1.A\>^[$!6M;B M[3ID/N(N.2O)YB8*MZV41CZNL-44O=76E!E,`3&FZS?WX>-;EWH,ZKOO^`]< MBWYW=OXN\SW_C?WJU_2[M_3>XY\+DKFSI1*U^?[\AQ_?_>7[3W\X__[=AS^? M_W#]W;OS7VO[#Z`MO__V#Q_>?_[QS^??_OC^W>S;/WSZX?VW]0.JLEG&6<=V MA#<<5B&^$`P-BFX8%$.(N1F3GTBWV30,(=273+-$CC]E[MG37^ASDS-4WW%H MYT<%H89[LH9$M"2L*:!K@W+X)MY*'P`&-].-_$]X`B:4%'K2M:6TW;%!;*N7T1B,J8_.^9/%R'T7\ M2UZ\=OQ?J!--`O?*261N<47CU/:%L*$*(*<,DS4E:5O"&[/-ETMX(86T2D5K;VB`??8ETOM%>,;(FUK74#]*XG@"H#9KPOR,QK:!#MC6L M;08-:E9E'-YH527LW;<$'@[J="VJO".$.:V#4,LD:4,L=A3=\$T-:-<`0"RG M4@YJS:9*"/J6V-16IU^^9K^+;0QHE0@&:RJ#5LM-F3.6,95HCLS2HH/3U@IW M#0B%A:Z5)VUS72=,PV@"[K77Z8%:=7?:%=)^5V$T\938@`%(_,N`8&O'NP0! M:LMKY*+1FLN%HM]#H6O/I]$E\Q[NPTAV)-1P!E;N#G_.>PJGYGA"-"-Y.R1F M&Q."=F>\G6!`<,(K%0[-`UZ99/1\OAMNMV&P3,+U/Y8/#EOUQ3[AV6`\"#C(PV0-H6LZ66Z6 M.%/%L7'B.X%P'Y_=.\Z.:X_OWU(_B?/?B`S:@AK)?OWK,F$JBSLCB\VU%SC! MVF,[BS#V&M)HI8K4B":4[V`(_)1C#]U(N"&'CB3OJ4C!!+-O-DNM-'H6ZSP< M0X_CF":Q;@9X3:^A[5[MX"L'^Z(!CA1N_4$OEY/5$M1"M1SKX`9'SWD_F*I'+Q$XJ-9\<8P`VS M4F2T++%*7H83_4LG?A@'+O]G\L^]]^CX;#3Q.+ETHNB9.;<_._Z^\PJ]RW[1G$>/EI1"XF'Z?S M^73^D2RNRCY$243I")AID."4YB=G(%A(K&Z)P&*1]I.0LR M)AIP?[!>AWLNAX&[2!YH=$O7E,GFG4_C.4TR%T9[VZY%#&PWKPFULG_(^@E' M0?0DA:XCPCJ/\MT%"B?!%F@%&QHK9,2EZNVX`8L"[=);[<[!K=`I%/5N'.\& M5C)T46WE$$=(6W=O1@O%8(8?/K@=E4J"^:9[<`F^B4*V:4B>;]B4BP("S,7= M\6`\TRJZYE-)`\IJ-@`[9;*\^8B(#FG9B+R+L)4(0N2&F-AO2=ZE#`B%N3== MH=L%VV.N?B%CMN&<_.>7ZE"DML):(#:!I:#\V.UX\4`LJ)(TE&R MTA`B86QK-,:=1GW2T"YK\:QF M5P4>?S4<+[@E*K.SP9YO<,&;>3^64%)YAM-Q56IS*V2OO3;+NY"PC0#B%YT/6%;D)(]DQ)8`? MTRE:4H*+PH?I$=\`RVD<8&D'-XV]&"TJF,-FH9V4/INY:AH^Z34;GFW>G9P* MM+M6"ZXVKS5K"9;$V@\<=!Z-FNOT(B\JE@.3GQ/QMLL95]*"3AEO`-HL646= M[_&D<8SYXBU1HC5M)NRJE3RNP:N#"F.TIVYUHV-ASVH((3!IM1`E7,G;DD)C MM(;-&-3D:4>#&.9BAB7O&)HW)0="!O8L3A6@K9<6:TD"=BB,DM;@RU<:"ET0 M;!V[!8`AD&]B*G')<(MH/+CQ*\-0B"\JZZ8>=YB,\OC>9]_ M)^_.1^Q7_'\D3BO+.OOD(8R\?U'WWTD0!I1X<@Z\1ZICR?,6\?+ZJI4,'SKNJ)"K^/?.)X[#2Z=G<>V&,;!VQHRT/:O M'EXEQGEH27A3,@U(UAA1UI@5G!UK>N8%9-T3G%91Z!X`@5OF!IG2BT4K!6HX M_7!+$\<+J#MQHH#IZ'A\+-'`[\*NI57KI/I1@Q*4%=<">2>2]R*OQJ7Z M%:+C:P1[9RMX$BS=0?F00@GH/:>/`@R8WZ`O84I/0EN\!CT:SH<@+@`R9V<7 MT0<:Q,QSFP;K<$MG8&%Y:('N*G*+?`,Y/6C720.PQ15D M5%Z1!<3T8C_(_>-.\AOZQPGN^>E*JFF*A$I,H0Y-F6NSB,0K<*Z(9=_02+QH MJ.OO:5*#JT2K";;A='7$?4"RB$C:.ST2X@_5IT]=(H@7=8`T/B)]1'/DU1VN M71TNP,JT)J+84*/60`ZAE$WZ5NKX<-K8+EFC0@W:X6D$VZADLG=SCYT0'6.U M0!>7T#G]H>LN6\4&7^4T'9UGHR>.%IDH-;((JVBF(F/!SI,I4<#AO9R`:LH' MRZ0M;8_.0=$&4]8=7C]HVCLFIGCD0)!X(C+Q,?`^)+(#JP@D#[RW<3FJC[WC M\CG*<#7UQ*(^:Q*9TZ$+KVR5%5FAZ-P.0X0O)^&U5ARM78ZJ+((DPK8-H^B0 M0I`N:[#]+F;0IC&%$''TI!5&E'&3+A#ABY@8B)QN"B^:6$EA3&T#)2I2T!Z+ M&J9:C6".CUCATHT<@+HH;9`UQGS`/10-L=/R3IIE#E"5F(5"ZKHC\$`:]MDR M=3'J*P;2TBSK0=&)?V`PQ\8Q`S63`9LI%J<\P0:U-&<8ISXB_DO3/J!2YSK!+-R`19;WKC%T^:'!;)&%Z+7-4 MY?CA!#7;!@7W><5BT^U@/0$H*Z6"5+D?F[<]5&S&MHMJAP:-$6OD,Z4Y:V*R M`0T;#=A0_''@CMVM%WA\&+R\4C8P8V/70`[<`#;"K6CHM(>X25;NDS,EHAV: M!;S)?'++'XF=7Y'QU>?I?+IV("NV+[5#W<\AE2O;VI*IZB(P%434D.K1B'2]EFUNT,/&,W2 M/22W`(G*(0$6W]%@PX:Z.\T\.)Q87=%=1->>.`)@/_N4_\"%?LO?M/N7^+VI M-=>B"6W2-8&?,FJQVX@<.J9FHM`5E?7K`&LC0'#C9\+)6A;0@(UUY'6W?8B% M%)Z_SV20_^;7RS"(]W[1J6\R9G7=AC9?]<.O1A7S1K6^TZ";2EPC=\/UGIL` MJ:[M9.B9$8W?@)O1!I:7&DXUOP/&B$SM8I4`M!&403*/IH#:-AT(:36G"A!$ MX=X.48`;XEHYT;*Z=4("(.?'8GC&4>!"5_#X;PE&O73W>Q+2*N:K1/!JME@N M7Y/KV\5GLKB9\"C48MY]],F\T%R7PX%02]479&$X01Y'@9A>1B93E$< M[B@U6S-!:(.N`[GZR/VQST$+9-U>`YX#=0XTK0)[BA"=_=1F6RU[JLNS0R;> M)I2QBVGL]K0;7*+MZ?"K>9QIB][\3+LT5.UAOZ(UHF$_\!;UV[L8.&"ZK)37 M&])D98P^G'Q>AQ'U[H/T&=3U\RIR@ICI"2\,/CI>P"WY+75\FZNA!I2A#:G1 M))PR9-:9Y+U)H3OA_0\5UW,BJ&QK*^PI,A+*T>,[,S7G=BVS:\SJP]O?U!L0 M3I&I#2YVA;;#91BUMB$O]R\:(C@A-1P^/WXI^J^H3+/1$J"SS1(YT++/52%` ML+7M;$L+;H%5$(VVL(C"O":8LG#O"]^S=K-7!;H1ZP5.]#Q-Z#9F<-B<)FQR?0$H51OZMK:_( M4NUK6FON4V8>*>=D;KG?AH+F7BLR-2^C`17QZ1\K=)_G$D._PA)S>+ M6U],KA>W$_;/?'(]7:5A[.G\AQ]Z7@2W7519"HG+]@*8 M!/AVW!U9*#=TWIX-6:(-W6X#:&AMW1$05#K62K!--@QJY3#@=IPFYLDBY4Y0+OGIT"M;:YJ4 M4T.&>J'0/*2F`X7_"86WWCC8R8JD[E/W3_:%L<>O\KR4\9J[_("#=;UX[8?Q M/J(?]Y[+WR_LDGWAKGQKJ#`=#U>F](;3T_E;UWF=W0LG]M;\(H[G[Q/S\\PF M4YD!*V^>IZ+R?3C)R[E MXY\GM^./$S+_\OF"R?KBFK"=W^?%/)7Z)5E\62U73"U,YQ_)&:EH"10>W;L;9Q/X]#&'NRPT\*%Y5=F+`M MG>?XQ.4$>=&#*=W^5L9J M.(M]J$VZV*2[%#:6RW"[B^@##6+&V]EO+>\/F)*'WC^83T>EUO!JO)I\GLQ7 M2VZ3%JM/S#@QRW1S._DTF2]YN1CAG\(6NNUTS4P<5CM^&/`F'$\^D0Q('%!) M$AQ]<48U=O]K'R<9YQ2IX?>4J?LB_`)9LP4DX-"F^WG\F0P1T1'CED;@F>+`0LX.&N57:G6=77 M,#M3JX,^BG(Z7+:&BXW.+#X:['3.^E#>#+?, M"LK.\,#]1`VNU7TCI8%E0;9#ET[\<.V'7XT+XRII0'EL#<"4+Z;P#D3TP/5B M"GY,-FY2[ZC`7``=X5+:=@W)&DY5'%V&>!7>4CXAGD]+I[VKD`_S)@H?/9>Z M%\]?8NI.@T.AB/$Z\1Z]Q%/6WE:JX%[&`.TF]#2QIX)3^`Q9A>3P(5+(_^'? MXG\4`2,K!;D=G*YF%].9Q/" M,U!$Z(O]EO]\.5Y^(E^6DRLRG>=U8.8?R?AR-?UYNII.EC^A\WCZ%'DM5ZE' M>8+&>>9[9*8N3/T,+9K0?H,F<$DBO&A.7N4=7_.S MR\,=[JRSB#D@2@2S1#M>KZ.]\%TR>$PLYV'"O):L&SECKI#/XYL\D)(\HS/" M)ORMFU*OR]R04GPPX9?.SDLT67>.O4>N3HQKJ*L M01&?[96`UI58$0`O=$5M=35POLI[OL?B M=:&4!J!OT`%@A>*!%7^>V<;[M/3DV**[S8,Z#,1L\7:.>XCS[@5>3;WXJ%@]D-,HT=O MG>4/N]G8&$DG(7?BJSP^%VZ]-;E++^G&HO]FG^PCF@VB^D#%H-DIG7(:L6(U MF`-L<]O>&3TEB,\7K4+6=$7SCGEP!-5YSH`X M$3IH-6QLZ9_)>1B1F&8Q.1Z2\YH?S+(EBR?PTP3?DK%'I>"F!_PJU^#P,01W M.V%4NQB1#O,#RSP/SL\\Y\[SO1I!-]>3IS11&N@J<'T>%R<:AQ\QQ.G2NE*:E*ZLI).R6E2U]TS>?4EO;?Z M6IK6A>!J=,_3E]9?+GP$C7O0A\`I?8<>I&W0VFSVRD==]%J?,K23830)LL)3 M1CF?J`(#[:#KI&8BNEPS/%AP)\MSQ5^7>='8GR?+IN1SD,`0'%S(`HN6HMY4 MA=%.SH=3_,=W=9=Y+W'Q%!821.:P]$4/EM[;"SD3[PB%&XZ0->!RE%_<,#]\S, M15C+,S.6WQ9Y1>D>]R3FQE7G)^HSA3F)V2Q]UR4+"28KQTCWU.?CF"@>0/=NRK@@N/?N?#J.8RI-TS0S-A6"Z)PY M"60='^[8C:3]$!WP66$L.#,]8NO#9^L:'3Z7K4XL[3RU&IG$&#KK/F3V`D)E M783(7EBHJ#$.?O&+-$:$X`!T>)`O(`[6Y70YJ2S61\,N%N,PC6EKG@5 M5=1GJ+^N(34?M?VA7#(%H,H&(FM*>-MR=0H4KI8-E$T%"MI<[";64_H9#7R' MT:OHSYMX05Y$%][#BW095!N%F]O%S].K=+,@,YPOU%U`!;GSS*\6@%]E.\/7 M6M!?D)?4DWEZ M2D8TH;PG0^"5%R-$=W%VGA$@G`(O_B4T/,^)$#\4R"#(]FJ)^J/C!7F^?ZCW M,`:8TV7#V4I'S(*M!WSP0#J,&U$2X?3HSM0],Z(-[:`93D1E=U\GO".2TB"2 MBV2HO):6$\#-^'1^>3L9+R<\?YN;=$0N2I?H7EU-TI]>UP$%=TALQ%KOB0AS MF1[PS8C];N>+LO2.GY>EGP:;,-JF]6!-GX_0)`?VDH0VW,I3!86>QZ<*2*$S MKF3S%DB_W-S,Q"N`XQFYFBXO9XOE%_$J[369+^9G8N=1.'Z:7Z'87PXX"X>X M-)N&Z\7MY_%JNIBC\<8,15K]:(61/+?(W!2;-L=SKT3-JU0Y\B>O3$_-](A! M>4ZZ4*6N$N]#TDZ9@Q3S=_-P'7NU0BB*;A6JGF5EQGCEL>Y/MYJ2&?N%5X`& MDK_80GAT?!\3,1RR:$E>&MMS=3V:4A^X$D.E@5<+;AS*O7LN`M]#<[AH+*:, M+QJJ\U288M#2.^&6B@OM83:$=L(Q?6@Z4;ZQ#WUM;5(]14``KL:<"58W( M;[=.],P3`Y;>?>!MO+43).1(@^1$,+XGW+Q^ZAIO38LWX!'2XK5'_.7SY_'M+]SE74X_SJ?7T\OQ M?,6\V\O%E[EP>V\6L^DEQF0U,Q;7VBD;\?>@J?ORXARFUJ69$&`R?R-$22J\ MZ%,NP(-KVSH(+LC$?CW&;,KPU^)*!`)WW,]:VU`CVM"6U'`BZC@Y*Y5UPM#% M4%.?AK5%*8:6\&]Y]<_5+R)T-/G/+],;'FQ"9TAMN%VO=H$YJP\GXQ_#T/WJ M^3X;UVE)!?OXLQE1*&-K"KWZ!/O&"[R$DIFWD=12P6BIK%9;:;5LEGK04_6: M(5D;+AV2T/9*#[;D[/N$@_&;)CND5Y/KZ7RZFIS-IM<\O7DUGG^<7LPFV6O/ MZ$R3`1MK'H7J\O"`]TH+EUJ-BTW+^H+5R)$#J>2@J^XL8[0=J@52ETBI7YTV M]30+5%NH=2U:H*=>S4#5K(57B=O"6ZPF2W(S_F7,53:3G,ELO)I#9OR>B_%AU4DO*+M3&?PI=Z4- M,)H6^;PKC8ITTH?CE,/C'>DX%IL9C>,PZF!_84`9>IMA-`FGW'A\[2?CRW!# MTOZ(+58GR&?\LB&^388Y2VOM-8SY&2!;V3[2I2(!^.BO`I8R<;G'0R/+]WNM MD.BE;T(^RMO$=TT/\#8P':@,M0BM*6A!&[L&H)K,B-.<66-#]D"?*8[YY>+S MA*S&?T-HCG4$R^S>`P:3.W&B@/D"O,3`\L$QM[>U_<$*"-4#JOA]81SSV[%$ M-,1HF)I61UT81[TT<#QF;8_J"4$;(Q7$2HVJK&V1]7":(1-4L\5R26XFMV3Y M:7P[0:>]&WE02W4W,>"`,O7/O9<\&VOKNG7AJP]X/WE<+OU$O$0#Z\: M%HK$\6TY%*W;":*AT5U!IFS27#YXO.[!% M)J2A#9'9-!@P\DO8/_4%'IWYL6!V+=MCSNE#5C>^B^D_]\PN3AZ%<30N9US3 M'ZY^<2V@:GF$O"E)VV*T*TT+U%"<5KDZ<&QF'W"K)01M(U00-3@/YP;$"-27 MB^7D/[^PO0:9_,QW'.@4?",7Z@7&&EAP.*FZ<&(O7FQ.JB,\I_^O$C&IIM&D M!J78M<&>\J7HR/,ZCUU':1619_+W[%\PZ>L8ZC[V`AJGP8X#[ALVZOSJ`!J[ M9L:[2BMGQ+@M[OK^E.+I]]CCL]DL:?77%YJI@=[WT0%;]?5%'U+H-(B$ MV>QNN@2)Z+:/#:+")I1I"^=8:FF7+MTFC$B4H7:.A)%=!]*6SN8+0;JB.>2Q M0!"S(;B.GM:I.4I1T(`[T%("JP;T"\V16_$VT-"8:1W&:SAN:^2ZX<3H.HRH M=Q_D3P660JR!6W@X,+:T[.T_!+V-;3-%IRR=T3IYFC&/?7(?M4@/C30/-S_[ M0/3D[V7E4_26Y+.VSG^5P#YHV1.CFVRYVXH3^-.7EA9;BQADE7P=J":O6B+1 M`,/@Q6/D39BVL2"]+L?3H>D:V&9"@.^9-4)LK)PV(FFW,]$/C[#VAQB-2=5F MT:97U+3XWM)U M>!^(2/J2;0GBQ69)HT=O36-=2]U,""ZSM1FB[`R)]2&%3B,BNHFW6K*.$+= M)V#A48N>:(RV-K(I@XGF M1+07U4[`1:_VJS(5VX1\&-)T#"\J5^>(1]*,1H3+$M.S>\'6[% MRP@2@;M/`<9CLK5`FST6_O>5>!H.IVVVPKO<;[=.],SW`KMBRB]]>2F_'2?[ M`M8F6C]0=^_3<%/(>ZRD1.X37J]S&T:)]R^A:K+#&\&BQA'>3K$5@.IVXFK MR$I&/HO9'!*,JX^/CTCZ%5+\3'YZ"JY%H.?.S5YN/_/YR^W>0Y MQ=HRLA_"TV58N]`IVV0D%A%;X[#"]Y?$E2E.Y5S3: M7M&[I)TSHTT7VF$QF`"5%M@>B/#_\AD9PD1SRPSN'?S>!7H"T'D.IEROY1T8 MLCR$K%_1#8TBD06:.BULUS7SG#O/%Z/NRA$P^PP>?\!T>E3RD-,2J>$I-6$6 M"_3`]<)0TW)T$]Q\5A(V*V+/05[Y1U*O$7L)5K)CZ"S8"`Z$'IEL-I2Y,8_T MD&UWRYP2<0^CM`OL99NBJ=[-/X7';[&9)I5D'>GQ_RHH MGCR,^BJC^AJ!V@&:HW5ICB2:Y]5=/D=<^%E[GF>PYTD7_-3#P?D>10>B9^CR MV,H=A#KZ*_7N'Q+JCAE+.O=TOM_>T6BQ$?G0S9NG!LUO0AS>T3&;"I4@Y91( M1HJDM,2M=$$-?)LTV%1\S:?"R:8B.$Q%G$X%/RL.$R8M/&79]?R]<`V9U&R9 M!Q3SYS,1^C068J/IS)C+S)`/`#._2IQF\W$8.R;EWN"^QBF8ZGN]68-,6E%% M,N`'W^XQX;;#AWV"7_G?5"895M0H^%06<51^L<%YRGHR)C:(]`0L`%O_I8'<15N'4^6G*U4 MF7(BT'Y`';3*7=\3GB-_3YMB<@OP86GC)72.!MQI4(J1EN^@DJ%AWU]LP@%?<:GA M^H:G6^0L;RJM,5V_N0\?W[K4XX+Z'?^!R^=W!?EDO_IU1N\=?Q(D3$W4./12 M%27K"F6:Y3`JE2EX"Y(V`?3_M&=31\W7KT)?[))^J-:A*PE"I?W0RELRX(HS MD/$#H`N@GC.5SJB9X`&O=CD1\RJX>^$$S[6F77VC1D("VL>7PZK\<=W M<1(YZT37R+7X`F@=:-M)J>D<-@2'N9C+!Y,EYE MU/!D`[>7E>8:S6T$I8T&X&?EDZ?U`ULL.KZ/J%`QQ7>(:<2KQCCWLC/LDGXS MIC>T";<`7&%CWIODWJ+`'6SR$R//]#LCY)88Z],B>K#"4:@W/R$BD.]='I:S"2X?- MBN]+^<)`.]?31.03J8!KZZ4LFW>19?.2(AVC;X[/Q^=GY^+6@+?I3_FUS]2E]$+^%VS?%J_\FGE5(I;6-XW MS*=6O'_F\HNRO_N>;VXS[<7?1WTM MC4TNW""+;;8X;/;X0W*^2+'@<\OF/][[(J@99P\POI0=2F?2+S&013Z5 ML6DMBZ9S_9*V.;:6J.5FR-(,=6Z/4^J?J.]>/+/1Q%3$L,5O'T+?95HWO?CI M!(U/_77T%43;*K/)T;:M6:R$TR47/,$WITR*I/E&+"..=1O2Q?Q(M$^FL!_X M_-P]"QV=S4]OS)S7GI1"IUN05[H''3MR]I,0[U" M3.D0MBDKYPJ^"']40T78^IS-^F'`S$(QEL4^B1.V:Q%\$8\DCUU7U&56ID/7[\[J:(`&4NJ!G?)0^F"V:"H*@4)E M.'>'Q1%8>,%.P`3F?N$@"U`TB%%S&$(M0YT)N..YJ_!G&KAAU'@_L:D[R+&3 M$DZC9+/V/-:5]8`_)+)`4Q`&CB8)R943>/%#^J3D%_+8$S;S`YY.P&5PD!S( M-`M3_4E+HR0-Y^Q^]H(P\I+G:<`,$HV3Q=>`&:8';W=4/!?/:=#3=.MK0AIZ MTVLV#95WUQGSA$'"/N_S\%).9$0.9`J>!#]T3"DA\"FZP<];NR3>W\6>Z_'; MC_6^!OCNUH+AM?:UYMP.4=J[_BW:FNJ]#36/&^C!%_!N!&SS/#.B._:&*ZM9 M<%IK61$\+G[QO&+?-BEI94(2VBCIP39BX!'A/;%5QK)8YW8O;U<6&0$O\Q'I ME=PR(06E@?5@6O$NEBI>%BNJ5+_ZR]DB!L"\PP-=]HUI$">1V,S%9I6]](B! MAOTTH%;*!SIW!6//KV84>F$J_M4&(#T`Y.+E#0'0/D#8.<:MZ(8L9J@KE%3F7FM[<3KQ`_.*F2(M=H%2 MGN5AUW`(-O=>,M=*?5*=Z`&C^8;O;^S-MH'XGID$(7BRW! M-(S%IGT)[XQ@.VL'<1(GWM;A+]'N4S0^:T=>/5,GJMYMP1=?KG*I77RYPJ(( M)/!C%,;=&9&4&EH#DH,U%$'1#4$PVAJ?^#W)NY7AO1QS6&+5=J:PR*?#">%X MO=YO]SY7A%=T%]&U)^+T[&>?9O54QMLP2KQ_B=_7CE[75G;V/2B#VN&$G8I$ M@30ITAZ1`W4A)T7Z(W*B*$9J40*PSSW.V(S&\4^D;M[06/&NA4QIZCN6L!;G MS3GITGEVBWYJ-9 M?=8=SO07M8.N^2[U@3+!)P,_93.5"0`P?P:C)?1I1X,8)'&Z>;EUC(^$/X9C MZ&LO\!(Z\QZI.PT2-LG>G4_'<4R3N&CQ)NDDSYGXK;Y2_Y%^#H/DP7C#V?)K MT!O2UI-URL@IP3-!D1Q)DI3FJ.2UDHSLB'#")*5,4M(HK%QOL\19%XV=ZU9P MM+:_G4@-5I7R"W6BU==0UYC:$8>RNK93T8V>X/28G@@1&/2N)D*F"OI6=GT# M^@&-Z])*-:QS9?N9EN3_%Z>E2GW&2+]C?44T+8\L?7[BC M4Q&*'CR<4XG`K""N&2OVY]L(ZB_'NGD.034Z7&H#U>>'N0,VD,([\\!OP!HKRT),S4!`& MK)IAO&&;9H5ZZ$#]EC_Q,KR"TVGI1C$XG"J<>AA@7E8/-*("9O?!G3!Q?)30 M7H@;)!7U#GTAF9RWR#BXHIOL\QMZ^O4VF0^(ZC(KZ1#O_L)8`6$*A`E(E0[#P M9Q2>@.W@T64Z-#*6.N>N@:L@RKW=4I$#>.-$R?,J\EQA?/I;_4U'Y3 M;ISL/@*]P[>=FLH[+QD=_M)+UIZ(#J1(:\1K/9;_7%-`#G2'CW52P(,#K01) M*S;01HH&+#>@-;::VA7R2_7Z%,&*%9B`KM0R*/.WM.H%B+'N'15JW[JV]F_)K"?XM9,7^'H?MI\?)IN?3LLNF)4N$6%UUHB MH!%N!;0JCR;T(*6?<['$5LG5&M"L`1!L:+J)!9OCT`W\U^:I>>\I>YGAAB'Q MXCB,G@M?6X5S_\[UDM77\/_2*%P$E/\SX=*\XV(;SWP3MZ*[KX$X&5U.5B5J MY!W>62-'ZJ3$YZN0I%_@Z?^$$R?L(^D/A<^,"/L0(B^DSVG[X7]79BNWN@F; MK=G%U71%&-N?GTS0[!*30X)SAI#X)IVKJ'I/I6O]!!Z;G-D6HFNDARE04@-8 M'6XH=%(6H$,31ND5):H@BXJ!C4,N"NX=3CQG87"_HM'VBMXEE_NHYATY:4!7 MUA7J,$`.HU**AK4Z8SIQ2WB[$K8:7"FYBX\S&FAHJ*0UHXU0#3+:)C7/O?D3X^XGI2J"R009@?!AJ% M3!J5J/E',%ACFZEILMM'FB-RI,K36@YTB1<,4;?$O#)!UW,#5:RD!W8U]0YL M!0*ICJBO3**E38V^@<4/,9R8CA0#3*&2(28$JKQ']QQJXP]8B`!F75!3ZZ.] MYAVTQ$=[-:XJ8=%*`_12VJ-GEP!C/8\N.;)S)P"N>H?Q,&N*=W2K7(>JX=&M MQJZI7M%&_"%J>0PR*5`E/7K@TUZ]`)`"'^:C-+C`;T?\Q3@!-3>X6RD!+/?U MNYH,J"H>'?)C+RX`2,T.@U$V%>SH2KD.7K6C*YW=5,?!1@OT7;ACD'@`UMH= M\/A>DM.CK.+1SU1":D,;CP:%H]*H>1`4R&D8[XH3)#X_'Q2C=B6C1N$R&'L" M':0=[P.Z\&,:?`I]UPONQ[O8(BV_G@IH7KX*7"7ME[4EHC')6A/6'%UF?H^0 M8'/S&QFQ.3F_B0O;/!OEQ'0=JH2CFBY[V@GP&69#&97=T`1NW"#,==7P+F>.\C_B+Q76+F+JM(0&LS.:Q3)CNT$DR& MR9,VPR&*GJ#SIS583$L+U_-7"Q^;3QGS*PP=9]=9:JY"5W#558(A M90'>`K$.J*Z#GA*H+$);?O`>:3U#R+FXV`=,"Y0'+F[ MY:(OO2=+'7#L":X"BB"DR\]+9.%5`)4UT)/_TP5HRPGTD0:&XE_L`R;^Y8'+ MUY\W02C_DCE7RW]UPENN^L2[?S`,)DG[@NN`,A`I%X@FB/6`9"WT-$%U(5IR MQ=PSCK<4NH!I@M*PI2S`6R#4`]7Y5JN!RF2WW0`J-'_#!G9(_=^P*6ZR`BN% M#6@]YJ8#YI9C3V@`#\KXHX5"'J_7T5X\_"D*GT^#K+"HZAW:5`?1'_XN'WY-N4;`])A:5FK(C:GCH^'$ M8)$\T&CY$$8)OV9T$491^-4+[HV3_6KI0*?(*`">LIEH2D3;-"?KV!J!J;0` M=!EN=T[P3.Y$H\Q9!"FB:\<[.H9%DP&'DZC"$K3A4X*L7+'+&A/.'21OSNM)#!\0Z0[5V'4]OFT3%\*= M@(3!4>SPF<%FKM0RA(TL.9R<\8].@SB)Q`XZUP:W3D(GFPU=)]XC5<9GI`K* MC"B4632%7KD_R#.UCP1&QQ`.IS$B!RI@\9Q>8$^#=42=N!C>J8_M@-E(*[Y6 M6DH;IH:3XW2-3J(YIJ93CRBT%=6%WB"_Q#D)[R$RJ;803R.6J,I-=@4*6/UT M($$FOH.)3+8XI;D,M]LP6#XXC!QW43CMF[2@TV+3\"Q--0E`GQI(2]A9G.&E_LMB0TFLVT!=A.L`:IUB]%*LGGG,66-E>)!!8\W<4STB4 MO0FS$V_".`GYX1]Y.IG/TXIEUQ'"$TNNAFO$HWQL>>J.+G.NCG#PE M-'"9%=OFZ-PF=$CBY@U,:Q`O5W,L3$ZAJ64H]86V!2=`E.F$B"+96L/>R8<- M;J-DS*-9OJW".<.Q_'+]0-V]3Q>;Q8Y&S-,-[F?B`&\L MZV]@*BYE*>C`7M!3`JQHN92WCLV):(^O`I$9*N>.Q/WB:'$+T6:!_.,""6#( M0E@:4J5Q8;%1I%K+_6*S\=94+?.2`$5-7YA05BV0&M9)FX+*=1L4V?"!Q;F# M=0@+0+!$WM1"H0BY*25B0(=R?Q?3?^[9PDT>V?_9%I^N(P.]LZJ'5WW0)6]) M1%/4-:@;5DUK'Z->,E`.-"M&74\`;/.B@*3)=]AJ4C>NDGIGTK!$8-QF5YM: M3@29KE,\777"<8BV*KUAP::R+2I6J[ANP!NLLM#"S`OH-*%;[6MV#52@%'U-TO('CYTE[,=F$T6F\%]^-,RUNU;M]K<&JPTGAX<[,-%B' M6[IRGOA-FLLP8"/73Z/F>^.WX+DXB9ZU=#Z2KST$9F>ZF MJW(X?;BEEI(FC$!V@>U(GASICPX-2/D;;-^;?:5[I]#F)GA_4[;<;[=.],S/ MB^AA]KQT]A(V.1&?G*A$#8T][UCNE(:_6Z%K\P0GW5">G,8^([R/R=.:QORC M"\985W3'UBK]Y+7WE#LH1N=25A^`?=+3;DJJ"3PI&:$41"N24A*_X+1(D1@1 MU#*'%X$KT>549+B94N#00P[]+@S_0=PJ?J?W!HZ60#YEJ71Y@?-SLAG%\Z431,]OM?W4BU_B4TH0T=+S';!J:N9YM]@H! M$D:"E&@@<."Z03YG`BX#2K(^:'R3%ORN>7O"E-D!9?QGQ]^G&T7?#[_*+@+7 M)[DWDX*[2J$#4TMV#SW)H2N*6Q0V`'O%\B'%$M![?F<;!QK`&R#:]!C01$D$F$* M6E)][W!(4SY^R4B0C$:?QS&&,8C!,(/;4'N^KM]\VS!U"ZE<)DZRYQ&.1%2S\KB1+6!GZ%.2#J9!%[I?I]DIM5)LTK6 M_+^/LW,K*4P`>"H"NO;([AK9JX7FXQ!KG=!"S8E"YVU47%7O&Y($<3^,8AGG*/$..4\%P]@&RO$B./>PDNM[OLA+G(=\P MD8Z,L:I+W?TZ\>[\?(BF\0P3TM!!#;-IT$Y^.^'[$2D1/&;$CK?AOH?X1YNR MRNUFA*NZJR/0["T4/-D9+=A?*_AASOO=1T#,#S8,J6&*?&C%R^L-$JXSCM9` MCW"HJ`K)*A=WV M<]".1OOID@5$4HJ\2'Q!3G+_^E5&]W5-*CY@QOW`4U7(N+_+PMOB%:QCTCU" M%Z4C`=-R6[J1K@&53WJ(U(W>D1YCM_@"5.I'JTFI:)>4V`O3*\/-2V%"P)V. M[J1"F9'16B0&UP\\,DS'@3MC7_(K(S9V0;2(@CL:FM#K&%MT)$[@$M%5+OFX M_`5+Q%=.X,4/!0V'SP4P86,]0V_`PUC,>39!E]H M%\&"PV9^=0,BS?1ZN7Y`![8>+/%R@$!#FT]!V_YVTU2;M_FR]@#89@B=5]&! M,!DE@O:[8:@Y&SG<,=4';L6D(#?C M>T2K5D)0%^.AEQ=9_JJA,#]+(@;+]!JA#93\Q&A?'9;&+G/53>JP%ID35CJ'S:1@:[HHG]"9166!CE!-,ASP6:XBE+^E4T/ MY&NFK9;!Y/!*;TD![NN-]\E#R)_"KGDS32K#-;VA3%HM&,6V_-`4\($TD[G5 M48O*98'DK=K7T/0NU9W2@=9_"H!Z'`?X-)K=C)NHNH9E:U,R6F18,LH&[[:> M]H$I^%P9>$WR*.<31.^;=C)NH++#TPT M/J+"I;R;N*]9@3>P'@8EWEYW(U39AIH:18S<.%\C/"#R.:*U,E\#H;UI:68Z M*.Y71WORM//23/4K)]&.$AO1!+4]^L`-I(@<.Y.K/NY\69LE>[AU8G9P\>@1 M,VOFA94W0`!W4O:P5P^TB,SE-X7Y*Y;.^D$U';S.AK]WJ2O.UL6)EVKR1B2, MQ!&\L]OYWIJ'VTDDCN;9M^(]^];)&+`EBQKJCV9WP4QY#/@*KQ,%;%3Q#8V6 M#TY$+YS86X\#]\KS>:E>40+QRHO7;(WWC,>-7]VU)`_VRJ[U=%0RI3-*A)$B M@M:("&KBZFQ&;T32]R<9`9)2X&8OI4$*1#*%@,*;ZGP"G&P"@L,$L/WREIG[.)V'?9PZ$W=" M)])<6S(SF;9`XP^TDA*MTSL;$1GT:#FBPDWU+\4*IN,:)TGDW>T3[MNMPER_ M4??&>>:-QY'P][8ZS\AV^"7`=(CVDR0)I.5$24HU5R)%NLP=3]T)7L0X+6=\ M4#=G=_QK)/L<*7X/@7/1RZ0=9\#-)R6FZWTD'B\:D3@)U_]@>Y>TQ`%WQ9@3 MS@C"/#_=EQAH9JYT(VW@CDKF3U7T94>N2BUYI,Z*8CI:NBL9Y9?@L-A,0I/+ MPK7%+N27.CVFD0_JI=PH/'[KX.,W5L/7#>;^QF<3J,#9IJS8N8X.J M&DY3+]/%_Z3ER;F2TU@RH24&Z>&E:E9G'66JA3X7?D[TO'0.(ZI)M58*<#TA:,NO@ECA0J?(@7"9 MUY93;:(5FQ9L0!X\?G_N;-F/*^8VQ\Y:Q/GK,K/EDME,"4P;ZH!L8$?`M&S; MZ=;2A[JK-F`]\;\V$ M8D,C[NRBRW>M92&]RPDG_#-@46+NA&1B.#/-:)5W!BM!7`.E<@->N)='_3I# MF*>J7!9U35O%F@QHW/GGIW&\I^[5GDOLC<@/X9?MZ9Q^%7\Q=S:UB$)K8%WH MU3=P.3>F'4G:DZ1=1Z),`QT1UCUM@*$N7%N\BUR7%T(?G-2(//*NJ")H`V$$ MMUY&8JNWWS"067#UE`:%5/I)[A#K40/;@^B"-=%(:6\XE=0MTGHY30.M*%*D M!T,'M[,T$DOU[M)$)@=4/.+[Z;AN(F]-\\0G8U^HEA"X_Z.`6-$PZ3%&VGA$ M1/-C-B`F)\<`5)VXD9V`A_#B<'?C2I[4H0U=),`"SV=T*F=*F=RIA M+6Y.C>_O(U'(,2T%N-ADR4%@IVV%_76IEHNLA(GLXI*^^#;? M6=*6W1;J1M"99%PVSIEL%?+'TB,W5W'%!,5I"PFSR9GKX M(DAMHZXG32[[^0?(X0MD%9+T&[G[4E!\V6XG(,30,!-759H\ M1SM*)ZXN)53US)6^K)I)@7J'JQM*:>69(&!:_SW.$-X%L.:G<.^!=CF MX)G9[OC>X+#A^.&&_R1;GFDV3N.?!IC`K$W,CJL0HLM^DNE*? M()2=-H%\RM$W)5[.>Y.\L$[:'R@3K6>PZ463WJ#9W.'N#EQ6I?FP`0QH@L;[ M,!91I>MA*I_#J:(9&\2]4(U+FB2^V/ZD%T%,G0P%)6B/0@FR\H3)H3$YMAYE M=\`0^0FVH.("*$<*"MPO:&9*+2>@D2-;1(BS0NGQ=1C=AL^.S^O.I_49M$X4 M%=U!3@25<"I:/&M,6&MR:)[558'.^K-#LF%(H@,2H)?@^@2#Y,"I66SJ#XP: M9::%.*]HM/4"L3"+S2$.:'1>4T,"]+BE%E;EPA:#(K%).L,^%;Y0$!!'S"WY[1&FVG&LL-M.VO&=;6G M?(O,S]^.?S?=B!K1AMZ:&DZ$-DN/"".1AEE>)>%K4FJ((FNAXQG8B1E(BD*- M='=KP_M:^UT+QA\PT$3O'?^:ZI.X]T&@B:2QH]>FO#K6P3MDA:\BS MW%+.R-NBL`IV6+R`^`)+W!<6^^U>>S#(MGIJ`6K>ZBFE9SB#Q,QBR21Z-+[< M1Q&/$0?NG$U.^A^ZYDJ7')0QTX=;"4/LQ>NS10_20U')TA[2C?.^-:1P.V@&0ML$I!P4-+M.;5"@Q:^VJ` M)JWPR(]'^/^<.G#([&V#4&E4>%1*U'`6=QS'-(D_45_D6NYC;=M:[0AE1640 M*FPFVA#>Z,P+SA+>#(&UU!GZA>/SU)28/+!FW!&5#A[,)M8RD-+ZU7!/"FK& MNO^)_7`9.LD9^?/*%M%E@ MY)Z\XGAU33 M?Y],/TZ^.YE,?YI\]]/''T]F7T[>OZ3T7U]N'YT56MOOL1_% MMN_L>]%A6/TFGS]_/DW_2II&^*3#V^1^X[R(`P\](`6)^GG?XJW&_3SNPBO-QXE._W=*D2+G]]MUJOH/>7C MQ[.L]U]RT=B^2_Z+XRWV%T&X3FE^=T+'_?7AID+\1\*?[Z8__##]\8,3K$]I MDU/A**?M*+P(_"CPL&O'R'VV/2J+:(50'*F3QQ^B*]HV=D@8L4(Q=FS/`*'5 M\0Q2_1B3_U+1S1?S#0I3B46_^G9")B9RFU$N&;,E]<7H$1F>L"2\"-:;$*V0 M'^$7=!M$3K:"UX-,I\Q9%O>)^NU'6[GBT>\],E*[MA^/'.< M("&3WE_>$QHYMP09TZ[@@M*;M% M9!/4X-*N? M2\YJ="+HZ`*C;^M5=+W&<;IBDXE)%D"Z8)!#J-;R(QJD)7UEC7\*;3^RG70; M5">..T+K-?PY0E\3`OKJ16LAK'63-PL6;8Z9KAZG)5 M9;#NZ8UUN:PQ9D?KIS:G90-U2^?$&*&3KFY!36>YGC#V'PC*.OTXS.!N_!*+W+-F69="1S M=V2[=KW59J3"6!W=F+5)E0VD12?K3<8+P^Q+/EK2+]$7F<_T16;R?8ID]^M; M^QEQM*'\O/.Y,E;6Z?1O)\>@D,P,'+A7?C-2:[V/2O-C3*3;@NI2_R/1_13$ MMM>(XE+/(]%ZAYKQMNAW+)[2A;,93_<]#=(:']*IS<@]!\DJM0E11)]5Z?IU M2\BH$$@V">2[])TH^RT=H-U+;?J<'CB5KWCT`3L(9:LW_8V5#TXOE.G@-_O! M9\]1')*5.!_(HS#3X2WEOM;';/%6HG''B)3)$7(^+(.74Q=APNS))_H#I?_3 M^X^3W3OZ7\BOK.S+#VB)Z0?]^,Y>(P;!O*;6[F!8%MLLK-)JATX^(OGQ0&;5 MA_]=B]/L^?>]L\)>(>Y%&*SU^9?3$DB1G`0A.9C\_([T22)"9+"A0^6GDHY% M<$&0A+9W0[3T[7_05BB#6EMK.EPA'$+)I3`YLAAF!(9+H5Q[]I+#_DH;ZVR( M;*]#R-D]/3*[+Y*0HKS&D6-[_T9V2(Y5EV2CXG">U]SZ-$0A"-#D\C@[LCQR M,$]D6(X,RDVL[X;(]QJ"G->?@'A=W"<$BL]L:WT_9.[7H>1B^`Y(#-DTS*BZ M)K^+)*(X:&_],&1QL.#D(OD>5"1T95072-':^G'XXBB#R87Q`\C!]!I[*+P@ M,W49A.)C::6E]7F(0F`#R07P(\S-(%BO`S\UG:96W6B>Q-1#FSJ?BZ\)@H[6 MY.-PY2,#ELOK,UM>IW4C0YT/9@P/?!_L1DJSL*/GE-M)]'YIVQNJ.=^=(B^. M\M^D]HF2"NU^;94<9*^Q3^C`9+D/(BPQ4NAT;VRG:(XJ\\-1H+_:$,ABH;%]E(GT_C"#L,M69?_:7L)ZXZCU1_(Y"(5'UO:JI!,2?\% MA<\!E/RO(L+)UTNTH8N90,Z5=D#6FX;RK)/.MU0.9]KNW`JI-W@:!?2`'$0T ME3I'WJ%XQQK1:JS2'\A8U%#,JI#XEM,AS=L*\].[M'Y>ZL1$4%4A1U`[)BZ9ZA)!",+]HGHL/NP!9 MPYH=C9GDCV.AO=[%DKP@MQY,(IZSXHY`=C85L;$%+84SBN/P[I08U?DCD#.O M"Y2IKKF(14A&<6A6%^HA"V#M3_K"9"$PMB(#GJ#RV'.)Z*S)D$Q+E-HQ'&]O ML?V,/1QC1*]AA\'4"N$EYUDS&_DS6!M4!IB4^J M`0QP([`L$IE!E_CJ,UM84UE0F$1'O.9&) M8Q2/$"4_6:G[5:VI-86VBC60)0O$2.Y#KHLSLN]M[-[X%_8&QQ0#_QS,[F%- M80U>C>0JP#*.B\X#3=3A(_?*#GWL+R-R[$_627JWH\FT'*%'G;RS-84U:#42 MNAHLU=C83-AL$/&!W.#4MV)6GQLFE->V/I,G"EYD+L[)T;.CZL M6OKB6["8\;OMO1W.PY12-[TG[-/,*UYW>0,,.KA,&>((W@ZK6+,@TED2KX(0 M_[&?QE(]J'<$#D,S*7\&M#'XC[!`WD11HBWTK!-P0)IY@1>PQF?15`F>5^P) M'+=F7NQ5;&.X5)=L@0VV>X7>P$%M[71`#9^Y!\E>Z('&-B_H!1S[9DSN#%S& M[M5]>?50W-\Y/8`#X@Q+NL#$S^TT:"FK;>S"U#&P9A/#\JX"X^>0:BUT`'.) MI-[FD54Q,SH7-"E823@]``PC#^@%^8G062=O`FS!&CX$GWL\J+8&M$MJ".R1_'(_XOX2T-D<8+(3/N:56P-8%;<%521]#D.!N M=_&75V\;Y$=()=\8MP^PU4!;G"(@X_`]_@7Y!*(W\]V9N\9^F@X^QB]H!U@T M2\4]@8T#0LEQYJX4T"@VT0[`%H(&@E=$!>U6QRFW0N^` MB5=&S!`@IR7P[5Y#5GP`X]AU#UBAZ4Q'DOC5T M8IOF!^(JAC$(\R[P@RJZG;8J7'BD?:&3WF@+6@G1.%Y+;GQR1$.1PA&XUA(Z M,8Z:C-CR94!I?;MA5[4\O6`;$_R]JD^"'3J MG#8JH(=R'`;(7.TS7J7>\PKSO=0:.EV.B3E?@S,&/R_.O7\`F##F95Y'&WNWWEN1]BA]G_L);'P0B#I M"9V!1UN\"GCX%<2&-%M_(S><%4$T(U382W27K)]1.%^DH$ON8>J:T&Q`Z!0_ MV@K2'.;^GFCZ.G$D+[N"2]%\<1A>3==#,#>[DM-?)E%:6^DP^%LO2%%E)`"W MO(;[;%_\5Q6YJK;]CB'>4)2I@&6)\C+AN?^71'%:L%J8]L'`Z/V)7&RG.V98 MT=[]@#U6@/@642?=A\(+)W#O?_AK14D7% MX__,B?%+EII$H2I7!Y_KSUZMH4P=,6(<#W-EK[QF'HIU%S[@0KD="9NM6F(^ MC.#V0+@6(CM"ERC[]\;/GPQV>>#%!>14ND-7XCVJPB@R9`Q.T(=0"X[MLFBJ MA2LJ#@)=Z1=8C01L&8.?`0-PK4"RGA+5.@.'4>B)4UDE#D$"NYIQ?.L/2;\/ MT<;&;NY^04-%LKJ./*=[C2&`(R?:R+H!U''8DPXQU\K1:,W^6E_@\(QN)O\A M1NC`FB-I0K4P41N]J(X$'/UQ%"TY0#R.J!\F[EIQ(UU%J77O04!)-^K!P#F& MW%PFC^M'LL%!A[(<]X9CFG-C<,$EZ-NKI/H@T&$VC9\.-/"-(5,(!_&-_X(B M[5<#_<&@0W&,JHD$YSC.0^2TMUM89\[7!(>(<(%,CWA[[]E^3.Z/---]FI9! MH"CJ@X"'[C03-5MO]&#WT]Z2[:*ULQYET3^01QAS%1'NOO(L+4J=P2-Y3(A< M#^XXG@,/U/N&",]?8G(YG$418AK@E/M"1]QTNQ"PT+8_7O3!^J;.-R,'"^C8 M&Z-JH@=[Q+>476)9,\=1P6#0(3]&CZ,2G&.PQ!#(#D)N&M-X%\1(P:+/ZP(= M#M10B)S]10!R%.YPZMPRLCY`AP(950X]V&,H"WZU6""'K*E7;\Z*'+/0`UEE MY^E!G+IBDW_HO>O%]NB13*`O.L-`EPYOMI/H(C17T1"PT@83W3T*<>#6;V^B M^`.-8>`KCC=1#EV$8\@)P,8\(PMH&&[)6BFM3Z[2'[YHN3EU8$`SED)@DZH: MH3:,1ZT-O:G295X;/IG+29!IPY4/9-=X3#8;+^63[>5\NO$70;BVRY5/1`%" M:B/`5T%OH@\:X*"3%O"2]M(SLHW=RR0D^IMM]!=QW&7:+2QPY7A`EH4I6C;9#6U-8PV'S\UI;U-UEC6F[;V>! M"\BE]L_Y@A!"T*B\3ZOTMV^%VOGC$2Q\O ML$,]+S)/9KKYDYTMS*W9DJ7F#'?Q)DNU0I3"AI7X!YQ:5IO[*KS"Z=88#G MF(H4^.^>.B@'OI5=H@7V<8QN\>+0U>K8)>F"P'W%'BW$5B=%ZS2N-0[`=.03 MI3(+%7H#3SY=_O-M"@I`!S[_RIX5I>BW[;'G7ID.I;HWA\VU9A+/,[@TKMJT M4.D&/!\XS&)=H.1`!J[OM_1E]^@[2_95!;VN-@38&XHPH8R2^>(615$0ZFT1 MZH,`SXP#=G.V`BU``Y\A)0/LL:=)\6FMXY:@%\CAZH`:M5,5OQOP)!'S5V;& M[W:.@)D):/QMGL3^V-.DGD1?88[PN@!,D#HI*K.#VP=X:@C8RID7(B0#WS@> M8P)C%7@$0T2-%L>_1&1?59D.E880EN8#7M&3M]Z6H3P&]"2I,YMG8];`,_C] MXR)8KW&6WB%-I9T:U)$/\6XC($7O$5IG'(`YIT2?RL33&PAX]NE*A??6KHMY MX)M9V196*E!Z],G)HT-A/LJZ`DQ!'DEZ\T]C%.#)IR`"SGS3PSCX[?`Q>8[0 MUX0,>O4"\.!:^[Q2:01.%XC#9(T4I<,CKP]TN00^6WG'1@&2@6]".S^?0.SG M\\W?IRD"6D4NFB]J-&VS_ZK,(K4!!NCOHPP,U-&:\XCW@%[H:&E:D@A3>N02 M5>L(7/Y#1Y+*@,:1MV=?>4E)W"K=H`MY-)BV$CAC2(3/JB27GZI]MU18+E+7 M@L9C0I?N:*`B;;":R\[3NU!Y]15#I3]T+8XF2XH0P(4U MFFB"!K0QY,ZHN_E=[_Q17Y";`=;PA3SH"UQKHXGX53"92XL!*/?UQL9A&G1& M'7DV061[\\5MX"]3K!EX]06AR7#`A3<::4B2;)+DE/Z+P!3O"-%W2OL#5-9JH@@HF8YDR3-H'TCP>,]=%[I/]IF@:$/6! MKGVA;1:0@3&6S0)TMD:(L'&55H-Z05Z0'F%V):*D&[M";_!R%(VFK!(LX*!H MPXZ8&GLXIPMT(8AFQS@^ED*^0TZG4/>D4Q>SI"=T/8_7",T75U&,UW8L/(-7&T)7 M:&@BW$,$A02';(Z[0Z\E;H2!3WYT4LV-=.>V[E#0%1F::$$3C(6>#-E2=Q_B M(,R229%+IV='4>H3D8JLJ)9VB2(GQ"DXH?E6;RCHD@S-[+CZ&`L],6[9.W+Z M#KMDMW[*ZF/WY9%A;$D\6CV7],5)IHN$'2/R1!.EZ8"97G^69!V/S@JYB8>" M1>DAYN"-)HDIE>L@C/$?J=AW-IU4-DK^H`8_,X[T'X8Y,O`%($T,L[VYW(F<4);MXN2D M<(OM9^RERM1@FFF-.,1T'LVACFIESFI+D8-@P41:78IZ0/@.84`JR@;JHS\L M\(K=4H<:X1U'G,*>"1?!>A/XU&H[7Q1\V-T>SI%/+MQ--GSM48&C'%IJ4A.X MQJ(@>I%\".9`,.P41'O]^0WAY8K<,&9$EO82W27K9Q3.%RF!30X"&N-!9V71 M3EW4%.7`+1]J0;B7*+:Q]RT&5W\NYJ4_GB1%CZL-!QA3>P#`U,3P8$XR.9PL M5]-^)YZ]89$;AK`?\+GV4$0247(P#%NR-5"7P=K&HL=T9GO@5/@I_G5OB"Z5PN$>=`6.,:5*Q&V`%GD]T%X$7(^+(.74Q=A*K=/]`)MYQUE-$*.-Q4MFJR*>;?Y[OE<$8$=U&K-P$*X.3P M[)"Q-5JYNGYT=Y$4'IVWMK^5KCJ,UD"ADRR>`BEQL)S:6"NAA'H[D2^?9 MS+RF)_6#[E!1BT>2.!/O*(H'[X&1<\<\3!='-XWT*+VA8AQ-*H8F M7-AT6%K+0,7$?F'[#O*R+$UZRP%W&*B8QR,M"T+VN-D/VZD[NO'IJI3$P5&SFD51)DQ/&DFP=3WUNHBA![E-0,9$T41?F M0%!!FT=5#R[R,>3>RB#.DSB*;=\E?!-9F>IMH6(QNSBI,L&-(5E6Z0A^86]P M;'L95)J!)GQ![G409K$S5,_I@4SM]J(VEC6!L4-V?)=1!V\L[19L3F<[6EU? MWES<^-0MT)VM*0]%>L)J;TU@K)B=Z`(/(&S"+J4T:U*S):>Y-1V)B5*`#SC? MEI+\;$P.(_]$OAN$W/LDOX'".]\^D6]+O*\5>D/[8&L( MDJT*:AA'J@44H=1C6Z$WL/^VH@PU%:`"#TH!.-4>\ M+Q=M@`L&M=]]RTB,20]FDTVA2.=CJ15PN9\*ZP72&8FS^A?[#:^3M51`E7;` M+NHU_G-L!S6"!RXF[*N)J=P.V/=<34PU@@>^VG$7_%N%6!!Y9^@J.1W>*RL8 MP>)(.M:"7R.T2#R:`+:)&NQ[0]?-492BI@I4\8W@7L)%^DL81(U6@K0C="F= M;J1?0!O#=67F.,DZ21-O7B)"M9,EY"(_>VCGXUI.>,MEBD!'3'T"NE1/*VTR MR80Q5/;F`KQ#C5YL2#?H"C[=K#8[8)W%+1SYQ;`,;?=BN'ME_?,^'')LQ"R6 M*48`*W0=WN.?!C)31S)0QYSR/B'0Q7(SH-<\'^CC20S=`3SXOLL@U'!'8_0-.F7;@.TP2 MW6MUN@X2T1M-LP&!75#`E&F'W=A%?6BZ1-J:U272%MC-!4Z7,NS0N00@=&FV M()W(XH[`GCW=*TB&T5QR@2"VO5Z:66(8 MVW+_K2T/1$&O1YV!C8R*\G*+FP^QK9>1?X>1:(WOEL#'Q`]QA,A)T?8=;'N_A$&RN?$=<=!GBR&!C?%L@3&N4>T@`E^K MN)H0HQV"+QG-,C&SVP,;P35DR*4?UE.:E],4YYFY[@EH'$5!N"UA>`KNO&<7 MQT^OP?^B,)C[B/YS1;5T0]4QNO4D\];8!X`-ULH:8!+P.-YD.;O>K4*0E:PK ML)'Z..>X,MJ!1]R5KT(EM!A%%YX=17B!D7N1A)($6QJC0`>_*DB4K0MZ&$<0 M?G4;^,LG%*XOT7,L5P%&:^@`VL:B9F,9AWM7CJVLS@IB+3>'#J-M+]@Z&G.Q M2S!OCA++Z.2;:51WP?MBQTF(Z>K^@`ACTYP_-&P;D[O>QO9N?`TG[5;C#LI4 MVA;IR'9-*0OD;MA-A@.VI7:H,AWX6@]*522.ULT&!#;!=JTNIKVIAZ0P$E?J M1N,!&V\[5I=1^4OKHQ=[MS8:#]A0W+6^C,DG6@.]JD-TTR&!CPB2^&:3+XYDWUS9OJFS?5-V^J;]Y4?R9OJL?$ M1W./B9<.[M"#F!5"2U9D-Q9SHD&\P!@1>L M]7N,9Q+FE]L,Q8VH1C.L/9'GW-?2-TS9$PHXR;RR\Y\Z'F,6/YB#`[VCQKL[ MJD(-)E9S8,\74 M:BBK3,!H#>V&PY<+6XX<"*!O_KQ"6('MD^U"4O6JW`@ZI;RJ,-B4]^T,20DD MN[:<_T4CZ*3NVORO4`Y6L$'$?_IPKB"!?3/H5.CZ,JC2#G8$%$B!OD?+A;!O M!9UN7%L&5=*-O:.:%`%^02HRV#>S)K#6!'TA5&DW]BAI4`J/^$TN@Z*1-8&U M*FA+H$*YL1=&D_Q'+\A7D,"^F36!M1+HRZ!*>RZ%'WHDA2N\7/$O"ZQFU@3V M6J\MA1KMN11^[)$4[K#*W6#?RIKTZ[XME4&5]%P$GWLD@B>5Q:AH9$V'<55F M4[Z_G0W3TM%EN.D4]MI]['C3Z03NKMB!V4O5X&5-86_W2G)1L'I1''VT=\T< M)TS2!'%ILHL;?QV/ MQX+F3.2@&4-@R#Q>H?!Q%80Q]5,]#$P>,7^4K2S\KI8T_YX0F@*6`2ILTIU M1Y1ROC#MDF`@Y$;7A(LW4938OD-.HY+# M%;^3->V/:X>FZ,6@QA!H0;'<^%$<)C2L)%?U!\*PJ\4"$4:](.'!K=$XUK3G M&5OX&J&-TUQH1W^4Q`F1':':V59#.9C]K6G/<[NH*P47GS'[K]D$?A?!>AWX MCRO"IX@N%\X]3@N@,?NR62GO]/$6+6WO&B'6 MH8[9SCJ#-8BUO'M7H#3Y8.>HMT[Q$A*=X*W82XO:RSP5FV M%%$-W6I=W2=V8;W;2\(MY>!NM3RT5VBR`EQ"J:1R$O] MK;/!FLV4\16*,&1+6ME(J&@9MOP%'Q[794/J:!A]\R@$DW M3VX?Z%(9?"$I2[4`,NS340V9-!B7V1XZ?%XD'26!%C!&D(6;N6K=*C@3_$B&OAN?_(B> M[#!3S0G(D!.X#O8 MP]D\D.,U]`5@:Z)8:IPI:`YZ/RM)7NX^3:A/EZ6K-P=%%,N$2;X!'=F-`VR2[(E^[)DQ!OM* M'7:T/^<$471AA^%V$82O=NB*#OD:HP`;1CM3HF:L&$.LS`'B?]I>DG'+\X)7 MZC6NHSJ'O8%-L\=7&28+V@?,Q>0`U5;(&!C3:RE4[478>RGG#+A7K(KF[$P2Y\A'"QP+R-0? M9$@WQD;H^GC4?R1\3N@S+`=,&GI3`<23M?Y(0-?!9K)CR+\1XCXJ01ISV5H! M]$8!NNL9$[XVVC%[Z9_KEF0& MPT6PW@0^2@M,S[2OV!GP#;25FH.5+<8U(2_5.AN"/PHUZ':L$' M;,Y@4#LS`KS&F-V=6HP*_-37V?;4CB7&5,VLU:%PD=BA:."FI#$$$->2PDR M3!%ZV/MHF)8AD/@?*78'#NLXON#WN&&-TC)C8Y416HY#S08"C@@QKPE-.-!3 M$_2A!97'II7M+\D?9^L@87IZM!D..)[$O(8TY\.X_(7T;RR2GM!Q*$9510/S M.$S=98>@F(R3$/J_&;Q;1'C5-QI9QAI)SR$:K.60AAV46S!EEL2K@.8VCZ,5H52&5_=5K[8$MA(K,%]E_#@&-XKFQ43!A[^Q_4E'I MSDF#*6',&O&X)%^];7!FA>#DZ];I#F2DTQ2C)J(.W^B.E>J70+RGQ9T(%X%2 M@%S9H4^K2>5DJ.3#X'2!2/Y1(^7&(P-87 M@4@X2V5SG"-(K76'=EXF=`(*E*'2#CI71W.!L36@#LZ47-V"B%\2[*8A$,>6 M[V^(%F!'[HRL[/82W27T+C9?9.5T2B4_4AX*Y*\U#G2N#M/ZH0L>VF7&F'$O M1#0+K.V5:S#-XCC$STE,[X1/01EBT!?'-!9S#OLX]QX/R^"CR7:N_7!,=; MV&?:JY0&E;-VI2%H#9&4A^?;"\^.-$J''/2"O@;4&V!C^Q2"7&N[APHPQ;H[OA' M]5N:O/R@+?2QF"<1M@!9Y/?H\2%"SH=E\'+J(DS%]XG^0*7VJ20U\BLK+71Z MY<=\MQ9&*^#CIM9*RB:??\_MEMT9$=R%KMX$Z%V5P[-#QM9HY>K_TAIE\92]_+!I'H%9EQ:#P"ZVP^VC74QQA=HUS#[0M3`:'?D$ M8`9>&:$$Z,Y>DQ]+94+E]6NDG:&K8H@$QY&U"J9A'PEO[N?2!;AH`QU=H"8/ MCA6T#&($"W&Z5NV8<:O@)L9L;TU@C2F-5F`N$F-&1O#;VU@0X+0I74-([&PO*&";M'B$Y(<[#U#KATF@XE!OGU43-ZVU-@%.9-!>Y M"-(8TE@>:+?:4Y.HFS4!SE#2=H+7L$`'`7D`PQ4N1)\-V0E*"UN]R%V5,YNW#[6!-8(IBUJ$9!< MNM_W*;-+2MW5FY.FDI@M0Y2^!\ZUG08UCP-.(40>Y7\C[TY/@6T,D/HY@I9]IZ_\2\"WT?I MT]-O.%Z5U%OO?-'P(]9T&*:_;I`76@03CM"9%LT7A'2V/=CP%ZSI,&R+'<`N ME`>F`LXQEJ#4^':4=2C]DC4=ALFR0_B%4L%8-SM?D3K6J,IGK.DPK)]=82]T M"<9(>HP%*C<:'F^AJGS1F@[#Z'H$-A3*UMIF:S9IB[EY=21=8W[.F@[>&FR$ M!X66M38=PSX`EQP0&5:*&[_DD*CH*RL;QCH;AI&Y*;9",V!LS%JK3P70!35_ M>IZM?^7G#F.=#<-:W!1;(>MA6XI+*DZ6OPB[NU3F9)U$^`6Y<_UE0#Z.=38L MNZ\VN+WSUX`?F^[#P$'(C:X)__(GDAN?G+QL[SYY]K`CL/!HCV&=#<,\W`A8 MH0X#,!1G&]P_D.>>;ZFR(UKE8)G^=I4V9X$6XNMCJ;9=KJKH.@@?@JWMQ01PYGK(6V?Y M/>!K"+<1H1Q<+ZNN/:%PC?V4U_-%L1'PA,=N#5V]UX#@N,#&D'8-U@$+^%1D M9F%N`KO#D(LCG8X>D$>CP>[M,-Z6+HM01R,>.0JG(5E7K0,09RGE?4.Q"H%B M=^"#C@(C6>NK.K@>Y0@RKJF7":)7;VK0W_]=7VN9PP"=GG2ERUY>-8&.0D?2 M!$+72!BL5+0!.F*9D6X9!70"9<[:3?;OI?V";OR4UD>RIV.'[SC*;@UTTFDG M(S&><<0#DV6DLH20L]]%$E*>DB/A7>`[V?\(YJ'B"$!YW\S,4G6,YG()FW0# M=UV<4:$TA3G-@1+*&9C#?$#&PGY!)_$LBE"`L``00E#@``!#D! M``#M7=UOVS@2?U]@_P==7JX'K.,X:?H1M%VX3;)K($V"V.T5][*@)=HF*I,N M227Q_?4WI"2;LD:RE*17N=J75A9GAC._(:D9?N7-[_?ST+NE4C'!W^[U]@_V M/,I]$3`^?;OW:73>>;7W^[M??WGSCT[GR_N;"^]4^-&<,;C$ MQ]VX<$4:ELC]<@&"7:&LA)AQI0GWUTKDE$Y,[+U^_;IK2U-23J=$TZ!0^.NN M%"'M)F0I5Z0Z4T(6*ZX)46/+D118N#L'O33' MA01:=HUI72#J`!65S%_Q;6=*&,SH1C@7FF@8'-^](8L%XQ-A7IM^=F)4'`&# M9QX^W0S*!BEK3CH.$Q[`OTPOC3@YM^+W/`:(E%*L*@[HA'%FE8):O,YZ@'<> M081W9F5X@[60-]U-":G02-'@BK^SS^`B9;0P!&:T2K@2$HQC+;`:O4]"/PJ+ M*^AF$'XXY!\$5R)D@6EP8Q*:H53-*-4JQKNX&`?[$!`>`BXT0=OE]]['`KRA ME?`WT@F4"P(CLIY1S4"5+;!G:7$?'%7W@??LVA7XKS;[9`79U>1J0:6M7'WB M)((0T'S^-_VRA1[WS?,RWZP+Q,1;R_2>K:2VSD$K2!2@#,U4?A!SL&Y&N6*W M]$*H30_58X91O,YDDQ1WSTH17 M3/FA4)&DQDNQ-.,*1YZW%NBE$MOFDVLI8'S7RSX/SKY%;&%:;.P!M`3'^]4F MWBEO'-NFW&W#]C36BUZP"1V85&'*QB'M*[6*:DLI<*Q?;V*=RO",$&\MQ8O% MM`WT2Z&INB9+`A#&$I"G;O8!-LR^\E`N!W(L.S0MH&]04E M*AVODV< MS-LV5"$-FS-MMPMHP`Q_EX$V='A`VK,D+:!KC[[1Y)PA7Q M[11%C'9A*0[UBTVH,U]USY70-IR'T5C1;Q$8!ER;`+?`4ZU`&'N6QN2^K<6D_8+'<1)[DR_A8NS*=0.U[80H-[ M()<(EN;3K<7?R0O=AI]_C:-H%H4U;<>\GX=T1.]UE.ZUJ$"' M>R"7OV[Q@)>(:YTGTG@OA'"/K:(]8H.]P.T%50AQ7^2RWJTQ9EN[106,M=L] M:M#CKLFEP55=T]K^4A3C9_K*-B+<&;ED>$LFT-9>L@7=7B4?]'`G'-5;WESW MAUX[W8"L&V/?\8JTN$OJ9LAM'Z+BE>1,")M]A<.<2Y%CIO:.,\[<0@9,Y#V. M:"X[SDXZM!M7;4#(#ME8`8YL+M%%D6WAH)QOFX=%C?:P`-M<\HIC>]A2;-WF MF0G&BXMQG',I*HYS:[]BSAQD]EN&%.`(YQ+/S=G)MH[`[LX6:G>G8`UZ*Q6. M>GYI%=D-\W?[=O:ND(WM+YGF7H$.]T,NG2S=+=/>SE"T,R;CA6U$J`N>YY+) MXETT/PW^YA]S\OR&3CQ[I/O$G$M]NZ?8?!&:H^#VWN36GXSOI$?B_P*3] M^WF8DAC))8?+K>\V44@J3D4D1W'+CYR#$#LU#)V@FRJ_UWT">P#PNO9D?=0H M:T(RKFL-L-"P<89`NZYKR$97>%ISNNG1;'A:']B&`K!$2.UQ]%J*HIL6XALM M+H1OQ92PF%^=E*]C7G5ZAYVCWOZ]"F+%:M2_LJAF_2E?O?KQVRLJUIPRF"J/ M*U16>H=$09VV/I2Q2T.MTC>=M:BJ5I?ENE,F^U2O]FWWT509C$(I,UQF1'IM!L'>B\=H4'$H M=&K7CZVY_,J3JMJX4L[60NHI5WHY3I56D?*8AWIC0?F%+)5@V.1ZA&/P:V3J M*2'XY4/T*+^DY^'?3"L+'2&3N[BL+NN+:,RN$7N)C'.'3'^LM+3-TJ1U)C+\ MJQIY'%[:*Z].X!TDS@--YR;UV?-(0O5V3\O(!)^6"L(])H*1Y0LBF=R4PUD8 MFG6KE%9%P,QT9$K_D"):I)4P$`_6>3GSS)GZ*#2I._02RE?G#:TQ6*&K^EQ` M?R=RB2D_(:':HGUZMG6KM]'PK_J]N$MU'&UL8WIIWH]/T#[7V\93?47%Y)^_ZWB"D[56.WT"XQVRK0 M-LRZSR2,:#\(:#`B]\6&E9,US*9J]Z8DZQ#(>/-`_N8,0G:UZPRR2\*GM#^5 MU!:ZK9)*WTRC3JEK=AVNQ.7@[T7\]L=Y&U7;K'T(;E>B+('::BC"D?&H?=
A@Z%S266%O"V7BK$T^9,@A^8-2A=DGEWTS/G-8*L6#Z M-:W7`NK+;3QBL:(FJ'B_-`D#M2.9?9NL]UY-S#5JA"^WHE1+UHX@,U`J@D^; MB"]@K(=$`6^#+,]^O+&AOY"B.<-\5D7(!D;B,^6!D*K0CBQ1G0G_D.EN.+4_'=F/+@P MKE(78=['3RBS24A%G%[!EX#_"1$-M-O^(C\TE]`TR))KHJ@O,/US)0W2^O2K M9OV\RMG7#=+W`1UG)_N%&;]!UWR8DGW?,(T!9%1CYWW3-)Y!BH'K[)8T3.MS M$4E4:;>@:3JS6UJ@M%O2,*WAJXOJ[+QOFL;TEG)<9[>D85J?L>E,HUIG2AJF M]24K&*+=@H;I/"IH':-&MHV^[P-GD&8W`WQ"O93J<=,1\3[.IUF(7<]Z)G-9 M`Y.CQ7\'P%VLRVPZJ,S3H'FPQ!\7=$K"TNL:'9@90?,LJH&C2`Q'I> M32;,IV66(!0-LN*43JAI1R-R;Z>TSNY]JA3\NH+0Z=3^[31F*SMG]S1P+_U/ M)\<>P/[=VNJ3[86H;-D\YG3"- MS)W6Y&O.[*GYLS>1&7T*++@!WV6M<*>5'L"\`_N#[)]J>@@>=1EW`(L":\SB M5;P'-0S%77RZ9UMGP'AV`('5L):XK=KWHA;73X!"_O-0F6,'K%^UZ&P/3O[4 MGEDK4NH#D7(Y$?*.R$!AO:$Z[PX@DN_,!79^L/L0!KP_-WO2-M:_'R1A%[*= M4\*9FH$I^76!S9(&Q;N!1E:.:D?^?&8[I5-JS97&_MANQ"K=!5B%NT.P-O@=K)$Q`)(-T M/V-F9JIX$]_6O5T/EOM3(99N='Q2N-9"?RJLG%9@MZ%]KR:6"-^%+_;3M96G M1W1#"&IH#8K+B8X[BW8@E M">'?0%&5,X9M^*N)BN'.984$33*BJ)[JXJC]\H< MS0GFH2U-R2VDKW:];DCE+?,SH6T1P2Z,\OT@L&,G"8NL*Z1HY!Q'-S[__^[7 M7_X'4$L!`AX#%`````@`9HBM1L%11RVC?0``,-(%`!$`&````````0```*2! M`````'!M:',M,C`Q-3`S,S$N>&UL550%``,0O%-5=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`9HBM1L93%?@?#```)ZT``!4`&````````0```*2![GT` M`'!M:',M,C`Q-3`S,S%?8V%L+GAM;%54!0`#$+Q3575X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`&:(K4:E;$ABR!$``+;^```5`!@```````$```"D@5R* M``!P;6AS+3(P,34P,S,Q7V1E9BYX;6Q55`4``Q"\4U5U>`L``00E#@``!#D! M``!02P$"'@,4````"`!FB*U&$Z"QD(],``"NI`0`%0`8```````!````I(%S MG```<&UH&UL550%``,0O%-5=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`9HBM1FC;!+(1*@``9=$"`!4`&````````0```*2! M4>D``'!M:',M,C`Q-3`S,S%?<')E+GAM;%54!0`#$+Q3575X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`&:(K487_G7_B@T```N,```1`!@```````$```"D M@;$3`0!P;6AS+3(P,34P,S,Q+GAS9%54!0`#$+Q3575X"P`!!"4.```$.0$` 7`%!+!08`````!@`&`!H"``"&(0$````` ` end XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9

Definite Life Intangible Assets
3 Months Ended

Mar. 31, 2015

Definite Life Intangible Assets [Abstract]

DEFINITE-LIFE INTANGIBLE ASSETS
NOTE 3 — DEFINITE-LIFE INTANGIBLE ASSETS

At March 31, 2015 and December 31, 2014, definite-life intangible assets, net of accumulated amortization, consist of patents on the Company’s products and processes of $161,062 and $186,414, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the three months ended March 31, 2015 and 2014 was $4,055 and $6,794. Expected future amortization expense for the years ended are as follows:

Year ending December 31,
2015 $ 11,462
2016 15,366
2017 15,324
2018 15,324
2019 15,324
Thereafter 88,262
$ 161,062

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T83`P-3-F,E\T,C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D1E9FEN:71E7TQI9F5?26YT86YG:6)L95]!#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQE87-E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQO#I%>&-E;%=O3PO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O5]4#I7;W)K#I%>&-E;%=O M5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E!R;W!E#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DYO=&5S7U!A>6%B;&5?4F5L M871E9%]087)T>5]483PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I7 M;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D1E9FEN:71E7TQI9F5?26YT86YG:6)L95]! M#I7;W)K#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DYO=&5S7U!A>6%B;&5?4F5L M871E9%]087)T>5]$93(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I%>&-E;%=O&5S7T1E M=&%I;'-?,3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DEN8V]M95]487AE#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS7T1E=#PO M>#I.86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@ M(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S1A,#`U,V8R7S0R-S=?-#@W,5\X-&,U7S(Q M,C1E-SEA.&)F80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\T83`P M-3-F,E\T,C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+ M97D\+W1D/@T*("`@("`@("`\=&0@8VQA'0^+2TQ,BTS,3QS<&%N/CPO'0^,3`M43QS<&%N/CPO M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^,C`Q-3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T83`P-3-F,E\T M,C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@+2!296QA=&5D(%!A6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%SF5D+"`Y+#4S M,RPR.3`L(&%N9"`Y+#4S,RPR.3`@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A M="!-87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(@,S$L(#(P,30L(')E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%SF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P+#`P M,#QS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(U,RPS M-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XT-#(L-37!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@+2!296QA=&5D(%!A6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q M,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@ M;&5T=&5R+7-P86-I;F#LG/E1H92!A M8V-O;7!A;GEI;F<@9FEN86YC:6%L('-T871E;65N=',@87)E('5N875D:71E M9"X@26X@=&AE(&]P:6YI;VX@;V8@;6%N86=E;65N="P@86QL(&%D:G5S=&UE M;G1S("AW:&EC:"!I;F-L=61E(&]N;'D@;F]R;6%L(')E8W5R28C.#(Q-SMS($1E8V5M8F5R(#,Q+"`R,#$T(&%U9&ET960@9FEN86YC M:6%L('-T871E;65N=',N(%1H92!R97-U;'1S(&]F(&]P97)A=&EO;G,@9F]R M('1H92!P97)I;V1S(&5N9&5D($UA'0M86QI9VXZ(&IU'0M#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I M;F#LG/CQB/D)U2!I;F-O6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,"XU:6X[(&QE='1E'0M2!E;F=A9V5S(&EN('1H M92!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0L(&UA;G5F86-T=7)I;F<@86YD M(&-L:6YI8V%L('1R:6%L'0M86QI9VXZ(&IU M'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@ M;&5T=&5R+7-P86-I;F#LG/CQB/E)E M=F5R2`Q,BP@,C`Q-"P@<'5R&-H86YG92!!9W)E96UE;G0B*2P@1&%N M1')I="!54T$@8V]M<&QE=&5D('1H92!A8W%U:7-I=&EO;B!O9B`Q,#`E(&]F M('1H92!I2`H=&AE("8C.#(R,#M087)E;G0F(S@R M,C$[*2X@4')I;W(@=&\@=&AE(%-H87)E($5X8VAA;F=E('1H97)E('=E#L@=&5X="UA;&EG M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S M-G!T.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R M+7-P86-I;F#LG/B8C,38P.SPO<#X- M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2`O($9O2!I M28C.#(Q-SMS(&)A;&%N M8V4@'!E;G-E'0M86QI9VXZ(&IU M'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@ M;&5T=&5R+7-P86-I;F#LG/CQB/D-A M2!C;VYS:61E2!L:7%U:60@9&5B="!I;G-T M#L@=&5X="UA M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`S-G!T.R!L971T97(M#L@=VAI=&4MF5D+"!U<&]N(&)E:6YG('!L86-E M9"!I;B!S97)V:6-E+B!%>'!E;F1I='5R97,@9F]R(&UA:6YT96YA;F-E(&%N M9"!R97!A:7)S(&%R92!C:&%R9V5D('1O(&5X<&5N65A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M2!A8V-O=6YTF5D('1H92!P871E M;G1S(&]N(&$@#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T M=&5R+7-P86-I;F#LG/B8C,38P.SPO M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6EN9R!A;6]U;G0@;V8@86X@87-S970@;6%Y(&YO="!B92!R M96-O=F5R86)L92X@0VER8W5M2!T:&%N(&YO="!B92!S;VQD(&]R(&1I#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T M=&5R+7-P86-I;F#LG/B8C,38P.SPO M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6EN9R!A;6]U;G0@;V8@86X@87-S970@=&\@97-T:6UA M=&5D('5N9&ES8V]U;G1E9`T*(&9U='5R92!C87-H(&9L;W=S(&5X<&5C=&5D M('1O(&)E(&=E;F5R871E9"!B>2!T:&4@87-S970N($EF('1H92!C87)R>6EN M9R!A;6]U;G0@;V8@86X@87-S970@97AC965D2!T:&4@86UO=6YT(&)Y('=H:6-H('1H M92!C87)R>6EN9R!A;6]U;G0@;V8@=&AE(&%S2!P#L@=&5X M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M28C.#(Q-SMS('-A;&5S(&]F(&ET6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU3L@:6YS=&5A9"P@=&AE(&%M;W5N="!I M2!O;B!T:&4@8F%L86YC92!S:&5E M="!U;G1I;"!S=6-H(%9!5"!I6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M2X@4F5S96%R M8V@@86YD(&1E=F5L;W!M96YT(&-O'0M86QI9VXZ(&IU'0M#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I M;F#LG/CQB/DEN8V]M92!487AE#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P M86-I;F#LG/B8C,38P.SPO<#X-"CQP M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'!A;F1S(&1I2!C871E9V]R>2!M96%S M=7)E9"!A="!F86ER('9A;'5E(&]N(&5I=&AE2X@07,@82!B87-I2P@=VAI M8V@@<')I;W)I=&EZ97,@=&AE(&EN<'5T'0M86QI9VXZ(&IU'0M#L@=&5X="UT M'0M:6YD96YT.B`P<'@[(&QE='1EF4Z(#$P<'0[('=O#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@6QE/3-$)W=I9'1H.B`T.'!X.R!T97AT+6%L M:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,34N,S-P>#LG/B8C,38P.SPO M=&0^#0H\=&0@'0M86QI9VXZ(&IU M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@ M,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P M>#L@;&5T=&5R+7-P86-I;F'0M86QI9VXZ(&IU3L@;&EN92UH96EG:'0Z(#$U+C,S<'@[)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T+S$U+C,S<'@@)W1I;65S(&YE=R!R;VUA;B#L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@ M;&5T=&5R+7-P86-I;F#LG/B8C,38P M.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@,34V-W!X.R!T97AT+71R M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I M;F'0M86QI M9VXZ(&IU3L@;&EN92UH M96EG:'0Z(#$U+C,S<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+S$U M+C,S<'@@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M&EM871E#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M'0M86QI M9VXZ(&IU'0M M65A#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T M97(M#L@=VAI=&4M M2!M86YA9V5M96YT M('1O(&AA=F4@82!M871E#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M2!A;F0@17%U:7!M96YT/&)R/CPO'0M86QI9VXZ(&IU#L@;&5T M=&5R+7-P86-I;F#LG/CQB/DY/5$4@ M,B`F(S@R,3([(%!23U!%4E19($%.1"!%455)4$U%3E0\+V(^/"]P/CQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\ M9F]N="!S='EL93TS1"=F;VYT.B`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`Q,'!T+VYO#L@ M9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS M1"=F;VYT.B`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`Q,'!T+VYO6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXV M,"PV-S`\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M86QI9VXZ(&QE M9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)W!A9&1I M;F6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI M9VXZ(&QE9G0[(&)O#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R M+7-P86-I;F#LG/D1E<')E8VEA=&EO M;B!E>'!E;G-E(&%M;W5N=&5D('1O("0P(&%N9"`D-3(S(&9O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,S9P=#L@;&5T=&5R+7-P86-I;F#LG M/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/D%T($UA2!Y96%R#L@=&5X="UA M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F'0M M:6YD96YT.B`P<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S M.B`Q.R`M=V5B:VET+71E>'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M M6QE M/3-$)V9O;G0M#L@9F]N="US M=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT M.B`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`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA3QB6%B;&4@+2!296QA=&5D(%!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M M'0M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU M'0M6QE/3-$)W=I9'1H M.B`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`@16YT97)P6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M86QI9VXZ M(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O M='1O;2UW:61T:#H@,2XU<'0[(&)O6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D M/CQT9"!S='EL93TS1"=F;VYT.B`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`P,#`[('1E>'0M M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P M86-I;F#LG/B8C,38P.SPO<#X\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/E1H92!F;VQL;W=I;F<@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R M+7-P86-I;F#LG/D]N($9E8G)U87)Y M(#$U+"`R,#$T(&%N9"!-87)C:"`Q."P@,C`Q-"P@1&%N1')I="!$96YM87)K M(')E8V5I=F5D($1+2R`R+#4P,"PP,#`@*"0T-C$L,#@T*2!A;F0@1$M+(#(L M,S`P+#`P,"`H)#0R-"PQ.3@I(&QO86YS("AT:&4@)B,X,C(P.S(P,30@3&]A M;G,F(S@R,C$[*2P@2!O=VYE9"!B>2!A('-H87)E:&]L9&5R(&]F('1H92!#;VUP86YY M("@F(S@R,C`[4&%S96-O)B,X,C(Q.RDN(%1H92`R,#$T($QO86YS('=E2!T:&4@=&5R;7,@;V8@=&AE(#(P,30@3&]A;G,@=V5R92!P87EA8FQE(&]N M($9E8G)U87)Y(#$L(#(P,34@86YD(&-O=6QD(&)E(&5X=&5N9&5D(&%T('1H M92!#;VUP86YY)B,X,C$W.W,@;W!T:6]N(&9O2!E M>&-H86YG92!R871E(&]F($]C=&]B97(@,36QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2!F2P@=VET:"!A(&=O86P@ M;V8@96YS=7)I;F<@9FEN86YC:6YG('5N=&EL(&YE=R!E<75I='D@:7,@:6YV M97-T960@:6X@=&AE($-O;7!A;GDN(%5N9&5R('1H92!L;V%N(&9A8VEL:71Y M($1A;D1R:70@1&5N;6%R:R!H87,@2`Q+"`R,#$T(&%N M9"!A8V-R=65D(&EN=&5R97-T(&%T(#4E('!E2!R97!A:60@=&AE(&QO86X@9F%C:6QI='D@86YD(&EN=&5R M97-T('1H97)E;VXN/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2!E>'1E;F1E9"!T:&4@;6%T=7)I='D@9&%T92!O9B!T M:&4@1$M+(#$L,#`P+#`P,"!L;V%N'0M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU2`Q+"`R,#$U+B!4:&4@;&5T=&5R(&5X<&ER960@;VX@1F5B'0M M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU'0M2!A M(')E;&%T960@<&%R='D@86YD(&%M;W5N=',@861V86YC960@=&\@=&AE(%!A M2X@5&AE("0S."PR,S4@;&]A;B!P87EA8FQE('=A6UE;G0@=&5R;7,N/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2P@=V%S(&%C<75I2!R96-O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L M971T97(M#L@=VAI M=&4M6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T M.R!L971T97(M#L@ M=VAI=&4M'0M M86QI9VXZ(&IU'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M'!E;G-E(&-H87)G960@=&\@;W!E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M2X@5&AE($QE87-E(&-A;&QS(&9O6UE;G1S(&]F($1+2R`Q,"PP,#`@*&%P<')O>&EM871E;'D@)#$L M-32`Q+"`R,#$T+B!4:&4@;&5A2!G:79I;F<@=&AE(&]T:&5R(#,@;6]N=&AS(&YO=&EC92X@5&AE($-O M;7!A;GD@9V%V928C,38P.VYO=&EC92!T97)M:6YA=&EN9R!T:&4@;&5A2`S,2P@,C`Q M-2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T83`P-3-F,E\T,C'0O:'1M;#L@8VAA'0^/'`@'0M86QI9VXZ(&IU#L@;&5T=&5R M+7-P86-I;F#LG/CQB/DY/5$4@-B`F M(S@R,3([($E.0T]-12!405A%4SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P M=#L@;&5T=&5R+7-P86-I;F#LG/B8C M,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2!E<75A;"!T;R!T:&4@97AP96-T M960@9G5T=7)E('1A>"!B96YE9FET(&]R(&5X<&5N"!A M8V-O=6YT:6YG(&%N9"!A;GD@879A:6QA8FQE(&]P97)A=&EN9R!L;W-S(&]R M('1A>"!CF%T:6]N(&]F('1H92!B96YE9FET28C.#(Q-SMS(&9U='5R92!E87)N:6YG6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T M.R!L971T97(M#L@ M=VAI=&4M'0M M86QI9VXZ(&IU'0M2UF;W)W M87)D&EM871E;'D@)#$W M.2PV-C$@9F]R(%4N4RX@1F5D97)A;"!487@@<'5R<&]S97,@=VAI8V@@97AP M:7)E('1H6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M2!F:6QE"!R971U2!A"!E>&%M:6YA=&EO;G,@9F]R('EE87)S('!R M:6]R('1O(#(P,3$@86YD(#(P,#@L(')E2X\+W`^#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T M97(M#L@=VAI=&4M M2!D:69F97)E;F-E"!A M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R M+7-P86-I;F#LG/B8C,38P.SPO<#X- M"CQT86)L92!S='EL93TS1"=W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@ M6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ M(&QE9G0[(&9O;G0M"!O M=F5R(&)O;VL@9&5P&5D(&%S#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[ M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT.B`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`Q,'!T M+VYO6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B M;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[(&9O;G0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M"!U;F-EF4@86YD(&1I2!I;F-O;64@=&%X('5N8V5R=&%I;G1I97,N(%1H92!G=6ED86YC M92!PF%T:6]N(&]F('1H92!T87@@<&]S:71I;VX@:7,@=6YC97)T M86EN+B!4:&4@9FERF5D M(&)AF%T M:6]N(&]F('1H92!B96YE9FET28C.#(Q-SMS(&9U='5R92!E87)N:6YG2!B92!E0T*('=I;&P@;F]T(&=E;F5R871E(&%D97%U M871E(&YE="!P2P@82!V86QU871I;VX@86QL;W=A;F-E('=A M"!A'0M86QI9VXZ(&IU M'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,S9P=#L@;&5T=&5R+7-P86-I;F#LG M/D$@"!E>'!E;G-E(&%T('1H M92!F961E2!R871E('1O(&EN8V]M92!T87@@97AP96YS M92!A="!T:&4@0V]M<&%N>28C.#(Q-SMS(&5F9F5C=&EV92!R871E(&ES(&%S M(&9O;&QO=W,@870@36%R8V@@,S$L(#(P,34@86YD(#(P,30Z/"]P/@T*/'`@ M'0M86QI9VXZ(&IU'0M:6YD96YT.B`P M<'@[(&QE='1E#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B M:VET+71E>'0M6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C M;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[ M)SY#;VUP=71E9"!487@@870@17AP96-T960@4W1A='5T;W)Y(%)A=&4\+W1D M/@T*/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0M'0M86QI9VXZ(&QE9G0[(&9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E M=&-H.B!N;W)M86P[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT.B`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`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!B;W)D97(M M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE6QE.B!D;W5B;&4[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M86QI9VXZ(&IU'0M#L@ M=&5X="UT'0M:6YD96YT.B`P<'@[(&QE='1E M#L@8F]R9&5R M+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M M6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[ M)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE"!%>'!E;G-E/"]B/CPO9F]N=#X\+W1D/@T*/'1D M('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[ M)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI M9VXZ(&QE9G0[(&)O6QE.B!S M;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXM/"]T9#X-"CQT9"!S='EL M93TS1"=F;VYT.B`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`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT M.B`S-G!T.R!L971T97(M#L@=VAI=&4M"!E>'!E;G-E("\@*&)E;F5F:70I(')E M2!T:6UI;F<@9&EF9F5R96YC97,@8F5T=V5E;B!T87@@86YD(&9I;F%N8VEA M;"!S=&%T96UE;G0@:6YC;VUE+CPO<#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S M-G!T.R!L971T97(M#L@=VAI=&4M'0M6QE/3-$)W=I9'1H.B`Q-38W<'@[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M M3H@)W1I;65S(&YE=R!R;VUA M;B6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UEF4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE6QE/3-$ M)V9O;G0M6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C M;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)W9E#L@=&5X="UA;&EG;CH@ M;&5F=#L@=&5X="UI;F1E;G0Z("TW+C5P=#L@<&%D9&EN9RUL969T.B`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`Q,'!T+VYO'0M86QI9VXZ(&IU M'0M'0M86QI9VXZ(&IU'0M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M83`P-3-F,E\T,C'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@ M'0M86QI9VXZ(&IU#LG/CQB/DY/5$4@."`F(S@R,3([(%-43T-+2$],1$524R8C.#(Q M-SL@15%52519/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI9VXZ(&IU M'0M2!H87,@,3`P+#`P,"PP,#`@875T:&]R:7IE9"!S:&%R M97,@;V8@0V]M;6]N('-T;V-K("0P+C`P,#$N($%S(&]F($UA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M2!R96-E:79E9"8C,38P.SQF;VYT('-T>6QE/3-$)V)A8VMG6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`S.2XV<'0[(&QE='1E'0M#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,SDN-G!T.R!L971T97(M#L@=VAI=&4M6QE/3-$)V)A M8VMG#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I M;F#LG/B8C,38P.SPO<#X-"CQP('-T M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2`Q,BP@ M,C`Q-"P@:6X@86-C;W)D86YC92!W:71H('1H92!T97)M&-H86YG92!!9W)E96UE;G0B*2P@=V4@8V]M<&QE=&5D('1H92!A8W%U M:7-I=&EO;B!O9B`Q,#`E(&]F('1H92!I&-H86YG928C.#(R,3LI M(&%N9"!A&-H86YG92`H M,2D@=&AE('-O;&4@&5C=71I=F4@;6%N86=E;65N M="!O9B!$86Y$&5C=71I=F4@;6%N86=E M;65N="!O9B!$86Y$6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M2`Q,2P@,C`Q-"`Q+#0P,"PP,#`@86YD(#0P M+#`P,"!C;VUM;VX@2!T:&4@0V]M M<&%N>2!P'0M86QI M9VXZ(&IU'0M M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,S9P=#L@;&5T=&5R+7-P86-I;F#LG M/D]N($9E8G)U87)Y(#$R+"`R,#$T+"!U<&]N('1H92!C;&]S:6YG(&]F('1H M92!3:&%R92!%>&-H86YG92P@=&AE($-O;7!A;GD@86YD('1H92!I=',@;6%J M;W)I='D@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A'0M86QI9VXZ(&IU'0M#L@=&5X M="UA;&EG;CH@8V5N=&5R.R!C;VQO'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2!S=6-H(&1I=FED96YD2!D96-L87)E(&]U="!O9B!F=6YD#L@=&5X="UA;&EG;CH@ M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T M.R!L971T97(M#L@ M=VAI=&4M2P@869T97(@ M<&%Y;65N="!O9B!A;&P@;V8@;W5R(&1E8G1S(&%N9"!L:6%B:6QI=&EE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@=VAI=&4M M'0M86QI9VXZ M(&IU'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P M=#L@;&5T=&5R+7-P86-I;F#LG/CQB M/CQI/E-H87)E&-H86YG92!A9W)E96UE;G0@8V5R=&%I;B!S:&%R96AO;&1E M2!S=6-H($YO;BU#;VYS M96YT:6YG(%-H87)E:&]L9&5R6EN9R!F:6YA;F-I86P@#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I M;F#LG/CQB/CQI/B8C,38P.SPO:3X\ M+V(^/"]P/@T*/'`@'0M M86QI9VXZ(&IU'0M2!(;W-P:71A;"!)4D-#4R`F(S@R,C`[4V%N M($UA2!G;V%L(&]F('1H92!S='5D>2!I6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M'0M86QI M9VXZ(&IU'0M M6QE/3-$)V)A8VMG28C.#(Q M-SMS($U#5BX@5&AI6QE/3-$)V)A8VMG2!O;B!A(&-O=6YT2!B87-I M65A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M2!O=F5R(&)I;W!H87)M86-E=71I8V%L('!R;V1U8W1S("AD2!T:&4@ M1D1!('=I=&@@&EC:71Y(&%N9"!S:61E(&5F9F5C=',N($9$02!A M<'!R;W9A;"!F;W(@=&AE('5S92!O9B!N97<@8FEO('!R;V1U8W1S("AW:&EC M:"!C86X@;F5V97(@8F4@87-S=7)E9"D@2!T:&4@F5D('1O('!R;V1U8V4@=&AE('!R;V1U8W0N($%C M8V]R9&EN9VQY+"!T:&4@0V]M<&%N>28C.#(Q-SMS(&-E;&P@2!T:&4@1D1!('5N9&5R('1H92!&961E#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M2!C;W5L9"!H879E(&$@;6%T97)I M86P@861V97)S92!E9F9E8W0@;VX@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M'0M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU'0M#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/CQB/CQI/D-O;G1I;F=E;F-I97,F(S$V,#L\+VD^)B,X,C$R M.R8C,38P.SPO8CY4:&4@0V]M<&%N>2!I2!P#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P M=#L@;&5T=&5R+7-P86-I;F#LG/B8C M,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M2X@3F]R=&AE2!I;B!C;VYN96-T M:6]N('=I=&@@<&QA;FYI;F<@86YD('-T2X@26X@,C`Q-"!C;VYS=6QT86YC>2!E>'!E M;G-E2!E>'!E;G-E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!46QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0M#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[ M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T M=&5R+7-P86-I;F#LG/D1U6%B M;&4@=VET:"!S:&%R96AO;&1E#L@=&5X="UA M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,S9P=#L@;&5T=&5R+7-P86-I;F#LG M/D]N($UA2X\+W`^/'`@'0M86QI9VXZ(&IU'0M'0M86QI M9VXZ(&IU'0M M6%B;&4@=&\@=&AE(&9I M2X\+W`^/'`@'0M86QI9VXZ(&IU'0M'0M86QI9VXZ(&IU'0M2!A('-H87)E M:&]L9&5R(&]F('1H92!#;VUP86YY+B!.;W)T:&5R;B!":6]T96-H($9U;F0@ M4T%23"!P2!E>'!E;G-E9"`D,C0P+#`P,"!A;F0@)#`@=6YD97(@=&AE M(&%G3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T83`P-3-F,E\T,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R#L@=&5X="UA;&EG M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI9VXZ(&IU M'0M28C.#(Q-SMS(&UA;F%G96UE;G0@ M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S.2XV<'0[(&QE='1E'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/D]N($%P2!A;F0@ M;VX@36%Y(#%S="P@=&AE($)O87)D(&%P<&]I;G1E9"!,;VYE($1E9VX@87,@ M=&AE($-H:65F($9I;F%N8VEA;"!/9F9I8V5R(&]F('1H92!#;VUP86YY+CPO M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[ M(&QE='1E'0M#L@=&5X="UA M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#L@;&5T=&5R+7-P86-I;F#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S.2XV M<'0[(&QE='1E'0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE#L@=&5X="UA;&EG;CH@:G5S M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T M97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/D]N($%P2!E M;G1E6%D:"!0:&%R;6$@:6X@4V%U9&D@07)A8FEA('1O('!R;VUO=&4@8V]O<&5R M871I;VX@:6X@=&AE(&UA;G5F86-T=7)I;F<@86YD(&UA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T'0^/&1I=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L M971T97(M#L@=VAI M=&4M28C.#(R,3LL("8C.#(R M,#MW928C.#(R,3LL("8C.#(R,#MU2`Q."P@,C`Q,2!A'0M86QI9VXZ(&IU M'0M#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@ M;&5T=&5R+7-P86-I;F#LG/CPO<#X- M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/D1A;D1R:70@0FEO5&5C:"!!+U,L(&$@1&%N:7-H M($-O2X\+W`^#0H\+V1I=CX\&ES=&EN9R!S:&%R96AO;&1E&-H86YG92!A;F0@82!F=71U&-H86YG M92PF(S$V,#L\9F]N="!S='EL93TS1"=F;VYT.B`Q,RXS,W!X+VYO'0M:6YD96YT.B`T.'!X.R!L971T97(M#L@=VAI=&4M"]N M;W)M86P@)W1I;65S(&YE=R!R;VUA;B3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@-#AP>#L@;&5T=&5R+7-P86-I;F#LG/BP@86YD(&1E96UE9"!I6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I M;F#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE2`O($9O2!O9B!$86Y$28C.#(Q-SMS(')E<&]R=&EN9R!C M=7)R96YC>2!I28C.#(Q M-SMS(&)A;&%N8V4@'!E;G-E2!O9B!T:')E92!M;VYT:',@;W(@;&5S2!H860@8F%L86YC M97,@:&5L9"!I;B!F:6YA;F-I86P@:6YS=&ET=71I;VYS(&EN('1H92!5;FET M960@4W1A=&5S(&EN(&5X8V5S2!I;G-U M2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\9&EV/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UEF5D+"!U<&]N(&)E:6YG('!L86-E9"!I;B!S97)V:6-E+B!%>'!E;F1I='5R M97,@9F]R(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S(&%R92!C:&%R9V5D('1O M(&5X<&5N65A'0^/&1I M=CX\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@ M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M65A MF5D(&-O'!E;G-E+CPO9F]N=#X\+W`^ M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P<'@[(&QE='1E'0MF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T'0M86QI9VXZ(&IU2!B969O'0M86QI9VXZ(&IU#L@=VAI M=&4MF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I M;F#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M6EN9R!A;6]U;G0@;V8@86X@87-S M970@=&\@97-T:6UA=&5D('5N9&ES8V]U;G1E9"!F=71U'!E8W1E9"!T;R!B92!G96YE2!W:&EC:"!T:&4@8V%R&-E M961S('1H92!F86ER('9A;'5E(&]F('1H92!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@:G5S=&EF M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT M+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M2!O=&AE&-H86YG92!#;VUM:7-S:6]N(%-T869F($%C8V]U;G1I;F<@0G5L;&5T:6X@ M3F\N(#$P,2P@)B,X,C(P.U)E=F5N=64@4F5C;V=N:71I;VX@:6X@1FEN86YC M:6%L(%-T871E;65N=',F(S@R,C$[("A304(@,3`Q*2P@86YD($9!4T(@05-# M(#8P-2!2979E;G5E(%)E8V]G;FET:6]N+B!4:&4@0V]M<&%N>2!R96-O9VYI M>F5S(')E=F5N=64@=VAE;B!R:6=H=',@86YD(')IF5D+"!A;F0@8V]L M;&5C=&EO;G,@;V8@2!A6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[ M(&QE='1E'0M"`F(S@R,3([/"]B/B8C,38P.TEN($1E;FUA"`H)B,X,C(P.U9!5"8C.#(R,3LI(&]F(#(U)2!O9B!T M:&4@:6YV;VEC92!A;6]U;G0@:7,@8V]L;&5C=&5D(&EN(')E2!E>'!E;G-E2!F;'5C='5A=&4@2!F&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N M=#H@,"XU:6X[(&QE='1E'0M'0M86QI9VXZ(&IU#L@=VAI=&4M2!S=&]C:R!O<'1I;VYS('1H870@:&%V92!B965N(&=R86YT960@8G5T M(&AA=F4@;F]T(&)E96X@97AE'0^/&1I=CX\<"!S='EL93TS1"=F;VYT.B`Q M,'!T+VYO#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M#L@=VAI=&4MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F#LG/CQF;VYT('-T>6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE2!A8V-O=6YT2!I;B!A;B!O'0M86QI9VXZ(&IU#L@ M=VAI=&4MF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T#L@;&5T=&5R+7-P86-I;F#LG(&-E;&QS<&%C:6YG/3-$,"!C M96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O,34N,S-P>"`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@ M9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T+VYOF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z M(#$P<'0O,34N,S-P>"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE#L@8V]L;W(Z(",P,#`P,#`[('1E M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E M'0MF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T M97(M#L@8F]R9&5R M+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R!F;VYT+7-I>F4M861J M=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O,34N,S-P>"`G M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E#L@ M=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@ M9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q M,'!T+VYOF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'0M M86QI9VXZ(&IU#L@8V]L;W(Z(",P M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU M:6X[(&QE='1E'0MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,'!X.R!L971T97(M#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R!F;VYT M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O M,34N,S-P>"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="US:7IE+6%D:G5S M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS M1"=F;VYT.B`Q,'!T+VYOF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'0M86QI9VXZ(&IUF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'0M86QI9VXZ(&IU#L@=VAI=&4MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`P+C5I;CL@ M;&5T=&5R+7-P86-I;F6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE#LG/CQF;VYT('-T>6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA;&EG M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N M;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E'0M M'!E;G-E6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD M96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M7-I2!M=7-T('!E2!A9&]P M=&EO;B!I2!I;7!A8W0@ M;VX@;W5R(&-O;G-O;&ED871E9"!F:6YA;F-I86P@#L@;&5T M=&5R+7-P86-I;F#LG/B8C,38P.SPO M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@ M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE M.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P86-I;F#LG/D]T:&5R(')E8V5N="!A8V-O=6YT:6YG('!R;VYO M=6YC96UE;G1S(&ES2!T:&4@1D%30B!D:60@;F]T(&]R(&%R92!N M;W0@8F5L:65V960@8GD@;6%N86=E;65N="!T;R!H879E(&$@;6%T97)I86P@ M:6UP86-T(&]N('1H92!#;VUP86YY)W,@<')E'0^/&1I=CX\<"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@ M,"XU:6X[(&QE='1E'0M7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!A;F0@17%U:7!M96YT("A486)L97,I/&)R M/CPO'0^/'`@'0M6QE/3-$)W=I9'1H.B`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`Q M,'!T+VYO6QE.B!S;VQI9#L@9F]N M="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F M;VYT.B`Q,'!T+VYO6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXH,C8Y M+#0Y,SPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'1A8FQE('-T>6QE M/3-$)W=I9'1H.B`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`P-3-F,E\T,C'0O:'1M;#L@ M8VAA6%B;&4@+2!296QA=&5D(%!A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6%B;&4@86YD(')E;&%T960@<&%R=&EE'0^/'`@'0M86QI9VXZ(&IU'0M6QE/3-$)W=I9'1H.B`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`@16YT97)P6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXT,BPW-3,\+W1D M/CQT9"!S='EL93TS1"=F;VYT.B`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`^/'1R('-T>6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE#L@=&5X="UA;&EG;CH@'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)W9E6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI M9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T6QE M.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXM/"]T9#X\=&0@F4Z(#$P<'0[ M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[('!A9&1I;F3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T83`P-3-F,E\T,C'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`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`P M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@ M;&5T=&5R+7-P86-I;F#LG/B8C,38P M.SPO<#X\'0^/'`@'0M86QI9VXZ(&IU'0M6QE/3-$)W=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M3H@)W1I;65S(&YE=R!R;VUA;B6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O M;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[ M)SY#;VUP=71E9"!487@@870@17AP96-T960@4W1A='5T;W)Y(%)A=&4\+W1D M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@9F]N="US=')E=&-H M.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M M86P[)SXD/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M#L@9F]N="US=')E=&-H.B!N M;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`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`@'0M86QI9VXZ(&IU'0M6QE/3-$)W=I9'1H.B`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`Q,'!T.R<^)B,Q-C`[/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L M("=T:6UE'0M86QI9VXZ M(')I9VAT.R!F;VYT+7-T6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI9VXZ(')I9VAT M.R!F;VYT+7-T&-E6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O M;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0M#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO#L@=&5X M="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\ M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO'0M86QI M9VXZ(')I9VAT.R!F;VYT+7-T'0M86QI9VXZ M(&QE9G0[(&9O;G0M6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE#L@=&5X="UA M;&EG;CH@#L@=&5X="UA;&EG M;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXI/"]T9#X\+W1R/CQT M6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M'0M86QI9VXZ(&QE9G0[ M(&)O6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE.B!S;VQI M9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXQ,#`L,#`P/"]T9#X\=&0@6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T M:6UE7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M:6YD96YT.B`S-G!T.R!L971T97(M#L@=VAI=&4M#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E6QE/3-$)W9E M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-RXU<'0[('!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P M<'0O;F]R;6%L("=T:6UE6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0Z(#$P<'0O;F]R M;6%L("=T:6UE#L@9F]N="US M=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT M.B`Q,'!T+VYO#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H M.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T M+VYO'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-T6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!F;VYT M+7-T6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&9O;G0M6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M M-RXU<'0[('!A9&1I;F6QE.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O6QE/3-$ M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P=#L@ M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!P861D:6YG+6QE9G0Z(#$P<'0[(&9O M;G0M6QE M.B!S;VQI9#L@9F]N="US=')E=&-H.B!N;W)M86P[)SXY+#4S,RPR.3`\+W1D M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO6QE M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE'0M86QI9VXZ(&QE9G0[(&)O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^)FYB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)FYB'0^)FYB'0^)FYB'0^)FYB'0^)FYB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S"!P97)C96YT86=E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\"!P M86ED('1O($1A;FES:"!A;F0@154@=F5N9&]R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A497AT M=6%L*3PO'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&-H86YG92!A9W)E96UE;G0@3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&-H86YG92!A9W)E96UE;G0@86-Q=6ES M:71I;VX@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#X@,C8Y+#0Y,SQS<&%N/CPO2!A;F0@17%U:7!M96YT/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\&EM=6T@6TUE;6)E2P@4&QA;G0@ M86YD($5Q=6EP;65N="!;3&EN92!)=&5M65A M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^-"!Y96%R65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$65A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T83`P-3-F,E\T,C'0O:'1M M;#L@8VAA3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\T83`P-3-F,E\T,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'1U86PI M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S M/3-$=&@@8V]LF%T:6]N(&5X<&5N'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\T83`P-3-F,E\T,C'0O:'1M;#L@8VAA6%B;&4@+2!296QA=&5D(%!A6%B;&5S("T@ M4F5L871E9"!087)T>2!,;VYG(%1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6%B;&4@+2!296QA=&5D(%!A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$6%B;&4@+2!296QA=&5D(%!A2!4'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2`H1&5T86EL'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYB'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA2`H M1&5T86EL'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S2!$871E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\2!E>'1E;F1E9"!M871U2!D871E(&]F('1H92!$2TL@,2PP,#`L M,#`P(&QO86YS('=I=&@@4W5N92!/;'-E;B!F2`Q+"`R,#$T('1O M(#$T(&1A>7,@869T97(@=&AE(&-O;7!L971I;VX@;V8@=&AE(&-O;G1E;7!L M871E9"!S=&]C:R!O9F9E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6UE;G1S(&9O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-E&-E"!!'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!296-O;F-I;&EA=&EO;B!%>'!E;G-E($)E;F5F:70\+W-T2!2871E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M/B0@*#(W-RPV-37!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA"!%>'!E;G-E/"]S=')O;F<^/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\"!%>'!E;G-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&-E M2!F;W)W87)D"!%>'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\T83`P-3-F,E\T,C'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T83`P-3-F,E\T,C'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$F5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H86YG92!A9W)E96UE M;G0@=&\@'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H86YG M92!A9W)E96UE;G0@=&\@'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&-H86YG92!A9W)E96UE M;G0@86-Q=6ES:71I;VX@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&-H86YG92!A9W)E96UE;G0@=&\@'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!;365M8F5R73PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&-H86YG92!A9W)E96UE;G0@86-Q=6ES M:71I;VX@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`@>65A'0^,3@P(&1A>7,\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!4'1U86PI/"]S=')O;F<^/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7S1A,#`U,V8R7S0R =-S=?-#@W,5\X-&,U7S(Q,C1E-SEA.&)F82TM#0H` ` end XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9

Notes Payable - Related Party (Details) (USD $)

Mar. 31, 2015

Dec. 31, 2014

Related Party Transaction [Line Items]

Notes Payable - Related Party $ 99,305 $ 99,951

Less Current Maturities (99,305)us-gaap_LongTermDebtCurrent (99,351)us-gaap_LongTermDebtCurrent

Note Payables - Related Party Long Term

Non Interest Bearing Loan Payable Sunrise Financial Group Inc [Member]

Related Party Transaction [Line Items]

Notes Payable - Related Party 38,235 38,235

Note Payable ML Group [Member]

Related Party Transaction [Line Items]

Notes Payable - Related Party 16,777 18,963,000

6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC [Member]

Related Party Transaction [Line Items]

Notes Payable - Related Party $ 44,293 $ 42,753

X

- Definition

Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NotePayableMlGroupMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9

Definite Life Intangible Assets (Details Textual) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Definite Life Intangible Assets (Textual)

Finite-Lived Intangible Assets, Net $ 161,062us-gaap_FiniteLivedIntangibleAssetsNet $ 186,414us-gaap_FiniteLivedIntangibleAssetsNet

Amortization expense $ 4,055us-gaap_AdjustmentForAmortization $ 6,794us-gaap_AdjustmentForAmortization

X

- Details

Name: pmhs_DefiniteLifeIntangibleAssetsTextualAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 22 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9

Notes Payable - Related Party (Details 1) (USD $)

Mar. 31, 2015

Notes Payable - Related Party [Abstract]

2015 $ 99,305

2016

2017

2018

2019

Thereafter

Total long term debt $ 99,305us-gaap_LongTermDebt

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.12-04.(a))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.12-04.(a))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.12-04.(a))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.12-04.(a))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.12-04.(a))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 3

-Subparagraph (SX 210.12-04.(a))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9

Notes Payable - Related Party (Details Textual)
0 Months Ended 3 Months Ended

Mar. 31, 2015

USD ($)

Dec. 02, 2013

Sune Olsen Holding Aps [Member]

Loan One [Member]

USD ($)

Dec. 02, 2013

Sune Olsen Holding Aps [Member]

Loan One [Member]

DKK

Nov. 20, 2013

Sune Olsen Holding Aps [Member]

Loan One [Member]

USD ($)

Nov. 20, 2013

Sune Olsen Holding Aps [Member]

Loan One [Member]

DKK

Nov. 11, 2013

Sune Olsen Holding Aps [Member]

Loan One [Member]

USD ($)

Nov. 11, 2013

Sune Olsen Holding Aps [Member]

Loan One [Member]

DKK

Dec. 20, 2013

Sune Olsen Holding Aps [Member]

Loan Two [Member]

USD ($)

Dec. 20, 2013

Sune Olsen Holding Aps [Member]

Loan Two [Member]

DKK

Mar. 18, 2014

Paseco Aps [Member]

Loan [Member]

USD ($)

Mar. 18, 2014

Paseco Aps [Member]

Loan [Member]

DKK

Feb. 15, 2014

Paseco Aps [Member]

Loan [Member]

USD ($)

Feb. 15, 2014

Paseco Aps [Member]

Loan [Member]

DKK

Mar. 31, 2014

Paseco Aps [Member]

Loan Three [Member]

DKK

Mar. 31, 2015

Nlbdit Two Zero One Zero Enterprises, Llc [Member]

Loan Ten [Member]

USD ($)

Mar. 31, 2014

Nlbdit Two Zero One Zero Enterprises, Llc [Member]

Loan Ten [Member]

USD ($)

Related Party Transaction [Line Items]

Unsecured loan $ 38,235us-gaap_UnsecuredDebt $ 165,990 900,000 $ 74,696 405,000 $ 276,651 1,500,000 $ 184,434 1,000,000 $ 424,198 2,300,000 $ 461,084 2,500,000 2,000,000 $ 44,293 $ 41,945

Accrued interest in percentage 5.00% 5.00% 5.00% 5.00%

Interest expense, borrowing loans 579 579

Increased interest percentage 7.00% 7.00% 7.00% 7.00% 6.00%

Debt Instrument, Maturity Date Feb. 01, 2015

Extended maturity date, Description The Company extended maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit Biotech USA, Inc. or February 1, 2015. The Company extended maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit Biotech USA, Inc. or February 1, 2015.

Loans payable $ 38,235us-gaap_LoansPayable

X

- Definition

Accrued interest.

+ References

No definition available.

+ Details

Name: pmhs_AccruedInterestInPercentage

Namespace Prefix: pmhs_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDateDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Interest expense incurred during the reporting period on other short-term borrowings.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.7)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpenseOtherShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LoansPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Article 5

-Subsection 19, 20, 22

+ Details

Name: us-gaap_UnsecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 24 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

Property and Equipment
3 Months Ended

Mar. 31, 2015

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT
NOTE 2 — PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at March 31, 2015 and December 31, 2014:

Useful Life March 31,
2015 December 31,
2014
Lab equipment and instruments 4-6 $ 208,823 $ 208,823
Computer equipment 4-6 60,670 60,670
269,493 269,493
Less Accumulated Depreciation (269,493 ) (269,493 )
Net Property and Equipment $ - $ -

Depreciation expense amounted to $0 and $523 for the three month period ended March 31, 2015 and 2014, respectively.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9

Leases (Details)
3 Months Ended 1 Months Ended

Mar. 31, 2015

USD ($)

Mar. 31, 2014

USD ($)

Mar. 31, 2015

Lab space [Member]

USD ($)

Mar. 31, 2015

Lab space [Member]

DKK

Mar. 27, 2014

Office space [Member]

USD ($)

Mar. 27, 2014

Office space [Member]

DKK

Jul. 01, 2014

Office space [Member]

Subsequent Event [Member]

USD ($)

Jul. 01, 2014

Office space [Member]

Subsequent Event [Member]

DKK

Operating Leased Assets [Line Items]

Rental payments for Operating Leases $ 11,918us-gaap_OperatingLeasesRentExpenseNet $ 7,255us-gaap_OperatingLeasesRentExpenseNet $ 906 6,000 $ 1,579 10,000 $ 3,393 20,000

X

- Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 26 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9

Related Party Transactions (Details)
3 Months Ended

Mar. 31, 2015

USD ($)

Mar. 31, 2014

USD ($)

Mar. 31, 2015

DKK

Dec. 31, 2014

USD ($)

Mar. 31, 2014

DKK

Related Party Transactions (Textual)

Related party transactions amount $ 3,019 $ 0 60,000 0

Legal expense 60,381us-gaap_LegalFees 100,912us-gaap_LegalFees

Payable to related parties 200,857 212,438

Balances held in trust $ 0us-gaap_AssetsHeldInTrust $ 0us-gaap_AssetsHeldInTrust

X

- Details

Name: pmhs_RelatedPartyTransactionsTextualAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(b))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_AssetsHeldInTrust

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(3),(4))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LegalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_RelatedPartyTransactionDueFromToRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 27 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Balance Sheets (USD $)

Mar. 31, 2015

Dec. 31, 2014

CURRENT ASSETS:

Cash $ 3,434,935 $ 3,008,831

Cash held in escrow 2,029,502us-gaap_EscrowDeposit

Other Receivables 41,120 8,016

Total Current Assets 3,476,055us-gaap_AssetsCurrent 5,046,349us-gaap_AssetsCurrent

PROPERTY AND EQUIPMENT, Net accumulated Depreciation

OTHER ASSETS

Definite Life Intangible Assets 161,062us-gaap_FiniteLivedIntangibleAssetsNet 186,414us-gaap_FiniteLivedIntangibleAssetsNet

Deposits 6,326us-gaap_DepositsAssetsNoncurrent 7,146us-gaap_DepositsAssetsNoncurrent

Total Other Assets 167,388us-gaap_AssetsNoncurrent 193,560us-gaap_AssetsNoncurrent

TOTAL ASSETS 3,643,443us-gaap_Assets 5,239,909us-gaap_Assets

CURRENT LIABILITIES:

Notes Payable - Related Party 99,305 99,951

Accounts Payable 622,187us-gaap_AccountsPayableCurrent 711,449us-gaap_AccountsPayableCurrent

Accounts Payable - Related Party 200,857 212,438

Accrued Expenses 49,619us-gaap_AccruedLiabilitiesCurrent 733,826us-gaap_AccruedLiabilitiesCurrent

Total Current Liabilities 971,968us-gaap_LiabilitiesCurrent 1,757,664us-gaap_LiabilitiesCurrent

Total Liabilities 971,968us-gaap_Liabilities 1,757,664us-gaap_Liabilities

STOCKHOLDER'S EQUITY:

Preferred stock, $.0001 par value; 10,000,000 shares authorized; none issued and outstanding

Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at March 31, 2015 and December 31, 2014, respectively 953us-gaap_CommonStockValue 953us-gaap_CommonStockValue

Additional paid-in capital 25,098,050us-gaap_AdditionalPaidInCapital 25,098,050us-gaap_AdditionalPaidInCapital

Accumulated Deficit (23,145,352) (21,892,007)

Other Comprehensive Income, net 717,824 275,249

Total Stockholder's Equity 2,671,475us-gaap_StockholdersEquity 3,482,245us-gaap_StockholdersEquity

TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY $ 3,643,443 $ 5,239,909

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.10-17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_EscrowDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Statement of Cash Flows (Unaudited) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Statement of Cash Flows [Abstract]

NET (LOSS) $ (1,253,345)us-gaap_NetIncomeLoss $ (426,054)us-gaap_NetIncomeLoss

ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:

Depreciation and Amortization 25,352us-gaap_DepreciationAndAmortization 6,794us-gaap_DepreciationAndAmortization

Accrued Interest on Notes Payable - Related Party 1,540

CHANGES IN ASSETS AND LIABILITIES:

(Increase) Decrease in Other Receivables (33,104) (44,256)

(Increase) Decrease in Prepaid Expenses/Deposits 820 8,047

Increase (Decrease) in Accounts Payable (89,262) 19,674

Increase (Decrease) in Accounts Payable - Related Party (11,581)

Increase (Decrease) in Accrued Expenses (684,207) (1,951)

Total Adjustments (790,442) (11,692)

NET CASH USED IN OPERATING ACTIVITIES (2,043,787) (437,746)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of Equipment (41,498)

Net (Increase) Decrease in Cash Held in Escrow 2,029,502 (346,501)

Purchase of Intangible Assets (7,907)

NET CASH USED BY INVESTING ACTIVITIES 2,029,502 (395,906)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from Notes Payable - Related Party 865,976us-gaap_ProceedsFromNotesPayable

NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES 865,976

Gain (Loss) on Currency Translation 440,389 3,354

NET INCREASE (DECREASE) IN CASH 426,104 35,678

CASH, BEGINNING OF PERIOD 3,008,831 18,794

CASH, END OF PERIOD 3,434,935 54,472

Cash paid during the periods for:

Interest

Income Taxes

X

- Details

Name: pmhs_CashPaidDuringPeriodsForAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services and deposits that bring economic benefits for future periods.

+ References

No definition available.

+ Details

Name: pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net increase decrease in Cash held in escrow.

+ References

No definition available.

+ Details

Name: pmhs_NetIncreaseDecreaseInCashHeldInEscrow

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from a borrowing supported by a written promise to pay an obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementOfCashFlowsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes (Details 2) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Current Tax Expense

Danish Income Tax

Total Current Tax Expense

Deferred Income Tax Expense (Benefit)

Excess of Tax over Book Depreciation Fixed Assets

Excess of Tax over Book Depreciation Patents

Net Operating Loss Carry forwards (179,661) (100,000)

Change in the Valuation allowance 179,661 100,000

Total Deferred Tax Expense

X

- Definition

Excess Tax Benefit Over Depreciation Fixed Assets.

+ References

No definition available.

+ Details

Name: pmhs_ExcessTaxBenefitOverDepreciationFixedAssets

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Excess Tax Benefit Over Depreciation Patents.

+ References

No definition available.

+ Details

Name: pmhs_ExcessTaxBenefitOverDepreciationPatents

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income Tax Expense Benefit Operating Loss Carryforwards.

+ References

No definition available.

+ Details

Name: pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Valuation Allowance Income Tax Expense Benefit Change in Amount.

+ References

No definition available.

+ Details

Name: pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes (Tables)
3 Months Ended

Mar. 31, 2015

Income Taxes [Abstract]

Summary of deferred tax asset (liabilities)
March 31,
2015 December 31,
2014
Excess of Tax over book depreciation Fixed assets $ 12,711 $ 12,711
Excess of Tax over book depreciation Patents 52,041 52,041
Net Operating Loss Carry forward 2,416,813 2,380,106
Valuation Allowance (2,481,565 ) (2,444,858 )
Total Deferred Tax Asset (Liabilities) $ - $ -

Schedule of reconciliation of income tax expense at the federal statutory rate
March 31, 2015 March 31, 2014
Computed Tax at Expected Statutory Rate $ (277,657 ) $ (144,858 )
Non-US Income Taxed at Different Rates 97,996 44,858
Non-Deductable expenses - -
Valuation allowance 179,661 100,000
Income Tax Expense $ - $ -

Schedule of components of income tax expense (benefit) from continuing operations
2015 2014
Current Tax Expense
Danish Income Tax $ - $ -
Total Current Tax Expense - -
Deferred Income Tax Expense (Benefit)
Excess of Tax over Book Depreciation Fixed Assets - -
Excess of Tax over Book Depreciation Patents - -
Net Operating Loss Carry forwards (179,661 ) (100,000 )
Change in the Valuation allowance 179,661 100,000
Total Deferred Tax Expense $ - $ -

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes (Details Textual) (USD $)
3 Months Ended

Mar. 31, 2015

Income Taxes (Textual)

Net operating loss carryforwards expiration period Through 2034

Danish Tax [Member]

Income Taxes (Textual)

Net operating loss carry forwards 2,416,813

U.S. Federal Tax [Member]

Income Taxes (Textual)

Net operating loss carry forwards 179,661

X

- Details

Name: pmhs_IncomeTaxTextualAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.

+ References

No definition available.

+ Details

Name: pmhs_OperatingLossCarryforwardExpirationDate

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=pmhs_DanishTaxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=pmhs_U.S.FederalTaxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies (Details) (USD $)
3 Months Ended 0 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Feb. 12, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 18, 2011

Summary of Significant Accounting Policies (Textual)

Common stock, Par value $ 0.0001 $ 0.0001

Shares of parent common stock outstanding

Common Stock reserved for issuance 185,053

Balances held in financial institutions $ 3,073,967us-gaap_CashFDICInsuredAmount $ 2,508,759us-gaap_CashFDICInsuredAmount

Value added tax percentage 25.00%pmhs_ValueAddedTaxPercentage

Value added tax paid to Danish and EU vendors 25.00%pmhs_ValueAddedTaxPaidToVendors

Research and development expense $ 151,813us-gaap_ResearchAndDevelopmentExpense

Owned subsidiary percentage 96.92%

Parent Company [Member]

Summary of Significant Accounting Policies (Textual)

Share exchange agreement acquisition percentage 97.00%

Common stock, Par value $ 0.0001

Common Stock reserved for issuance 185,053

Common Stock [Member]

Summary of Significant Accounting Policies (Textual)

Shares prior to share exchange agreement 5,000,000

Share exchange agreement number of share cancellation 4,400,000

Common shares issued for legal and consulting services 1,440,000

Share exchange agreement shares held by consenting shareholders of company 1.498842

Shares of parent common stock outstanding 8,185,100 6,000,000 6,000,000 5,318,151

Common Stock [Member] | Parent Company [Member]

Summary of Significant Accounting Policies (Textual)

Share exchange agreement acquisition percentage 100.00%

Share exchange agreement shares issued to parent company 6,000,000

Shares of parent common stock outstanding 8,040,000

X

- Definition

Share exchange agreement acquisition percentage.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementAcquisitionPercentage

Namespace Prefix: pmhs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Share exchange agreement common share in connection with acquisition and offering shares.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Common stock shares prior to the share exchange agreement.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementCommonStockShares

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share exchange agreement number of share cancellation.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementNumberOfShareCancellation

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share Exchange Agreement Shares held by consnting shareholders of comany.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share Exchange Agreement Shares Issued To Parent Company.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementSharesIssuedToParentCompany

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Value added tax paid to vendors.

+ References

No definition available.

+ Details

Name: pmhs_ValueAddedTaxPaidToVendors

Namespace Prefix: pmhs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Value added tax percentage.

+ References

No definition available.

+ Details

Name: pmhs_ValueAddedTaxPercentage

Namespace Prefix: pmhs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.

+ References

No definition available.

+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The parent entity's interest in net assets of the subsidiary, expressed as a percentage.

+ References

No definition available.

+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=us-gaap_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 34 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies
3 Months Ended

Mar. 31, 2015

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying financial statements are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at March 31, 2015 and 2014 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2014 audited financial statements. The results of operations for the periods ended March 31, 2015 and 2014 are not necessarily indicative of the operating results for the full year.

Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) (formerly Putnam Hills Corp) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.

DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) a 96,92% owned subsidiary of the Company. The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology.

Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes.

Consolidation — For the three months ended March 31, 2015 and 2014, the consolidated financial statements include the accounts and operations of the DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation.

Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending March 31, 2015 and 2014. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in the United States in excess of federally insured amounts of $3,073,967 at March 31, 2015, and had $2,508,759 held in financial institutions in the United States in excess of federally insured amounts at December 31, 2014.

Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).

Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

Revenue Recognition and Sales — The Company’s sales of its MCV colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.

Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.

Research and Development Cost — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development costs were included in operating expenses for the three month periods ended March 31, 2015 and 2014, totaled $151,813, and $0, respectively. Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.

Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

● Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.

Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.

Recent Accounting Pronouncements — In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not anticipate that the adoption of ASU 2015-02 will have any impact on our consolidated financial statements.

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Reclassification — The financial statements for the period ended March 31, 2014 and December 31, 2014 have been reclassified to conform to the headings and classifications used in the March 31, 2015 financial statements.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Balance Sheets (Parenthetical) (USD $)

Mar. 31, 2015

Dec. 31, 2014

Statement of Financial Position [Abstract]

Preferred stock, Par value $ 0.0001 $ 0.0001

Preferred stock, Shares authorized 10,000,000us-gaap_PreferredStockSharesAuthorized 10,000,000us-gaap_PreferredStockSharesAuthorized

Preferred stock, Shares issued

Preferred stock, shares outstanding

Common stock, Par value $ 0.0001 $ 0.0001

Common stock, Shares authorized 100,000,000us-gaap_CommonStockSharesAuthorized 100,000,000us-gaap_CommonStockSharesAuthorized

Common stock, Shares issued 9,533,290us-gaap_CommonStockSharesIssued 9,533,290us-gaap_CommonStockSharesIssued

Common stock, Shares outstanding 9,533,290us-gaap_CommonStockSharesOutstanding 9,533,290us-gaap_CommonStockSharesOutstanding

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9

Subsequent Event
3 Months Ended

Mar. 31, 2015

Subsequent Events [Abstract]

SUBSEQUENT EVENTS
NOTE 11 — SUBSEQUENT EVENTS

The Company’s management reviewed material events through May 13, 2015.

On April 28, 2015 Robert Wolfe resigned as Chief Financial Officer of the Company and on May 1st, the Board appointed Lone Degn as the Chief Financial Officer of the Company.

On April 28, 2015 the Company entered into a service agreement with Fondazione Giscad per la Ricerca sui Tumori to support Dandrit in a clinical trial to be conducted in Italy.

On April 1st, 2015 DanDrit entered into a project agreement with IRCCS Azienda Ospedaliera Univeritaria San Martino IST- Istituto Nazionale per la ricerca sul Cancro to perform certain services with respect to a multicenter clinical trial.

On April 23, 2015, the Company entered into a collaboration agreement with Riyadh Pharma in Saudi Arabia to promote cooperation in the manufacturing and marketing of DanDrit's dendritic cell cancer vaccine.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document and Entity Information
3 Months Ended

Mar. 31, 2015

May 11, 2015

Document and Entity Information [Abstract]

Entity Registrant Name DanDrit Biotech USA, Inc.

Entity Central Index Key 0001527728

Amendment Flag false

Current Fiscal Year End Date --12-31

Document Type 10-Q

Document Period End Date Mar. 31, 2015

Document Fiscal Period Focus Q1

Document Fiscal Year Focus 2015

Entity Filer Category Smaller Reporting Company

Entity Common Stock Shares Outstanding 9,533,290dei_EntityCommonStockSharesOutstanding

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pmhs_DocumentAndEntityInformationAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

Summary of Significant Accounting Policies (Policies)
3 Months Ended

Mar. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Business and Basis of Presentation

Business and Basis of Presentation — DanDrit Biotech USA, Inc. (“DanDrit USA”, the “Company”, “we”, “us”, “our”) (formerly Putnam Hills Corp) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.

DanDrit BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (“DanDrit Denmark”) a 96,92% owned subsidiary of the Company. The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of cancer using the dendritic cell technology.

Reverse Acquisition
Reverse Acquisition — On February 12, 2014, pursuant to the Share Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the “Common Stock”) of Parent outstanding. Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent’s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent’s Common Stock outstanding immediately following the Share Exchange, including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the Share Exchange (the “Non-Consenting Shareholders”), and deemed issued and outstanding for accounting purposes.

Consolidation
Consolidation — For the three months ended March 31, 2015 and 2014, the consolidated financial statements include the accounts and operations of the DanDrit Denmark, and the accounts and operations of DanDrit USA. All material inter-company transactions and accounts have been eliminated in the consolidation.

Functional Currency / Foreign currency translation
Functional Currency / Foreign currency translation — The functional currency of DanDrit USA is the U.S. Dollar. The functional currency of DanDrit Denmark is the Danish Kroner (“DKK”). The Company’s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company’s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the periods ending March 31, 2015 and 2014. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders’ equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.

Cash and Cash Equivalents
Cash and Cash Equivalents — The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held in financial institutions in the United States in excess of federally insured amounts of $3,073,967 at March 31, 2015, and had $2,508,759 held in financial institutions in the United States in excess of federally insured amounts at December 31, 2014.

Property and Equipment
Property and Equipment — Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).

Intangible Assets
Intangible Assets — Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification, (“ASC”) Topic 350, “Goodwill and Other Intangible Assets” and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets — Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.

Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.

Revenue Recognition and Sales

Revenue Recognition and Sales — The Company’s sales of its MCV colorectal cancer vaccine have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company's accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101), and FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.

Value Added Tax

Value Added Tax — In Denmark, Value Added Tax (“VAT”) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices these amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.

Research and Development Cost
Research and Development Cost — The Company expenses research and development costs incurred in formulating, improving, validating and creating alternative or modified processes related to and expanding the use of our MAGE –A dendrite cell cancer therapy. Research and development costs were included in operating expenses for the three month periods ended March 31, 2015 and 2014, totaled $151,813, and $0, respectively. Our research and development expenses may fluctuate substantially from quarter to quarter depending on the clinical studies and the timing of samples supporting the clinical studies.

Income Taxes

Income Taxes — The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.

Loss Per Share
Loss Per Share — The Company calculates earnings /(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.

Fair Value of Financial Instruments

Fair Value of Financial Instruments — The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;

● Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.

Accounting Estimates

Accounting Estimates — The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.

Recent Accounting Pronouncements
Recent Accounting Pronouncements — In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02) "Consolidation (Topic 810): Amendments to the Consolidation Analysis." ASU 2015-02 changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. It is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not anticipate that the adoption of ASU 2015-02 will have any impact on our consolidated financial statements.

Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Reclassification
Reclassification — The financial statements for the period ended March 31, 2014 and December 31, 2014 have been reclassified to conform to the headings and classifications used in the March 31, 2015 financial statements.

X

- Definition

Disclosure of accounting policy for reverse acquisition.

+ References

No definition available.

+ Details

Name: pmhs_ReverseAcquisitionPolicyTextBlock

Namespace Prefix: pmhs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for value added tax.

+ References

No definition available.

+ Details

Name: pmhs_ValueAddedTaxPolicyTextBlock

Namespace Prefix: pmhs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51717228&loc=d3e202-110218

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition for sales of a service. The entity also may disclose how it recognizes cost of sales for such a service transaction and its treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 20

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51660065&loc=d3e47769-111627

+ Details

Name: us-gaap_RevenueRecognitionSalesOfServices

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

Consolidated Statement of Operations (Unaudited) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Statement of Operations [Abstract]

Revenues

Cost of Goods Sold 44,622us-gaap_CostOfGoodsSold 17,739us-gaap_CostOfGoodsSold

Gross (Loss) (44,622)us-gaap_GrossProfit (17,739)us-gaap_GrossProfit

Operating Expenses

General and Administrative Expenses 372,996us-gaap_GeneralAndAdministrativeExpense 326,428us-gaap_GeneralAndAdministrativeExpense

Research and development expense 151,813us-gaap_ResearchAndDevelopmentExpense

Depreciation and Amortization 4,055 6,794

Consulting Expenses 291,998pmhs_ConsultingExpenses 61,145pmhs_ConsultingExpenses

Total Operating Expense 820,862us-gaap_OperatingExpenses 394,367us-gaap_OperatingExpenses

(LOSS) FROM OPERATIONS (865,484)us-gaap_OperatingIncomeLoss (412,106)us-gaap_OperatingIncomeLoss

Other Income (Expense)

Interest (expense) (1,540)us-gaap_InterestExpense (13,999)us-gaap_InterestExpense

(Loss) on Currency Transactions (392,474)

Interest and Other Income 6,153us-gaap_InterestIncomeOther 51us-gaap_InterestIncomeOther

Total Other Income (Expense) (387,861)us-gaap_NonoperatingIncomeExpense (13,948)us-gaap_NonoperatingIncomeExpense

(Loss) Before Income Taxes (1,253,345) (426,054)

Income Tax Expense (Benefit)

NET (LOSS) $ (1,253,345)us-gaap_NetIncomeLoss $ (426,054)us-gaap_NetIncomeLoss

BASIC AND DILUTED LOSS PER SHARE $ (0.13)us-gaap_EarningsPerShareBasicAndDiluted $ (0.06)us-gaap_EarningsPerShareBasicAndDiluted

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED 9,553,290 6,880,278

X

- Definition

Consulting expenses.

+ References

No definition available.

+ Details

Name: pmhs_ConsultingExpenses

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894

+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossRealized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of interest income earned from interest bearing assets not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_InterestIncomeOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes
3 Months Ended

Mar. 31, 2015

Income Taxes [Abstract]

INCOME TAXES
NOTE 6 — INCOME TAXES

The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined.

As of March 31, 2015, the Company had net operating loss carry-forwards of approximately $2,416,813 for Danish tax purposes which do not expire and net operating loss carry-forwards of approximately $179,661 for U.S. Federal Tax purposes which expire through 2034, a portion of which shall be limited due to the change in control of the Parent.

The Company files U.S. and Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2011 and 2008, respectively.

The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at March 31, 2015 and December 31, 2014:

March 31,
2015 December 31,
2014

Excess of Tax over book depreciation Fixed assets $ 12,711 $ 12,711

Excess of Tax over book depreciation Patents 52,041 52,041

Net Operating Loss Carry forward 2,416,813 2,380,106

Valuation Allowance (2,481,565 ) (2,444,858 )

Total Deferred Tax Asset (Liabilities) $ - $ -

In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meet the more-likely-than-not condition for recognition and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets.



A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows at March 31, 2015 and 2014:

March 31, 2015 March 31, 2014

Computed Tax at Expected Statutory Rate $ (277,657 ) $ (144,858 )

Non-US Income Taxed at Different Rates 97,996 44,858

Non-Deductable expenses - -

Valuation allowance 179,661 100,000

Income Tax Expense $ - $ -

The components of income tax expense (benefit) from continuing operations for the three months ended March 31, 2015 and 2014 consisted of the following

2015 2014

Current Tax Expense

Danish Income Tax $ - $ -

Total Current Tax Expense - -

Deferred Income Tax Expense (Benefit)

Excess of Tax over Book Depreciation Fixed Assets - -

Excess of Tax over Book Depreciation Patents - -

Net Operating Loss Carry forwards (179,661 ) (100,000 )

Change in the Valuation allowance 179,661 100,000

Total Deferred Tax Expense $ - $ -

Deferred income tax expense / (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

Leases
3 Months Ended

Mar. 31, 2015

Leases [Abstract]

LEASES
NOTE 5 — LEASES

Operating Leases — The Company leases laboratory and production space under operating lease agreements which can be cancelled with 3 month notice. The lease calls for monthly payments of DKK 6,000 (approximately $906 at March 31, 2015).

Lease expense charged to operations was $11,918 and, $7,255 for the three months ended March 31, 2015 and 2014, respectively.

On March 27, 2014, the Company entered into an operating lease agreement for office space from a related party. The Lease calls for monthly payments of DKK 10,000 (approximately $1,579), increasing to DKK 20,000 (approximately $3,393) on July 1, 2014. The lease can be terminated by either the Company or the landlord by giving the other 3 months notice. The Company gave notice terminating the lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.

X

- Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for operating leases of a lessor. This may include a general description of lessor's leasing arrangements for operating leases, including the basis on which contingent rental payments are determined, the existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6452767&loc=d3e37045-112695

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 932

-SubTopic 235

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=51678428&loc=d3e61901-109447

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6453916&loc=d3e41460-112716

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6453916&loc=d3e41457-112716

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6452767&loc=d3e37051-112695

+ Details

Name: us-gaap_OperatingLeasesOfLessorDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

Loss Per Share (Tables)
3 Months Ended

Mar. 31, 2015

Loss Per Share [Abstract]

Schedule of weighted average number of shares of potential dilutive common stock
For the Three
Months Ended
March 31,
2015 2014
Net (Loss) (1,253,345 ) (426,054 )
Weighted average number of common shares used in basic earnings per share 9,533,290 6,880,278
Effect of dilutive securities, stock options and warrants - -
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share 9,533,290 6,880,278

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

Property and Equipment (Tables)
3 Months Ended

Mar. 31, 2015

Property and Equipment [Abstract]

Summary of property and equipment
Useful Life March 31,
2015 December 31,
2014
Lab equipment and instruments 4-6 $ 208,823 $ 208,823
Computer equipment 4-6 60,670 60,670
269,493 269,493
Less Accumulated Depreciation (269,493 ) (269,493 )
Net Property and Equipment $ - $ -

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies
3 Months Ended

Mar. 31, 2015

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES
NOTE 9 — COMMITMENTS AND CONTINGENCIES

Shares held for non-consenting shareholders – In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements.

Clinical Trial Agreement - On October 1, 2014 the Company’s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS “San Martino” - IST – National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit’s vaccine in patients with no evident disease (“NED”) stage IV colorectal cancer (“CRC”). The primary goal of the study is to evaluate the efficacy of DanDrit’s MelCancerVac® (“MCV”) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.

Patient Name Use Program — On December 16, 2013, DanDrit Denmark entered into an agreement with a Dutch company (the “MCV Partner”) regarding a Patient Name Use Program (PNU) for the Company’s MCV. This program will allow DanDrit Denmark to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner. The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmaco vigilance. The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 days written notice.

Food and Drug Administration (FDA) — The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company’s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended.

Product liability — The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company’s operations.

Employment Agreements — The Company and its Subsidiary have employment agreements with officers of the Company.

Contingencies — The Company is from time to time involved in routine legal and administrative proceedings and claims of various types. While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.

Consulting Agreement — As of December 11, 2014, the Company entered into an agreement with Northern Biotech Fund SARL, an entity controlled by a shareholder of the Company. Northern Biotech Fund SARL provides consulting services to the Company in connection with planning and structuring a fund raising for the Company. In 2014 consultancy expenses were $148,395 and for the three month ended March 31, 2015 the consultancy expenses were $240,000.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

Loss Per Share
3 Months Ended

Mar. 31, 2015

Loss Per Share [Abstract]

LOSS PER SHARE
NOTE 7 — LOSS PER SHARE

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of potential dilutive common stock for the three month period ended March 31, 2015, and 2014:

For the Three
Months Ended
March 31,
2015 2014
Net (Loss) (1,253,345 ) (426,054 )
Weighted average number of common shares used in basic earnings per share 9,533,290 6,880,278
Effect of dilutive securities, stock options and warrants - -
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share 9,533,290 6,880,278

For the three months ended March 31, 2015 and 2014, the Company had no common stock equivalents.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stockholder's Equity
3 Months Ended

Mar. 31, 2015

Stockholder's Equity [Abstract]

STOCKHOLDERS' EQUITY
NOTE 8 — STOCKHOLDERS’ EQUITY

Common Stock — The Company has 100,000,000 authorized shares of Common stock $0.0001. As of March 31, 2015 and December 31, 2014 there were 9,533,290 shares issued and outstanding, respectively.

Common Stock Issuances — On December 31, 2014, the Company received $2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.

During the year ended December 31, 2014, pursuant to the Company’s offering of up to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for gross proceeds of $5,466,450 less offering costs of $156,360.

Share Exchange Agreement/Reverse Acquisition — On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), we completed the acquisition of 100% of the issued and outstanding capital stock of DanDrit Denmark (the “Share Exchange”) and as a result became DanDrit Denmark’s parent company (the “Parent”). In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA’s common stock, par value $.0001 per share (the “Common Stock”) for an aggregate of 6,000,000 shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.

On February 11, 2014 1,400,000 and 40,000 common shares of the Company were issued for consulting and legal services valued at $5 per share or $7,000,000 and $200,000, respectively. These shares were issued by the Company prior to the reverse acquisition of DanDrit Denmark and the $7,200,000 was closed out to additional paid in capital in connection with the recapitalization of DanDrit Denmark.

On February 12, 2014, upon the closing of the Share Exchange, the Company and the its majority shareholder immediately prior to the closing agreed to cancel up to 4,400,000 shares of our common stock. In addition, following the closing of the Share Exchange, DanDrit Biotech USA, Inc., a wholly owned subsidiary of the Company merged with and into the Company, thereby changing the Company’s name to “DanDrit Biotech USA, Inc.”

Voting — Holders of the Company’s common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.

Dividends — Holders of the Company’s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.

Liquidation Rights — In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of the Company’s common stock will be entitled to share ratably in the distribution of any of our remaining assets.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

Related Party Transactions
3 Months Ended

Mar. 31, 2015

Related Party Transactions [Abstract]

Related Party Transactions
NOTE 10 — Related Party Transactions

During the three month ended March 31, 2015 and 2014, the Company entered into various notes payable with shareholders of the Company (See Note 4).

On March 27, 2014 the Company entered into an operating lease agreement for office space from a shareholder of the Company (See Note 5). During the three months ended March 31, 2015 and 2014, the Company paid the related party DKK60,000 and DKK 0 or approximately $3,019 and $0, respectively.

During the three months ended March 31, 2015 and 2014, a law firm partially owned by the Company’s Chairman of the Board of Directors provided legal services of $60,381 and $100,912, respectively, to the Company. At March 31, 2015 and December 31, 2014, the Company had a payable to the firm in the amount of $200,857 and $212,438, respectively.

As of December 11, 2014, the Company entered into an agreement with Northern Biotech Fund SARL, an entity controlled by a shareholder of the Company. Northern Biotech Fund SARL provides consulting services to the Company in connection with planning and structuring a fund raising for the Company. During the three months ended March 31, 2015 and 2014 the Company expensed $240,000 and $0 under the agreement.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes (Details 1) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Income Tax Reconciliation Expense Benefit

Computed Tax at Expected Statutory Rate $ (277,657) $ (144,858)

Non-US Income Taxed at Different Rates 97,996 44,858

Non-Deductible expenses

Valuation allowance 179,661 100,000

Income Tax Expense

X

- Details

Name: pmhs_IncomeTaxReconciliationExpenseBenefitAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Income Tax Reconciliation Valuation Allowance.

+ References

No definition available.

+ Details

Name: pmhs_IncomeTaxReconciliationValuationAllowance

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Other Income Tax Reconciliation Rate Expense Benefit.

+ References

No definition available.

+ Details

Name: pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Statutory Income Tax Reconciliation Rate Expense Benefit.

+ References

No definition available.

+ Details

Name: pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 49 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

Notes Payable - Related Party (Tables)
3 Months Ended

Mar. 31, 2015

Notes Payable - Related Party [Abstract]

Summary of notes payable and related parties
March 31,
2015 Dec. 31,
2014
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc. $ 38,235 $ 38,235
Note Payable ML Group 16,777 18,963
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC 44,293 42,753
Total Notes Payable – Related Party 99,305 99,951
Less Current Maturities (99,305 ) (99,951 )
Note Payables – Related Party Long Term $ - $ -

Schedule of maturities of long term debt
Year ending December 31,
2015 99,305
2016 -
2017 -
2018 -
2019 -
Thereafter -
99,305

X

- Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

Property and Equipment (Details Textual) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Property and Equipment (Textual)

Depreciation expense $ 0us-gaap_Depreciation $ 523us-gaap_Depreciation

X

- Details

Name: pmhs_PropertyAndEquipmentTextualAbstract

Namespace Prefix: pmhs_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 51 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

Statements of Other Comprehensive Loss (Unaudited) (USD $)
3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract]

Net Loss $ (1,253,345)us-gaap_NetIncomeLoss $ (426,054)us-gaap_NetIncomeLoss

Currency Translation, Net of Taxes 442,575 (3,354)

Other Comprehensive Loss $ (810,770)us-gaap_ComprehensiveIncomeNetOfTax $ (429,408)us-gaap_ComprehensiveIncomeNetOfTax

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

Notes Payable - Related Party
3 Months Ended

Mar. 31, 2015

Notes Payable - Related Party [Abstract]

NOTES PAYABLE - RELATED PARTY
NOTE 4 — NOTES PAYABLE – RELATED PARTY

Notes payable to related parties consists of the following as of March 31, 2015 and December 31, 2014:

March 31,
2015 Dec. 31,
2014
Non-Interest Bearing Loan Payable Sunrise Financial Group Inc. $ 38,235 $ 38,235
Note Payable ML Group 16,777 18,963
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC 44,293 42,753
Total Notes Payable – Related Party 99,305 99,951
Less Current Maturities (99,305 ) (99,951 )
Note Payables – Related Party Long Term $ - $ -

The following represents the future maturities of long-term debt as of March 31, 2015:

Year ending December 31,
2015 99,305
2016 -
2017 -
2018 -
2019 -
Thereafter -
99,305

On February 15, 2014 and March 18, 2014, DanDrit Denmark received DKK 2,500,000 ($461,084) and DKK 2,300,000 ($424,198) loans (the “2014 Loans”), respectively, from Paseco ApS, an entity owned by a shareholder of the Company (“Paseco”). The 2014 Loans were payable 14 days after the completion of the contemplated public offering in DanDrit USA or February 1, 2015, and accrued interest at 5% per annum. On April 29, 2014, DanDrit Denmark and Paseco entered into an amendment whereby the terms of the 2014 Loans were payable on February 1, 2015 and could be extended at the Company’s option for an additional year with an increase in the interest rate to 7.00%. As of October 17, 2014, the outstanding balance on the 2014 Loans including accrued interest was $836,830 based on the currency exchange rate of October 17, 2014. On October 17, 2014 the Company repaid the loan and interest in its entirety.

DanDrit Denmark has received an unsecured loan facility from Sune Olsen Holding ApS (“Sune Olsen Holding”), a shareholder of the Company, with a goal of ensuring financing until new equity is invested in the Company. Under the loan facility DanDrit Denmark has received the following amounts: on November 11, 2013 DKK 1,500,000 ($276,651), on November 20, 2013 DKK 405,000 ($74,696), and on December 2, 2013 DKK 900,000 ($165,990). The loans were due May 1, 2014 and accrued interest at 5% per year. During March 2014, the Company extended maturity date of the loans with Sune Olsen Holdings from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014, the Company repaid the loan facility and interest thereon.

DanDrit Denmark has received an unsecured loan from Sune Olsen, managing member of Sune Olsen Holding, with a goal of ensuring financing until new equity is invested in the Company. The loan in the amount of DKK 1,000,000 ($184,434) was issued on December 20, 2013. The loan was due May 1, 2014 and accrued interest of 5% per year. During March 2014, the Company extended the maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014 the Company repaid the unsecured loan and interest thereon.

During March 2014, the Company received a 2,000,000 DKK letter of support from Paseco committing to the additional financing to ensure continued operations until February 1, 2015. The letter expired on February 1, 2015.

As of March 31, 2015, the outstanding balance of $38,235 for professional fees paid by a related party and amounts advanced to the Parent are reported as loan payable - related party. The $38,235 loan payable was acquired in the reverse acquisition. The amount is unsecured, non-interest bearing and has no stipulated repayment terms.

A 6% Promissory Note payable (the “Note”) to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired by the Company in the reverse acquisition, payable on February 12, 2014 upon the completion date of the Share Exchange. As of March 31, 2015 and 2014, the outstanding balance on the Note, including accrued interest, was $44,293 and $41,945. During the three months ended March 31, 2015 and 2014 the Company recorded related party interest on the Note of $579, and $579.

X

- Definition

Notes payable text block.

+ References

No definition available.

+ Details

Name: pmhs_NotesPayableDisclosureTextBlock

Namespace Prefix: pmhs_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9

Definite Life Intangible Assets (Details) (USD $)

Mar. 31, 2015

Dec. 31, 2014

Definite Life Intangible Assets [Abstract]

2015 $ 11,462

2016 15,366

2017 15,324

2018 15,324

2019 15,324

Thereafter 88,262

Finite-Lived Intangible Assets, Net $ 161,062us-gaap_FiniteLivedIntangibleAssetsNet $ 186,414us-gaap_FiniteLivedIntangibleAssetsNet

X

- Definition

Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 63 194 1 false 23 0 false 5 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.0001527728.com/role/Documentandentityinformation Document and Entity Information true false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://www.0001527728.com/role/Consolidatedbalancesheets Consolidated Balance Sheets false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.0001527728.com/role/Consolidatedbalancesheetsparenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 004 - Statement - Consolidated Statement of Operations (Unaudited) Sheet http://www.0001527728.com/role/ConsolidatedStatementOfOperationsUnaudited Consolidated Statement of Operations (Unaudited) false false R5.htm 005 - Statement - Statements of Other Comprehensive Loss (Unaudited) Sheet http://www.0001527728.com/role/StatementsOfOtherComprehensiveLossUnaudited Statements of Other Comprehensive Loss (Unaudited) false false R6.htm 006 - Statement - Consolidated Statement of Cash Flows (Unaudited) Sheet http://www.0001527728.com/role/ConsolidatedStatementOfCashFlowsUnaudited Consolidated Statement of Cash Flows (Unaudited) false false R7.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.0001527728.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R8.htm 008 - Disclosure - Property and Equipment Sheet http://www.0001527728.com/role/PropertyAndEquipment Property and Equipment false false R9.htm 009 - Disclosure - Definite Life Intangible Assets Sheet http://www.0001527728.com/role/DefiniteLifeIntangibleAssets Definite Life Intangible Assets false false R10.htm 010 - Disclosure - Notes Payable - Related Party Notes http://www.0001527728.com/role/NotesPayableRelatedParty Notes Payable - Related Party false false R11.htm 011 - Disclosure - Leases Sheet http://www.0001527728.com/role/Leases Leases false false R12.htm 012 - Disclosure - Income Taxes Sheet http://www.0001527728.com/role/IncomeTaxes Income Taxes false false R13.htm 013 - Disclosure - Loss Per Share Sheet http://www.0001527728.com/role/LossPerShare Loss Per Share false false R14.htm 014 - Disclosure - Stockholder's Equity Sheet http://www.0001527728.com/role/StockholdersEquity Stockholder's Equity false false R15.htm 015 - Disclosure - Commitments and Contingencies Sheet http://www.0001527728.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R16.htm 016 - Disclosure - Related Party Transactions Sheet http://www.0001527728.com/role/RelatedPartyTransactions Related Party Transactions false false R17.htm 017 - Disclosure - Subsequent Event Sheet http://www.0001527728.com/role/SubsequentEvent Subsequent Event false false R18.htm 018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R19.htm 019 - Disclosure - Property and Equipment (Tables) Sheet http://www.0001527728.com/role/PropertyandEquipmentTables Property and Equipment (Tables) false false R20.htm 020 - Disclosure - Definite Life Intangible Assets (Tables) Sheet http://www.0001527728.com/role/DefiniteLifeIntangibleAssetsTables Definite Life Intangible Assets (Tables) false false R21.htm 021 - Disclosure - Notes Payable - Related Party (Tables) Notes http://www.0001527728.com/role/Notespayablerelatedpartytables Notes Payable - Related Party (Tables) false false R22.htm 022 - Disclosure - Income Taxes (Tables) Sheet http://www.0001527728.com/role/IncomeTaxesTables Income Taxes (Tables) false false R23.htm 023 - Disclosure - Loss Per Share (Tables) Sheet http://www.0001527728.com/role/LossPerShareTables Loss Per Share (Tables) false false R24.htm 024 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R25.htm 025 - Disclosure - Property and Equipment (Details) Sheet http://www.0001527728.com/role/PropertyandEquipmentDetails Property and Equipment (Details) false false R26.htm 026 - Disclosure - Property and Equipment (Details Textual) Sheet http://www.0001527728.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) false false R27.htm 027 - Disclosure - Definite Life Intangible Assets (Details) Sheet http://www.0001527728.com/role/Definitelifeintangibleassetsdetails Definite Life Intangible Assets (Details) false false R28.htm 028 - Disclosure - Definite Life Intangible Assets (Details Textual) Sheet http://www.0001527728.com/role/Definitelifeintangibleassetsdetailstextual Definite Life Intangible Assets (Details Textual) false false R29.htm 029 - Disclosure - Notes Payable - Related Party (Details) Notes http://www.0001527728.com/role/Notespayablerelatedpartydetails Notes Payable - Related Party (Details) false false R30.htm 030 - Disclosure - Notes Payable - Related Party (Details 1) Notes http://www.0001527728.com/role/Notespayablerelatedpartydetails1 Notes Payable - Related Party (Details 1) false false R31.htm 031 - Disclosure - Notes Payable - Related Party (Details Textual) Notes http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual Notes Payable - Related Party (Details Textual) false false R32.htm 032 - Disclosure - Leases (Details) Sheet http://www.0001527728.com/role/LeasesDetails Leases (Details) false false R33.htm 033 - Disclosure - Income Taxes (Details) Sheet http://www.0001527728.com/role/IncomeTaxesDetails Income Taxes (Details) false false R34.htm 034 - Disclosure - Income Taxes (Details 1) Sheet http://www.0001527728.com/role/Incometaxesdetails1 Income Taxes (Details 1) false false R35.htm 035 - Disclosure - Income Taxes (Details 2) Sheet http://www.0001527728.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) false false R36.htm 036 - Disclosure - Income Taxes (Details Textual) Sheet http://www.0001527728.com/role/Incometaxesdetailstextual Income Taxes (Details Textual) false false R37.htm 037 - Disclosure - Loss Per Share (Details) Sheet http://www.0001527728.com/role/LossPerShareDetails Loss Per Share (Details) false false R38.htm 038 - Disclosure - Stockholder's Equity (Details Textual) Sheet http://www.0001527728.com/role/Stockholdersequitydetailstextual Stockholder's Equity (Details Textual) false false R39.htm 039 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.0001527728.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) false false R40.htm 040 - Disclosure - Related Party Transactions (Details) Sheet http://www.0001527728.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) false false All Reports Book All Reports Process Flow-Through: 002 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2014' Process Flow-Through: Removing column 'Dec. 31, 2013' Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 004 - Statement - Consolidated Statement of Operations (Unaudited) Process Flow-Through: 005 - Statement - Statements of Other Comprehensive Loss (Unaudited) Process Flow-Through: 006 - Statement - Consolidated Statement of Cash Flows (Unaudited) pmhs-20150331.xml pmhs-20150331.xsd pmhs-20150331_cal.xml pmhs-20150331_def.xml pmhs-20150331_lab.xml pmhs-20150331_pre.xml true true XML 55 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9

Stockholder's Equity (Details Textual) (USD $)
0 Months Ended 3 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended

Feb. 11, 2014

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Aug. 12, 2014

Feb. 12, 2014

Aug. 21, 2014

Class of Stock [Line Items]

Common stock, shares authorized 100,000,000us-gaap_CommonStockSharesAuthorized 100,000,000us-gaap_CommonStockSharesAuthorized

Common stock, Par value $ 0.0001 $ 0.0001

Common stock, Shares outstanding 9,533,290us-gaap_CommonStockSharesOutstanding 9,533,290us-gaap_CommonStockSharesOutstanding

Common stock, Shares issued 9,533,290us-gaap_CommonStockSharesIssued 9,533,290us-gaap_CommonStockSharesIssued

Offering of common stock, value $ 12,000,000 $ 2,000,000

Offering of common stock, shares 2,400,000 400,000

Offering of common stock price per share $ 5.00us-gaap_SharesIssuedPricePerShare $ 5.00us-gaap_SharesIssuedPricePerShare

Common Stock reserved for issuance 185,053

Share exchange agreement to record number of common shares in connection with acquisition, Shares 1,400,000

Share exchange agreement to record number of common shares in connection with offering, Shares 40,000

Share exchange agreement to record number of common shares in connection with acquisition, Value 7,000,000

Share exchange agreement to record number of common shares in connection with offering, Value 200,000

Share exchange agreement to record number of common shares in connection with acquisition, Per Share $ 5

Share exchange agreement to record number of common shares in connection with offering, Per Share $ 5

Proceeds from Stock Offering

Initial public offering [Member]

Class of Stock [Line Items]

Offering of common stock, value 12,000,000 12,000,000

Offering of common stock, shares 2,400,000 2,400,000

Offering of common stock price per share $ 5.00 $ 5.00

Parent Company [Member]

Class of Stock [Line Items]

Common stock, Par value $ 0.0001

Share exchange agreement acquisition percentage 97.00%

Common Stock reserved for issuance 185,053

Share exchange agreement to record number of common shares in connection with acquisition, Value 7,200,000

Common Stock [Member]

Class of Stock [Line Items]

Sale of stock common shares 141,000

Share exchange agreement number of share cancellation 4,400,000

Share exchange agreement shares held by consenting shareholders of company 1.498842

Common Stock [Member] | Initial public offering [Member]

Class of Stock [Line Items]

Sale of stock common shares 1,093,290

Gross proceeds from escrow 5,466,450

Proceeds from Stock Offering $ 156,360

Common Stock [Member] | Parent Company [Member]

Class of Stock [Line Items]

Share exchange agreement acquisition percentage 100.00%

Share exchange agreement shares issued to parent company 6,000,000

X

- Definition

Share exchange agreement acquisition percentage.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementAcquisitionPercentage

Namespace Prefix: pmhs_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Share exchange agreement number of share cancellation.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementNumberOfShareCancellation

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share Exchange Agreement Shares held by consnting shareholders of comany.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share Exchange Agreement Shares Issued To Parent Company.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementSharesIssuedToParentCompany

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share exchange agreement to record number of common shares in connection with acquisition.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementToRecordNumberOfCommonSharesInConnectionWithAcquisition

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share exchange agreement to record number of common shares in connection with acquisition per share value.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementToRecordNumberOfCommonSharesInConnectionWithAcquisitionPerShareValue

Namespace Prefix: pmhs_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Share exchange agreement to record number of common shares in connection with acquisition value.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementToRecordNumberOfCommonSharesInConnectionWithAcquisitionValue

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Share exchange agreement to record number of common shares in connection with offering.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementToRecordNumberOfCommonSharesInConnectionWithOffering

Namespace Prefix: pmhs_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Share exchange agreement to record number of common shares in connection with offering per share value.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementToRecordNumberOfCommonSharesInConnectionWithOfferingPerShareValue

Namespace Prefix: pmhs_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Share exchange agreement to record number of common shares in connection with offering value.

+ References

No definition available.

+ Details

Name: pmhs_ShareExchangeAgreementToRecordNumberOfCommonSharesInConnectionWithOfferingValue

Namespace Prefix: pmhs_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow associated with the amount received from entity's first offering of stock to the public.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Per share or per unit amount of equity securities issued.

+ References

No definition available.

+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=us-gaap_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

Definite Life Intangible Assets (Tables)
3 Months Ended

Mar. 31, 2015

Definite Life Intangible Assets [Abstract]

Schedule of definite-life intangible assets, future amortization expense
Year ending December 31,
2015 $ 11,462
2016 15,366
2017 15,324
2018 15,324
2019 15,324
Thereafter 88,262
$ 161,062

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Income Taxes (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Summary of effective income tax rate reconciliation
Excess of Tax over book depreciation Fixed assets	$ 12,711	$ 12,711
Excess of Tax over book depreciation Patents	52,041	52,041
Net Operating Loss Carry forward	2,416,813	2,380,106
Valuation Allowance	(2,481,565)	(2,444,858)
Total Deferred Tax Asset (Liabilities)

Property and Equipment (Details) (USD $)	3 Months Ended
Property and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Gross Property and Equipment	269,493us-gaap_PropertyPlantAndEquipmentGross	$ 269,493us-gaap_PropertyPlantAndEquipmentGross
Less: Accumulated Depreciation	(269,493)	269,493
Net Property and Equipment
Lab equipment and instruments [Member]
Property, Plant and Equipment [Line Items]
Gross Property and Equipment	208,823	208,823
Lab equipment and instruments [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life (years)	6 years
Lab equipment and instruments [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life (years)	4 years
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Gross Property and Equipment		$ 60,670
Computer equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life (years)	6 years
Computer equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life (years)	4 years

Loss Per Share (Details) (USD $)	3 Months Ended
Loss Per Share (Details) (USD $)	Mar. 31, 2015	Mar. 31, 2014
LOSS PER SHARE
Net (Loss)	$ (1,253,345)us-gaap_NetIncomeLoss	$ (426,054)us-gaap_NetIncomeLoss
Weighted average number of common shares used in basic earnings per share	9,533,290	6,880,278
Effect of dilutive securities, stock options and warrants
Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share	9,533,290	6,880,278

Notes Payable - Related Party (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Notes Payable - Related Party	$ 99,305	$ 99,951
Less Current Maturities	(99,305)us-gaap_LongTermDebtCurrent	(99,351)us-gaap_LongTermDebtCurrent
Note Payables - Related Party Long Term
Non Interest Bearing Loan Payable Sunrise Financial Group Inc [Member]
Related Party Transaction [Line Items]
Notes Payable - Related Party	38,235	38,235
Note Payable ML Group [Member]
Related Party Transaction [Line Items]
Notes Payable - Related Party	16,777	18,963,000
6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC [Member]
Related Party Transaction [Line Items]
Notes Payable - Related Party	$ 44,293	$ 42,753

Notes Payable - Related Party (Details 1) (USD $)	Mar. 31, 2015
Notes Payable - Related Party [Abstract]
2015	$ 99,305
2016
2017
2018
2019
Thereafter
Total long term debt	$ 99,305us-gaap_LongTermDebt

Notes Payable - Related Party (Details Textual)								0 Months Ended						3 Months Ended
Notes Payable - Related Party (Details Textual)	Mar. 31, 2015 USD ($)	Dec. 02, 2013 Sune Olsen Holding Aps [Member] Loan One [Member] USD ($)	Dec. 02, 2013 Sune Olsen Holding Aps [Member] Loan One [Member] DKK	Nov. 20, 2013 Sune Olsen Holding Aps [Member] Loan One [Member] USD ($)	Nov. 20, 2013 Sune Olsen Holding Aps [Member] Loan One [Member] DKK	Nov. 11, 2013 Sune Olsen Holding Aps [Member] Loan One [Member] USD ($)	Nov. 11, 2013 Sune Olsen Holding Aps [Member] Loan One [Member] DKK	Dec. 20, 2013 Sune Olsen Holding Aps [Member] Loan Two [Member] USD ($)	Dec. 20, 2013 Sune Olsen Holding Aps [Member] Loan Two [Member] DKK	Mar. 18, 2014 Paseco Aps [Member] Loan [Member] USD ($)	Mar. 18, 2014 Paseco Aps [Member] Loan [Member] DKK	Feb. 15, 2014 Paseco Aps [Member] Loan [Member] USD ($)	Feb. 15, 2014 Paseco Aps [Member] Loan [Member] DKK	Mar. 31, 2014 Paseco Aps [Member] Loan Three [Member] DKK	Mar. 31, 2015 Nlbdit Two Zero One Zero Enterprises, Llc [Member] Loan Ten [Member] USD ($)	Mar. 31, 2014 Nlbdit Two Zero One Zero Enterprises, Llc [Member] Loan Ten [Member] USD ($)
Related Party Transaction [Line Items]
Unsecured loan	$ 38,235us-gaap_UnsecuredDebt	$ 165,990	900,000	$ 74,696	405,000	$ 276,651	1,500,000	$ 184,434	1,000,000	$ 424,198	2,300,000	$ 461,084	2,500,000	2,000,000	$ 44,293	$ 41,945
Accrued interest in percentage										5.00%	5.00%	5.00%	5.00%
Interest expense, borrowing loans															579	579
Increased interest percentage										7.00%	7.00%	7.00%	7.00%		6.00%
Debt Instrument, Maturity Date														Feb. 01, 2015
Extended maturity date, Description								The Company extended maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit Biotech USA, Inc. or February 1, 2015.	The Company extended maturity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit Biotech USA, Inc. or February 1, 2015.
Loans payable	$ 38,235us-gaap_LoansPayable

Leases (Details)	3 Months Ended				1 Months Ended
Leases (Details)	Mar. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2015 Lab space [Member] USD ($)	Mar. 31, 2015 Lab space [Member] DKK	Mar. 27, 2014 Office space [Member] USD ($)	Mar. 27, 2014 Office space [Member] DKK	Jul. 01, 2014 Office space [Member] Subsequent Event [Member] USD ($)	Jul. 01, 2014 Office space [Member] Subsequent Event [Member] DKK
Operating Leased Assets [Line Items]
Rental payments for Operating Leases	$ 11,918us-gaap_OperatingLeasesRentExpenseNet	$ 7,255us-gaap_OperatingLeasesRentExpenseNet	$ 906	6,000	$ 1,579	10,000	$ 3,393	20,000

Related Party Transactions (Details)	3 Months Ended
Related Party Transactions (Details)	Mar. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2015 DKK	Dec. 31, 2014 USD ($)	Mar. 31, 2014 DKK
Related Party Transactions (Textual)
Related party transactions amount	$ 3,019	$ 0	60,000		0
Legal expense	60,381us-gaap_LegalFees	100,912us-gaap_LegalFees
Payable to related parties	200,857			212,438
Balances held in trust	$ 0us-gaap_AssetsHeldInTrust	$ 0us-gaap_AssetsHeldInTrust

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash	$ 3,434,935	$ 3,008,831
Cash held in escrow		2,029,502us-gaap_EscrowDeposit
Other Receivables	41,120	8,016
Total Current Assets	3,476,055us-gaap_AssetsCurrent	5,046,349us-gaap_AssetsCurrent
PROPERTY AND EQUIPMENT, Net accumulated Depreciation
OTHER ASSETS
Definite Life Intangible Assets	161,062us-gaap_FiniteLivedIntangibleAssetsNet	186,414us-gaap_FiniteLivedIntangibleAssetsNet
Deposits	6,326us-gaap_DepositsAssetsNoncurrent	7,146us-gaap_DepositsAssetsNoncurrent
Total Other Assets	167,388us-gaap_AssetsNoncurrent	193,560us-gaap_AssetsNoncurrent
TOTAL ASSETS	3,643,443us-gaap_Assets	5,239,909us-gaap_Assets
CURRENT LIABILITIES:
Notes Payable - Related Party	99,305	99,951
Accounts Payable	622,187us-gaap_AccountsPayableCurrent	711,449us-gaap_AccountsPayableCurrent
Accounts Payable - Related Party	200,857	212,438
Accrued Expenses	49,619us-gaap_AccruedLiabilitiesCurrent	733,826us-gaap_AccruedLiabilitiesCurrent
Total Current Liabilities	971,968us-gaap_LiabilitiesCurrent	1,757,664us-gaap_LiabilitiesCurrent
Total Liabilities	971,968us-gaap_Liabilities	1,757,664us-gaap_Liabilities
STOCKHOLDER'S EQUITY:
Preferred stock, $.0001 par value; 10,000,000 shares authorized; none issued and outstanding
Common stock, par value $0.0001, 100,000,000 shares authorized, 9,533,290, and 9,533,290 issued and outstanding at March 31, 2015 and December 31, 2014, respectively	953us-gaap_CommonStockValue	953us-gaap_CommonStockValue
Additional paid-in capital	25,098,050us-gaap_AdditionalPaidInCapital	25,098,050us-gaap_AdditionalPaidInCapital
Accumulated Deficit	(23,145,352)	(21,892,007)
Other Comprehensive Income, net	717,824	275,249
Total Stockholder's Equity	2,671,475us-gaap_StockholdersEquity	3,482,245us-gaap_StockholdersEquity
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY	$ 3,643,443	$ 5,239,909

Consolidated Statement of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Cash Flows [Abstract]
NET (LOSS)	$ (1,253,345)us-gaap_NetIncomeLoss	$ (426,054)us-gaap_NetIncomeLoss
ADJUSTMENT TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and Amortization	25,352us-gaap_DepreciationAndAmortization	6,794us-gaap_DepreciationAndAmortization
Accrued Interest on Notes Payable - Related Party	1,540
CHANGES IN ASSETS AND LIABILITIES:
(Increase) Decrease in Other Receivables	(33,104)	(44,256)
(Increase) Decrease in Prepaid Expenses/Deposits	820	8,047
Increase (Decrease) in Accounts Payable	(89,262)	19,674
Increase (Decrease) in Accounts Payable - Related Party	(11,581)
Increase (Decrease) in Accrued Expenses	(684,207)	(1,951)
Total Adjustments	(790,442)	(11,692)
NET CASH USED IN OPERATING ACTIVITIES	(2,043,787)	(437,746)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of Equipment		(41,498)
Net (Increase) Decrease in Cash Held in Escrow	2,029,502	(346,501)
Purchase of Intangible Assets		(7,907)
NET CASH USED BY INVESTING ACTIVITIES	2,029,502	(395,906)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Notes Payable - Related Party		865,976us-gaap_ProceedsFromNotesPayable
NET CASH PROVIDED BY (USED BY) FINANCING ACTIVITIES		865,976
Gain (Loss) on Currency Translation	440,389	3,354
NET INCREASE (DECREASE) IN CASH	426,104	35,678
CASH, BEGINNING OF PERIOD	3,008,831	18,794
CASH, END OF PERIOD	3,434,935	54,472
Cash paid during the periods for:
Interest
Income Taxes

Income Taxes (Details 2) (USD $)	3 Months Ended
Income Taxes (Details 2) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Current Tax Expense
Danish Income Tax
Total Current Tax Expense
Deferred Income Tax Expense (Benefit)
Excess of Tax over Book Depreciation Fixed Assets
Excess of Tax over Book Depreciation Patents
Net Operating Loss Carry forwards	(179,661)	(100,000)
Change in the Valuation allowance	179,661	100,000
Total Deferred Tax Expense

Income Taxes (Details Textual) (USD $)	3 Months Ended
Income Taxes (Details Textual) (USD $)	Mar. 31, 2015
Income Taxes (Textual)
Net operating loss carryforwards expiration period	Through 2034
Danish Tax [Member]
Income Taxes (Textual)
Net operating loss carry forwards	2,416,813
U.S. Federal Tax [Member]
Income Taxes (Textual)
Net operating loss carry forwards	179,661

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 12, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 18, 2011
Summary of Significant Accounting Policies (Textual)
Common stock, Par value	$ 0.0001			$ 0.0001
Shares of parent common stock outstanding
Common Stock reserved for issuance	185,053
Balances held in financial institutions	$ 3,073,967us-gaap_CashFDICInsuredAmount			$ 2,508,759us-gaap_CashFDICInsuredAmount
Value added tax percentage	25.00%pmhs_ValueAddedTaxPercentage
Value added tax paid to Danish and EU vendors	25.00%pmhs_ValueAddedTaxPaidToVendors
Research and development expense	$ 151,813us-gaap_ResearchAndDevelopmentExpense
Owned subsidiary percentage	96.92%
Parent Company [Member]
Summary of Significant Accounting Policies (Textual)
Share exchange agreement acquisition percentage			97.00%
Common stock, Par value			$ 0.0001
Common Stock reserved for issuance			185,053
Common Stock [Member]
Summary of Significant Accounting Policies (Textual)
Shares prior to share exchange agreement	5,000,000
Share exchange agreement number of share cancellation			4,400,000
Common shares issued for legal and consulting services	1,440,000
Share exchange agreement shares held by consenting shareholders of company	1.498842
Shares of parent common stock outstanding	8,185,100			6,000,000	6,000,000	5,318,151
Common Stock [Member] \| Parent Company [Member]
Summary of Significant Accounting Policies (Textual)
Share exchange agreement acquisition percentage			100.00%
Share exchange agreement shares issued to parent company			6,000,000
Shares of parent common stock outstanding	8,040,000

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, Par value	$ 0.0001	$ 0.0001
Preferred stock, Shares authorized	10,000,000us-gaap_PreferredStockSharesAuthorized	10,000,000us-gaap_PreferredStockSharesAuthorized
Preferred stock, Shares issued
Preferred stock, shares outstanding
Common stock, Par value	$ 0.0001	$ 0.0001
Common stock, Shares authorized	100,000,000us-gaap_CommonStockSharesAuthorized	100,000,000us-gaap_CommonStockSharesAuthorized
Common stock, Shares issued	9,533,290us-gaap_CommonStockSharesIssued	9,533,290us-gaap_CommonStockSharesIssued
Common stock, Shares outstanding	9,533,290us-gaap_CommonStockSharesOutstanding	9,533,290us-gaap_CommonStockSharesOutstanding

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2015	May 11, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	DanDrit Biotech USA, Inc.
Entity Central Index Key	0001527728
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2015
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015
Entity Filer Category	Smaller Reporting Company
Entity Common Stock Shares Outstanding		9,533,290dei_EntityCommonStockSharesOutstanding

Consolidated Statement of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Operations [Abstract]
Revenues
Cost of Goods Sold	44,622us-gaap_CostOfGoodsSold	17,739us-gaap_CostOfGoodsSold
Gross (Loss)	(44,622)us-gaap_GrossProfit	(17,739)us-gaap_GrossProfit
Operating Expenses
General and Administrative Expenses	372,996us-gaap_GeneralAndAdministrativeExpense	326,428us-gaap_GeneralAndAdministrativeExpense
Research and development expense	151,813us-gaap_ResearchAndDevelopmentExpense
Depreciation and Amortization	4,055	6,794
Consulting Expenses	291,998pmhs_ConsultingExpenses	61,145pmhs_ConsultingExpenses
Total Operating Expense	820,862us-gaap_OperatingExpenses	394,367us-gaap_OperatingExpenses
(LOSS) FROM OPERATIONS	(865,484)us-gaap_OperatingIncomeLoss	(412,106)us-gaap_OperatingIncomeLoss
Other Income (Expense)
Interest (expense)	(1,540)us-gaap_InterestExpense	(13,999)us-gaap_InterestExpense
(Loss) on Currency Transactions	(392,474)
Interest and Other Income	6,153us-gaap_InterestIncomeOther	51us-gaap_InterestIncomeOther
Total Other Income (Expense)	(387,861)us-gaap_NonoperatingIncomeExpense	(13,948)us-gaap_NonoperatingIncomeExpense
(Loss) Before Income Taxes	(1,253,345)	(426,054)
Income Tax Expense (Benefit)
NET (LOSS)	$ (1,253,345)us-gaap_NetIncomeLoss	$ (426,054)us-gaap_NetIncomeLoss
BASIC AND DILUTED LOSS PER SHARE	$ (0.13)us-gaap_EarningsPerShareBasicAndDiluted	$ (0.06)us-gaap_EarningsPerShareBasicAndDiluted
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED	9,553,290	6,880,278

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 10 — Related Party Transactions During the three month ended March 31, 2015 and 2014, the Company entered into various notes payable with shareholders of the Company (See Note 4). On March 27, 2014 the Company entered into an operating lease agreement for office space from a shareholder of the Company (See Note 5). During the three months ended March 31, 2015 and 2014, the Company paid the related party DKK60,000 and DKK 0 or approximately $3,019 and $0, respectively. During the three months ended March 31, 2015 and 2014, a law firm partially owned by the Company’s Chairman of the Board of Directors provided legal services of $60,381 and $100,912, respectively, to the Company. At March 31, 2015 and December 31, 2014, the Company had a payable to the firm in the amount of $200,857 and $212,438, respectively. As of December 11, 2014, the Company entered into an agreement with Northern Biotech Fund SARL, an entity controlled by a shareholder of the Company. Northern Biotech Fund SARL provides consulting services to the Company in connection with planning and structuring a fund raising for the Company. During the three months ended March 31, 2015 and 2014 the Company expensed $240,000 and $0 under the agreement.

Income Taxes (Details 1) (USD $)	3 Months Ended
Income Taxes (Details 1) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Income Tax Reconciliation Expense Benefit
Computed Tax at Expected Statutory Rate	$ (277,657)	$ (144,858)
Non-US Income Taxed at Different Rates	97,996	44,858
Non-Deductible expenses
Valuation allowance	179,661	100,000
Income Tax Expense

Property and Equipment (Details Textual) (USD $)	3 Months Ended
Property and Equipment (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014
Property and Equipment (Textual)
Depreciation expense	$ 0us-gaap_Depreciation	$ 523us-gaap_Depreciation

Statements of Other Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract]
Net Loss	$ (1,253,345)us-gaap_NetIncomeLoss	$ (426,054)us-gaap_NetIncomeLoss
Currency Translation, Net of Taxes	442,575	(3,354)
Other Comprehensive Loss	$ (810,770)us-gaap_ComprehensiveIncomeNetOfTax	$ (429,408)us-gaap_ComprehensiveIncomeNetOfTax

Definite Life Intangible Assets (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Definite Life Intangible Assets [Abstract]
2015	$ 11,462
2016	15,366
2017	15,324
2018	15,324
2019	15,324
Thereafter	88,262
Finite-Lived Intangible Assets, Net	$ 161,062us-gaap_FiniteLivedIntangibleAssetsNet	$ 186,414us-gaap_FiniteLivedIntangibleAssetsNet

Stockholder's Equity (Details Textual) (USD $)	0 Months Ended	3 Months Ended		12 Months Ended	0 Months Ended		1 Months Ended
Stockholder's Equity (Details Textual) (USD $)	Feb. 11, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Aug. 12, 2014	Feb. 12, 2014	Aug. 21, 2014
Class of Stock [Line Items]
Common stock, shares authorized		100,000,000us-gaap_CommonStockSharesAuthorized		100,000,000us-gaap_CommonStockSharesAuthorized
Common stock, Par value		$ 0.0001		$ 0.0001
Common stock, Shares outstanding		9,533,290us-gaap_CommonStockSharesOutstanding		9,533,290us-gaap_CommonStockSharesOutstanding
Common stock, Shares issued		9,533,290us-gaap_CommonStockSharesIssued		9,533,290us-gaap_CommonStockSharesIssued
Offering of common stock, value		$ 12,000,000		$ 2,000,000
Offering of common stock, shares		2,400,000		400,000
Offering of common stock price per share		$ 5.00us-gaap_SharesIssuedPricePerShare		$ 5.00us-gaap_SharesIssuedPricePerShare
Common Stock reserved for issuance		185,053
Share exchange agreement to record number of common shares in connection with acquisition, Shares	1,400,000
Share exchange agreement to record number of common shares in connection with offering, Shares	40,000
Share exchange agreement to record number of common shares in connection with acquisition, Value	7,000,000
Share exchange agreement to record number of common shares in connection with offering, Value	200,000
Share exchange agreement to record number of common shares in connection with acquisition, Per Share	$ 5
Share exchange agreement to record number of common shares in connection with offering, Per Share	$ 5
Proceeds from Stock Offering
Initial public offering [Member]
Class of Stock [Line Items]
Offering of common stock, value		12,000,000			12,000,000
Offering of common stock, shares		2,400,000			2,400,000
Offering of common stock price per share		$ 5.00			$ 5.00
Parent Company [Member]
Class of Stock [Line Items]
Common stock, Par value						$ 0.0001
Share exchange agreement acquisition percentage						97.00%
Common Stock reserved for issuance						185,053
Share exchange agreement to record number of common shares in connection with acquisition, Value	7,200,000
Common Stock [Member]
Class of Stock [Line Items]
Sale of stock common shares							141,000
Share exchange agreement number of share cancellation						4,400,000
Share exchange agreement shares held by consenting shareholders of company		1.498842
Common Stock [Member] \| Initial public offering [Member]
Class of Stock [Line Items]
Sale of stock common shares					1,093,290
Gross proceeds from escrow					5,466,450
Proceeds from Stock Offering					$ 156,360
Common Stock [Member] \| Parent Company [Member]
Class of Stock [Line Items]
Share exchange agreement acquisition percentage						100.00%
Share exchange agreement shares issued to parent company						6,000,000